cancer.type	eQTL.type	tagSNP	LD	SNP.ID	SNP.position.hg19	Gene.symbol	Gene.position.hg19	Beta	t-stat	P-value	GWAS-Traits	
LUSC	cis	1	rs1000113	chr5:150240076	LOC134466	chr5:150310000-150326146:-	0.42	5.85	9.32E-9	Crohn's disease	
LUSC	cis	1	rs10002332	chr4:129875301	C4orf33	chr4:130014829-130033842:+	0.38	7.03	7.39E-12	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs10003708	chr4:90643051	MMRN1	chr4:90816003-90875778:+	0.25	3.95	9.0E-5	Parkinson's disease	
LUSC	cis	1	rs10006789	chr4:1330333	CRIPAK	chr4:1385340-1389782:+	0.3	5.13	4.2E-7	Systolic blood pressure	
LUSC	cis	1	rs10007119	chr4:3473066	LRPAP1	chr4:3514290-3534224:-	0.18	3.97	8.36E-5	Triglycerides;Cholesterol, total;LDL cholesterol	
LUSC	cis	1	rs10008757	chr4:76903036	NAAA	chr4:76831809-76862166:-	-0.27	-5.79	1.28E-8	Longevity	
LUSC	cis	1	rs10009741	chr4:75711506	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs10011647	chr4:75711216	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs1001204	chr2:30478779	LBH	chr2:30454397-30482899:+	-0.23	-3.75	0.000202	Systemic lupus erythematosus	
LUSC	cis	1	rs10012335	chr4:17628630	MED28	chr4:17616273-17629791:+	0.18	3.74	0.000209	Parasitemia in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs10030019	chr4:106998448	TBCK	chr4:106967233-107237861:-	0.28	5.3	1.75E-7	Airflow obstruction	
LUSC	cis	1	rs10033209	chr4:90653704	MMRN1	chr4:90816003-90875778:+	0.25	3.8	0.000166	Parkinson's disease	
LUSC	cis	1	rs1003719	chr21:38491095	PIGP	chr21:38437664-38445458:-	-0.33	-6.34	5.27E-10	Eye color traits	
LUSC	cis	1	rs10047845	chr14:103481677	MARK3	chr14:103851701-103970164:+	-0.31	-3.72	0.000223	Large B-cell lymphoma	
LUSC	cis	1	rs10051747	chr5:56083289	C5orf35	chr5:56205103-56213010:+	0.88	15.04	4.26E-42	Type 2 diabetes	
LUSC	cis	1	rs1006396	chr22:30017000	CCDC157	chr22:30752627-30772816:+	0.22	3.83	0.000143	Lipid traits	
LUSC	cis	1	rs1006396	chr22:30017000	NIPSNAP1	chr22:29950800-29977144:-	0.26	4.5	8.54E-6	Lipid traits	
LUSC	cis	1	rs1006581	chr7:150511923	TMEM176A	chr7:150497854-150502208:+	-0.11	-3.76	0.000189	Forced expiratory volume in 1 second (environmental interaction)	
LUSC	cis	1	rs1006599	chr3:132716570	TMEM108	chr3:132757171-133116618:+	0.21	4.91	1.24E-6	IgE grass sensitization	
LUSC	cis	1	rs1006722	chr4:17618713	MED28	chr4:17616273-17629791:+	-0.18	-3.85	0.000133	Parasitemia in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs10076701	chr5:131596419	C5orf56	chr5:131746673-131822549:+	0.12	4.15	3.87E-5	Blood metabolite levels	
LUSC	cis	1	rs10076701	chr5:131596419	SLC22A5	chr5:131705401-131731302:+	-0.19	-4.07	5.56E-5	Blood metabolite levels	
LUSC	cis	1	rs10080429	chr6:109738106	AKD1	chr6:109814059-110012415:-	-0.16	-3.8	0.000163	Height	
LUSC	cis	1	rs10080429	chr6:109738106	SMPD2	chr6:109761931-109765121:+	0.23	4.26	2.48E-5	Height	
LUSC	cis	1	rs10088439	chr8:8576699	FLJ10661	chr8:8086092-8102386:+	0.22	3.7	0.000244	Obesity-related traits	
LUSC	cis	1	rs1009051	chr3:49521549	AMT	chr3:49454212-49460012:-	0.21	4.92	1.22E-6	Menarche (age at onset)	
LUSC	cis	1	rs10095630	chr8:92071264	SLC26A7	chr8:92221722-92410380:+	0.23	4.32	1.94E-5	Migraine - clinic-based	
LUSC	cis	1	rs10110267	chr8:92073814	SLC26A7	chr8:92221722-92410380:+	0.24	4.44	1.14E-5	Migraine - clinic-based	
LUSC	cis	1	rs10117059	chr9:123653477	LOC253039	chr9:123605320-123616644:+	-0.32	-6.12	1.91E-9	Rheumatoid arthritis	
LUSC	cis	1	rs10128711	chr11:18632984	SPTY2D1	chr11:18627949-18656020:-	-0.23	-4	7.39E-5	Cholesterol, total	
LUSC	cis	1	rs1013391	chr3:132725363	TMEM108	chr3:132757171-133116618:+	0.21	5.2	2.92E-7	IgE grass sensitization	
LUSC	cis	1	rs10135248	chr14:104122310	C14orf153	chr14:104029299-104057227:+	0.15	4	7.32E-5	Body mass index	
LUSC	cis	1	rs10135	chr22:39082174	CBY1	chr22:39052658-39069853:+	-0.2	-3.79	0.000172	Resting heart rate	
LUSC	cis	1	rs10136440	chr14:104397367	TDRD9	chr14:104394817-104519002:+	-0.25	-4.28	2.21E-5	Bipolar disorder	
LUSC	cis	1	rs10136948	chr14:75511075	MLH3	chr14:75480467-75518235:-	0.25	5.23	2.54E-7	Height	
LUSC	cis	1	rs10138183	chr14:75615227	MLH3	chr14:75480467-75518235:-	0.27	5.74	1.73E-8	Height	
LUSC	cis	1	rs10140851	chr14:75512612	MLH3	chr14:75480467-75518235:-	0.26	5.59	3.84E-8	Height	
LUSC	cis	1	rs10142626	chr14:75555636	MLH3	chr14:75480467-75518235:-	0.26	5.56	4.54E-8	Height	
LUSC	cis	1	rs10142865	chr14:75555624	MLH3	chr14:75480467-75518235:-	0.26	5.56	4.54E-8	Height	
LUSC	cis	1	rs10143132	chr14:75525850	MLH3	chr14:75480467-75518235:-	0.28	5.86	8.43E-9	Height	
LUSC	cis	1	rs10146482	chr14:75574087	MLH3	chr14:75480467-75518235:-	0.23	4.89	1.36E-6	Height	
LUSC	cis	1	rs10149880	chr14:75633008	MLH3	chr14:75480467-75518235:-	-0.28	-5.92	6.22E-9	Height	
LUSC	cis	1	rs10154865	chr3:85409299	CADM2	chr3:85008133-86117948:+	0.27	4.11	4.75E-5	Longevity (90 years and older)	
LUSC	cis	1	rs10155014	chr3:49432321	AMT	chr3:49454212-49460012:-	0.21	4.99	8.54E-7	Menarche (age at onset)	
LUSC	cis	1	rs10155014	chr3:49432321	TREX1	chr3:48501186-48509043:+	-0.2	-3.74	0.00021	Menarche (age at onset)	
LUSC	cis	1	rs10157597	chr1:45990278	CCDC163P	chr1:45960581-45965646:-	-0.75	-18.03	9.6E-56	Homocysteine levels	
LUSC	cis	1	rs10157597	chr1:45990278	MMACHC	chr1:45965856-45976737:+	-0.15	-3.85	0.000136	Homocysteine levels	
LUSC	cis	1	rs10164319	chr19:18569833	LRRC25	chr19:18501955-18508421:-	-0.12	-4.13	4.21E-5	Breast cancer	
LUSC	cis	1	rs10164319	chr19:18569833	SSBP4	chr19:18530221-18545371:+	-0.19	-3.7	0.000237	Breast cancer	
LUSC	cis	1	rs10164323	chr19:18569492	LRRC25	chr19:18501955-18508421:-	-0.11	-3.82	0.000154	Breast cancer	
LUSC	cis	1	rs10164323	chr19:18569492	SSBP4	chr19:18530221-18545371:+	-0.19	-3.72	0.000227	Breast cancer	
LUSC	cis	1	rs10165099	chr2:3402591	TTC15	chr2:3383446-3488857:+	0.2	3.79	0.000168	Obesity-related traits	
LUSC	cis	1	rs10169714	chr2:73808773	ALMS1P	chr2:73872046-73912692:+	0.4	7.51	3.03E-13	Metabolite levels	
LUSC	cis	1	rs10169714	chr2:73808773	NAT8	chr2:73867850-73869537:-	0.27	4.78	2.36E-6	Metabolite levels	
LUSC	cis	1	rs10171296	chr2:30481309	LBH	chr2:30454397-30482899:+	-0.24	-3.8	0.000166	Systemic lupus erythematosus	
LUSC	cis	1	rs1017302	chr12:9367402	PZP	chr12:9301437-9360966:-	0.25	4.17	3.62E-5	Non-alcoholic fatty liver disease histology (AST)	
LUSC	cis	1	rs10178409	chr2:73855507	ALMS1P	chr2:73872046-73912692:+	0.41	7.44	4.74E-13	Urinary metabolites	
LUSC	cis	1	rs10178409	chr2:73855507	NAT8	chr2:73867850-73869537:-	0.26	4.38	1.49E-5	Urinary metabolites	
LUSC	cis	1	rs10178982	chr2:202227640	ALS2CR12	chr2:202153148-202222101:-	-0.22	-4.03	6.53E-5	Basal cell carcinoma	
LUSC	cis	1	rs10179134	chr2:73637519	ALMS1P	chr2:73872046-73912692:+	0.43	7.97	1.22E-14	Metabolite levels	
LUSC	cis	1	rs10179134	chr2:73637519	NAT8	chr2:73867850-73869537:-	0.28	4.73	3.03E-6	Metabolite levels	
LUSC	cis	1	rs1018184	chr6:86648475	SNHG5	chr6:86386726-86388451:-	0.67	12.61	1.24E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs10183486	chr2:171990971	GAD1	chr2:171673200-171717657:+	0.23	4.24	2.67E-5	Menopause (age at onset)	
LUSC	cis	1	rs10184268	chr2:73627044	ALMS1P	chr2:73872046-73912692:+	0.43	7.85	2.85E-14	Metabolite levels	
LUSC	cis	1	rs10184268	chr2:73627044	NAT8	chr2:73867850-73869537:-	0.24	4.12	4.4E-5	Metabolite levels	
LUSC	cis	1	rs10187192	chr2:73713500	ALMS1P	chr2:73872046-73912692:+	0.41	7.45	4.49E-13	Metabolite levels	
LUSC	cis	1	rs10187192	chr2:73713500	NAT8	chr2:73867850-73869537:-	0.27	4.59	5.76E-6	Metabolite levels	
LUSC	cis	1	rs10190219	chr2:73658331	ALMS1P	chr2:73872046-73912692:+	0.41	7.57	2.02E-13	Metabolite levels	
LUSC	cis	1	rs10190219	chr2:73658331	NAT8	chr2:73867850-73869537:-	0.26	4.56	6.67E-6	Metabolite levels	
LUSC	cis	1	rs10193373	chr2:281886	SH3YL1	chr2:218138-264810:-	-0.5	-8.74	4.16E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs10193373	chr2:281886	SNTG2	chr2:946555-1371382:+	0.2	3.83	0.000147	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs10206231	chr2:202229225	ALS2CR12	chr2:202153148-202222101:-	-0.22	-4.15	3.97E-5	Basal cell carcinoma	
LUSC	cis	1	rs10206231	chr2:202229225	TRAK2	chr2:202241931-202316319:-	-0.18	-3.74	0.000204	Basal cell carcinoma	
LUSC	cis	1	rs10207220	chr2:73785046	ALMS1P	chr2:73872046-73912692:+	0.41	7.67	9.53E-14	Metabolite levels	
LUSC	cis	1	rs10207220	chr2:73785046	NAT8	chr2:73867850-73869537:-	0.27	4.78	2.34E-6	Metabolite levels	
LUSC	cis	1	rs10215948	chr7:65747786	NCRNA00174	chr7:65841032-65865395:-	0.29	6.28	7.46E-10	Aortic root size	
LUSC	cis	1	rs10216533	chr8:143763690	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs10216533	chr8:143763690	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs10216533	chr8:143763690	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs10218458	chr1:107571327	PRMT6	chr1:107599267-107601907:+	0.23	3.8	0.000163	AIDS	
LUSC	cis	1	rs10218795	chr1:145416056	NOTCH2NL	chr1:145209111-145295525:+	0.74	6.18	1.41E-9	Coronary heart disease	
LUSC	cis	1	rs10228845	chr7:21583617	DNAH11	chr7:21582833-21941455:+	-0.54	-10.24	2.26E-22	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs10229224	chr7:21583921	DNAH11	chr7:21582833-21941455:+	-0.54	-10.13	5.69E-22	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs10231883	chr7:97616154	MGC72080	chr7:97503667-97601638:-	0.37	4.05	6.09E-5	Sudden cardiac arrest	
LUSC	cis	1	rs10234018	chr7:66146284	NCRNA00174	chr7:65841032-65865395:-	0.25	5.4	1.06E-7	Aortic root size	
LUSC	cis	1	rs10234309	chr7:135311167	PL-5283	chr7:135347221-135378160:+	0.49	8.22	1.91E-15	Paget's disease	
LUSC	cis	1	rs10234309	chr7:135311167	SLC13A4	chr7:135365993-135412933:-	-0.41	-5.71	1.94E-8	Paget's disease	
LUSC	cis	1	rs10244498	chr7:66116056	NCRNA00174	chr7:65841032-65865395:-	-0.3	-6.32	5.99E-10	Aortic root size	
LUSC	cis	1	rs10251155	chr7:97618536	MGC72080	chr7:97503667-97601638:-	0.36	3.9	0.000111	Sudden cardiac arrest	
LUSC	cis	1	rs10252765	chr7:66228732	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.33	1.52E-7	Aortic root size	
LUSC	cis	1	rs10256972	chr7:1039003	ZFAND2A	chr7:1192544-1199855:-	0.32	6.57	1.3E-10	Longevity;Endometriosis	
LUSC	cis	1	rs10257427	chr7:65743208	NCRNA00174	chr7:65841032-65865395:-	0.29	6.28	7.46E-10	Aortic root size	
LUSC	cis	1	rs10274773	chr7:66133578	NCRNA00174	chr7:65841032-65865395:-	0.25	5.39	1.09E-7	Aortic root size	
LUSC	cis	1	rs1028449	chr14:35512995	PPP2R3C	chr14:35554679-35591679:-	0.32	5.76	1.48E-8	Atopic dermatitis	
LUSC	cis	1	rs1029406	chr11:2309580	C11orf21	chr11:2317507-2323143:-	-0.37	-7.36	8.13E-13	Obesity-related traits	
LUSC	cis	1	rs1029407	chr11:2309582	C11orf21	chr11:2317507-2323143:-	-0.37	-7.36	8.13E-13	Obesity-related traits	
LUSC	cis	1	rs1030831	chr4:130025037	C4orf33	chr4:130014829-130033842:+	-0.37	-7.53	2.52E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1034219	chr1:93022678	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs1035142	chr2:202153078	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.86	0.000127	Melanoma;Esophageal squamous cell carcinoma	
LUSC	cis	1	rs1037147	chr4:130025873	C4orf33	chr4:130014829-130033842:+	-0.37	-7.63	1.27E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs10403249	chr19:18604942	LRRC25	chr19:18501955-18508421:-	-0.11	-3.72	0.000224	Breast cancer	
LUSC	cis	1	rs10403249	chr19:18604942	SSBP4	chr19:18530221-18545371:+	-0.19	-3.77	0.000187	Breast cancer	
LUSC	cis	1	rs10403540	chr19:39204846	LGALS7B	chr19:39279850-39282393:+	0.2	4.21	3.06E-5	Heart rate	
LUSC	cis	1	rs10405636	chr19:18538742	SSBP4	chr19:18530221-18545371:+	-0.19	-3.82	0.000149	Breast cancer	
LUSC	cis	1	rs10406778	chr19:39170473	LGALS7B	chr19:39279850-39282393:+	0.2	4.29	2.18E-5	Heart rate	
LUSC	cis	1	rs1040727	chr20:3264292	ITPA	chr20:3190056-3204504:+	-0.25	-3.73	0.000217	IFN-related cytopenia	
LUSC	cis	1	rs10409483	chr19:18590223	LRRC25	chr19:18501955-18508421:-	-0.11	-3.77	0.000183	Breast cancer	
LUSC	cis	1	rs10409483	chr19:18590223	SSBP4	chr19:18530221-18545371:+	-0.19	-3.79	0.000171	Breast cancer	
LUSC	cis	1	rs10409505	chr19:18590251	LRRC25	chr19:18501955-18508421:-	-0.11	-3.77	0.000183	Breast cancer	
LUSC	cis	1	rs10409505	chr19:18590251	SSBP4	chr19:18530221-18545371:+	-0.19	-3.79	0.000171	Breast cancer	
LUSC	cis	1	rs10411009	chr19:18606266	SSBP4	chr19:18530221-18545371:+	-0.19	-3.73	0.000211	Breast cancer	
LUSC	cis	1	rs10412219	chr19:33413246	SLC7A9	chr19:33321421-33360683:-	-0.31	-6.14	1.79E-9	Blood metabolite levels;Urinary metabolites (H-NMR features);Urinary metabolites	
LUSC	cis	1	rs1041530	chr10:130938725	MGMT	chr10:131265454-131565783:+	-0.2	-3.79	0.000169	Gut microbiota (functional units)	
LUSC	cis	1	rs1041748	chr22:24700854	POM121L9P	chr22:24647589-24661490:+	-0.28	-6.64	8.57E-11	Gut microbiome composition (summer)	
LUSC	cis	1	rs10418728	chr19:39247302	LGALS7B	chr19:39279850-39282393:+	0.2	4.17	3.62E-5	Heart rate	
LUSC	cis	1	rs10419418	chr19:9994286	ZNF266	chr19:9523272-9546234:-	0.2	3.78	0.00018	Menarche (age at onset)	
LUSC	cis	1	rs10421560	chr19:39186613	LGALS7B	chr19:39279850-39282393:+	0.21	4.42	1.24E-5	Heart rate	
LUSC	cis	1	rs10422101	chr19:52320115	HAS1	chr19:52216365-52227221:-	0.23	4.07	5.59E-5	HDL cholesterol	
LUSC	cis	1	rs10425738	chr19:41417727	PLD3	chr19:40854332-40884389:+	0.23	3.93	9.7E-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio)	
LUSC	cis	1	rs10425982	chr19:18586519	LRRC25	chr19:18501955-18508421:-	-0.11	-3.73	0.000218	Breast cancer	
LUSC	cis	1	rs10425982	chr19:18586519	SSBP4	chr19:18530221-18545371:+	-0.19	-3.79	0.000171	Breast cancer	
LUSC	cis	1	rs10426297	chr19:37798373	ZNF781	chr19:38158650-38183216:-	0.26	4.17	3.58E-5	Coronary artery calcification	
LUSC	cis	1	rs1042658	chr17:38173902	GSDMA	chr17:38119226-38134019:+	-0.43	-8.81	2.38E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs1043096	chr1:111682307	DRAM2	chr1:111659955-111682838:-	0.25	3.9	0.00011	Liver enzyme levels (gamma-glutamyl transferase)	
LUSC	cis	1	rs10431505	chr12:58178589	FAM119B	chr12:58166383-58176323:+	0.53	9.43	1.79E-19	Multiple sclerosis	
LUSC	cis	1	rs10431505	chr12:58178589	TSFM	chr12:58176536-58191367:+	-0.38	-8.21	2.05E-15	Multiple sclerosis	
LUSC	cis	1	rs10431505	chr12:58178589	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.99	7.63E-5	Multiple sclerosis	
LUSC	cis	1	rs1043441	chr22:39130964	CBY1	chr22:39052658-39069853:+	0.23	4.19	3.28E-5	Resting heart rate	
LUSC	cis	1	rs1043550	chr7:128409225	OPN1SW	chr7:128412545-128415844:-	0.27	4.66	4.19E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs1043674	chr14:75549370	MLH3	chr14:75480467-75518235:-	0.27	5.75	1.57E-8	Height	
LUSC	cis	1	rs10439607	chr20:30258541	COX4I2	chr20:30225691-30232800:+	0.2	4.13	4.35E-5	Subcortical brain region volumes	
LUSC	cis	1	rs10439608	chr20:30258814	COX4I2	chr20:30225691-30232800:+	0.2	4.2	3.22E-5	Subcortical brain region volumes	
LUSC	cis	1	rs10443172	chr1:85485768	MCOLN2	chr1:85391267-85462796:-	0.22	4.21	3.05E-5	Serum sulfate level	
LUSC	cis	1	rs1044717	chr1:45976587	CCDC163P	chr1:45960581-45965646:-	-0.76	-18.16	2.46E-56	Homocysteine levels	
LUSC	cis	1	rs1044717	chr1:45976587	MMACHC	chr1:45965856-45976737:+	-0.16	-4.05	6.07E-5	Homocysteine levels	
LUSC	cis	1	rs10455158	chr6:86672825	SNHG5	chr6:86386726-86388451:-	-0.66	-12.07	1.97E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs1045531	chr8:143763547	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045531	chr8:143763547	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045531	chr8:143763547	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs10455449	chr6:86592226	SNHG5	chr6:86386726-86388451:-	-0.67	-12.18	6.7E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs10455455	chr6:86670214	SNHG5	chr6:86386726-86388451:-	-0.68	-12.38	1.03E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs10455456	chr6:86670322	SNHG5	chr6:86386726-86388451:-	-0.66	-12.15	9.11E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs1045547	chr8:143763757	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045547	chr8:143763757	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045547	chr8:143763757	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045574	chr8:143763958	LY6K	chr8:143781529-143785582:+	0.24	4.86	1.61E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045574	chr8:143763958	LYNX1	chr8:143845758-143859640:-	-0.19	-3.7	0.000241	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045574	chr8:143763958	PSCA	chr8:143761875-143764142:+	0.45	9.68	2.4E-20	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045605	chr8:143764101	LY6K	chr8:143781529-143785582:+	0.26	5.11	4.61E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs1045605	chr8:143764101	PSCA	chr8:143761875-143764142:+	0.46	10.03	1.31E-21	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs10456622	chr6:49396453	CENPQ	chr6:49431096-49460820:+	-0.34	-7.68	9.17E-14	Folate pathway vitamin levels	
LUSC	cis	1	rs10456622	chr6:49396453	MUT	chr6:49398994-49431031:-	0.34	6.35	5.18E-10	Folate pathway vitamin levels	
LUSC	cis	1	rs1045722	chr4:90645671	MMRN1	chr4:90816003-90875778:+	0.25	3.81	0.000157	Parkinson's disease	
LUSC	cis	1	rs1046073	chr20:25281333	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs10461617	chr5:56104308	C5orf35	chr5:56205103-56213010:+	0.87	14.4	2.94E-39	Type 2 diabetes	
LUSC	cis	1	rs10465756	chr1:93029698	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs10470686	chr3:48449956	ATRIP	chr3:48488141-48507708:+	0.19	3.91	0.000106	Longevity	
LUSC	cis	1	rs10470686	chr3:48449956	TREX1	chr3:48501186-48509043:+	-0.42	-9.15	1.69E-18	Longevity	
LUSC	cis	1	rs1047171	chr20:25428786	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.71	0.000232	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs1047418	chr14:75605792	MLH3	chr14:75480467-75518235:-	0.28	6.08	2.49E-9	Height	
LUSC	cis	1	rs10484032	chr14:93738663	COX8C	chr14:93813537-93814700:+	-0.25	-3.87	0.000122	Body mass index	
LUSC	cis	1	rs10484286	chr6:118956447	C6orf204	chr6:118786239-119031238:-	-0.24	-3.76	0.000191	Renal cell carcinoma	
LUSC	cis	1	rs10485508	chr20:33605098	PROCR	chr20:33758727-33765164:+	-0.33	-4.24	2.65E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs10489073	chr4:10272788	SLC2A9	chr4:9827850-10041872:-	0.23	3.93	9.63E-5	Schizophrenia (age at onset)	
LUSC	cis	1	rs10492096	chr12:6580582	TAPBPL	chr12:6561177-6575601:+	-0.3	-4.74	2.77E-6	Hip geometry	
LUSC	cis	1	rs10494057	chr1:107576399	PRMT6	chr1:107599267-107601907:+	0.24	3.89	0.000117	AIDS	
LUSC	cis	1	rs10494874	chr1:205754688	PM20D1	chr1:205797154-205819245:-	-0.37	-6.79	3.41E-11	Prostate-specific antigen levels	
LUSC	cis	1	rs10498958	chr6:86649705	SNHG5	chr6:86386726-86388451:-	0.69	12.72	4.27E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs10500303	chr19:50512033	SIGLEC16	chr19:50472912-50479075:+	0.79	7.65	1.13E-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs10500636	chr11:5386755	OR51B5	chr11:5363816-5526882:-	0.2	3.73	0.000217	Fetal hemoglobin levels	
LUSC	cis	1	rs10505430	chr8:124191933	FAM83A	chr8:124191287-124222317:+	0.24	3.93	9.94E-5	Urinary uromodulin levels	
LUSC	cis	1	rs10509744	chr10:102271579	SEC31B	chr10:102246403-102289636:-	-0.28	-8.25	1.56E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10510026	chr10:118862420	KIAA1598	chr10:118644308-118886097:-	0.24	3.81	0.000157	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs10516844	chr4:90639847	MMRN1	chr4:90816003-90875778:+	0.25	4.01	7.04E-5	Parkinson's disease	
LUSC	cis	1	rs10517579	chr4:154666321	TLR2	chr4:154605441-154627240:+	-0.2	-4.05	6.05E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs10518128	chr4:75713368	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs1051875	chr22:23466031	RTDR1	chr22:23401594-23484241:-	-0.25	-4.77	2.41E-6	Bone mineral density	
LUSC	cis	1	rs1054399	chr10:102312565	SEC31B	chr10:102246403-102289636:-	-0.27	-7.87	2.43E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs1056610	chr22:39080078	CBY1	chr22:39052658-39069853:+	-0.21	-4	7.48E-5	Resting heart rate	
LUSC	cis	1	rs1056964	chr22:51017476	CPT1B	chr22:51007291-51017096:-	-0.38	-5.05	6.36E-7	Narcolepsy	
LUSC	cis	1	rs1060041	chr1:167973976	MGC4473	chr1:168756179-168762120:+	0.22	4.12	4.47E-5	Schizophrenia	
LUSC	cis	1	rs1060330	chr3:52288945	ITIH4	chr3:52847007-52866554:-	0.14	3.89	0.000113	Electroencephalogram traits	
LUSC	cis	1	rs1062794	chr20:30381758	COX4I2	chr20:30225691-30232800:+	0.2	4.15	3.94E-5	Subcortical brain region volumes	
LUSC	cis	1	rs1065201	chr22:39069510	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs10732856	chr11:116907113	PCSK7	chr11:117075789-117102811:-	-0.32	-4.53	7.37E-6	Protein quantitative trait loci	
LUSC	cis	1	rs10734765	chr12:9369385	PZP	chr12:9301437-9360966:-	0.25	4.17	3.62E-5	Non-alcoholic fatty liver disease histology (AST)	
LUSC	cis	1	rs10736426	chr1:45984353	CCDC163P	chr1:45960581-45965646:-	0.71	16.82	3.95E-50	Homocysteine levels	
LUSC	cis	1	rs10739388	chr9:115977175	CDC26	chr9:116029290-116037869:-	-0.37	-7.95	1.39E-14	Hematology traits	
LUSC	cis	1	rs1074286	chr8:130737601	GSDMC	chr8:130760443-130799134:-	0.26	5.25	2.34E-7	Infant length;Height	
LUSC	cis	1	rs10747783	chr12:58176614	FAM119B	chr12:58166383-58176323:+	0.53	9.2	1.14E-18	Multiple sclerosis	
LUSC	cis	1	rs10747783	chr12:58176614	TSFM	chr12:58176536-58191367:+	-0.4	-8.63	8.96E-17	Multiple sclerosis	
LUSC	cis	1	rs10747783	chr12:58176614	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.46	1.04E-5	Multiple sclerosis	
LUSC	cis	1	rs10749860	chr1:46328210	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.15	3.31E-12	Body mass index	
LUSC	cis	1	rs10750100	chr11:116917244	PCSK7	chr11:117075789-117102811:-	-0.36	-5.1	4.84E-7	Protein quantitative trait loci	
LUSC	cis	1	rs10750101	chr11:116979689	PCSK7	chr11:117075789-117102811:-	-0.36	-4.93	1.14E-6	Protein quantitative trait loci	
LUSC	cis	1	rs10758161	chr9:32755028	APTX	chr9:32972609-33025110:-	-0.27	-3.73	0.000215	Immune response to anthrax vaccine	
LUSC	cis	1	rs10758161	chr9:32755028	SMU1	chr9:33041850-33076714:-	-0.36	-4.45	1.05E-5	Immune response to anthrax vaccine	
LUSC	cis	1	rs10759636	chr9:116018777	CDC26	chr9:116029290-116037869:-	-0.35	-7.37	7.76E-13	Hematology traits	
LUSC	cis	1	rs10759927	chr9:100542176	CTSL2	chr9:99794940-99822167:-	-0.2	-3.72	0.000221	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs10760118	chr9:123641616	LOC253039	chr9:123605320-123616644:+	-0.34	-6.47	2.37E-10	Rheumatoid arthritis	
LUSC	cis	1	rs10760121	chr9:123647915	LOC253039	chr9:123605320-123616644:+	-0.33	-6.2	1.26E-9	Rheumatoid arthritis	
LUSC	cis	1	rs1076392	chr17:59493008	C17orf82	chr17:59489112-59490641:+	-0.15	-3.75	0.000196	Sitting height ratio	
LUSC	cis	1	rs10769371	chr11:48531184	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.77	0.000186	HDL cholesterol	
LUSC	cis	1	rs10771431	chr12:9380859	GABARAPL1	chr12:10365489-10375722:+	-0.18	-3.79	0.000171	Breast size	
LUSC	cis	1	rs1077889	chr20:25267893	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.000208	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs10782922	chr1:92974595	EVI5	chr1:92974255-93257961:-	-0.32	-4.6	5.42E-6	Cholesterol, total	
LUSC	cis	1	rs10783847	chr12:58196447	FAM119B	chr12:58166383-58176323:+	0.52	9.22	1.0E-18	Multiple sclerosis	
LUSC	cis	1	rs10783847	chr12:58196447	TSFM	chr12:58176536-58191367:+	-0.39	-8.53	2.03E-16	Multiple sclerosis	
LUSC	cis	1	rs10783847	chr12:58196447	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-4.03	6.58E-5	Multiple sclerosis	
LUSC	cis	1	rs10783848	chr12:58196528	FAM119B	chr12:58166383-58176323:+	0.52	9.22	1.0E-18	Multiple sclerosis	
LUSC	cis	1	rs10783848	chr12:58196528	TSFM	chr12:58176536-58191367:+	-0.39	-8.53	2.03E-16	Multiple sclerosis	
LUSC	cis	1	rs10783848	chr12:58196528	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-4.03	6.58E-5	Multiple sclerosis	
LUSC	cis	1	rs10785814	chr1:107610540	PRMT6	chr1:107599267-107601907:+	0.27	4.11	4.76E-5	AIDS	
LUSC	cis	1	rs10786596	chr10:102282126	SEC31B	chr10:102246403-102289636:-	-0.28	-8.53	1.98E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10786597	chr10:102291287	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10786598	chr10:102291579	SEC31B	chr10:102246403-102289636:-	-0.28	-8.28	1.27E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10787751	chr10:118826441	KIAA1598	chr10:118644308-118886097:-	-0.25	-4.06	5.76E-5	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs10788795	chr1:150758047	HORMAD1	chr1:150670542-150693352:-	0.44	4.88	1.47E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs10789475	chr1:46304177	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.23	1.91E-12	Body mass index	
LUSC	cis	1	rs10789481	chr1:46383583	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.11	4.39E-12	Body mass index	
LUSC	cis	1	rs10789487	chr1:46420221	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.17	2.97E-12	Body mass index	
LUSC	cis	1	rs10790172	chr11:116927740	PCSK7	chr11:117075789-117102811:-	-0.37	-5.08	5.41E-7	Protein quantitative trait loci	
LUSC	cis	1	rs10804111	chr2:202145612	ALS2CR12	chr2:202153148-202222101:-	-0.2	-3.87	0.000123	Melanoma;Esophageal squamous cell carcinoma	
LUSC	cis	1	rs10804632	chr3:134294501	ANAPC13	chr3:134196547-134204865:-	0.41	8.07	5.64E-15	Height	
LUSC	cis	1	rs1080698	chr10:102295114	SEC31B	chr10:102246403-102289636:-	-0.28	-8.41	4.69E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10818480	chr9:123643170	LOC253039	chr9:123605320-123616644:+	-0.33	-6.27	8.22E-10	Rheumatoid arthritis	
LUSC	cis	1	rs10819469	chr9:131882067	CRAT	chr9:131857075-131873070:-	0.25	5.1	4.93E-7	Blood metabolite ratios	
LUSC	cis	1	rs10819471	chr9:131896325	CRAT	chr9:131857075-131873070:-	0.25	5.02	7.35E-7	Blood metabolite ratios	
LUSC	cis	1	rs10838738	chr11:47663049	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.15	3.99E-5	Subjective well-being	
LUSC	cis	1	rs10838747	chr11:47716324	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.21	3.09E-5	Subjective well-being	
LUSC	cis	1	rs10838748	chr11:47716381	C1QTNF4	chr11:47611216-47615961:-	-0.23	-4.27	2.38E-5	Subjective well-being	
LUSC	cis	1	rs10838757	chr11:47763016	C1QTNF4	chr11:47611216-47615961:-	-0.21	-3.91	0.000107	Subjective well-being	
LUSC	cis	1	rs10838912	chr11:48496477	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.7	0.000241	HDL cholesterol	
LUSC	cis	1	rs10838917	chr11:48503127	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.82	0.000149	HDL cholesterol	
LUSC	cis	1	rs10838931	chr11:48540973	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.77	0.000184	HDL cholesterol	
LUSC	cis	1	rs10838943	chr11:48557442	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.9	0.000111	HDL cholesterol	
LUSC	cis	1	rs10838944	chr11:48559571	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.9	0.000111	HDL cholesterol	
LUSC	cis	1	rs10838966	chr11:48589723	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.72	0.00022	HDL cholesterol	
LUSC	cis	1	rs10849462	chr12:6575992	TAPBPL	chr12:6561177-6575601:+	-0.29	-4.6	5.39E-6	Hip geometry	
LUSC	cis	1	rs10851599	chr15:56154064	NEDD4	chr15:56119131-56285835:-	0.24	4.47	9.89E-6	Keloid	
LUSC	cis	1	rs1085243	chr1:46544768	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.52	2.7E-13	Body mass index	
LUSC	cis	1	rs1085244	chr1:46563680	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.27	1.53E-12	Body mass index	
LUSC	cis	1	rs10857712	chr10:135225666	MTG1	chr10:135207621-135234173:+	0.25	4.36	1.63E-5	Systemic lupus erythematosus	
LUSC	cis	1	rs10859106	chr12:91476568	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs10864655	chr1:231172810	CAPN9	chr1:230883130-230937749:+	-0.2	-3.96	8.62E-5	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs10865940	chr3:46350367	CCR2	chr3:46395235-46402412:+	-0.1	-3.78	0.000175	Celiac disease	
LUSC	cis	1	rs10865956	chr3:49581559	AMT	chr3:49454212-49460012:-	0.21	4.77	2.46E-6	Menarche (age at onset)	
LUSC	cis	1	rs10871290	chr16:74472696	CLEC18B	chr16:74442531-74455649:-	-0.22	-3.92	0.000103	Breast cancer	
LUSC	cis	1	rs10872032	chr6:109676776	SMPD2	chr6:109761931-109765121:+	0.23	4.16	3.72E-5	Height	
LUSC	cis	1	rs10873275	chr14:75531460	MLH3	chr14:75480467-75518235:-	0.27	5.76	1.52E-8	Height	
LUSC	cis	1	rs10874122	chr1:75235866	CRYZ	chr1:75171175-75199092:-	-0.32	-6.1	2.17E-9	Resistin levels	
LUSC	cis	1	rs10874656	chr1:92947024	EVI5	chr1:92974255-93257961:-	-0.3	-4.24	2.68E-5	Cholesterol, total	
LUSC	cis	1	rs10877012	chr12:58162085	FAM119B	chr12:58166383-58176323:+	0.53	9.28	6.2E-19	Multiple sclerosis	
LUSC	cis	1	rs10877012	chr12:58162085	TSFM	chr12:58176536-58191367:+	-0.39	-8.5	2.39E-16	Multiple sclerosis	
LUSC	cis	1	rs10877012	chr12:58162085	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.35	1.68E-5	Multiple sclerosis	
LUSC	cis	1	rs10877013	chr12:58165085	FAM119B	chr12:58166383-58176323:+	0.52	9.28	6.21E-19	Multiple sclerosis	
LUSC	cis	1	rs10877013	chr12:58165085	TSFM	chr12:58176536-58191367:+	-0.37	-8.2	2.31E-15	Multiple sclerosis	
LUSC	cis	1	rs10877013	chr12:58165085	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-3.99	7.51E-5	Multiple sclerosis	
LUSC	cis	1	rs10877014	chr12:58167661	FAM119B	chr12:58166383-58176323:+	0.52	9.15	1.74E-18	Multiple sclerosis	
LUSC	cis	1	rs10877014	chr12:58167661	TSFM	chr12:58176536-58191367:+	-0.38	-8.29	1.21E-15	Multiple sclerosis	
LUSC	cis	1	rs10877014	chr12:58167661	XRCC6BP1	chr12:58335445-58351051:+	-0.19	-3.98	8.09E-5	Multiple sclerosis	
LUSC	cis	1	rs10877015	chr12:58167788	FAM119B	chr12:58166383-58176323:+	0.52	9.07	3.28E-18	Multiple sclerosis	
LUSC	cis	1	rs10877015	chr12:58167788	TSFM	chr12:58176536-58191367:+	-0.39	-8.52	2.05E-16	Multiple sclerosis	
LUSC	cis	1	rs10877015	chr12:58167788	XRCC6BP1	chr12:58335445-58351051:+	-0.21	-4.16	3.79E-5	Multiple sclerosis	
LUSC	cis	1	rs10877019	chr12:58172929	FAM119B	chr12:58166383-58176323:+	-0.51	-9.1	2.49E-18	Multiple sclerosis	
LUSC	cis	1	rs10877019	chr12:58172929	TSFM	chr12:58176536-58191367:+	0.39	8.77	3.15E-17	Multiple sclerosis	
LUSC	cis	1	rs10877019	chr12:58172929	XRCC6BP1	chr12:58335445-58351051:+	0.19	3.99	7.59E-5	Multiple sclerosis	
LUSC	cis	1	rs10882644	chr10:97388579	ENTPD1	chr10:97471536-97637022:+	0.17	5.17	3.51E-7	Blood metabolite levels	
LUSC	cis	1	rs10883492	chr10:102206089	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883493	chr10:102208188	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883496	chr10:102221931	SEC31B	chr10:102246403-102289636:-	-0.27	-7.99	1.03E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883497	chr10:102228519	SEC31B	chr10:102246403-102289636:-	-0.27	-8.15	3.32E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883499	chr10:102232188	SEC31B	chr10:102246403-102289636:-	-0.26	-7.97	1.22E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883500	chr10:102238324	SEC31B	chr10:102246403-102289636:-	-0.27	-8.11	4.35E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883501	chr10:102238326	SEC31B	chr10:102246403-102289636:-	-0.27	-8.11	4.35E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883502	chr10:102238343	SEC31B	chr10:102246403-102289636:-	-0.27	-8.11	4.35E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883503	chr10:102275504	SEC31B	chr10:102246403-102289636:-	-0.28	-8.34	8.1E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883504	chr10:102280687	SEC31B	chr10:102246403-102289636:-	-0.28	-8.24	1.73E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883505	chr10:102280772	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883506	chr10:102289743	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883507	chr10:102291275	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883508	chr10:102294413	SEC31B	chr10:102246403-102289636:-	-0.28	-8.3	1.11E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883509	chr10:102296461	SEC31B	chr10:102246403-102289636:-	-0.28	-8.41	4.99E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883510	chr10:102297018	SEC31B	chr10:102246403-102289636:-	-0.29	-8.32	9.14E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883511	chr10:102299407	SEC31B	chr10:102246403-102289636:-	-0.28	-8.38	6.06E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883512	chr10:102308516	SEC31B	chr10:102246403-102289636:-	-0.27	-7.92	1.71E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10883513	chr10:102316964	SEC31B	chr10:102246403-102289636:-	-0.25	-7.01	8.17E-12	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs10888396	chr1:150777514	HORMAD1	chr1:150670542-150693352:-	0.46	5.06	6.07E-7	Congenital left-sided heart lesions	
LUSC	cis	1	rs10888576	chr1:150200792	HORMAD1	chr1:150670542-150693352:-	0.32	4.99	8.62E-7	Morning vs. evening chronotype	
LUSC	cis	1	rs1088984	chr11:2377581	C11orf21	chr11:2317507-2323143:-	-0.2	-4.73	3.01E-6	Bacteremia	
LUSC	cis	1	rs1088985	chr11:2377852	C11orf21	chr11:2317507-2323143:-	-0.2	-4.62	4.89E-6	Bacteremia	
LUSC	cis	1	rs1088986	chr11:2377862	C11orf21	chr11:2317507-2323143:-	-0.2	-4.7	3.4E-6	Bacteremia	
LUSC	cis	1	rs1088987	chr11:2379196	C11orf21	chr11:2317507-2323143:-	-0.2	-4.7	3.41E-6	Bacteremia	
LUSC	cis	1	rs1088988	chr11:2380470	C11orf21	chr11:2317507-2323143:-	-0.2	-4.6	5.54E-6	Bacteremia	
LUSC	cis	1	rs1088990	chr11:2381771	C11orf21	chr11:2317507-2323143:-	-0.2	-4.72	3.11E-6	Bacteremia	
LUSC	cis	1	rs1088993	chr11:2382631	C11orf21	chr11:2317507-2323143:-	-0.2	-4.69	3.6E-6	Bacteremia	
LUSC	cis	1	rs10890352	chr1:46283628	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.12	4.06E-12	Body mass index	
LUSC	cis	1	rs10890354	chr1:46305347	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.1	4.66E-12	Body mass index	
LUSC	cis	1	rs10890363	chr1:46356148	CCDC163P	chr1:45960581-45965646:-	0.34	7.04	6.87E-12	Body mass index	
LUSC	cis	1	rs10890383	chr1:46588503	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.12	4.07E-12	Body mass index	
LUSC	cis	1	rs10892761	chr11:121497884	LOC399959	chr11:121959811-122238467:-	0.14	3.77	0.000181	Spontaneous preterm birth (preterm birth)	
LUSC	cis	1	rs10896043	chr11:65543827	CTSW	chr11:65647284-65651212:+	0.25	5.54	5.14E-8	Systemic lupus erythematosus	
LUSC	cis	1	rs10896043	chr11:65543827	SNX32	chr11:65601410-65621170:+	-0.44	-6.87	2.04E-11	Systemic lupus erythematosus	
LUSC	cis	1	rs10901513	chr10:127699936	UROS	chr10:127477148-127511837:-	-0.26	-5.42	9.67E-8	Visceral fat	
LUSC	cis	1	rs10901514	chr10:127700066	UROS	chr10:127477148-127511837:-	-0.26	-5.42	9.67E-8	Visceral fat	
LUSC	cis	1	rs10901520	chr10:127718837	UROS	chr10:127477148-127511837:-	-0.24	-4.98	8.93E-7	Visceral fat	
LUSC	cis	1	rs10908495	chr1:156263940	BGLAP	chr1:156182784-156213112:+	0.21	3.7	0.000239	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LUSC	cis	1	rs10908502	chr1:156300082	BGLAP	chr1:156182784-156213112:+	0.21	3.74	0.000208	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LUSC	cis	1	rs10911326	chr1:172192145	VAMP4	chr1:171669298-171711214:-	0.19	3.73	0.000215	Height	
LUSC	cis	1	rs10911504	chr1:172260521	VAMP4	chr1:171669298-171711214:-	0.19	3.78	0.000177	Height	
LUSC	cis	1	rs10935120	chr3:134233092	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.5	2.55E-16	Height	
LUSC	cis	1	rs10935186	chr3:136346206	PCCB	chr3:135969167-136056737:+	0.2	4.17	3.62E-5	Schizophrenia	
LUSC	cis	1	rs10944161	chr6:86630376	SNHG5	chr6:86386726-86388451:-	-0.65	-12.15	8.93E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs10944163	chr6:86658693	SNHG5	chr6:86386726-86388451:-	-0.67	-12.02	3.05E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs10944169	chr6:86683036	SNHG5	chr6:86386726-86388451:-	-0.67	-12.48	4.09E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs10944170	chr6:86685469	SNHG5	chr6:86386726-86388451:-	-0.66	-12.21	5.38E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs10946198	chr6:167404432	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs10946199	chr6:167404492	RNASET2	chr6:167343008-167412795:-	-0.24	-4.74	2.86E-6	Crohn's disease	
LUSC	cis	1	rs10946700	chr6:24442158	ALDH5A1	chr6:24495197-24537434:+	-0.24	-3.95	9.13E-5	Liver enzyme levels	
LUSC	cis	1	rs10955934	chr8:120676929	DSCC1	chr8:120846182-120868170:-	0.25	4.21	3.08E-5	Height	
LUSC	cis	1	rs10957961	chr8:81031822	TPD52	chr8:80831096-81083836:-	-0.2	-3.9	0.00011	Metabolite levels (Pyroglutamine)	
LUSC	cis	1	rs10966	chr20:25282944	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.84	0.000138	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs10983700	chr9:100537455	CTSL2	chr9:99794940-99822167:-	-0.2	-3.86	0.000131	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs10983701	chr9:100537577	CTSL2	chr9:99794940-99822167:-	-0.2	-3.84	0.000139	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs10988125	chr9:131572903	ENDOG	chr9:131580779-131584954:+	0.23	5.22	2.63E-7	Blood metabolite levels	
LUSC	cis	1	rs11039255	chr11:47495746	C1QTNF4	chr11:47611216-47615961:-	-0.24	-4.51	8.04E-6	Subjective well-being	
LUSC	cis	1	rs11039390	chr11:47796295	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.02	6.78E-5	Subjective well-being	
LUSC	cis	1	rs11039412	chr11:47841581	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.11	4.67E-5	Subjective well-being	
LUSC	cis	1	rs11039426	chr11:47863119	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.12	4.47E-5	Subjective well-being	
LUSC	cis	1	rs11039745	chr11:48463811	C1QTNF4	chr11:47611216-47615961:-	-0.2	-4.01	7.08E-5	HDL cholesterol	
LUSC	cis	1	rs11039777	chr11:48517049	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.79	0.00017	HDL cholesterol	
LUSC	cis	1	rs11039779	chr11:48517895	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.8	0.000165	HDL cholesterol	
LUSC	cis	1	rs11039817	chr11:48561480	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.86	0.000129	HDL cholesterol	
LUSC	cis	1	rs11039819	chr11:48562181	C1QTNF4	chr11:47611216-47615961:-	-0.2	-4.11	4.61E-5	HDL cholesterol	
LUSC	cis	1	rs11039820	chr11:48562252	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.91	0.000107	HDL cholesterol	
LUSC	cis	1	rs11039821	chr11:48562875	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.86	0.000129	HDL cholesterol	
LUSC	cis	1	rs11040899	chr11:6520015	FAM160A2	chr11:6232565-6255941:-	-0.19	-3.87	0.000124	DNA methylation (variation)	
LUSC	cis	1	rs11041476	chr11:1875067	LSP1	chr11:1874200-1913492:+	-0.19	-5.01	7.65E-7	Ulcerative colitis;Inflammatory bowel disease;Bladder cancer	
LUSC	cis	1	rs11045892	chr12:21392794	SLCO1B1	chr12:21284128-21392728:+	0.25	3.7	0.000236	Blood metabolite levels	
LUSC	cis	1	rs11045982	chr12:8665760	CLEC4D	chr12:8666136-8674958:+	0.3	5.92	6.01E-9	Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	
LUSC	cis	1	rs11045983	chr12:8666118	CLEC4D	chr12:8666136-8674958:+	0.3	5.96	4.99E-9	Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	
LUSC	cis	1	rs1106287	chr1:113242122	ST7L	chr1:113066142-113162405:-	0.24	4.04	6.22E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs11064210	chr12:6576721	TAPBPL	chr12:6561177-6575601:+	-0.25	-4.01	6.96E-5	Hip geometry	
LUSC	cis	1	rs11064218	chr12:6586261	TAPBPL	chr12:6561177-6575601:+	-0.3	-4.7	3.4E-6	Hip geometry	
LUSC	cis	1	rs11064881	chr12:120146925	PRKAB1	chr12:120105757-120119428:+	-0.57	-6.34	5.43E-10	Ulcerative colitis;Inflammatory bowel disease	
LUSC	cis	1	rs1106565	chr10:102211613	SEC31B	chr10:102246403-102289636:-	-0.27	-7.77	4.73E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11067231	chr12:109993603	MYO1H	chr12:109826524-109886176:+	0.23	4.21	3.08E-5	HDL cholesterol	
LUSC	cis	1	rs11079508	chr17:61750066	FTSJ3	chr17:61896795-61905031:-	0.32	6.3	6.96E-10	Body mass index	
LUSC	cis	1	rs11079509	chr17:61762148	FTSJ3	chr17:61896795-61905031:-	0.34	6.38	4.14E-10	Body mass index	
LUSC	cis	1	rs11079511	chr17:61858537	FTSJ3	chr17:61896795-61905031:-	0.34	6.51	1.87E-10	Body mass index	
LUSC	cis	1	rs11079706	chr17:65835470	LOC440461	chr17:66194801-66196436:+	0.26	3.94	9.51E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs11080114	chr17:28407287	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.79	1.26E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs1108131	chr10:12497747	CAMK1D	chr10:12391583-12871731:+	0.25	3.91	0.000108	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis	
LUSC	cis	1	rs1108131	chr10:12497747	UPF2	chr10:11962022-12085023:-	0.19	3.81	0.00016	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis	
LUSC	cis	1	rs11083475	chr19:39188112	LGALS7B	chr19:39279850-39282393:+	0.2	4.32	1.9E-5	Heart rate	
LUSC	cis	1	rs11086102	chr19:18398628	KIAA1683	chr19:18367906-18385319:-	-0.23	-4.56	6.57E-6	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs11087520	chr20:25436827	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.89	0.000114	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs11087520	chr20:25436827	FAM182A	chr20:26035250-26067552:+	-0.2	-3.91	0.000106	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs11087521	chr20:25440648	FAM182A	chr20:26035250-26067552:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs1109227	chr3:48479207	ATRIP	chr3:48488141-48507708:+	0.19	3.83	0.000143	Longevity	
LUSC	cis	1	rs1109227	chr3:48479207	TREX1	chr3:48501186-48509043:+	-0.42	-9.17	1.48E-18	Longevity	
LUSC	cis	1	rs11097912	chr4:107000462	TBCK	chr4:106967233-107237861:-	0.28	5.3	1.75E-7	Airflow obstruction	
LUSC	cis	1	rs11098451	chr4:119717673	SEC24D	chr4:119643979-119759827:-	0.39	5.31	1.73E-7	Cannabis dependence	
LUSC	cis	1	rs1110042	chr1:113236534	ST7L	chr1:113066142-113162405:-	0.25	4.13	4.37E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs11100	chr20:25281184	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs11105972	chr12:91471955	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11105973	chr12:91472347	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11105974	chr12:91476481	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11105983	chr12:91480976	KERA	chr12:91444273-91452131:-	0.24	3.94	9.5E-5	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs1112137	chr1:247215375	ZNF670	chr1:247200087-247242069:-	-0.22	-4.21	3.1E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs11122198	chr1:231171139	CAPN9	chr1:230883130-230937749:+	-0.2	-3.92	0.000103	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs11122199	chr1:231172686	CAPN9	chr1:230883130-230937749:+	-0.2	-3.92	0.000101	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs11123170	chr2:113978940	LOC654433	chr2:113993107-114024579:+	-0.61	-10.97	4.15E-25	Renal function-related traits (BUN)	
LUSC	cis	1	rs11123170	chr2:113978940	PAX8	chr2:113973575-114036498:-	-0.57	-9.97	2.21E-21	Renal function-related traits (BUN)	
LUSC	cis	1	rs11123170	chr2:113978940	RPL23AP7	chr2:114368816-114384715:-	0.22	3.71	0.000228	Renal function-related traits (BUN)	
LUSC	cis	1	rs11127188	chr2:28972852	TRMT61B	chr2:29072690-29093175:-	-0.26	-5.4	1.06E-7	Body mass index	
LUSC	cis	1	rs111279024	chr14:103483181	MARK3	chr14:103851701-103970164:+	-0.33	-3.99	7.58E-5	Large B-cell lymphoma	
LUSC	cis	1	rs111295372	chr2:86283357	LOC90784	chr2:86247339-86250991:-	-0.39	-3.94	9.19E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LUSC	cis	1	rs11130170	chr3:48449897	ATRIP	chr3:48488141-48507708:+	0.19	3.89	0.000115	Longevity	
LUSC	cis	1	rs11130170	chr3:48449897	TREX1	chr3:48501186-48509043:+	-0.42	-9.27	6.59E-19	Longevity	
LUSC	cis	1	rs11130171	chr3:48462461	ATRIP	chr3:48488141-48507708:+	0.18	3.82	0.000149	Longevity	
LUSC	cis	1	rs11130171	chr3:48462461	TREX1	chr3:48501186-48509043:+	-0.4	-8.79	2.67E-17	Longevity	
LUSC	cis	1	rs11130190	chr3:49402137	AMT	chr3:49454212-49460012:-	0.2	4.82	1.89E-6	Menarche (age at onset)	
LUSC	cis	1	rs11130190	chr3:49402137	TREX1	chr3:48501186-48509043:+	-0.2	-3.76	0.000193	Menarche (age at onset)	
LUSC	cis	1	rs111315781	chr2:201738724	CFLAR	chr2:201980816-202029001:+	-0.31	-5.23	2.54E-7	Triptolide cytotoxicity	
LUSC	cis	1	rs111315781	chr2:201738724	PPIL3	chr2:201735680-201753999:-	-0.81	-11.78	2.87E-28	Triptolide cytotoxicity	
LUSC	cis	1	rs11132254	chr4:185611592	MLF1IP	chr4:185615220-185655286:-	-0.47	-9.39	2.57E-19	Kawasaki disease	
LUSC	cis	1	rs111384103	chr18:12606482	SPIRE1	chr18:12446512-12657912:-	-0.31	-3.75	0.000202	Immune response to smallpox vaccine (IL-6)	
LUSC	cis	1	rs1114380	chr2:73804708	ALMS1P	chr2:73872046-73912692:+	0.41	7.66	1.04E-13	Metabolite levels	
LUSC	cis	1	rs1114380	chr2:73804708	NAT8	chr2:73867850-73869537:-	0.28	4.82	1.92E-6	Metabolite levels	
LUSC	cis	1	rs11156875	chr14:35619816	PPP2R3C	chr14:35554679-35591679:-	0.31	5.49	6.57E-8	Atopic dermatitis	
LUSC	cis	1	rs11157696	chr14:50105746	RPL36AL	chr14:50085407-50087349:-	-0.2	-4.3	2.1E-5	Carotid intima media thickness	
LUSC	cis	1	rs11159117	chr14:75584867	MLH3	chr14:75480467-75518235:-	0.25	5.42	9.57E-8	Height	
LUSC	cis	1	rs111597890	chr2:30492116	LBH	chr2:30454397-30482899:+	-0.24	-3.74	0.000208	Systemic lupus erythematosus	
LUSC	cis	1	rs11160110	chr14:93737108	COX8C	chr14:93813537-93814700:+	-0.24	-3.85	0.000133	Body mass index	
LUSC	cis	1	rs11164654	chr1:92968312	EVI5	chr1:92974255-93257961:-	-0.32	-4.56	6.66E-6	Cholesterol, total;LDL cholesterol	
LUSC	cis	1	rs1116636	chr4:154657151	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs11167254	chr20:33654584	PROCR	chr20:33758727-33765164:+	-0.31	-4.07	5.43E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11167260	chr20:33775200	GDF5	chr20:33897002-34042568:-	0.28	3.79	0.00017	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11167260	chr20:33775200	PROCR	chr20:33758727-33765164:+	-0.31	-4.06	5.85E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11171803	chr12:56718422	NXPH4	chr12:57610578-57620231:+	0.43	3.75	0.000202	Psoriasis vulgaris	
LUSC	cis	1	rs11171803	chr12:56718422	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.000239	Psoriasis vulgaris	
LUSC	cis	1	rs11172254	chr12:57968738	FAM119B	chr12:58166383-58176323:+	-0.24	-4.06	5.68E-5	Rheumatoid arthritis	
LUSC	cis	1	rs11172333	chr12:58170335	FAM119B	chr12:58166383-58176323:+	0.52	9.12	2.09E-18	Multiple sclerosis	
LUSC	cis	1	rs11172333	chr12:58170335	TSFM	chr12:58176536-58191367:+	-0.4	-8.74	4.01E-17	Multiple sclerosis	
LUSC	cis	1	rs11172333	chr12:58170335	XRCC6BP1	chr12:58335445-58351051:+	-0.21	-4.33	1.82E-5	Multiple sclerosis	
LUSC	cis	1	rs11172335	chr12:58175201	FAM119B	chr12:58166383-58176323:+	0.54	9.32	4.28E-19	Multiple sclerosis	
LUSC	cis	1	rs11172335	chr12:58175201	TSFM	chr12:58176536-58191367:+	-0.4	-8.6	1.16E-16	Multiple sclerosis	
LUSC	cis	1	rs11172335	chr12:58175201	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.41	1.29E-5	Multiple sclerosis	
LUSC	cis	1	rs11172342	chr12:58187758	FAM119B	chr12:58166383-58176323:+	0.54	9.35	3.36E-19	Multiple sclerosis	
LUSC	cis	1	rs11172342	chr12:58187758	TSFM	chr12:58176536-58191367:+	-0.4	-8.58	1.31E-16	Multiple sclerosis	
LUSC	cis	1	rs11172342	chr12:58187758	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.35	1.64E-5	Multiple sclerosis	
LUSC	cis	1	rs11172343	chr12:58188157	FAM119B	chr12:58166383-58176323:+	0.54	9.35	3.36E-19	Multiple sclerosis	
LUSC	cis	1	rs11172343	chr12:58188157	TSFM	chr12:58176536-58191367:+	-0.4	-8.58	1.31E-16	Multiple sclerosis	
LUSC	cis	1	rs11172343	chr12:58188157	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.35	1.64E-5	Multiple sclerosis	
LUSC	cis	1	rs11172344	chr12:58193448	FAM119B	chr12:58166383-58176323:+	0.52	9.22	1.0E-18	Multiple sclerosis	
LUSC	cis	1	rs11172344	chr12:58193448	TSFM	chr12:58176536-58191367:+	-0.39	-8.53	2.03E-16	Multiple sclerosis	
LUSC	cis	1	rs11172344	chr12:58193448	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-4.03	6.58E-5	Multiple sclerosis	
LUSC	cis	1	rs11172349	chr12:58212528	FAM119B	chr12:58166383-58176323:+	0.53	9.15	1.74E-18	Multiple sclerosis	
LUSC	cis	1	rs11172349	chr12:58212528	TSFM	chr12:58176536-58191367:+	-0.39	-8.49	2.63E-16	Multiple sclerosis	
LUSC	cis	1	rs11172349	chr12:58212528	XRCC6BP1	chr12:58335445-58351051:+	-0.21	-4.16	3.84E-5	Multiple sclerosis	
LUSC	cis	1	rs11172351	chr12:58213485	FAM119B	chr12:58166383-58176323:+	0.54	9.28	5.95E-19	Multiple sclerosis	
LUSC	cis	1	rs11172351	chr12:58213485	TSFM	chr12:58176536-58191367:+	-0.38	-8.08	5.57E-15	Multiple sclerosis	
LUSC	cis	1	rs11172351	chr12:58213485	XRCC6BP1	chr12:58335445-58351051:+	-0.2	-4.03	6.5E-5	Multiple sclerosis	
LUSC	cis	1	rs11180559	chr12:75920285	GLIPR1L2	chr12:75784889-75825591:+	0.33	4.12	4.55E-5	Daytime sleep phenotypes	
LUSC	cis	1	rs11185056	chr1:107578610	PRMT6	chr1:107599267-107601907:+	0.25	4	7.38E-5	AIDS	
LUSC	cis	1	rs11185057	chr1:107596964	PRMT6	chr1:107599267-107601907:+	0.27	4.17	3.57E-5	AIDS	
LUSC	cis	1	rs11188394	chr10:97365458	ENTPD1	chr10:97471536-97637022:+	0.17	5	8.22E-7	Blood metabolite levels	
LUSC	cis	1	rs11188396	chr10:97367510	ENTPD1	chr10:97471536-97637022:+	0.17	5.02	7.19E-7	Blood metabolite levels	
LUSC	cis	1	rs11188398	chr10:97369093	ENTPD1	chr10:97471536-97637022:+	0.17	5.22	2.64E-7	Blood metabolite levels	
LUSC	cis	1	rs11188400	chr10:97371327	ENTPD1	chr10:97471536-97637022:+	0.17	5.21	2.88E-7	Blood metabolite levels	
LUSC	cis	1	rs11188406	chr10:97390195	ENTPD1	chr10:97471536-97637022:+	0.17	5.17	3.51E-7	Blood metabolite levels	
LUSC	cis	1	rs11188407	chr10:97390533	ENTPD1	chr10:97471536-97637022:+	0.17	5.17	3.51E-7	Blood metabolite levels	
LUSC	cis	1	rs11188411	chr10:97397344	ENTPD1	chr10:97471536-97637022:+	0.16	4.99	8.36E-7	Blood metabolite levels	
LUSC	cis	1	rs11188417	chr10:97411680	ENTPD1	chr10:97471536-97637022:+	-0.17	-5.11	4.64E-7	Blood metabolite levels	
LUSC	cis	1	rs111899361	chr7:1112348	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs111901203	chr11:58297542	CNTF	chr11:58390146-58393203:+	0.38	4.92	1.2E-6	Lymphoma	
LUSC	cis	1	rs111902838	chr19:50496614	SIGLEC16	chr19:50472912-50479075:+	0.81	8.09	4.92E-15	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs11190540	chr10:102202629	SEC31B	chr10:102246403-102289636:-	-0.26	-8.08	5.26E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190541	chr10:102203071	SEC31B	chr10:102246403-102289636:-	-0.26	-7.76	5.29E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190551	chr10:102204734	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190552	chr10:102206607	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.18E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190555	chr10:102209160	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190556	chr10:102209223	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190557	chr10:102209369	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190558	chr10:102209397	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190569	chr10:102227409	SEC31B	chr10:102246403-102289636:-	-0.27	-8.25	1.62E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190570	chr10:102227702	SEC31B	chr10:102246403-102289636:-	-0.27	-8.21	2.18E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190572	chr10:102232879	SEC31B	chr10:102246403-102289636:-	-0.26	-7.97	1.22E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190578	chr10:102238953	SEC31B	chr10:102246403-102289636:-	-0.27	-8.09	5.16E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190587	chr10:102266638	SEC31B	chr10:102246403-102289636:-	-0.29	-8.64	8.79E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190589	chr10:102275471	SEC31B	chr10:102246403-102289636:-	-0.28	-8.47	2.98E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190592	chr10:102291059	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190595	chr10:102291761	SEC31B	chr10:102246403-102289636:-	-0.28	-8.28	1.27E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190596	chr10:102293238	SEC31B	chr10:102246403-102289636:-	-0.29	-8.47	3.13E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190597	chr10:102293676	SEC31B	chr10:102246403-102289636:-	-0.28	-8.28	1.27E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190599	chr10:102295420	SEC31B	chr10:102246403-102289636:-	-0.28	-8.38	5.89E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190601	chr10:102296730	SEC31B	chr10:102246403-102289636:-	-0.28	-8.28	1.26E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190602	chr10:102297256	SEC31B	chr10:102246403-102289636:-	-0.28	-8.38	5.89E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190604	chr10:102302457	SEC31B	chr10:102246403-102289636:-	-0.27	-7.93	1.62E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190607	chr10:102303614	SEC31B	chr10:102246403-102289636:-	-0.27	-8.11	4.38E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11190613	chr10:102313997	SEC31B	chr10:102246403-102289636:-	0.27	8.24	1.71E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs11191419	chr10:104612335	C10orf32	chr10:104613967-104624718:+	-0.36	-7.68	9.13E-14	Schizophrenia	
LUSC	cis	1	rs11201660	chr10:81854531	LOC219347	chr10:81805991-81838949:-	-0.36	-4.1	4.9E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs11204700	chr1:150660702	HORMAD1	chr1:150670542-150693352:-	0.46	5.11	4.78E-7	Congenital left-sided heart lesions	
LUSC	cis	1	rs11211132	chr1:45990516	CCDC163P	chr1:45960581-45965646:-	-0.75	-18.03	9.6E-56	Homocysteine levels	
LUSC	cis	1	rs11211132	chr1:45990516	MMACHC	chr1:45965856-45976737:+	-0.15	-3.85	0.000136	Homocysteine levels	
LUSC	cis	1	rs11211199	chr1:46287869	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.03	7.42E-12	Body mass index	
LUSC	cis	1	rs11211208	chr1:46334256	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.03	7.18E-12	Body mass index	
LUSC	cis	1	rs11211230	chr1:46406767	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.03	7.37E-12	Body mass index	
LUSC	cis	1	rs11211234	chr1:46438787	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.17	2.97E-12	Body mass index	
LUSC	cis	1	rs11211241	chr1:46452683	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.17	2.97E-12	Body mass index	
LUSC	cis	1	rs112143304	chr17:61822401	FTSJ3	chr17:61896795-61905031:-	0.35	6.6	1.09E-10	Body mass index	
LUSC	cis	1	rs112143304	chr17:61822401	MAP3K3	chr17:61699775-61773669:+	0.16	3.69	0.000247	Body mass index	
LUSC	cis	1	rs11215031	chr11:114390447	FAM55D	chr11:114441314-114466484:-	0.42	5.73	1.75E-8	IgG glycosylation	
LUSC	cis	1	rs11216316	chr11:117081500	PCSK7	chr11:117075789-117102811:-	0.33	4.42	1.23E-5	Protein quantitative trait loci	
LUSC	cis	1	rs11227284	chr11:65503224	CTSW	chr11:65647284-65651212:+	-0.25	-5.24	2.37E-7	Systemic lupus erythematosus	
LUSC	cis	1	rs11227284	chr11:65503224	SNX32	chr11:65601410-65621170:+	0.46	6.92	1.5E-11	Systemic lupus erythematosus	
LUSC	cis	1	rs11227288	chr11:65516588	CTSW	chr11:65647284-65651212:+	-0.25	-5.47	7.46E-8	Systemic lupus erythematosus	
LUSC	cis	1	rs11227288	chr11:65516588	SNX32	chr11:65601410-65621170:+	0.45	6.91	1.61E-11	Systemic lupus erythematosus	
LUSC	cis	1	rs11229535	chr11:58348386	CNTF	chr11:58390146-58393203:+	0.37	4.73	2.9E-6	Lymphoma	
LUSC	cis	1	rs11229535	chr11:58348386	ZFP91-CNTF	chr11:58346587-58393203:+	0.26	3.71	0.000233	Lymphoma	
LUSC	cis	1	rs11292	chr10:102313607	SEC31B	chr10:102246403-102289636:-	-0.28	-8.63	9.52E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs113066613	chr7:1094128	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.11	4.71E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs113104783	chr11:60348915	MS4A14	chr11:60145958-60185226:+	0.2	4.2	3.25E-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	
LUSC	cis	1	rs113134232	chr17:61715461	FTSJ3	chr17:61896795-61905031:-	0.35	6.47	2.51E-10	Body mass index	
LUSC	cis	1	rs113146460	chr7:1105164	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.27	2.02E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs1133483	chr4:100023923	ADH4	chr4:100044835-100065449:-	-0.2	-3.87	0.000123	HDL cholesterol	
LUSC	cis	1	rs113520408	chr7:128402782	OPN1SW	chr7:128412545-128415844:-	0.27	4.01	7.11E-5	Educational attainment (years of education)	
LUSC	cis	1	rs113575110	chr7:1084394	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.2	2.93E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs113638727	chr15:40706101	C15orf23	chr15:40674922-40686488:+	0.27	4.19	3.29E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs113638727	chr15:40706101	IVD	chr15:40697686-40713512:+	-0.34	-3.73	0.000218	Heschl's gyrus morphology	
LUSC	cis	1	rs1138273	chr3:134261437	ANAPC13	chr3:134196547-134204865:-	0.42	8.38	5.82E-16	Height	
LUSC	cis	1	rs113858334	chr7:1073476	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.25	2.25E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs114007205	chr20:33647503	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs1141321	chr6:49412433	CENPQ	chr6:49431096-49460820:+	-0.35	-7.71	7.53E-14	Folate pathway vitamin levels	
LUSC	cis	1	rs1141321	chr6:49412433	MUT	chr6:49398994-49431031:-	0.34	6.11	2.05E-9	Folate pathway vitamin levels	
LUSC	cis	1	rs114200987	chr14:35586916	PPP2R3C	chr14:35554679-35591679:-	0.33	5.73	1.81E-8	Atopic dermatitis	
LUSC	cis	1	rs1144894	chr7:65542894	NCRNA00174	chr7:65841032-65865395:-	0.28	5.96	4.92E-9	Aortic root size	
LUSC	cis	1	rs1144895	chr7:65541307	NCRNA00174	chr7:65841032-65865395:-	0.28	5.96	4.92E-9	Aortic root size	
LUSC	cis	1	rs114682099	chr4:119702004	SEC24D	chr4:119643979-119759827:-	0.38	4.36	1.62E-5	Cannabis dependence	
LUSC	cis	1	rs114778020	chr4:119662584	SEC24D	chr4:119643979-119759827:-	0.38	4.24	2.69E-5	Cannabis dependence	
LUSC	cis	1	rs1148000	chr12:75936301	GLIPR1L2	chr12:75784889-75825591:+	-0.25	-4.42	1.24E-5	Polycystic ovary syndrome	
LUSC	cis	1	rs114827034	chr12:91480042	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs114912871	chr4:119697004	SEC24D	chr4:119643979-119759827:-	0.38	4.36	1.62E-5	Cannabis dependence	
LUSC	cis	1	rs114948279	chr20:33733641	GDF5	chr20:33897002-34042568:-	0.29	3.82	0.000154	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs114948279	chr20:33733641	PROCR	chr20:33758727-33765164:+	-0.32	-4.09	5.13E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs114976176	chr2:264621	SH3YL1	chr2:218138-264810:-	-0.51	-8.89	1.32E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs115097949	chr1:169546986	SLC19A2	chr1:169433151-169455208:-	0.36	3.97	8.33E-5	Hippocampal atrophy	
LUSC	cis	1	rs11513751	chr12:91482180	KERA	chr12:91444273-91452131:-	0.24	3.9	0.000112	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11513752	chr12:91482198	KERA	chr12:91444273-91452131:-	0.24	3.9	0.000112	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11513822	chr12:91482005	KERA	chr12:91444273-91452131:-	0.24	3.94	9.5E-5	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11513823	chr12:91482359	KERA	chr12:91444273-91452131:-	0.24	3.94	9.5E-5	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11519665	chr12:91482036	KERA	chr12:91444273-91452131:-	0.24	3.94	9.5E-5	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs11532322	chr12:123731423	ABCB9	chr12:123413540-123459752:-	-0.3	-4.78	2.39E-6	Schizophrenia	
LUSC	cis	1	rs11532322	chr12:123731423	OGFOD2	chr12:123459354-123464588:+	-0.19	-4.04	6.26E-5	Schizophrenia	
LUSC	cis	1	rs11553746	chr2:272203	SH3YL1	chr2:218138-264810:-	-0.5	-8.8	2.56E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs11557072	chr15:40713374	C15orf23	chr15:40674922-40686488:+	0.26	4.05	6.09E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs11557072	chr15:40713374	IVD	chr15:40697686-40713512:+	-0.33	-3.77	0.000181	Heschl's gyrus morphology	
LUSC	cis	1	rs115743514	chr22:51011933	CPT1B	chr22:51007291-51017096:-	-0.34	-4.32	1.92E-5	Narcolepsy	
LUSC	cis	1	rs11579634	chr1:46466391	CCDC163P	chr1:45960581-45965646:-	0.34	6.88	1.89E-11	Body mass index	
LUSC	cis	1	rs11589190	chr1:228991772	WNT3A	chr1:228194752-228248961:+	0.21	3.74	0.000205	Basal cell carcinoma	
LUSC	cis	1	rs11589562	chr1:46466721	CCDC163P	chr1:45960581-45965646:-	0.29	5.82	1.08E-8	Body mass index	
LUSC	cis	1	rs11592213	chr10:97396103	ENTPD1	chr10:97471536-97637022:+	0.17	5.14	4.05E-7	Blood metabolite levels	
LUSC	cis	1	rs115965884	chr22:24594662	SUSD2	chr22:24577444-24585074:+	0.46	6.4	3.73E-10	Amyotrophic lateral sclerosis	
LUSC	cis	1	rs11605774	chr11:47832793	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.13	4.24E-5	Subjective well-being	
LUSC	cis	1	rs11606049	chr11:112033129	IL18	chr11:112013976-112034840:-	-0.24	-4.37	1.55E-5	Interleukin-18 levels	
LUSC	cis	1	rs11610206	chr12:47639526	HDAC7	chr12:48176509-48213763:-	0.27	3.74	0.000206	Alzheimer's disease	
LUSC	cis	1	rs116139393	chr7:6771660	PMS2CL	chr7:6749757-6793492:+	-0.41	-6.47	2.38E-10	Alzheimer's disease (APOE e4 interaction)	
LUSC	cis	1	rs11621025	chr14:93740831	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000202	Body mass index	
LUSC	cis	1	rs11621084	chr14:93764989	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs11622158	chr14:93718378	COX8C	chr14:93813537-93814700:+	-0.23	-3.7	0.000244	Body mass index	
LUSC	cis	1	rs11623413	chr14:75588824	MLH3	chr14:75480467-75518235:-	-0.24	-5.12	4.35E-7	Height	
LUSC	cis	1	rs11628028	chr14:93721152	COX8C	chr14:93813537-93814700:+	0.23	3.86	0.000129	Body mass index	
LUSC	cis	1	rs11628070	chr14:93721392	COX8C	chr14:93813537-93814700:+	-0.23	-3.76	0.000191	Body mass index	
LUSC	cis	1	rs11628538	chr14:93746562	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000202	Body mass index	
LUSC	cis	1	rs11628710	chr14:74649280	LIN52	chr14:74551656-74667117:+	0.28	6.23	1.04E-9	Common traits (Other)	
LUSC	cis	1	rs11628710	chr14:74649280	PTGR2	chr14:74318534-74352166:+	-0.21	-4.14	4.04E-5	Common traits (Other)	
LUSC	cis	1	rs11630417	chr15:68012609	IQCH	chr15:67547188-67794139:+	0.22	3.96	8.75E-5	Motion sickness	
LUSC	cis	1	rs11631963	chr15:83318202	LOC80154	chr15:82944795-82975797:+;chr15	-0.25	-5.07	5.67E-7	Schizophrenia	
LUSC	cis	1	rs11632096	chr15:56210499	NEDD4	chr15:56119131-56285835:-	0.23	4.25	2.56E-5	Keloid	
LUSC	cis	1	rs11632465	chr15:85282045	LOC388152	chr15:84867600-84898920:-	-0.22	-4.01	7.11E-5	Schizophrenia	
LUSC	cis	1	rs11633263	chr15:56135559	NEDD4	chr15:56119131-56285835:-	0.26	4.69	3.58E-6	Keloid	
LUSC	cis	1	rs11633313	chr15:56135709	NEDD4	chr15:56119131-56285835:-	0.26	4.76	2.63E-6	Keloid	
LUSC	cis	1	rs11637142	chr15:85295927	LOC388152	chr15:84867600-84898920:-	-0.23	-4.23	2.85E-5	Schizophrenia	
LUSC	cis	1	rs11637433	chr15:83321336	LOC80154	chr15:82944795-82975797:+;chr15	-0.24	-4.95	1.03E-6	Schizophrenia	
LUSC	cis	1	rs11638290	chr15:85227636	LOC388152	chr15:84867600-84898920:-	-0.24	-4.29	2.2E-5	Schizophrenia	
LUSC	cis	1	rs11638297	chr15:84782417	LOC388152	chr15:84867600-84898920:-	-0.27	-4.98	8.88E-7	Schizophrenia	
LUSC	cis	1	rs11638394	chr15:84778928	LOC388152	chr15:84867600-84898920:-	-0.27	-4.77	2.41E-6	Schizophrenia	
LUSC	cis	1	rs11638815	chr15:83352282	GOLGA6L9	chr15:82711895-82731584:+;chr15	0.16	3.89	0.000113	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	
LUSC	cis	1	rs11645002	chr16:20617841	ACSM1	chr16:20634559-20709066:-	0.43	5.2	2.9E-7	Urinary metabolites	
LUSC	cis	1	rs11650372	chr17:45721795	C17orf57	chr17:45401142-45518675:+	0.3	6.65	8.02E-11	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs11651264	chr17:79576394	TSPAN10	chr17:79609349-79615778:+	-0.46	-9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs11652797	chr17:79574124	TSPAN10	chr17:79609349-79615778:+	0.45	9.3	5.2E-19	Eye color traits	
LUSC	cis	1	rs11653	chr7:128409580	OPN1SW	chr7:128412545-128415844:-	0.27	4.66	4.06E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs11654335	chr17:61797579	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.97E-10	Body mass index	
LUSC	cis	1	rs116551361	chr6:24483512	GPLD1	chr6:24428405-24489850:-	0.41	5.39	1.08E-7	Hematological and biochemical traits	
LUSC	cis	1	rs11657081	chr17:61792339	FTSJ3	chr17:61896795-61905031:-	0.33	6.64	8.74E-11	Body mass index	
LUSC	cis	1	rs11657120	chr17:61857218	FTSJ3	chr17:61896795-61905031:-	0.33	6.49	2.13E-10	Body mass index	
LUSC	cis	1	rs11657306	chr17:61704822	FTSJ3	chr17:61896795-61905031:-	0.32	6.25	9.4E-10	Body mass index	
LUSC	cis	1	rs11658175	chr17:61923838	FTSJ3	chr17:61896795-61905031:-	0.32	6.25	8.92E-10	Body mass index	
LUSC	cis	1	rs11658740	chr17:61751069	FTSJ3	chr17:61896795-61905031:-	0.33	6.38	4.28E-10	Body mass index	
LUSC	cis	1	rs116588966	chr4:154664794	TLR2	chr4:154605441-154627240:+	-0.2	-3.88	0.000117	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs11666415	chr19:24228512	LOC100101266	chr19:24344995-24346249:-	0.28	3.81	0.000158	Response to taxane treatment (placlitaxel)	
LUSC	cis	1	rs1167411	chr7:65539264	NCRNA00174	chr7:65841032-65865395:-	0.29	6	3.82E-9	Aortic root size	
LUSC	cis	1	rs11674602	chr2:73723185	ALMS1P	chr2:73872046-73912692:+	0.4	7.41	6.01E-13	Metabolite levels	
LUSC	cis	1	rs11674602	chr2:73723185	NAT8	chr2:73867850-73869537:-	0.26	4.42	1.22E-5	Metabolite levels	
LUSC	cis	1	rs1167612	chr7:65567976	NCRNA00174	chr7:65841032-65865395:-	0.29	6.08	2.46E-9	Aortic root size	
LUSC	cis	1	rs1167827	chr7:75163169	PMS2L3	chr7:75137070-75157418:-	-0.38	-9.16	1.59E-18	Body mass index	
LUSC	cis	1	rs1167827	chr7:75163169	STAG3L1	chr7:74988447-75026250:+	-0.25	-4.55	6.85E-6	Body mass index	
LUSC	cis	1	rs11681451	chr2:225334104	FAM124B	chr2:225243416-225266711:-	0.2	3.9	0.00011	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
LUSC	cis	1	rs11684337	chr2:3395287	TTC15	chr2:3383446-3488857:+	-0.21	-3.96	8.75E-5	Obesity-related traits	
LUSC	cis	1	rs11686590	chr2:225334070	FAM124B	chr2:225243416-225266711:-	0.2	3.83	0.000145	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
LUSC	cis	1	rs116867513	chr19:22166026	ZNF100	chr19:21906844-21950430:-	-0.31	-4.37	1.52E-5	Body mass index (change over time)	
LUSC	cis	1	rs11688129	chr2:28952581	TRMT61B	chr2:29072690-29093175:-	0.26	5.36	1.27E-7	Body mass index	
LUSC	cis	1	rs11690423	chr2:28951537	TRMT61B	chr2:29072690-29093175:-	0.26	5.28	1.98E-7	Body mass index	
LUSC	cis	1	rs11696501	chr20:44124523	WFDC3	chr20:44402847-44420547:-	0.35	5.25	2.28E-7	Brain structure	
LUSC	cis	1	rs11698834	chr20:23832595	CST2	chr20:23804404-23807312:-	0.36	5.45	7.93E-8	Response to TNF antagonist treatment	
LUSC	cis	1	rs11699452	chr20:23837189	CST2	chr20:23804404-23807312:-	-0.35	-5.22	2.74E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs11699520	chr20:23837634	CST2	chr20:23804404-23807312:-	-0.35	-5.22	2.74E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs11699607	chr20:23830834	CST2	chr20:23804404-23807312:-	-0.35	-5.27	2.08E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs11703914	chr22:24767602	POM121L9P	chr22:24647589-24661490:+	-0.29	-6.94	1.27E-11	Gut microbiome composition (summer)	
LUSC	cis	1	rs11704021	chr22:39074716	CBY1	chr22:39052658-39069853:+	0.23	4.11	4.72E-5	Resting heart rate	
LUSC	cis	1	rs11704899	chr22:29918482	NIPSNAP1	chr22:29950800-29977144:-	0.28	4.36	1.62E-5	Lipid traits	
LUSC	cis	1	rs11705483	chr22:46630544	PKDREJ	chr22:46651561-46659219:-	-0.57	-6.88	1.91E-11	Cholesterol, total;LDL cholesterol	
LUSC	cis	1	rs11706117	chr3:134212526	ANAPC13	chr3:134196547-134204865:-	0.43	8.69	6.09E-17	Height	
LUSC	cis	1	rs11708531	chr3:134224902	ANAPC13	chr3:134196547-134204865:-	0.42	8.33	8.77E-16	Height	
LUSC	cis	1	rs11709819	chr3:132736004	TMEM108	chr3:132757171-133116618:+	0.19	4.5	8.7E-6	IgE grass sensitization	
LUSC	cis	1	rs11710434	chr3:49346130	AMT	chr3:49454212-49460012:-	0.2	4.68	3.67E-6	Menarche (age at onset)	
LUSC	cis	1	rs11711054	chr3:46345611	CCR2	chr3:46395235-46402412:+	-0.1	-3.78	0.000174	Celiac disease	
LUSC	cis	1	rs11712111	chr3:156608940	LEKR1	chr3:156544076-156763918:+	0.24	5.47	7.12E-8	Multiple sclerosis (severity)	
LUSC	cis	1	rs11712561	chr3:48435272	TREX1	chr3:48501186-48509043:+	-0.44	-9.78	1.08E-20	Longevity	
LUSC	cis	1	rs11712653	chr3:53070875	TMEM110	chr3:52867139-52931547:-	-0.37	-4.6	5.35E-6	Immune reponse to smallpox (secreted IL-2)	
LUSC	cis	1	rs11712915	chr3:85596665	CADM2	chr3:85008133-86117948:+	0.31	4.79	2.28E-6	Longevity (90 years and older)	
LUSC	cis	1	rs11714406	chr3:121372513	IQCB1	chr3:121488610-121553926:-	0.21	4.45	1.09E-5	Cognitive performance	
LUSC	cis	1	rs11719458	chr3:121382005	IQCB1	chr3:121488610-121553926:-	0.24	5.19	3.12E-7	Cognitive performance	
LUSC	cis	1	rs11719762	chr3:49409002	AMT	chr3:49454212-49460012:-	0.21	5.02	7.39E-7	Menarche (age at onset)	
LUSC	cis	1	rs11719762	chr3:49409002	TREX1	chr3:48501186-48509043:+	-0.2	-3.73	0.000217	Menarche (age at onset)	
LUSC	cis	1	rs11720454	chr3:132733833	TMEM108	chr3:132757171-133116618:+	0.2	4.77	2.42E-6	IgE grass sensitization	
LUSC	cis	1	rs11720542	chr3:49357427	AMT	chr3:49454212-49460012:-	0.19	4.64	4.58E-6	Menarche (age at onset)	
LUSC	cis	1	rs11721233	chr3:132733933	TMEM108	chr3:132757171-133116618:+	0.2	4.63	4.63E-6	IgE grass sensitization	
LUSC	cis	1	rs11721318	chr3:121429485	IQCB1	chr3:121488610-121553926:-	0.21	4.37	1.53E-5	Cognitive performance	
LUSC	cis	1	rs117236853	chr20:33667783	PROCR	chr20:33758727-33765164:+	-0.36	-4.47	9.9E-6	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs117249133	chr20:33773630	GDF5	chr20:33897002-34042568:-	0.31	4.12	4.45E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11727803	chr4:88213158	HSD17B13	chr4:88224941-88244056:-	-0.19	-3.95	9.02E-5	Platelet count	
LUSC	cis	1	rs11727835	chr4:88213244	HSD17B13	chr4:88224941-88244056:-	-0.19	-3.95	9.02E-5	Platelet count	
LUSC	cis	1	rs11735092	chr4:88226231	HSD17B13	chr4:88224941-88244056:-	-0.18	-3.76	0.000192	Platelet count	
LUSC	cis	1	rs11739344	chr5:56111087	C5orf35	chr5:56205103-56213010:+	0.87	14.56	5.56E-40	Type 2 diabetes	
LUSC	cis	1	rs11741861	chr5:150277909	LOC134466	chr5:150310000-150326146:-	-0.47	-6.33	5.77E-10	Crohn's disease	
LUSC	cis	1	rs117573845	chr20:33651621	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11758849	chr6:86708262	SNHG5	chr6:86386726-86388451:-	-0.65	-12.37	1.15E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs11759855	chr6:86610841	SNHG5	chr6:86386726-86388451:-	-0.67	-12.46	5.11E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs11761941	chr7:1097183	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.07	5.8E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11763020	chr7:1060288	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.29	1.87E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11763147	chr7:65326821	NCRNA00174	chr7:65841032-65865395:-	0.25	5.43	8.98E-8	Corneal structure	
LUSC	cis	1	rs11763793	chr7:1094342	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.11	4.6E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs117638181	chr19:22163014	ZNF100	chr19:21906844-21950430:-	-0.31	-4.47	9.85E-6	Body mass index (change over time)	
LUSC	cis	1	rs117638181	chr19:22163014	ZNF43	chr19:21987753-22034830:-	-0.27	-3.95	8.87E-5	Body mass index (change over time)	
LUSC	cis	1	rs117638181	chr19:22163014	ZNF493	chr19:21579921-21610294:+	-0.24	-3.72	0.000221	Body mass index (change over time)	
LUSC	cis	1	rs11763835	chr7:1094513	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.11	4.6E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11764748	chr7:1094508	ZFAND2A	chr7:1192544-1199855:-	-0.35	-4.92	1.19E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11766175	chr7:128405013	OPN1SW	chr7:128412545-128415844:-	0.27	4.66	4.02E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs11766526	chr7:1101433	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.76E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11767527	chr7:1097394	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.07	5.8E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11768761	chr7:1069807	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11770909	chr7:1086716	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.87E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11773829	chr7:66141074	NCRNA00174	chr7:65841032-65865395:-	0.25	5.52	5.69E-8	Aortic root size	
LUSC	cis	1	rs117802529	chr20:33786677	GDF5	chr20:33897002-34042568:-	0.32	4.28	2.31E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs117802529	chr20:33786677	PROCR	chr20:33758727-33765164:+	-0.3	-3.91	0.000108	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11782652	chr8:82653644	CHMP4C	chr8:82644688-82671746:+	-0.62	-6.59	1.15E-10	Epithelial ovarian cancer;Ovarian cancer	
LUSC	cis	1	rs11785712	chr8:120675220	DSCC1	chr8:120846182-120868170:-	0.29	4.41	1.26E-5	Height	
LUSC	cis	1	rs117907570	chr6:86601283	SNHG5	chr6:86386726-86388451:-	-0.69	-13.24	2.78E-34	Response to antipsychotic treatment	
LUSC	cis	1	rs11801695	chr1:205916175	PM20D1	chr1:205797154-205819245:-	-0.37	-7.03	7.03E-12	Cystic fibrosis-related diabetes	
LUSC	cis	1	rs118059236	chr7:1073202	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.25	2.25E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs11810993	chr1:46478793	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.93	1.37E-11	Body mass index	
LUSC	cis	1	rs118110670	chr10:81792242	LOC219347	chr10:81805991-81838949:-	0.44	4.5	8.63E-6	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs11816840	chr10:102309220	SEC31B	chr10:102246403-102289636:-	-0.27	-7.79	4.24E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs1182882	chr7:65562063	NCRNA00174	chr7:65841032-65865395:-	0.28	5.89	7.43E-9	Aortic root size	
LUSC	cis	1	rs1183245	chr7:65541185	NCRNA00174	chr7:65841032-65865395:-	0.28	5.96	4.92E-9	Aortic root size	
LUSC	cis	1	rs11845639	chr14:75570293	MLH3	chr14:75480467-75518235:-	0.26	5.56	4.42E-8	Height	
LUSC	cis	1	rs11856184	chr15:43919162	CATSPER2	chr15:43922774-43959900:-	-0.29	-4.3	2.08E-5	Tumor biomarkers	
LUSC	cis	1	rs11858714	chr15:40717447	C15orf23	chr15:40674922-40686488:+	0.29	4.32	1.89E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs11862083	chr16:4649720	NMRAL1	chr16:4511696-4526307:-	-0.44	-4.08	5.38E-5	Obesity-related traits	
LUSC	cis	1	rs11867405	chr17:40570741	CNTD1	chr17:40950854-40963604:+	0.17	3.75	0.0002	Crohn's disease	
LUSC	cis	1	rs11869819	chr17:65868669	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs11870797	chr17:61804622	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.97E-10	Body mass index	
LUSC	cis	1	rs11870935	chr17:45732605	C17orf57	chr17:45401142-45518675:+	-0.29	-6.45	2.78E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs11871767	chr17:61698723	FTSJ3	chr17:61896795-61905031:-	0.31	6.18	1.38E-9	Body mass index	
LUSC	cis	1	rs11871801	chr17:40570772	CNTD1	chr17:40950854-40963604:+	0.18	4.03	6.38E-5	Crohn's disease	
LUSC	cis	1	rs1187446	chr14:104409896	TDRD9	chr14:104394817-104519002:+	0.26	4.47	9.95E-6	Bipolar disorder	
LUSC	cis	1	rs1187448	chr14:104406627	TDRD9	chr14:104394817-104519002:+	0.26	4.54	7.03E-6	Bipolar disorder	
LUSC	cis	1	rs11880706	chr19:6080482	FUT5	chr19:5865838-5904025:-	-0.38	-3.97	8.46E-5	Bipolar disorder and schizophrenia	
LUSC	cis	1	rs11881224	chr19:22220340	ZNF100	chr19:21906844-21950430:-	-0.29	-4.08	5.29E-5	Body mass index (change over time)	
LUSC	cis	1	rs11881224	chr19:22220340	ZNF43	chr19:21987753-22034830:-	-0.28	-4.04	6.34E-5	Body mass index (change over time)	
LUSC	cis	1	rs11882144	chr19:42072602	CEACAM21	chr19:42055886-42093196:+	0.54	15.84	1.14E-45	Schizophrenia	
LUSC	cis	1	rs11882234	chr19:22145727	ZNF100	chr19:21906844-21950430:-	-0.31	-4.42	1.22E-5	Body mass index (change over time)	
LUSC	cis	1	rs11882234	chr19:22145727	ZNF429	chr19:21688437-21739068:+	-0.29	-4.13	4.31E-5	Body mass index (change over time)	
LUSC	cis	1	rs11882234	chr19:22145727	ZNF430	chr19:21203497-21241652:+	-0.26	-3.74	0.000204	Body mass index (change over time)	
LUSC	cis	1	rs11882234	chr19:22145727	ZNF43	chr19:21987753-22034830:-	-0.28	-4.07	5.54E-5	Body mass index (change over time)	
LUSC	cis	1	rs11882234	chr19:22145727	ZNF493	chr19:21579921-21610294:+	-0.24	-3.71	0.00023	Body mass index (change over time)	
LUSC	cis	1	rs11893832	chr2:88507537	THNSL2	chr2:88469835-88486145:+	-0.74	-8.33	8.49E-16	Plasma clusterin levels	
LUSC	cis	1	rs11893881	chr2:73824373	ALMS1P	chr2:73872046-73912692:+	0.41	7.59	1.71E-13	Metabolite levels	
LUSC	cis	1	rs11893881	chr2:73824373	NAT8	chr2:73867850-73869537:-	0.28	4.77	2.49E-6	Metabolite levels	
LUSC	cis	1	rs11899740	chr2:73631212	ALMS1P	chr2:73872046-73912692:+	0.42	7.76	5.16E-14	Metabolite levels	
LUSC	cis	1	rs11899740	chr2:73631212	NAT8	chr2:73867850-73869537:-	0.28	4.79	2.23E-6	Metabolite levels	
LUSC	cis	1	rs11899902	chr2:73631564	ALMS1P	chr2:73872046-73912692:+	0.44	7.91	1.83E-14	Metabolite levels	
LUSC	cis	1	rs11899902	chr2:73631564	NAT8	chr2:73867850-73869537:-	0.27	4.49	9.13E-6	Metabolite levels	
LUSC	cis	1	rs11903916	chr2:73815328	ALMS1P	chr2:73872046-73912692:+	0.41	7.53	2.61E-13	Metabolite levels	
LUSC	cis	1	rs11903916	chr2:73815328	NAT8	chr2:73867850-73869537:-	0.25	4.25	2.56E-5	Metabolite levels	
LUSC	cis	1	rs11905354	chr20:33677164	PROCR	chr20:33758727-33765164:+	-0.3	-3.87	0.000126	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs1190553	chr14:102915331	ZNF839	chr14:102783714-102809044:+	0.2	3.75	0.0002	QT interval	
LUSC	cis	1	rs1190554	chr14:102918686	ZNF839	chr14:102783714-102809044:+	-0.21	-3.95	8.85E-5	QT interval	
LUSC	cis	1	rs11906148	chr20:33784021	GDF5	chr20:33897002-34042568:-	0.32	4.28	2.31E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11906148	chr20:33784021	PROCR	chr20:33758727-33765164:+	-0.3	-3.91	0.000108	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11907010	chr20:33737661	GDF5	chr20:33897002-34042568:-	0.29	3.84	0.000139	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11907010	chr20:33737661	PROCR	chr20:33758727-33765164:+	-0.32	-4.07	5.48E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11907011	chr20:33767770	GDF5	chr20:33897002-34042568:-	0.3	4.12	4.48E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11907011	chr20:33767770	PROCR	chr20:33758727-33765164:+	-0.31	-4.03	6.48E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11907438	chr20:33641220	GDF5	chr20:33897002-34042568:-	0.28	3.77	0.000186	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11907438	chr20:33641220	PROCR	chr20:33758727-33765164:+	-0.33	-4.37	1.52E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11907594	chr20:33673843	PROCR	chr20:33758727-33765164:+	-0.31	-4.07	5.43E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs11908424	chr20:61863955	BIRC7	chr20:61867276-61871853:+	0.29	3.74	0.000205	Response to cytadine analogues (cytosine arabinoside)	
LUSC	cis	1	rs11919350	chr3:134235970	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.54	1.79E-16	Height	
LUSC	cis	1	rs11927068	chr3:134266321	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs11928090	chr3:49604904	AMT	chr3:49454212-49460012:-	0.19	4.42	1.22E-5	Menarche (age at onset)	
LUSC	cis	1	rs11928090	chr3:49604904	KLHDC8B	chr3:49209068-49213918:+	-0.24	-3.86	0.000129	Menarche (age at onset)	
LUSC	cis	1	rs11928499	chr3:134232350	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.28	1.29E-15	Height	
LUSC	cis	1	rs11931074	chr4:90639515	MMRN1	chr4:90816003-90875778:+	0.26	4	7.22E-5	Parkinson's disease	
LUSC	cis	1	rs11942153	chr4:106960172	TBCK	chr4:106967233-107237861:-	0.3	5.45	7.99E-8	Airflow obstruction	
LUSC	cis	1	rs11945223	chr4:90643325	MMRN1	chr4:90816003-90875778:+	0.25	3.99	7.77E-5	Parkinson's disease	
LUSC	cis	1	rs11957134	chr5:150230950	LOC134466	chr5:150310000-150326146:-	-0.43	-5.64	2.92E-8	Crohn's disease	
LUSC	cis	1	rs11962469	chr6:24482421	GPLD1	chr6:24428405-24489850:-	0.41	5.39	1.08E-7	Hematological and biochemical traits	
LUSC	cis	1	rs11971949	chr7:65626014	NCRNA00174	chr7:65841032-65865395:-	0.3	6.41	3.57E-10	Aortic root size	
LUSC	cis	1	rs11974219	chr7:65647410	NCRNA00174	chr7:65841032-65865395:-	0.3	6.39	4.03E-10	Aortic root size	
LUSC	cis	1	rs11974264	chr7:65647582	NCRNA00174	chr7:65841032-65865395:-	0.3	6.35	5.11E-10	Aortic root size	
LUSC	cis	1	rs11975942	chr7:143740580	ARHGEF35	chr7:143883677-143892736:-	-0.36	-7.19	2.52E-12	Obesity-related traits	
LUSC	cis	1	rs11975942	chr7:143740580	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.29	2.16E-5	Obesity-related traits	
LUSC	cis	1	rs11976020	chr7:72247800	TYW1B	chr7:72023729-72298813:-	0.91	18.89	9.21E-60	Educational attainment (years of education)	
LUSC	cis	1	rs11976037	chr7:143741024	ARHGEF35	chr7:143883677-143892736:-	-0.36	-7.19	2.51E-12	Obesity-related traits	
LUSC	cis	1	rs11976037	chr7:143741024	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.34	1.71E-5	Obesity-related traits	
LUSC	cis	1	rs11976180	chr7:143741580	ARHGEF35	chr7:143883677-143892736:-	-0.36	-7.31	1.13E-12	Obesity-related traits	
LUSC	cis	1	rs11976180	chr7:143741580	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.38	1.46E-5	Obesity-related traits	
LUSC	cis	1	rs11984666	chr8:130730280	GSDMC	chr8:130760443-130799134:-	0.25	5.09	5.25E-7	Infant length;Height	
LUSC	cis	1	rs11988157	chr8:124194740	FAM83A	chr8:124191287-124222317:+	0.3	5.19	3.07E-7	Urinary uromodulin levels	
LUSC	cis	1	rs11992152	chr8:124189455	FAM83A	chr8:124191287-124222317:+	-0.28	-4.48	9.45E-6	Urinary uromodulin levels	
LUSC	cis	1	rs12021578	chr1:107597501	PRMT6	chr1:107599267-107601907:+	0.26	4.11	4.61E-5	AIDS	
LUSC	cis	1	rs12021587	chr1:46472759	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.92	1.49E-11	Body mass index	
LUSC	cis	1	rs12030612	chr1:113215637	ST7L	chr1:113066142-113162405:-	0.25	4.01	6.99E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs12030641	chr1:113215717	ST7L	chr1:113066142-113162405:-	0.25	4.01	6.99E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs1203156	chr6:88079694	C6orf164	chr6:88032306-88109459:+	-0.23	-4.48	9.35E-6	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs12037569	chr1:109923677	AMIGO1	chr1:110049447-110052336:-	0.25	3.95	8.93E-5	Major depressive disorder	
LUSC	cis	1	rs12037569	chr1:109923677	SYPL2	chr1:110009100-110024763:+	-0.26	-4.48	9.53E-6	Major depressive disorder	
LUSC	cis	1	rs12040988	chr1:113173804	ST7L	chr1:113066142-113162405:-	0.25	4.03	6.48E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs12045339	chr1:156294211	BGLAP	chr1:156182784-156213112:+	0.21	3.7	0.000239	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LUSC	cis	1	rs12045807	chr1:150584834	HORMAD1	chr1:150670542-150693352:-	0.43	4.95	1.02E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs12049330	chr1:110031188	AMIGO1	chr1:110049447-110052336:-	0.3	4.55	6.69E-6	Major depressive disorder	
LUSC	cis	1	rs12049588	chr1:46472422	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.92	1.49E-11	Body mass index	
LUSC	cis	1	rs12050434	chr14:74341438	LIN52	chr14:74551656-74667117:+	0.33	3.78	0.000174	Morning vs. evening chronotype	
LUSC	cis	1	rs12081206	chr1:16087731	FAM131C	chr1:16361814-16400127:-	-0.23	-3.72	0.000221	Gut microbiota (bacterial taxa)	
LUSC	cis	1	rs12091731	chr1:16087824	FAM131C	chr1:16361814-16400127:-	0.23	3.86	0.000132	Gut microbiota (bacterial taxa)	
LUSC	cis	1	rs12105167	chr2:48175338	STON1-GTF2A1L	chr2:48796159-48906746:+	0.19	3.85	0.000136	Asthma	
LUSC	cis	1	rs12120956	chr1:113202571	ST7L	chr1:113066142-113162405:-	0.23	3.84	0.000141	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs12122290	chr1:247215810	ZNF670	chr1:247200087-247242069:-	-0.22	-4.2	3.12E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs12126971	chr1:113231286	ST7L	chr1:113066142-113162405:-	0.25	4.02	6.79E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs12130075	chr1:247218491	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs12130219	chr1:152162106	FLG	chr1:152274651-152297679:-	0.25	5.12	4.46E-7	Inflammatory skin disease	
LUSC	cis	1	rs12130243	chr1:113169667	ST7L	chr1:113066142-113162405:-	0.25	4.03	6.48E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs12132794	chr1:156281020	BGLAP	chr1:156182784-156213112:+	-0.21	-3.72	0.000223	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LUSC	cis	1	rs12133583	chr1:113240790	ST7L	chr1:113066142-113162405:-	0.25	4.11	4.57E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs12139630	chr1:46350935	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.26	1.56E-12	Body mass index	
LUSC	cis	1	rs12139690	chr1:119491316	WARS2	chr1:119573841-119683295:-	0.3	3.83	0.000144	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs12139860	chr1:120262848	ZNF697	chr1:120162000-120190390:-	-0.36	-5.09	5.28E-7	Height	
LUSC	cis	1	rs12141236	chr1:156302575	BGLAP	chr1:156182784-156213112:+	0.21	3.74	0.000208	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
LUSC	cis	1	rs12141651	chr1:119492703	WARS2	chr1:119573841-119683295:-	0.28	3.75	0.000201	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs12141994	chr1:4667996	DFFB	chr1:3773845-3801992:+	-0.33	-3.78	0.000177	Dental caries	
LUSC	cis	1	rs12144094	chr1:120264823	ZNF697	chr1:120162000-120190390:-	-0.37	-5.18	3.35E-7	Height	
LUSC	cis	1	rs12144263	chr1:46352446	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.27	1.53E-12	Body mass index	
LUSC	cis	1	rs12154056	chr6:86634094	SNHG5	chr6:86386726-86388451:-	-0.65	-12.15	8.93E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12171333	chr4:129879711	C4orf33	chr4:130014829-130033842:+	0.35	6.33	5.84E-10	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs12185102	chr15:75352201	SCAMP5	chr15:75287901-75313836:+	0.27	4.38	1.48E-5	Blood trace element (Zn levels)	
LUSC	cis	1	rs12190007	chr6:169727601	C6orf70	chr6:170151721-170181617:+	-0.19	-3.86	0.000129	Obesity-related traits	
LUSC	cis	1	rs12190598	chr6:86686074	SNHG5	chr6:86386726-86388451:-	-0.64	-11.9	9.7E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs12190604	chr6:86716215	SNHG5	chr6:86386726-86388451:-	-0.68	-12.58	1.58E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs12192992	chr6:86609915	SNHG5	chr6:86386726-86388451:-	-0.67	-12.37	1.16E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12196037	chr6:86694631	SNHG5	chr6:86386726-86388451:-	-0.66	-11.99	3.94E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs12196411	chr6:86779762	SNHG5	chr6:86386726-86388451:-	-0.68	-12.14	9.56E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12196937	chr6:49382808	CENPQ	chr6:49431096-49460820:+	-0.39	-8.75	3.62E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs12196937	chr6:49382808	MUT	chr6:49398994-49431031:-	0.31	5.43	9.04E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs12197114	chr6:109735498	AKD1	chr6:109814059-110012415:-	-0.19	-4.45	1.09E-5	Height	
LUSC	cis	1	rs12197114	chr6:109735498	SMPD2	chr6:109761931-109765121:+	0.27	4.87	1.52E-6	Height	
LUSC	cis	1	rs12198188	chr6:24442482	ALDH5A1	chr6:24495197-24537434:+	-0.24	-3.76	0.000189	Liver enzyme levels	
LUSC	cis	1	rs12199516	chr6:86726221	SNHG5	chr6:86386726-86388451:-	-0.68	-12.81	1.82E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12199784	chr6:86726808	SNHG5	chr6:86386726-86388451:-	-0.68	-12.85	1.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12200330	chr6:86656653	SNHG5	chr6:86386726-86388451:-	-0.68	-12.36	1.28E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12201571	chr6:86609750	SNHG5	chr6:86386726-86388451:-	-0.67	-12.46	5.11E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs12201735	chr6:86656939	SNHG5	chr6:86386726-86388451:-	-0.66	-12.05	2.35E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs12201741	chr6:86602619	SNHG5	chr6:86386726-86388451:-	-0.66	-12.39	9.32E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs12201880	chr6:86627007	SNHG5	chr6:86386726-86388451:-	-0.65	-12.15	8.93E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12202075	chr6:49427655	CENPQ	chr6:49431096-49460820:+	-0.4	-8.79	2.84E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs12202075	chr6:49427655	MUT	chr6:49398994-49431031:-	0.3	5.35	1.34E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs12203493	chr6:86758642	SNHG5	chr6:86386726-86388451:-	-0.69	-12.51	3.23E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs12203924	chr6:86776412	SNHG5	chr6:86386726-86388451:-	-0.69	-12.33	1.61E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12204015	chr6:86598334	SNHG5	chr6:86386726-86388451:-	-0.69	-13.26	2.39E-34	Response to antipsychotic treatment	
LUSC	cis	1	rs12204365	chr6:86700532	SNHG5	chr6:86386726-86388451:-	-0.65	-12.07	1.9E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs12205336	chr6:86722367	SNHG5	chr6:86386726-86388451:-	-0.68	-12.63	9.58E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12205548	chr6:86759770	SNHG5	chr6:86386726-86388451:-	-0.69	-12.51	3.23E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs12207305	chr6:86723502	SNHG5	chr6:86386726-86388451:-	-0.68	-12.85	1.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12207610	chr6:86688016	SNHG5	chr6:86386726-86388451:-	-0.66	-12.27	2.88E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12208493	chr6:86662267	SNHG5	chr6:86386726-86388451:-	-0.68	-12.38	1.03E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12209127	chr6:86724427	SNHG5	chr6:86386726-86388451:-	-0.68	-12.63	9.58E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12212733	chr6:86726013	SNHG5	chr6:86386726-86388451:-	-0.68	-12.72	4.18E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12213149	chr6:86668644	SNHG5	chr6:86386726-86388451:-	-0.68	-12.38	1.03E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12213740	chr6:86656733	SNHG5	chr6:86386726-86388451:-	-0.66	-12.11	1.33E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs12215037	chr6:86727631	SNHG5	chr6:86386726-86388451:-	-0.7	-12.82	1.61E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12215903	chr6:86675028	SNHG5	chr6:86386726-86388451:-	-0.64	-11.85	1.51E-28	Response to antipsychotic treatment	
LUSC	cis	1	rs12216203	chr6:86675301	SNHG5	chr6:86386726-86388451:-	-0.68	-12.41	8.06E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs12216328	chr6:86703418	SNHG5	chr6:86386726-86388451:-	-0.67	-12.34	1.59E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12219158	chr10:102302923	SEC31B	chr10:102246403-102289636:-	-0.27	-8	9.87E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs12219789	chr10:102213778	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.18E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs12220777	chr10:81788104	LOC219347	chr10:81805991-81838949:-	-0.42	-4.31	1.95E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs12232351	chr15:56140995	NEDD4	chr15:56119131-56285835:-	0.24	4.41	1.28E-5	Keloid	
LUSC	cis	1	rs1227969	chr10:71263264	TSPAN15	chr10:71211226-71267423:+	-0.2	-4.17	3.65E-5	Response to taxane treatment (placlitaxel)	
LUSC	cis	1	rs12287832	chr11:65553492	CTSW	chr11:65647284-65651212:+	-0.28	-5.83	1.01E-8	Systemic lupus erythematosus	
LUSC	cis	1	rs12287832	chr11:65553492	SNX32	chr11:65601410-65621170:+	0.48	7.09	5.0E-12	Systemic lupus erythematosus	
LUSC	cis	1	rs12299125	chr12:123862447	ABCB9	chr12:123413540-123459752:-	0.3	4.19	3.38E-5	Educational attainment;Height;Head circumference (infant)	
LUSC	cis	1	rs12299125	chr12:123862447	CDK2AP1	chr12:123745542-123756687:-	-0.26	-3.78	0.000178	Educational attainment;Height;Head circumference (infant)	
LUSC	cis	1	rs12324912	chr15:75361006	SCAMP5	chr15:75287901-75313836:+	0.23	3.72	0.000223	Blood trace element (Zn levels)	
LUSC	cis	1	rs12325866	chr17:61755974	FTSJ3	chr17:61896795-61905031:-	0.32	6.3	6.96E-10	Body mass index	
LUSC	cis	1	rs12333080	chr6:118845410	C6orf204	chr6:118786239-119031238:-	-0.23	-3.72	0.000227	Renal cell carcinoma	
LUSC	cis	1	rs12354411	chr10:102294537	SEC31B	chr10:102246403-102289636:-	-0.28	-8.28	1.27E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs12355721	chr10:102244911	SEC31B	chr10:102246403-102289636:-	-0.27	-8.03	7.58E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs12358187	chr10:102284449	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs12359272	chr10:97365163	ENTPD1	chr10:97471536-97637022:+	0.16	4.87	1.52E-6	Blood metabolite levels	
LUSC	cis	1	rs12361031	chr11:47783076	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.02	6.78E-5	Subjective well-being	
LUSC	cis	1	rs12361812	chr11:48563104	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.89	0.000116	HDL cholesterol	
LUSC	cis	1	rs12363232	chr11:47623890	C1QTNF4	chr11:47611216-47615961:-	-0.24	-4.45	1.05E-5	Subjective well-being	
LUSC	cis	1	rs12365220	chr11:48555957	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.9	0.000111	HDL cholesterol	
LUSC	cis	1	rs12365551	chr11:58358368	CNTF	chr11:58390146-58393203:+	0.38	4.8	2.12E-6	Lymphoma	
LUSC	cis	1	rs12365551	chr11:58358368	ZFP91-CNTF	chr11:58346587-58393203:+	0.26	3.73	0.000217	Lymphoma	
LUSC	cis	1	rs12366208	chr11:48563128	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.92	0.000103	HDL cholesterol	
LUSC	cis	1	rs12370842	chr12:21393586	SLCO1B1	chr12:21284128-21392728:+	0.25	3.7	0.000236	Blood metabolite levels	
LUSC	cis	1	rs12372593	chr12:21393829	SLCO1B1	chr12:21284128-21392728:+	0.25	3.7	0.000236	Blood metabolite levels	
LUSC	cis	1	rs12372754	chr12:91481578	KERA	chr12:91444273-91452131:-	0.24	3.94	9.5E-5	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs12402454	chr1:172205262	VAMP4	chr1:171669298-171711214:-	0.19	3.77	0.000184	Height	
LUSC	cis	1	rs12405451	chr1:46384326	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.06	5.84E-12	Body mass index	
LUSC	cis	1	rs12409773	chr1:46358831	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.18	2.78E-12	Body mass index	
LUSC	cis	1	rs12410060	chr1:75245848	CRYZ	chr1:75171175-75199092:-	-0.32	-6.05	3.02E-9	Resistin levels	
LUSC	cis	1	rs12410071	chr1:46358886	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.18	2.78E-12	Body mass index	
LUSC	cis	1	rs12411269	chr1:46271052	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.12	4.06E-12	Body mass index	
LUSC	cis	1	rs12414891	chr10:81690385	PLAC9	chr10:81892258-81904784:+	-0.35	-4.19	3.28E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs12416687	chr10:104629011	C10orf32	chr10:104613967-104624718:+	-0.48	-9.73	1.63E-20	Arsenic metabolism	
LUSC	cis	1	rs12418015	chr11:60343295	MS4A14	chr11:60145958-60185226:+	0.18	3.8	0.000167	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect)	
LUSC	cis	1	rs12418852	chr11:47868853	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.15	3.98E-5	Subjective well-being	
LUSC	cis	1	rs12419576	chr11:48581644	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.72	0.00022	HDL cholesterol	
LUSC	cis	1	rs12419692	chr11:47624714	C1QTNF4	chr11:47611216-47615961:-	0.24	4.54	7.1E-6	Subjective well-being	
LUSC	cis	1	rs12420372	chr11:48497603	C1QTNF4	chr11:47611216-47615961:-	0.19	3.85	0.000136	HDL cholesterol	
LUSC	cis	1	rs12421210	chr11:47779586	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.02	6.78E-5	Subjective well-being	
LUSC	cis	1	rs1242229	chr11:117062370	PCSK7	chr11:117075789-117102811:-	-0.34	-4.74	2.88E-6	Protein quantitative trait loci	
LUSC	cis	1	rs12422771	chr12:6580273	TAPBPL	chr12:6561177-6575601:+	-0.3	-4.74	2.77E-6	Hip geometry	
LUSC	cis	1	rs12426318	chr12:102635521	CHPT1	chr12:102091417-102123424:+	0.26	4.01	7.17E-5	Height	
LUSC	cis	1	rs12435391	chr14:75601737	MLH3	chr14:75480467-75518235:-	0.27	5.86	8.91E-9	Height	
LUSC	cis	1	rs12446632	chr16:19935389	C16orf88	chr16:19717676-19729492:-	0.32	3.72	0.000221	Body mass index;Menarche (age at onset);Childhood body mass index;Obesity	
LUSC	cis	1	rs12447949	chr16:53681237	RBL2	chr16:53468351-53525559:+	0.38	4	7.3E-5	Vitiligo (non-segmental)	
LUSC	cis	1	rs12451511	chr17:65874861	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs12451707	chr17:65871598	LOC440461	chr17:66194801-66196436:+	0.25	3.89	0.000113	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs12452511	chr17:65832576	LOC440461	chr17:66194801-66196436:+	0.25	3.7	0.000243	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs1245507	chr10:73799349	SPOCK2	chr10:73818793-73848790:-	0.13	4.54	7.05E-6	Smoking behavior	
LUSC	cis	1	rs1245513	chr10:73802257	SPOCK2	chr10:73818793-73848790:-	0.13	4.8	2.17E-6	Smoking behavior	
LUSC	cis	1	rs1245574	chr10:73808467	SPOCK2	chr10:73818793-73848790:-	-0.13	-4.7	3.39E-6	Smoking behavior	
LUSC	cis	1	rs1245577	chr10:73810914	SPOCK2	chr10:73818793-73848790:-	0.13	4.68	3.72E-6	Smoking behavior	
LUSC	cis	1	rs12459123	chr19:12689741	GCDH	chr19:13001974-13010782:+	-0.19	-3.82	0.000153	Bipolar disorder	
LUSC	cis	1	rs12462270	chr19:39201488	LGALS7B	chr19:39279850-39282393:+	0.19	4.04	6.35E-5	Heart rate	
LUSC	cis	1	rs12470077	chr2:225334971	FAM124B	chr2:225243416-225266711:-	0.2	3.83	0.000143	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
LUSC	cis	1	rs12470450	chr2:232113888	ARMC9	chr2:232063342-232238606:+	0.22	4.77	2.49E-6	Food antigen IgG levels	
LUSC	cis	1	rs12470837	chr2:132582511	C2orf27A	chr2:132480064-132524977:+	0.34	5.31	1.67E-7	Cerebrospinal fluid clusterin levels in APOEe4+ carriers;Cerebrospinal fluid clusterin levels	
LUSC	cis	1	rs12473740	chr2:88527647	THNSL2	chr2:88469835-88486145:+	-0.65	-7.69	8.68E-14	Plasma clusterin levels	
LUSC	cis	1	rs12479491	chr20:30265450	COX4I2	chr20:30225691-30232800:+	0.2	4.11	4.66E-5	Subcortical brain region volumes	
LUSC	cis	1	rs12487542	chr3:48426076	TREX1	chr3:48501186-48509043:+	-0.44	-9.78	1.02E-20	Longevity	
LUSC	cis	1	rs12490835	chr3:134223730	ANAPC13	chr3:134196547-134204865:-	0.42	8.39	5.46E-16	Height	
LUSC	cis	1	rs12509366	chr4:107003343	TBCK	chr4:106967233-107237861:-	0.28	5.27	2.1E-7	Airflow obstruction	
LUSC	cis	1	rs12509640	chr4:106996677	TBCK	chr4:106967233-107237861:-	-0.28	-5.26	2.14E-7	Airflow obstruction	
LUSC	cis	1	rs12510966	chr4:106983604	TBCK	chr4:106967233-107237861:-	0.27	5.09	5.17E-7	Airflow obstruction	
LUSC	cis	1	rs12512683	chr4:106999471	TBCK	chr4:106967233-107237861:-	0.27	5.14	4.0E-7	Airflow obstruction	
LUSC	cis	1	rs12532998	chr7:65967459	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.13E-9	Aortic root size	
LUSC	cis	1	rs12533022	chr7:128382873	OPN1SW	chr7:128412545-128415844:-	0.25	4.45	1.07E-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs12533997	chr7:65965377	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.13E-9	Aortic root size	
LUSC	cis	1	rs12545771	chr8:8567977	FLJ10661	chr8:8086092-8102386:+	0.25	4.28	2.29E-5	Obesity-related traits	
LUSC	cis	1	rs12547941	chr8:29980332	MBOAT4	chr8:29989188-30002200:-	0.35	4.65	4.3E-6	Migraine	
LUSC	cis	1	rs12550458	chr8:8567832	FLJ10661	chr8:8086092-8102386:+	0.25	4.28	2.29E-5	Obesity-related traits	
LUSC	cis	1	rs12561806	chr1:46396776	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.03	7.18E-12	Body mass index	
LUSC	cis	1	rs12564541	chr1:46380237	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.11	4.39E-12	Body mass index	
LUSC	cis	1	rs12567136	chr1:11883731	CLCN6	chr1:11866207-11907674:+	-0.21	-4.35	1.7E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs12570188	chr10:100855702	C10orf28	chr10:99894381-100004653:+	-0.46	-4.54	7.01E-6	Asthma (childhood onset)	
LUSC	cis	1	rs12570188	chr10:100855702	COX15	chr10:101468507-101492423:-	-0.43	-4.44	1.11E-5	Asthma (childhood onset)	
LUSC	cis	1	rs12570188	chr10:100855702	GOT1	chr10:101156628-101190530:-	-0.36	-3.76	0.000194	Asthma (childhood onset)	
LUSC	cis	1	rs12570188	chr10:100855702	HPS1	chr10:100175956-100206704:-	-0.57	-5.84	9.72E-9	Asthma (childhood onset)	
LUSC	cis	1	rs12570188	chr10:100855702	SLC25A28	chr10:101370275-101418994:-	-0.36	-3.94	9.31E-5	Asthma (childhood onset)	
LUSC	cis	1	rs12577464	chr11:43662440	HSD17B12	chr11:43702143-43878160:+	-0.46	-8.14	3.43E-15	Forced vital capacity	
LUSC	cis	1	rs12583	chr3:49571462	AMT	chr3:49454212-49460012:-	-0.2	-4.66	4.05E-6	Menarche (age at onset)	
LUSC	cis	1	rs12587394	chr14:93754437	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs12588240	chr14:75612083	MLH3	chr14:75480467-75518235:-	0.27	5.84	9.73E-9	Height	
LUSC	cis	1	rs12589376	chr14:75561152	MLH3	chr14:75480467-75518235:-	0.28	6.03	3.23E-9	Height	
LUSC	cis	1	rs12589815	chr14:75544101	MLH3	chr14:75480467-75518235:-	0.28	5.9	6.97E-9	Height	
LUSC	cis	1	rs12589876	chr14:75544189	MLH3	chr14:75480467-75518235:-	0.28	5.93	5.73E-9	Height	
LUSC	cis	1	rs12590407	chr14:24835115	ADCY4	chr14:24787571-24804277:-	0.18	4.5	8.74E-6	Height	
LUSC	cis	1	rs12590407	chr14:24835115	NYNRIN	chr14:24867992-24888493:+	0.16	4.17	3.57E-5	Height	
LUSC	cis	1	rs12590452	chr14:75548756	MLH3	chr14:75480467-75518235:-	0.27	5.75	1.57E-8	Height	
LUSC	cis	1	rs12590553	chr14:93737668	COX8C	chr14:93813537-93814700:+	-0.24	-3.74	0.000203	Body mass index	
LUSC	cis	1	rs1259180	chr15:83244680	LOC80154	chr15:82944795-82975797:+;chr15	0.25	5	8.07E-7	Schizophrenia	
LUSC	cis	1	rs12600855	chr17:28279591	EFCAB5	chr17:28256874-28435469:+	0.3	5.62	3.2E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs12600993	chr17:28291222	EFCAB5	chr17:28256874-28435469:+	0.3	5.7	2.06E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs12602901	chr17:4824625	INCA1	chr17:4891426-4900905:-	-0.25	-3.79	0.00017	Blood metabolite levels	
LUSC	cis	1	rs12602912	chr17:65870073	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs12610373	chr19:18398284	KIAA1683	chr19:18367906-18385319:-	-0.21	-4.05	6.06E-5	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs12621280	chr2:232132984	ARMC9	chr2:232063342-232238606:+	0.25	5.14	3.98E-7	Food antigen IgG levels	
LUSC	cis	1	rs12621280	chr2:232132984	HTR2B	chr2:231972952-231989824:-	0.24	4.5	8.75E-6	Food antigen IgG levels	
LUSC	cis	1	rs12621567	chr2:232118813	ARMC9	chr2:232063342-232238606:+	0.23	4.9	1.31E-6	Food antigen IgG levels	
LUSC	cis	1	rs12627787	chr22:51012381	CPT1B	chr22:51007291-51017096:-	-0.34	-4.34	1.76E-5	Narcolepsy	
LUSC	cis	1	rs12630254	chr3:31981227	STT3B	chr3:31574491-31677554:+	0.17	3.7	0.000239	Periodontal disease-related phenotypes	
LUSC	cis	1	rs12637751	chr3:134266124	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs12638253	chr3:156626091	LEKR1	chr3:156544076-156763918:+	-0.25	-5.79	1.27E-8	Multiple sclerosis (severity)	
LUSC	cis	1	rs12639255	chr3:41861738	ULK4	chr3:41288091-42003660:-	0.58	8.91	1.11E-17	Diastolic blood pressure	
LUSC	cis	1	rs12642900	chr4:107010329	TBCK	chr4:106967233-107237861:-	0.28	5.19	3.2E-7	Airflow obstruction	
LUSC	cis	1	rs12648232	chr4:17612537	MED28	chr4:17616273-17629791:+	-0.19	-3.93	9.73E-5	Parasitemia in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs12652003	chr5:150231945	LOC134466	chr5:150310000-150326146:-	0.44	5.65	2.71E-8	Crohn's disease	
LUSC	cis	1	rs12661204	chr6:86678586	SNHG5	chr6:86386726-86388451:-	-0.66	-11.9	9.55E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs12663651	chr6:86701655	SNHG5	chr6:86386726-86388451:-	-0.65	-12.07	1.9E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs12663690	chr6:86640162	SNHG5	chr6:86386726-86388451:-	0.66	12.22	4.77E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs12664335	chr6:86597774	SNHG5	chr6:86386726-86388451:-	0.69	12.82	1.66E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs12665321	chr6:86769289	SNHG5	chr6:86386726-86388451:-	-0.69	-12.51	3.23E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs12672761	chr7:151118604	CRYGN	chr7:151127057-151137899:-	-0.28	-3.84	0.000138	Coronary heart disease	
LUSC	cis	1	rs12672761	chr7:151118604	WDR86	chr7:151078207-151107740:-	-0.29	-4.27	2.41E-5	Coronary heart disease	
LUSC	cis	1	rs12675542	chr8:29986454	MBOAT4	chr8:29989188-30002200:-	-0.36	-4.46	1.03E-5	Migraine	
LUSC	cis	1	rs1267657	chr15:83215251	LOC80154	chr15:82944795-82975797:+;chr15	0.23	4.59	5.71E-6	Schizophrenia	
LUSC	cis	1	rs1267817	chr7:66110040	CCT6P1	chr7:65216092-65228661:+	0.24	3.79	0.00017	Gout	
LUSC	cis	1	rs1267818	chr7:66107024	CCT6P1	chr7:65216092-65228661:+	0.24	3.77	0.000183	Gout	
LUSC	cis	1	rs1267820	chr7:66050295	CCT6P1	chr7:65216092-65228661:+	0.25	3.86	0.000129	Diabetic kidney disease	
LUSC	cis	1	rs12681963	chr8:29982518	MBOAT4	chr8:29989188-30002200:-	-0.4	-4.83	1.88E-6	Migraine	
LUSC	cis	1	rs12691307	chr16:29939877	LOC595101	chr16:30278914-30346695:-	-0.28	-4.41	1.29E-5	Schizophrenia	
LUSC	cis	1	rs12698523	chr7:65968113	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.24	9.6E-10	Aortic root size	
LUSC	cis	1	rs12709812	chr19:37794850	ZNF781	chr19:38158650-38183216:-	-0.28	-4.48	9.28E-6	Coronary artery calcification	
LUSC	cis	1	rs12714629	chr3:85598424	CADM2	chr3:85008133-86117948:+	0.31	4.79	2.28E-6	Longevity (90 years and older)	
LUSC	cis	1	rs12733173	chr1:152173972	FLG	chr1:152274651-152297679:-	0.26	5.15	3.76E-7	Inflammatory skin disease	
LUSC	cis	1	rs12744221	chr1:145645606	NUDT17	chr1:145586494-145590461:-	0.22	4.18	3.4E-5	Epilepsy (remission after treatment)	
LUSC	cis	1	rs1275468	chr12:75935157	GLIPR1L2	chr12:75784889-75825591:+	-0.27	-4.61	5.28E-6	Polycystic ovary syndrome	
LUSC	cis	1	rs1275469	chr12:75935230	GLIPR1L2	chr12:75784889-75825591:+	-0.26	-4.53	7.56E-6	Polycystic ovary syndrome	
LUSC	cis	1	rs12760175	chr1:46447840	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.93	1.34E-11	Body mass index	
LUSC	cis	1	rs12767633	chr10:102056440	PKD2L1	chr10:102047903-102090243:-	-0.27	-4.57	6.32E-6	Obesity-related traits	
LUSC	cis	1	rs12781019	chr10:102057568	PKD2L1	chr10:102047903-102090243:-	0.24	4.04	6.32E-5	Obesity-related traits	
LUSC	cis	1	rs1278493	chr3:135814009	PCCB	chr3:135969167-136056737:+	-0.18	-3.81	0.000156	Gestational age at birth (child effect)	
LUSC	cis	1	rs12787330	chr11:47812311	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.14	4.16E-5	Subjective well-being	
LUSC	cis	1	rs12815795	chr12:21391818	SLCO1B1	chr12:21284128-21392728:+	0.25	3.7	0.000236	Blood metabolite levels	
LUSC	cis	1	rs12828421	chr12:7335217	VAMP1	chr12:6571406-6579843:-	-0.14	-3.7	0.000239	IgG glycosylation	
LUSC	cis	1	rs12829704	chr12:21388621	SLCO1B1	chr12:21284128-21392728:+	0.25	3.7	0.000243	Blood metabolite levels	
LUSC	cis	1	rs1284464	chr12:57964617	FAM119B	chr12:58166383-58176323:+	0.24	4.1	4.94E-5	Rheumatoid arthritis	
LUSC	cis	1	rs12879542	chr14:75507525	MLH3	chr14:75480467-75518235:-	0.26	5.53	5.32E-8	Height	
LUSC	cis	1	rs12881444	chr14:93784302	COX8C	chr14:93813537-93814700:+	-0.23	-3.72	0.000226	Body mass index	
LUSC	cis	1	rs12884084	chr14:93762704	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs12885232	chr14:93771020	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs12889168	chr14:104481957	TDRD9	chr14:104394817-104519002:+	0.27	4.66	4.14E-6	Bipolar disorder	
LUSC	cis	1	rs12889309	chr14:75593902	MLH3	chr14:75480467-75518235:-	0.26	5.63	3.09E-8	Height	
LUSC	cis	1	rs12889472	chr14:75543979	MLH3	chr14:75480467-75518235:-	0.28	5.9	6.97E-9	Height	
LUSC	cis	1	rs12889579	chr14:93789660	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs12892710	chr14:93746091	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000202	Body mass index	
LUSC	cis	1	rs12894309	chr14:93783067	COX8C	chr14:93813537-93814700:+	-0.24	-3.76	0.000189	Body mass index	
LUSC	cis	1	rs12896142	chr14:93783443	COX8C	chr14:93813537-93814700:+	-0.23	-3.72	0.000226	Body mass index	
LUSC	cis	1	rs12897094	chr14:75579416	MLH3	chr14:75480467-75518235:-	0.26	5.61	3.41E-8	Height	
LUSC	cis	1	rs12899981	chr15:85302373	LOC388152	chr15:84867600-84898920:-	-0.23	-4.23	2.85E-5	Schizophrenia	
LUSC	cis	1	rs12902672	chr15:84716986	LOC388152	chr15:84867600-84898920:-	-0.27	-4.87	1.52E-6	Schizophrenia	
LUSC	cis	1	rs12903134	chr15:85337699	LOC388152	chr15:84867600-84898920:-	-0.24	-4.35	1.67E-5	Schizophrenia	
LUSC	cis	1	rs12903820	chr15:84723820	LOC388152	chr15:84867600-84898920:-	-0.27	-4.84	1.72E-6	Schizophrenia	
LUSC	cis	1	rs12905057	chr15:85210765	LOC388152	chr15:84867600-84898920:-	-0.24	-4.22	2.97E-5	Schizophrenia	
LUSC	cis	1	rs12908161	chr15:85207825	LOC388152	chr15:84867600-84898920:-	-0.24	-4.21	3.07E-5	Schizophrenia	
LUSC	cis	1	rs12908549	chr15:85322351	LOC388152	chr15:84867600-84898920:-	-0.23	-4.24	2.71E-5	Schizophrenia	
LUSC	cis	1	rs12910012	chr15:85298662	LOC388152	chr15:84867600-84898920:-	-0.23	-4.23	2.85E-5	Schizophrenia	
LUSC	cis	1	rs12910644	chr15:75358388	SCAMP5	chr15:75287901-75313836:+	0.24	3.88	0.000121	Blood trace element (Zn levels)	
LUSC	cis	1	rs12911736	chr15:85240008	LOC388152	chr15:84867600-84898920:-	-0.24	-4.29	2.2E-5	Schizophrenia	
LUSC	cis	1	rs12912388	chr15:85344550	LOC388152	chr15:84867600-84898920:-	-0.24	-4.3	2.1E-5	Schizophrenia	
LUSC	cis	1	rs12914773	chr15:68019958	IQCH	chr15:67547188-67794139:+	0.22	3.87	0.000126	Motion sickness	
LUSC	cis	1	rs12915234	chr15:84758301	LOC388152	chr15:84867600-84898920:-	-0.27	-4.77	2.47E-6	Schizophrenia	
LUSC	cis	1	rs12916348	chr15:84765527	LOC388152	chr15:84867600-84898920:-	-0.27	-4.84	1.75E-6	Schizophrenia	
LUSC	cis	1	rs12936076	chr17:78601195	NPTX1	chr17:78440633-78450404:-	-0.23	-4.37	1.51E-5	Obesity	
LUSC	cis	1	rs12938856	chr17:40570649	CNTD1	chr17:40950854-40963604:+	0.18	3.77	0.000186	Crohn's disease	
LUSC	cis	1	rs12939613	chr17:78588202	NPTX1	chr17:78440633-78450404:-	-0.26	-4.95	1.05E-6	Obesity	
LUSC	cis	1	rs12948099	chr17:79600799	TSPAN10	chr17:79609349-79615778:+	0.45	9.18	1.32E-18	Eye color traits	
LUSC	cis	1	rs12948909	chr17:40570602	CNTD1	chr17:40950854-40963604:+	0.18	3.79	0.00017	Crohn's disease	
LUSC	cis	1	rs12973620	chr19:58249643	ZNF586	chr19:58281025-58311962:+	-0.27	-3.69	0.000246	Allergic rhinitis	
LUSC	cis	1	rs12980403	chr19:18398139	KIAA1683	chr19:18367906-18385319:-	-0.22	-4.05	5.91E-5	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs12989701	chr2:127887985	BIN1	chr2:127805607-127864864:-	-0.32	-4.47	9.97E-6	Alzheimer's disease (late onset)	
LUSC	cis	1	rs12995491	chr2:88527414	THNSL2	chr2:88469835-88486145:+	-0.33	-6.07	2.6E-9	Response to metformin (IC50)	
LUSC	cis	1	rs13003464	chr2:61186829	C2orf74	chr2:61372243-61391964:+	0.35	6.27	7.89E-10	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LUSC	cis	1	rs13004848	chr2:127887560	BIN1	chr2:127805607-127864864:-	0.33	4.92	1.2E-6	Alzheimer's disease (late onset)	
LUSC	cis	1	rs13006833	chr2:191205499	HIBCH	chr2:191069361-191184559:-	0.24	4.12	4.41E-5	Urinary metabolites	
LUSC	cis	1	rs13009551	chr2:127889118	BIN1	chr2:127805607-127864864:-	-0.3	-4.18	3.46E-5	Alzheimer's disease (late onset)	
LUSC	cis	1	rs13014235	chr2:202215492	ALS2CR12	chr2:202153148-202222101:-	-0.22	-4.06	5.69E-5	Basal cell carcinoma	
LUSC	cis	1	rs13016963	chr2:202162811	ALS2CR12	chr2:202153148-202222101:-	-0.21	-3.93	9.66E-5	Melanoma;Esophageal squamous cell carcinoma	
LUSC	cis	1	rs13016963	chr2:202162811	CASP8	chr2:202098166-202152434:+	0.2	3.7	0.00024	Melanoma;Esophageal squamous cell carcinoma	
LUSC	cis	1	rs13026475	chr2:239178455	LOC151174	chr2:239133754-239140318:-	0.34	3.98	7.84E-5	Irritable bowel syndrome	
LUSC	cis	1	rs13033501	chr2:239181860	LOC151174	chr2:239133754-239140318:-	0.34	3.97	8.45E-5	Irritable bowel syndrome	
LUSC	cis	1	rs13038834	chr20:25441433	FAM182A	chr20:26035250-26067552:+	-0.2	-3.84	0.000139	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs13054985	chr22:23458577	RTDR1	chr22:23401594-23484241:-	-0.24	-4.56	6.48E-6	Bone mineral density	
LUSC	cis	1	rs13056719	chr22:24724099	POM121L9P	chr22:24647589-24661490:+	-0.3	-6.93	1.38E-11	Gut microbiome composition (summer)	
LUSC	cis	1	rs13059720	chr3:134242021	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.38	5.97E-16	Height	
LUSC	cis	1	rs13068434	chr3:85508814	CADM2	chr3:85008133-86117948:+	0.3	4.58	5.86E-6	Longevity (90 years and older)	
LUSC	cis	1	rs13069724	chr3:48478039	ATRIP	chr3:48488141-48507708:+	0.21	4.38	1.48E-5	Longevity	
LUSC	cis	1	rs13069724	chr3:48478039	TREX1	chr3:48501186-48509043:+	-0.39	-8.69	5.87E-17	Longevity	
LUSC	cis	1	rs13071337	chr3:48438189	TREX1	chr3:48501186-48509043:+	-0.43	-9.59	5.07E-20	Longevity	
LUSC	cis	1	rs13071551	chr3:134310867	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.09	4.93E-15	Height	
LUSC	cis	1	rs13076076	chr3:48479039	ATRIP	chr3:48488141-48507708:+	0.18	3.82	0.000153	Longevity	
LUSC	cis	1	rs13076076	chr3:48479039	TREX1	chr3:48501186-48509043:+	-0.4	-8.82	2.18E-17	Longevity	
LUSC	cis	1	rs13076830	chr3:85409979	CADM2	chr3:85008133-86117948:+	0.27	4.13	4.37E-5	Longevity (90 years and older)	
LUSC	cis	1	rs13081177	chr3:134289860	ANAPC13	chr3:134196547-134204865:-	-0.41	-7.98	1.07E-14	Height	
LUSC	cis	1	rs13081688	chr3:134259954	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.23	1.85E-15	Height	
LUSC	cis	1	rs13083794	chr3:121464928	IQCB1	chr3:121488610-121553926:-	0.21	4.37	1.53E-5	Cognitive performance	
LUSC	cis	1	rs13087578	chr3:121369207	IQCB1	chr3:121488610-121553926:-	0.24	5.01	7.63E-7	Cognitive performance	
LUSC	cis	1	rs13087875	chr3:134261123	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs13088309	chr3:49368317	AMT	chr3:49454212-49460012:-	0.18	4.4	1.34E-5	Menarche (age at onset)	
LUSC	cis	1	rs13089966	chr3:134279197	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.48	2.97E-16	Height	
LUSC	cis	1	rs13090969	chr3:134307257	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.09	4.93E-15	Height	
LUSC	cis	1	rs13091785	chr3:48494098	ATRIP	chr3:48488141-48507708:+	0.2	4.02	6.69E-5	Longevity	
LUSC	cis	1	rs13091785	chr3:48494098	TREX1	chr3:48501186-48509043:+	-0.4	-8.77	3.3E-17	Longevity	
LUSC	cis	1	rs13092437	chr3:85595726	CADM2	chr3:85008133-86117948:+	0.31	4.79	2.28E-6	Longevity (90 years and older)	
LUSC	cis	1	rs13096474	chr3:49443081	AMT	chr3:49454212-49460012:-	-0.2	-4.98	9.03E-7	Menarche (age at onset)	
LUSC	cis	1	rs13096474	chr3:49443081	TREX1	chr3:48501186-48509043:+	0.21	3.98	8.0E-5	Menarche (age at onset)	
LUSC	cis	1	rs13096604	chr3:134250099	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.23	1.85E-15	Height	
LUSC	cis	1	rs13099	chr14:75599155	MLH3	chr14:75480467-75518235:-	-0.26	-5.62	3.19E-8	Height	
LUSC	cis	1	rs13130762	chr4:130022875	C4orf33	chr4:130014829-130033842:+	-0.37	-7.49	3.38E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs13133311	chr4:88217223	HSD17B13	chr4:88224941-88244056:-	-0.2	-4.03	6.55E-5	Platelet count	
LUSC	cis	1	rs13134489	chr4:165889437	TRIM61	chr4:165875600-165898818:-	0.17	3.93	9.72E-5	Ovarian cancer in BRCA1 mutation carriers	
LUSC	cis	1	rs13142655	chr4:88195494	HSD17B13	chr4:88224941-88244056:-	-0.2	-4.11	4.6E-5	Platelet count	
LUSC	cis	1	rs1317149	chr11:47486885	C1QTNF4	chr11:47611216-47615961:-	-0.24	-4.39	1.41E-5	Subjective well-being	
LUSC	cis	1	rs131801	chr22:50966634	TYMP	chr22:50964184-50968514:-	0.19	4.71	3.3E-6	Mean corpuscular hemoglobin	
LUSC	cis	1	rs13194429	chr6:86646705	SNHG5	chr6:86386726-86388451:-	-0.67	-12.46	5.11E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs13195401	chr6:26463574	BTN3A2	chr6:26365398-26378546:+	-0.89	-11.92	7.99E-29	Schizophrenia	
LUSC	cis	1	rs13195402	chr6:26463575	BTN3A2	chr6:26365398-26378546:+	-0.89	-11.92	7.99E-29	Schizophrenia	
LUSC	cis	1	rs13196930	chr6:86652245	SNHG5	chr6:86386726-86388451:-	-0.68	-12.42	7.28E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs13199006	chr6:86608708	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs1320893	chr7:143752112	ARHGEF35	chr7:143883677-143892736:-	-0.38	-7.94	1.42E-14	Obesity-related traits	
LUSC	cis	1	rs1320893	chr7:143752112	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.55	6.82E-6	Obesity-related traits	
LUSC	cis	1	rs1320894	chr7:143751802	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.56	2.16E-13	Obesity-related traits	
LUSC	cis	1	rs1320894	chr7:143751802	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.48	9.3E-6	Obesity-related traits	
LUSC	cis	1	rs1320996	chr6:56100431	COL21A1	chr6:55921389-56258892:-	0.19	3.9	0.000111	Pulse pressure	
LUSC	cis	1	rs13217384	chr6:86720000	SNHG5	chr6:86386726-86388451:-	-0.66	-12.64	9.03E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs13219760	chr6:110761189	SLC22A16	chr6:110745907-110797844:-	0.37	4.14	4.12E-5	Glucose homeostasis traits	
LUSC	cis	1	rs13220495	chr6:26441640	BTN3A2	chr6:26365398-26378546:+	-0.91	-11.92	7.42E-29	Schizophrenia	
LUSC	cis	1	rs13220510	chr6:56779141	BEND6	chr6:56819773-56892138:+	-0.34	-4.88	1.42E-6	Menarche (age at onset)	
LUSC	cis	1	rs13226728	chr7:143746578	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.55	2.32E-13	Obesity-related traits	
LUSC	cis	1	rs13226728	chr7:143746578	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.49	9.07E-6	Obesity-related traits	
LUSC	cis	1	rs13232179	chr7:151120948	CRYGN	chr7:151127057-151137899:-	0.28	3.74	0.000206	Coronary heart disease	
LUSC	cis	1	rs13232179	chr7:151120948	WDR86	chr7:151078207-151107740:-	0.29	4.31	2.02E-5	Coronary heart disease	
LUSC	cis	1	rs13234580	chr7:97622829	MGC72080	chr7:97503667-97601638:-	0.37	4.12	4.54E-5	Sudden cardiac arrest	
LUSC	cis	1	rs13235265	chr7:97623339	MGC72080	chr7:97503667-97601638:-	0.35	3.8	0.000162	Sudden cardiac arrest	
LUSC	cis	1	rs13237037	chr7:65997882	CCT6P1	chr7:65216092-65228661:+	0.25	3.86	0.000129	Diabetic kidney disease	
LUSC	cis	1	rs13239306	chr7:66136017	NCRNA00174	chr7:65841032-65865395:-	0.25	5.34	1.47E-7	Aortic root size	
LUSC	cis	1	rs13243677	chr7:143746572	ARHGEF35	chr7:143883677-143892736:-	-0.36	-7.51	2.99E-13	Obesity-related traits	
LUSC	cis	1	rs13243677	chr7:143746572	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.54	7.14E-6	Obesity-related traits	
LUSC	cis	1	rs13252719	chr8:71734569	XKR9	chr8:71581600-71648176:+	0.92	20.58	9.84E-68	Bone mineral density	
LUSC	cis	1	rs13253842	chr8:71625503	XKR9	chr8:71581600-71648176:+	0.91	20.3	1.94E-66	Bone mineral density	
LUSC	cis	1	rs13256369	chr8:8577379	FLJ10661	chr8:8086092-8102386:+	0.24	4.04	6.33E-5	Obesity-related traits	
LUSC	cis	1	rs13259806	chr8:124190103	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13260318	chr8:124190165	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13260626	chr8:124190317	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13260775	chr8:124190167	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13260798	chr8:124190192	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13261021	chr8:124190239	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13261066	chr8:124190276	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13261100	chr8:124190312	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs13266699	chr8:8570313	FLJ10661	chr8:8086092-8102386:+	-0.22	-3.75	0.000197	Obesity-related traits	
LUSC	cis	1	rs13308002	chr7:97620247	MGC72080	chr7:97503667-97601638:-	0.37	4.11	4.6E-5	Sudden cardiac arrest	
LUSC	cis	1	rs13310597	chr7:65598540	LOC493754	chr7:65993446-66057363:-	0.32	3.71	0.000228	Diabetic kidney disease	
LUSC	cis	1	rs13314659	chr3:48449149	ATRIP	chr3:48488141-48507708:+	-0.21	-4.29	2.18E-5	Longevity	
LUSC	cis	1	rs13314659	chr3:48449149	TREX1	chr3:48501186-48509043:+	0.42	9.25	7.84E-19	Longevity	
LUSC	cis	1	rs13322305	chr3:134310791	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs13322887	chr3:49555583	AMT	chr3:49454212-49460012:-	-0.2	-4.73	2.98E-6	Menarche (age at onset)	
LUSC	cis	1	rs13324410	chr3:132739514	TMEM108	chr3:132757171-133116618:+	0.19	4.5	8.44E-6	IgE grass sensitization	
LUSC	cis	1	rs13325965	chr3:41914942	ULK4	chr3:41288091-42003660:-	0.58	8.57	1.5E-16	Diastolic blood pressure	
LUSC	cis	1	rs13361189	chr5:150223387	LOC134466	chr5:150310000-150326146:-	0.34	4.92	1.18E-6	Crohn's disease	
LUSC	cis	1	rs1337844	chr6:86677273	SNHG5	chr6:86386726-86388451:-	-0.66	-12.16	8.14E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs1337850	chr6:86729103	SNHG5	chr6:86386726-86388451:-	-0.68	-12.63	9.58E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs13380863	chr17:61780793	FTSJ3	chr17:61896795-61905031:-	0.33	6.3	6.9E-10	Body mass index	
LUSC	cis	1	rs13383871	chr2:73631779	ALMS1P	chr2:73872046-73912692:+	0.43	7.94	1.51E-14	Metabolite levels	
LUSC	cis	1	rs13383871	chr2:73631779	NAT8	chr2:73867850-73869537:-	0.28	4.73	3.0E-6	Metabolite levels	
LUSC	cis	1	rs13384952	chr2:73723959	ALMS1P	chr2:73872046-73912692:+	-0.31	-4.72	3.15E-6	Metabolite levels	
LUSC	cis	1	rs13385191	chr2:20888265	C2orf43	chr2:20883803-21022827:-	-0.44	-6.67	7.11E-11	Prostate cancer	
LUSC	cis	1	rs13386455	chr2:30480865	LBH	chr2:30454397-30482899:+	-0.22	-3.7	0.000237	Systemic lupus erythematosus	
LUSC	cis	1	rs13387221	chr2:44135314	LRPPRC	chr2:44113363-44223144:-	-0.24	-4.41	1.25E-5	Intelligence (childhood)	
LUSC	cis	1	rs13389106	chr2:30480750	LBH	chr2:30454397-30482899:+	-0.23	-3.82	0.00015	Systemic lupus erythematosus	
LUSC	cis	1	rs13395018	chr2:170937606	FASTKD1	chr2:170386265-170430424:-	-0.41	-4.49	9.12E-6	Pulse pressure	
LUSC	cis	1	rs13398075	chr2:202376269	PPIL3	chr2:201735680-201753999:-	0.48	5	8.22E-7	Rheumatoid arthritis	
LUSC	cis	1	rs13398956	chr2:73720258	ALMS1P	chr2:73872046-73912692:+	0.4	7.33	1.01E-12	Metabolite levels	
LUSC	cis	1	rs13398956	chr2:73720258	NAT8	chr2:73867850-73869537:-	0.26	4.52	7.95E-6	Metabolite levels	
LUSC	cis	1	rs13404123	chr2:219916797	RNF25	chr2:219528588-219536781:-	0.31	3.76	0.000191	Height	
LUSC	cis	1	rs13408294	chr2:202171573	CFLAR	chr2:201980816-202029001:+	-0.27	-4.16	3.84E-5	Rheumatoid arthritis	
LUSC	cis	1	rs13408294	chr2:202171573	PPIL3	chr2:201735680-201753999:-	-0.5	-6.21	1.15E-9	Rheumatoid arthritis	
LUSC	cis	1	rs13409250	chr2:37463642	CEBPZ	chr2:37428778-37458740:-	-0.17	-3.88	0.000119	Chronic lymphocytic leukemia	
LUSC	cis	1	rs13415839	chr2:232126534	ARMC9	chr2:232063342-232238606:+	0.22	4.71	3.19E-6	Food antigen IgG levels	
LUSC	cis	1	rs13421462	chr2:73719875	ALMS1P	chr2:73872046-73912692:+	0.39	7.26	1.63E-12	Metabolite levels	
LUSC	cis	1	rs13421462	chr2:73719875	NAT8	chr2:73867850-73869537:-	0.26	4.47	9.79E-6	Metabolite levels	
LUSC	cis	1	rs13428235	chr2:73633430	ALMS1P	chr2:73872046-73912692:+	0.44	7.91	1.83E-14	Metabolite levels	
LUSC	cis	1	rs13428235	chr2:73633430	NAT8	chr2:73867850-73869537:-	0.27	4.49	9.13E-6	Metabolite levels	
LUSC	cis	1	rs13431267	chr2:73782200	ALMS1P	chr2:73872046-73912692:+	0.4	7.52	2.82E-13	Metabolite levels	
LUSC	cis	1	rs13431267	chr2:73782200	NAT8	chr2:73867850-73869537:-	0.27	4.74	2.88E-6	Metabolite levels	
LUSC	cis	1	rs13432605	chr2:73810981	ALMS1P	chr2:73872046-73912692:+	0.41	7.61	1.49E-13	Metabolite levels	
LUSC	cis	1	rs13432605	chr2:73810981	NAT8	chr2:73867850-73869537:-	0.27	4.75	2.69E-6	Metabolite levels	
LUSC	cis	1	rs13437605	chr6:118899014	C6orf204	chr6:118786239-119031238:-	-0.23	-3.79	0.000168	Renal cell carcinoma	
LUSC	cis	1	rs13438327	chr7:97620691	MGC72080	chr7:97503667-97601638:-	0.35	3.95	9.15E-5	Sudden cardiac arrest	
LUSC	cis	1	rs134869	chr22:42652074	CYP2D6	chr22:42522502-42526883:-	-0.43	-9.82	7.63E-21	Cognitive function	
LUSC	cis	1	rs134873	chr22:42657566	CYP2D6	chr22:42522502-42526883:-	-0.42	-9.74	1.47E-20	Cognitive function	
LUSC	cis	1	rs134882	chr22:42670965	CYP2D6	chr22:42522502-42526883:-	-0.41	-9.53	7.82E-20	Cognitive function	
LUSC	cis	1	rs134900	chr22:42683343	CYP2D6	chr22:42522502-42526883:-	-0.44	-10.23	2.57E-22	Cognitive function	
LUSC	cis	1	rs134902	chr22:42683997	CYP2D6	chr22:42522502-42526883:-	-0.43	-9.95	2.69E-21	Cognitive function	
LUSC	cis	1	rs1349636	chr4:75712260	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs1351452	chr11:116943354	PCSK7	chr11:117075789-117102811:-	0.35	4.91	1.25E-6	Protein quantitative trait loci	
LUSC	cis	1	rs1355412	chr8:29985683	MBOAT4	chr8:29989188-30002200:-	0.3	3.84	0.000139	Migraine	
LUSC	cis	1	rs1357762	chr3:134264859	ANAPC13	chr3:134196547-134204865:-	0.42	8.33	8.46E-16	Height	
LUSC	cis	1	rs1363055	chr7:65943275	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs1371135	chr15:90391270	AP3S2	chr15:90373832-90456222:-	-0.61	-10.46	3.62E-23	Type 2 diabetes	
LUSC	cis	1	rs1371161	chr4:154655171	TLR2	chr4:154605441-154627240:+	-0.2	-3.95	9.06E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs1377032	chr4:75712104	G3BP2	chr4:76567955-76598667:-	0.33	3.94	9.43E-5	Electroencephalogram traits	
LUSC	cis	1	rs1377032	chr4:75712104	MTHFD2L	chr4:74979896-75168812:+	0.32	3.7	0.000241	Electroencephalogram traits	
LUSC	cis	1	rs138209	chr22:50539413	MLC1	chr22:50497820-50524358:-	-0.2	-4.05	6.08E-5	Gestational age at birth in labor-initiated deliveries (child effect)	
LUSC	cis	1	rs138702	chr22:39132601	CBY1	chr22:39052658-39069853:+	-0.21	-3.95	9.15E-5	Resting heart rate	
LUSC	cis	1	rs138704	chr22:39133410	CBY1	chr22:39052658-39069853:+	0.26	4.73	2.99E-6	Resting heart rate	
LUSC	cis	1	rs138705	chr22:39133803	CBY1	chr22:39052658-39069853:+	0.26	4.63	4.67E-6	Resting heart rate	
LUSC	cis	1	rs138706	chr22:39137834	CBY1	chr22:39052658-39069853:+	0.25	4.68	3.82E-6	Resting heart rate	
LUSC	cis	1	rs138709	chr22:39139216	CBY1	chr22:39052658-39069853:+	0.26	4.78	2.31E-6	Resting heart rate	
LUSC	cis	1	rs138712	chr22:39141600	CBY1	chr22:39052658-39069853:+	0.27	5.17	3.53E-7	Resting heart rate	
LUSC	cis	1	rs138713	chr22:39142615	CBY1	chr22:39052658-39069853:+	0.25	4.66	4.02E-6	Resting heart rate	
LUSC	cis	1	rs138716	chr22:39146527	CBY1	chr22:39052658-39069853:+	0.24	4.34	1.77E-5	Resting heart rate	
LUSC	cis	1	rs1390006	chr17:56890663	RAD51C	chr17:56769963-56811690:+	-0.3	-6.63	9.39E-11	Cognitive test performance	
LUSC	cis	1	rs1391708	chr12:57305580	DCTN2	chr12:57924094-57940978:-	-0.26	-3.74	0.00021	Airway wall thickness	
LUSC	cis	1	rs1393244	chr5:132186007	SLC22A5	chr5:131705401-131731302:+	-0.28	-4.02	6.66E-5	Apolipoprotein A-IV levels	
LUSC	cis	1	rs1403284	chr2:73726662	ALMS1P	chr2:73872046-73912692:+	-0.38	-7.01	8.06E-12	Metabolite levels	
LUSC	cis	1	rs1403284	chr2:73726662	NAT8	chr2:73867850-73869537:-	-0.25	-4.37	1.51E-5	Metabolite levels	
LUSC	cis	1	rs1404147	chr7:65264524	CCT6P1	chr7:65216092-65228661:+	0.25	4.2	3.18E-5	Diabetic kidney disease	
LUSC	cis	1	rs1404147	chr7:65264524	LOC493754	chr7:65993446-66057363:-	0.37	4.52	7.82E-6	Diabetic kidney disease	
LUSC	cis	1	rs1406384	chr11:62083530	TMEM138	chr11:61129856-61136680:+	0.27	3.71	0.00023	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs1406947	chr20:33969530	CEP250	chr20:34042996-34099802:+	-0.15	-4.02	6.73E-5	Height	
LUSC	cis	1	rs1406947	chr20:33969530	CPNE1	chr20:34213968-34262539:-	0.27	4.61	5.09E-6	Height	
LUSC	cis	1	rs1406947	chr20:33969530	UQCC	chr20:33890383-33999833:-	0.28	5.05	6.4E-7	Height	
LUSC	cis	1	rs1408916	chr1:92992627	EVI5	chr1:92974255-93257961:-	-0.31	-4.57	6.31E-6	Cholesterol, total	
LUSC	cis	1	rs1411690	chr9:112305107	TXN	chr9:113006310-113018833:-	0.12	3.84	0.000142	Vascular brain injury	
LUSC	cis	1	rs1412444	chr10:91002927	LIPA	chr10:90973328-91174382:-	0.23	6.42	3.22E-10	Fibrinogen levels	
LUSC	cis	1	rs1412445	chr10:91002804	LIPA	chr10:90973328-91174382:-	0.24	6.51	1.88E-10	Fibrinogen levels	
LUSC	cis	1	rs1415753	chr6:86753074	SNHG5	chr6:86386726-86388451:-	-0.69	-12.41	7.67E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs1417823	chr10:102227886	SEC31B	chr10:102246403-102289636:-	0.27	8.46	3.22E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs1419183	chr6:28242794	ZNF187	chr6:28234788-28245978:+	-0.22	-3.7	0.00024	Depression	
LUSC	cis	1	rs1423620	chr5:56100996	C5orf35	chr5:56205103-56213010:+	0.87	14.58	4.56E-40	Type 2 diabetes	
LUSC	cis	1	rs1423621	chr5:56101035	C5orf35	chr5:56205103-56213010:+	0.82	15	6.35E-42	Type 2 diabetes	
LUSC	cis	1	rs1428555	chr5:150257391	LOC134466	chr5:150310000-150326146:-	-0.4	-5.59	3.88E-8	Crohn's disease	
LUSC	cis	1	rs144098432	chr18:51816394	POLI	chr18:51795849-51824602:+	0.24	4.42	1.21E-5	Inflammatory skin disease	
LUSC	cis	1	rs1443438	chr9:100550028	CTSL2	chr9:99794940-99822167:-	-0.2	-3.84	0.000141	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs1449572	chr13:49466931	RCBTB1	chr13:50106082-50159719:-	0.27	3.91	0.000106	Multiple myeloma (IgH translocation)	
LUSC	cis	1	rs1451707	chr6:56801877	BEND6	chr6:56819773-56892138:+	-0.39	-5.44	8.51E-8	Menarche (age at onset)	
LUSC	cis	1	rs1451708	chr6:56802201	BEND6	chr6:56819773-56892138:+	-0.39	-5.44	8.51E-8	Menarche (age at onset)	
LUSC	cis	1	rs1452311	chr4:75715017	G3BP2	chr4:76567955-76598667:-	0.33	4	7.28E-5	Electroencephalogram traits	
LUSC	cis	1	rs1459242	chr3:48413537	ATRIP	chr3:48488141-48507708:+	-0.2	-4.05	5.97E-5	Longevity	
LUSC	cis	1	rs1459242	chr3:48413537	TREX1	chr3:48501186-48509043:+	0.43	9.21	1.08E-18	Longevity	
LUSC	cis	1	rs1460561	chr6:56797574	BEND6	chr6:56819773-56892138:+	-0.34	-4.76	2.53E-6	Menarche (age at onset)	
LUSC	cis	1	rs1464400	chr3:132726096	TMEM108	chr3:132757171-133116618:+	0.2	4.77	2.5E-6	IgE grass sensitization	
LUSC	cis	1	rs1464569	chr3:49460350	AMT	chr3:49454212-49460012:-	0.21	5.09	5.07E-7	Menarche (age at onset)	
LUSC	cis	1	rs1464569	chr3:49460350	TREX1	chr3:48501186-48509043:+	-0.23	-4.28	2.29E-5	Menarche (age at onset)	
LUSC	cis	1	rs1474698	chr6:56064197	COL21A1	chr6:55921389-56258892:-	-0.21	-4.37	1.54E-5	Pulse pressure	
LUSC	cis	1	rs148369819	chr2:142873026	LRP1B	chr2:140988996-142889270:-	0.17	3.69	0.000245	Parental longevity (mother's age at death)	
LUSC	cis	1	rs1484994	chr20:30305975	COX4I2	chr20:30225691-30232800:+	0.21	4.27	2.4E-5	Subcortical brain region volumes	
LUSC	cis	1	rs1498315	chr1:76159225	ACADM	chr1:76190043-76229353:+	0.22	3.94	9.3E-5	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs1498316	chr1:76159198	ACADM	chr1:76190043-76229353:+	0.21	3.73	0.000218	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs1498718	chr3:134205920	ANAPC13	chr3:134196547-134204865:-	0.43	8.77	3.29E-17	Height	
LUSC	cis	1	rs1503960	chr14:93778741	COX8C	chr14:93813537-93814700:+	-0.24	-3.74	0.000205	Body mass index	
LUSC	cis	1	rs151222	chr16:20674492	ACSM1	chr16:20634559-20709066:-	-0.35	-4.22	2.95E-5	Schizophrenia	
LUSC	cis	1	rs151964	chr5:96123666	ERAP1	chr5:96096515-96149837:-	-0.45	-11.06	1.78E-25	Ankylosing spondylitis	
LUSC	cis	1	rs151964	chr5:96123666	ERAP2	chr5:96211644-96255398:+	0.37	7.23	1.89E-12	Ankylosing spondylitis	
LUSC	cis	1	rs1521092	chr3:132740912	TMEM108	chr3:132757171-133116618:+	0.19	4.48	9.31E-6	IgE grass sensitization	
LUSC	cis	1	rs1525738	chr7:16889926	ANKMY2	chr7:16639413-16685398:-	0.21	3.73	0.000217	Type 2 diabetes (dietary heme iron intake interaction)	
LUSC	cis	1	rs1529957	chr19:37739801	ZNF781	chr19:38158650-38183216:-	0.27	4.4	1.36E-5	Coronary artery calcification	
LUSC	cis	1	rs1533266	chr7:143766714	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7	8.56E-12	Obesity-related traits	
LUSC	cis	1	rs1533266	chr7:143766714	OR2A9P	chr7:143991573-143997832:+;chr7	-0.23	-4.15	4.0E-5	Obesity-related traits	
LUSC	cis	1	rs1533267	chr7:143766440	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.97	1.1E-11	Obesity-related traits	
LUSC	cis	1	rs1533267	chr7:143766440	OR2A9P	chr7:143991573-143997832:+;chr7	-0.23	-4.09	5.11E-5	Obesity-related traits	
LUSC	cis	1	rs1533268	chr7:143766358	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.97	1.1E-11	Obesity-related traits	
LUSC	cis	1	rs1533268	chr7:143766358	OR2A9P	chr7:143991573-143997832:+;chr7	-0.23	-4.09	5.11E-5	Obesity-related traits	
LUSC	cis	1	rs1534025	chr3:134313304	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.09	5.2E-15	Height	
LUSC	cis	1	rs1534026	chr3:134284767	ANAPC13	chr3:134196547-134204865:-	0.41	8.07	5.72E-15	Height	
LUSC	cis	1	rs1534471	chr2:73647508	ALMS1P	chr2:73872046-73912692:+	0.42	7.62	1.38E-13	Metabolite levels	
LUSC	cis	1	rs1534471	chr2:73647508	NAT8	chr2:73867850-73869537:-	0.24	4.03	6.42E-5	Metabolite levels	
LUSC	cis	1	rs1540651	chr7:65650121	NCRNA00174	chr7:65841032-65865395:-	0.3	6.35	5.11E-10	Aortic root size	
LUSC	cis	1	rs1540894	chr7:143767676	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7.18	2.69E-12	Obesity-related traits	
LUSC	cis	1	rs1540894	chr7:143767676	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.31	2.01E-5	Obesity-related traits	
LUSC	cis	1	rs1540927	chr20:33931344	CEP250	chr20:34042996-34099802:+	-0.16	-4.22	2.94E-5	Height	
LUSC	cis	1	rs1540927	chr20:33931344	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.4E-6	Height	
LUSC	cis	1	rs1540927	chr20:33931344	UQCC	chr20:33890383-33999833:-	0.28	5.2	2.99E-7	Height	
LUSC	cis	1	rs1544549	chr7:66090663	NCRNA00174	chr7:65841032-65865395:-	0.27	5.74	1.72E-8	Aortic root size	
LUSC	cis	1	rs1548226	chr20:43983777	SYS1	chr20:43991701-44004724:+	0.23	4.19	3.31E-5	Psoriasis	
LUSC	cis	1	rs1548226	chr20:43983777	SYS1-DBNDD2	chr20:43991701-44039245:+	0.23	3.72	0.000223	Psoriasis	
LUSC	cis	1	rs1552994	chr1:152171461	FLG	chr1:152274651-152297679:-	0.26	5.15	3.76E-7	Inflammatory skin disease	
LUSC	cis	1	rs1553609	chr7:66197139	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.47	7.11E-8	Aortic root size	
LUSC	cis	1	rs1553610	chr7:66197233	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.47	7.11E-8	Aortic root size	
LUSC	cis	1	rs1555337	chr20:61863641	BIRC7	chr20:61867276-61871853:+	-0.32	-4.42	1.21E-5	Response to cytadine analogues (cytosine arabinoside)	
LUSC	cis	1	rs1556562	chr1:93034023	EVI5	chr1:92974255-93257961:-	0.33	4.7	3.36E-6	Cholesterol, total	
LUSC	cis	1	rs1557503	chr22:51013072	CPT1B	chr22:51007291-51017096:-	-0.33	-4.21	3.05E-5	Narcolepsy	
LUSC	cis	1	rs1558299	chr7:151121676	WDR86	chr7:151078207-151107740:-	0.26	3.98	8.1E-5	Coronary heart disease	
LUSC	cis	1	rs1559282	chr5:56099375	C5orf35	chr5:56205103-56213010:+	0.84	14.29	8.29E-39	Type 2 diabetes	
LUSC	cis	1	rs1561962	chr9:100546219	CTSL2	chr9:99794940-99822167:-	-0.2	-3.72	0.000222	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs1563736	chr3:48436794	TREX1	chr3:48501186-48509043:+	-0.43	-9.59	5.07E-20	Longevity	
LUSC	cis	1	rs15637	chr17:61772050	FTSJ3	chr17:61896795-61905031:-	0.32	6.22	1.07E-9	Body mass index	
LUSC	cis	1	rs156407	chr7:23315639	GPNMB	chr7:23286316-23314728:+	-0.25	-4.96	9.77E-7	Parkinson's disease	
LUSC	cis	1	rs156421	chr7:23312487	GPNMB	chr7:23286316-23314728:+	-0.25	-5.03	7.02E-7	Parkinson's disease	
LUSC	cis	1	rs156425	chr7:23309119	GPNMB	chr7:23286316-23314728:+	0.25	5.06	5.92E-7	Parkinson's disease	
LUSC	cis	1	rs1564716	chr3:41862613	ULK4	chr3:41288091-42003660:-	0.58	8.91	1.11E-17	Diastolic blood pressure	
LUSC	cis	1	rs1565531	chr7:65663113	NCRNA00174	chr7:65841032-65865395:-	0.29	6.28	7.57E-10	Aortic root size	
LUSC	cis	1	rs15676	chr9:131572027	ENDOG	chr9:131580779-131584954:+	-0.24	-5.47	7.13E-8	Blood metabolite levels	
LUSC	cis	1	rs1568750	chr2:225342597	FAM124B	chr2:225243416-225266711:-	0.2	3.8	0.000166	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
LUSC	cis	1	rs1570004	chr20:33958253	CPNE1	chr20:34213968-34262539:-	0.3	5.35	1.4E-7	Height	
LUSC	cis	1	rs1570004	chr20:33958253	UQCC	chr20:33890383-33999833:-	0.31	5.85	9.35E-9	Height	
LUSC	cis	1	rs1570836	chr1:92972457	EVI5	chr1:92974255-93257961:-	-0.32	-4.6	5.42E-6	Cholesterol, total	
LUSC	cis	1	rs1570837	chr1:93006816	EVI5	chr1:92974255-93257961:-	-0.32	-4.64	4.53E-6	Cholesterol, total	
LUSC	cis	1	rs1573897	chr1:247215054	ZNF670	chr1:247200087-247242069:-	-0.21	-3.93	9.59E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs1577917	chr6:86691940	SNHG5	chr6:86386726-86388451:-	-0.66	-12.06	2.14E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs1577919	chr6:86757296	SNHG5	chr6:86386726-86388451:-	-0.69	-12.46	4.88E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs1588635	chr9:100537802	CTSL2	chr9:99794940-99822167:-	-0.22	-3.9	0.00011	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs1599280	chr6:56792576	BEND6	chr6:56819773-56892138:+	-0.39	-5.49	6.59E-8	Menarche (age at onset)	
LUSC	cis	1	rs1599281	chr6:56789311	BEND6	chr6:56819773-56892138:+	0.35	5.41	9.99E-8	Menarche (age at onset)	
LUSC	cis	1	rs1599932	chr12:58177943	FAM119B	chr12:58166383-58176323:+	0.54	9.35	3.36E-19	Multiple sclerosis	
LUSC	cis	1	rs1599932	chr12:58177943	TSFM	chr12:58176536-58191367:+	-0.4	-8.58	1.31E-16	Multiple sclerosis	
LUSC	cis	1	rs1599932	chr12:58177943	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.35	1.64E-5	Multiple sclerosis	
LUSC	cis	1	rs1609810	chr9:123642351	LOC253039	chr9:123605320-123616644:+	-0.34	-6.39	3.89E-10	Rheumatoid arthritis	
LUSC	cis	1	rs1612028	chr10:73805290	SPOCK2	chr10:73818793-73848790:-	-0.12	-4.61	5.23E-6	Smoking behavior	
LUSC	cis	1	rs1612124	chr3:41967893	ULK4	chr3:41288091-42003660:-	-0.62	-9.49	1.14E-19	Diastolic blood pressure	
LUSC	cis	1	rs1630642	chr10:73804620	SPOCK2	chr10:73818793-73848790:-	0.14	4.93	1.14E-6	Smoking behavior	
LUSC	cis	1	rs1633360	chr12:58108052	FAM119B	chr12:58166383-58176323:+	-0.36	-6.21	1.14E-9	Rheumatoid arthritis	
LUSC	cis	1	rs1633360	chr12:58108052	TSFM	chr12:58176536-58191367:+	0.33	7.35	8.89E-13	Rheumatoid arthritis	
LUSC	cis	1	rs1665364	chr4:1727206	FAM53A	chr4:1641609-1685854:-	0.28	4.81	2.01E-6	Urinary bladder cancer;Bladder cancer	
LUSC	cis	1	rs1665366	chr4:1728381	FAM53A	chr4:1641609-1685854:-	0.31	5.24	2.46E-7	Urinary bladder cancer;Bladder cancer	
LUSC	cis	1	rs1665982	chr3:47905079	NME6	chr3:48335591-48342886:-	0.22	4.14	4.05E-5	Educational attainment (years of education)	
LUSC	cis	1	rs166663	chr7:23316742	GPNMB	chr7:23286316-23314728:+	-0.22	-4.42	1.2E-5	Parkinson's disease	
LUSC	cis	1	rs166870	chr15:80069762	MTHFS	chr15:80137320-80189370:-	0.22	3.88	0.000118	Disease-free survival in breast cancer	
LUSC	cis	1	rs1678618	chr10:73806288	SPOCK2	chr10:73818793-73848790:-	0.13	4.68	3.74E-6	Smoking behavior	
LUSC	cis	1	rs1679381	chr12:75946124	GLIPR1L2	chr12:75784889-75825591:+	-0.25	-4.34	1.76E-5	Polycystic ovary syndrome	
LUSC	cis	1	rs16826864	chr3:156580033	LEKR1	chr3:156544076-156763918:+	-0.39	-6.28	7.66E-10	Bone mineral density	
LUSC	cis	1	rs16837131	chr2:202173812	PPIL3	chr2:201735680-201753999:-	0.48	5.93	5.89E-9	Rheumatoid arthritis	
LUSC	cis	1	rs16840074	chr1:150683156	HORMAD1	chr1:150670542-150693352:-	-0.51	-5.17	3.45E-7	Congenital left-sided heart lesions	
LUSC	cis	1	rs16854186	chr1:179473704	TDRD5	chr1:179561025-179660398:+	-0.42	-4.34	1.78E-5	Multiple sclerosis (age of onset)	
LUSC	cis	1	rs16862375	chr1:169547407	SLC19A2	chr1:169433151-169455208:-	0.33	3.71	0.000234	Hippocampal atrophy	
LUSC	cis	1	rs16863064	chr3:187887577	FLJ42393	chr3:187896331-187898596:+	0.34	4.93	1.15E-6	Schizophrenia	
LUSC	cis	1	rs16876529	chr6:86591202	SNHG5	chr6:86386726-86388451:-	-0.69	-13.19	4.51E-34	Response to antipsychotic treatment	
LUSC	cis	1	rs16892900	chr8:120644433	DSCC1	chr8:120846182-120868170:-	-0.23	-4.02	6.79E-5	Height	
LUSC	cis	1	rs16892938	chr8:120684434	DSCC1	chr8:120846182-120868170:-	0.23	3.91	0.000107	Height	
LUSC	cis	1	rs16898084	chr8:124190377	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs16898086	chr8:124190445	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs16898088	chr8:124190501	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs16898095	chr8:124193523	FAM83A	chr8:124191287-124222317:+	-0.28	-4.49	8.76E-6	Urinary uromodulin levels	
LUSC	cis	1	rs16898097	chr8:124195034	FAM83A	chr8:124191287-124222317:+	-0.28	-4.51	8.24E-6	Urinary uromodulin levels	
LUSC	cis	1	rs16902321	chr5:2015148	MRPL36	chr5:1798500-1799956:-	-0.19	-3.85	0.000134	Gut microbiome composition (winter)	
LUSC	cis	1	rs16916041	chr10:63146547	C10orf107	chr10:63422719-63526089:+	-0.25	-3.9	0.000111	Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia	
LUSC	cis	1	rs16928809	chr11:2936952	SLC22A18	chr11:2920951-2946475:+	-0.35	-4.85	1.68E-6	Bilirubin levels	
LUSC	cis	1	rs16942155	chr15:60418758	BNIP2	chr15:59955064-59981642:-	0.37	4.16	3.73E-5	Type 2 diabetes	
LUSC	cis	1	rs16947005	chr17:61702989	FTSJ3	chr17:61896795-61905031:-	-0.32	-6.3	6.67E-10	Body mass index	
LUSC	cis	1	rs16947014	chr17:61719032	FTSJ3	chr17:61896795-61905031:-	0.33	6.34	5.51E-10	Body mass index	
LUSC	cis	1	rs16947042	chr17:61766457	FTSJ3	chr17:61896795-61905031:-	0.32	6.23	1.02E-9	Body mass index	
LUSC	cis	1	rs16954776	chr13:98700617	FARP1	chr13:98794816-99102016:+	0.41	3.82	0.000151	Smooth-surface caries	
LUSC	cis	1	rs16954776	chr13:98700617	IPO5	chr13:98605929-98676549:+	0.48	4.82	1.96E-6	Smooth-surface caries	
LUSC	cis	1	rs16954776	chr13:98700617	RAP2A	chr13:98086475-98120251:+	0.52	5.15	3.75E-7	Smooth-surface caries	
LUSC	cis	1	rs16954776	chr13:98700617	STK24	chr13:99102455-99229396:-	0.56	4.73	2.9E-6	Smooth-surface caries	
LUSC	cis	1	rs16967057	chr19:32914078	DPY19L3	chr19:32896677-32975236:+	-0.28	-4.52	7.66E-6	Bipolar disorder	
LUSC	cis	1	rs16967141	chr19:32971223	DPY19L3	chr19:32896677-32975236:+	0.25	3.8	0.000167	Bipolar disorder	
LUSC	cis	1	rs16972767	chr19:39153044	LGALS7B	chr19:39279850-39282393:+	0.19	3.96	8.48E-5	Heart rate	
LUSC	cis	1	rs16973234	chr15:82234533	RPS17	chr15:82821161-82824865:-;chr15	0.42	4.66	4.09E-6	Colorectal cancer (aspirin and/or NSAID use interaction)	
LUSC	cis	1	rs16979306	chr19:13802760	KLF1	chr19:12995239-12998017:-	0.2	3.76	0.000195	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
LUSC	cis	1	rs16987832	chr22:29978749	NIPSNAP1	chr22:29950800-29977144:-	0.27	4.61	5.14E-6	Lipid traits	
LUSC	cis	1	rs1699392	chr4:130022347	C4orf33	chr4:130014829-130033842:+	-0.37	-7.49	3.38E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1699393	chr4:130019352	C4orf33	chr4:130014829-130033842:+	-0.37	-7.56	2.14E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1699394	chr4:130019312	C4orf33	chr4:130014829-130033842:+	-0.39	-7.87	2.48E-14	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs16996444	chr19:9997238	ZNF266	chr19:9523272-9546234:-	0.24	4.56	6.38E-6	Menarche (age at onset)	
LUSC	cis	1	rs17001074	chr19:11104121	C19orf52	chr19:11039424-11040917:+	-0.4	-3.98	8.02E-5	LDL cholesterol	
LUSC	cis	1	rs17016071	chr4:90644281	MMRN1	chr4:90816003-90875778:+	0.25	3.97	8.46E-5	Parkinson's disease	
LUSC	cis	1	rs17018691	chr12:91473900	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs17018694	chr12:91474052	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs17018731	chr12:91499367	KERA	chr12:91444273-91452131:-	0.22	3.75	0.000199	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs17030613	chr1:113190807	ST7L	chr1:113066142-113162405:-	0.24	3.89	0.000116	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs17030651	chr1:113239382	ST7L	chr1:113066142-113162405:-	0.25	4.13	4.27E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs17031294	chr2:66236037	SPRED2	chr2:65537986-65659656:-	0.28	3.83	0.000147	Bipolar disorder (body mass index interaction)	
LUSC	cis	1	rs17032414	chr3:10158302	GHRL	chr3:10327434-10334631:-	-0.2	-3.75	0.000199	Alzheimer's disease	
LUSC	cis	1	rs17036023	chr1:117129711	C1orf203	chr1:116935487-116961244:-	0.4	4.36	1.58E-5	Asthma (childhood onset)	
LUSC	cis	1	rs17036023	chr1:117129711	CD58	chr1:117057157-117113715:-	0.3	4.4	1.34E-5	Asthma (childhood onset)	
LUSC	cis	1	rs17036023	chr1:117129711	TTF2	chr1:117602949-117645489:+	0.36	4.39	1.42E-5	Asthma (childhood onset)	
LUSC	cis	1	rs17037427	chr1:11873416	CLCN6	chr1:11866207-11907674:+	0.21	4.31	2.02E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs17037429	chr1:11873787	CLCN6	chr1:11866207-11907674:+	-0.22	-4.6	5.39E-6	QRS complex (12-leadsum)	
LUSC	cis	1	rs17037452	chr1:11895675	CLCN6	chr1:11866207-11907674:+	0.2	4.2	3.23E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs17062109	chr3:41810364	ULK4	chr3:41288091-42003660:-	0.66	10.11	6.76E-22	Diastolic blood pressure	
LUSC	cis	1	rs17063584	chr3:41861463	ULK4	chr3:41288091-42003660:-	0.58	8.84	1.89E-17	Diastolic blood pressure	
LUSC	cis	1	rs17063599	chr3:41861676	ULK4	chr3:41288091-42003660:-	0.58	8.84	1.89E-17	Diastolic blood pressure	
LUSC	cis	1	rs17063649	chr3:41863406	ULK4	chr3:41288091-42003660:-	0.58	8.97	6.79E-18	Diastolic blood pressure	
LUSC	cis	1	rs17070580	chr6:109738714	AKD1	chr6:109814059-110012415:-	0.17	4.03	6.57E-5	Height	
LUSC	cis	1	rs17070580	chr6:109738714	SMPD2	chr6:109761931-109765121:+	-0.21	-3.81	0.00016	Height	
LUSC	cis	1	rs17072467	chr13:49472776	RCBTB1	chr13:50106082-50159719:-	0.28	4.04	6.23E-5	Multiple myeloma (IgH translocation)	
LUSC	cis	1	rs1707304	chr1:46598269	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.5	3.21E-13	Body mass index	
LUSC	cis	1	rs1707321	chr1:46505309	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.39	6.67E-13	Body mass index	
LUSC	cis	1	rs1707335	chr1:46571921	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.27	1.51E-12	Body mass index	
LUSC	cis	1	rs1707336	chr1:46493460	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.73	5.02E-11	Body mass index	
LUSC	cis	1	rs1707340	chr1:46514942	CCDC163P	chr1:45960581-45965646:-	-0.37	-7.64	1.17E-13	Body mass index	
LUSC	cis	1	rs17080292	chr6:118850266	C6orf204	chr6:118786239-119031238:-	-0.23	-3.72	0.000227	Renal cell carcinoma	
LUSC	cis	1	rs17080302	chr6:118854037	C6orf204	chr6:118786239-119031238:-	-0.23	-3.72	0.000227	Renal cell carcinoma	
LUSC	cis	1	rs17092215	chr20:33595913	GDF5	chr20:33897002-34042568:-	0.28	3.76	0.000188	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs17092215	chr20:33595913	PROCR	chr20:33758727-33765164:+	-0.32	-4.27	2.33E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs17093141	chr14:74326903	LIN52	chr14:74551656-74667117:+	0.29	4.28	2.26E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs17093474	chr14:74342413	LIN52	chr14:74551656-74667117:+	0.27	4.28	2.25E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs17096228	chr14:74558669	LIN52	chr14:74551656-74667117:+	0.28	6.3	6.66E-10	Common traits (Other)	
LUSC	cis	1	rs17096228	chr14:74558669	PTGR2	chr14:74318534-74352166:+	-0.23	-4.45	1.06E-5	Common traits (Other)	
LUSC	cis	1	rs17101201	chr14:103488068	MARK3	chr14:103851701-103970164:+	-0.33	-3.98	7.89E-5	Large B-cell lymphoma	
LUSC	cis	1	rs17112901	chr10:102066185	PKD2L1	chr10:102047903-102090243:-	-0.24	-4.08	5.32E-5	Obesity-related traits	
LUSC	cis	1	rs17113137	chr10:102241998	SEC31B	chr10:102246403-102289636:-	-0.27	-8.08	5.52E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs17115231	chr12:75933675	GLIPR1L2	chr12:75784889-75825591:+	-0.26	-4.48	9.16E-6	Polycystic ovary syndrome	
LUSC	cis	1	rs17118439	chr12:56667604	PAN2	chr12:56710718-56727825:-	-0.33	-3.76	0.000189	Psoriasis vulgaris	
LUSC	cis	1	rs17121651	chr14:50097172	RPL36AL	chr14:50085407-50087349:-	0.21	4.61	5.29E-6	Carotid intima media thickness	
LUSC	cis	1	rs17127529	chr1:65799440	DNAJC6	chr1:65720148-65881552:+	0.22	4.05	6.06E-5	Idiopathic osteonecrosis of the femoral head	
LUSC	cis	1	rs17129006	chr14:93788891	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs17161692	chr7:98953863	CYP3A5	chr7:99245818-99332821:-	-0.41	-5.25	2.31E-7	Blood metabolite levels	
LUSC	cis	1	rs17164851	chr7:130003487	CPA5	chr7:129984630-130008571:+	0.52	7.87	2.46E-14	Age-related hearing impairment (interaction)	
LUSC	cis	1	rs17166268	chr5:132180990	SLC22A5	chr5:131705401-131731302:+	0.27	4.09	5.06E-5	Apolipoprotein A-IV levels	
LUSC	cis	1	rs1716644	chr3:41968028	ULK4	chr3:41288091-42003660:-	-0.62	-9.49	1.14E-19	Diastolic blood pressure	
LUSC	cis	1	rs1716661	chr3:41962818	ULK4	chr3:41288091-42003660:-	-0.66	-10.52	2.08E-23	Diastolic blood pressure	
LUSC	cis	1	rs1716987	chr3:41970516	ULK4	chr3:41288091-42003660:-	-0.62	-9.49	1.14E-19	Diastolic blood pressure	
LUSC	cis	1	rs1716993	chr3:41974556	ULK4	chr3:41288091-42003660:-	-0.62	-9.48	1.23E-19	Diastolic blood pressure	
LUSC	cis	1	rs1717006	chr3:41940448	ULK4	chr3:41288091-42003660:-	0.65	10.31	1.29E-22	Diastolic blood pressure	
LUSC	cis	1	rs1717020	chr3:41981490	ULK4	chr3:41288091-42003660:-	0.67	10.49	2.6E-23	Diastolic blood pressure	
LUSC	cis	1	rs1717024	chr3:41984888	ULK4	chr3:41288091-42003660:-	-0.62	-10.22	2.63E-22	Diastolic blood pressure	
LUSC	cis	1	rs1717027	chr3:41987920	ULK4	chr3:41288091-42003660:-	-0.65	-10.3	1.41E-22	Diastolic blood pressure	
LUSC	cis	1	rs17172185	chr7:43286839	HECW1	chr7:43152198-43602938:+	-0.41	-3.78	0.00018	Esophageal adenocarcinoma	
LUSC	cis	1	rs17185933	chr1:119474772	WARS2	chr1:119573841-119683295:-	0.29	3.9	0.000111	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs1719271	chr15:65183801	PIF1	chr15:65107833-65117838:-	0.16	3.77	0.000184	Platelet count	
LUSC	cis	1	rs17197710	chr11:47225996	MADD	chr11:47290927-47351582:+	-0.44	-5.51	5.84E-8	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs17216786	chr16:83487471	LRRC50	chr16:84178865-84211523:+	-0.37	-3.72	0.000222	Response to antipsychotic treatment	
LUSC	cis	1	rs17258106	chr4:119675406	SEC24D	chr4:119643979-119759827:-	-0.35	-4.15	3.97E-5	Cannabis dependence	
LUSC	cis	1	rs17279521	chr3:99938137	TBC1D23	chr3:99979686-100044078:+	-0.2	-3.73	0.000214	Visceral adipose tissue/subcutaneous adipose tissue ratio	
LUSC	cis	1	rs17299041	chr4:154673127	TLR2	chr4:154605441-154627240:+	-0.2	-4.04	6.33E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs17304569	chr19:24240905	LOC100101266	chr19:24344995-24346249:-	0.27	4.01	7.18E-5	Response to taxane treatment (placlitaxel)	
LUSC	cis	1	rs17310467	chr20:33545616	PROCR	chr20:33758727-33765164:+	-0.33	-4.14	4.11E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs17311679	chr19:50521331	SIGLEC16	chr19:50472912-50479075:+	-0.73	-7.52	2.72E-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs17317888	chr20:33594959	PROCR	chr20:33758727-33765164:+	-0.33	-4.24	2.65E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs17321999	chr2:30479857	LBH	chr2:30454397-30482899:+	0.25	4.18	3.43E-5	Systemic lupus erythematosus	
LUSC	cis	1	rs17323510	chr8:124186089	FAM83A	chr8:124191287-124222317:+	0.27	4.24	2.64E-5	Urinary uromodulin levels	
LUSC	cis	1	rs173334	chr6:88080223	C6orf164	chr6:88032306-88109459:+	-0.24	-4.48	9.34E-6	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs17353600	chr3:132695039	TMEM108	chr3:132757171-133116618:+	-0.24	-3.77	0.000183	Alcoholism (heaviness of drinking)	
LUSC	cis	1	rs17371021	chr4:154664295	TLR2	chr4:154605441-154627240:+	0.2	3.95	9.03E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs17396823	chr7:128384605	OPN1SW	chr7:128412545-128415844:-	-0.25	-4.45	1.07E-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs17401737	chr20:33552642	PROCR	chr20:33758727-33765164:+	-0.32	-4.1	4.85E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs17407324	chr4:10273043	SLC2A9	chr4:9827850-10041872:-	-0.23	-3.82	0.000152	Schizophrenia (age at onset)	
LUSC	cis	1	rs17433780	chr1:89474818	GBP3	chr1:89472367-89488549:-	0.74	19.28	1.38E-61	Carotid intima media thickness	
LUSC	cis	1	rs17433780	chr1:89474818	GBP7	chr1:89597434-89641723:-	0.26	5.09	5.1E-7	Carotid intima media thickness	
LUSC	cis	1	rs17450788	chr19:22224755	ZNF100	chr19:21906844-21950430:-	-0.3	-4.2	3.19E-5	Body mass index (change over time)	
LUSC	cis	1	rs17450788	chr19:22224755	ZNF43	chr19:21987753-22034830:-	-0.29	-4.07	5.5E-5	Body mass index (change over time)	
LUSC	cis	1	rs17450853	chr6:56788004	BEND6	chr6:56819773-56892138:+	-0.37	-5.4	1.06E-7	Menarche (age at onset)	
LUSC	cis	1	rs17475665	chr7:128408313	OPN1SW	chr7:128412545-128415844:-	0.27	4.71	3.29E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs17496332	chr1:107546375	PRMT6	chr1:107599267-107601907:+	0.39	7.65	1.09E-13	Sex hormone-binding globulin levels	
LUSC	cis	1	rs17515241	chr7:74132014	GATSL1	chr7:74379083-74438803:+	0.23	3.74	0.000204	Menarche (age at onset)	
LUSC	cis	1	rs17516673	chr5:132196711	SLC22A5	chr5:131705401-131731302:+	-0.28	-3.82	0.000153	Apolipoprotein A-IV levels	
LUSC	cis	1	rs175425	chr14:75626131	MLH3	chr14:75480467-75518235:-	-0.28	-5.86	8.76E-9	Height	
LUSC	cis	1	rs175426	chr14:75624134	MLH3	chr14:75480467-75518235:-	-0.27	-5.77	1.4E-8	Height	
LUSC	cis	1	rs175436	chr14:75608683	MLH3	chr14:75480467-75518235:-	-0.29	-6.18	1.37E-9	Height	
LUSC	cis	1	rs175442	chr14:75603564	MLH3	chr14:75480467-75518235:-	-0.27	-5.82	1.07E-8	Height	
LUSC	cis	1	rs175443	chr14:75601963	MLH3	chr14:75480467-75518235:-	-0.27	-5.82	1.07E-8	Height	
LUSC	cis	1	rs175449	chr14:75590846	MLH3	chr14:75480467-75518235:-	-0.26	-5.67	2.5E-8	Height	
LUSC	cis	1	rs175492	chr14:75545220	MLH3	chr14:75480467-75518235:-	0.26	5.62	3.31E-8	Height	
LUSC	cis	1	rs17549954	chr17:61707032	FTSJ3	chr17:61896795-61905031:-	0.34	6.59	1.18E-10	Body mass index	
LUSC	cis	1	rs17549954	chr17:61707032	MAP3K3	chr17:61699775-61773669:+	0.17	3.96	8.58E-5	Body mass index	
LUSC	cis	1	rs175512	chr14:75523382	MLH3	chr14:75480467-75518235:-	-0.26	-5.51	6.03E-8	Height	
LUSC	cis	1	rs17566701	chr7:66193183	NCRNA00174	chr7:65841032-65865395:-	-0.26	-5.41	9.83E-8	Aortic root size	
LUSC	cis	1	rs1757924	chr4:130019599	C4orf33	chr4:130014829-130033842:+	-0.39	-7.94	1.47E-14	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1757925	chr4:130020791	C4orf33	chr4:130014829-130033842:+	0.38	7.78	4.51E-14	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1757927	chr4:130022069	C4orf33	chr4:130014829-130033842:+	-0.37	-7.5	3.13E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1757928	chr4:130022161	C4orf33	chr4:130014829-130033842:+	-0.37	-7.5	3.13E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1757930	chr4:130022356	C4orf33	chr4:130014829-130033842:+	-0.36	-7.3	1.21E-12	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs1757935	chr4:130023759	C4orf33	chr4:130014829-130033842:+	-0.37	-7.47	3.85E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs17587779	chr1:169548206	SLC19A2	chr1:169433151-169455208:-	0.35	3.87	0.000125	Hippocampal atrophy	
LUSC	cis	1	rs17596617	chr11:43690717	HSD17B12	chr11:43702143-43878160:+	-0.49	-9.15	1.71E-18	Forced vital capacity	
LUSC	cis	1	rs17600551	chr15:85319258	LOC388152	chr15:84867600-84898920:-	-0.23	-4.23	2.77E-5	Schizophrenia	
LUSC	cis	1	rs17601029	chr15:85347709	LOC388152	chr15:84867600-84898920:-	-0.24	-4.36	1.61E-5	Schizophrenia	
LUSC	cis	1	rs17605685	chr19:50486741	SIGLEC16	chr19:50472912-50479075:+	0.8	7.81	3.65E-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs17608059	chr17:13910549	CDRT15P	chr17:13927815-13928915:+	-0.34	-7.47	3.76E-13	Temperament	
LUSC	cis	1	rs17608677	chr2:219936871	RNF25	chr2:219528588-219536781:-	0.32	4.55	6.83E-6	Height	
LUSC	cis	1	rs17661933	chr19:50534520	SIGLEC16	chr19:50472912-50479075:+	-0.69	-7.37	7.83E-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs17671250	chr15:40673124	IVD	chr15:40697686-40713512:+	0.34	4.25	2.54E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs17685143	chr6:56774788	BEND6	chr6:56819773-56892138:+	-0.36	-5.21	2.84E-7	Menarche (age at onset)	
LUSC	cis	1	rs1768803	chr1:46546208	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.61E-13	Body mass index	
LUSC	cis	1	rs1768816	chr1:46528599	CCDC163P	chr1:45960581-45965646:-	-0.37	-7.69	8.35E-14	Body mass index	
LUSC	cis	1	rs17691170	chr3:121357626	IQCB1	chr3:121488610-121553926:-	0.2	4.1	4.93E-5	Cognitive performance	
LUSC	cis	1	rs17694011	chr3:134213981	ANAPC13	chr3:134196547-134204865:-	0.42	8.6	1.16E-16	Height	
LUSC	cis	1	rs17694493	chr9:22041998	CDKN2A	chr9:21967752-21994490:-	0.32	4.2	3.24E-5	Prostate cancer	
LUSC	cis	1	rs17694493	chr9:22041998	CDKN2BAS	chr9:21994790-22121091:+	0.36	4.85	1.69E-6	Prostate cancer	
LUSC	cis	1	rs17694493	chr9:22041998	CDKN2B	chr9:22002906-22009312:-	0.27	3.8	0.000164	Prostate cancer	
LUSC	cis	1	rs17694493	chr9:22041998	LOC554202	chr9:21454267-21559832:-	0.26	4.16	3.85E-5	Prostate cancer	
LUSC	cis	1	rs17713396	chr2:227201	SH3YL1	chr2:218138-264810:-	-0.52	-9.09	2.65E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs17713729	chr2:249092	SH3YL1	chr2:218138-264810:-	-0.52	-9.34	3.77E-19	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs17714252	chr2:285471	SH3YL1	chr2:218138-264810:-	-0.5	-8.55	1.76E-16	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs177377	chr14:73753519	HEATR4	chr14:73945193-74025651:-	-0.3	-5.91	6.68E-9	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs17746014	chr10:102315354	SEC31B	chr10:102246403-102289636:-	-0.27	-7.85	2.7E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs1775151	chr1:205745684	PM20D1	chr1:205797154-205819245:-	-0.25	-4.46	1.01E-5	Parkinson's disease	
LUSC	cis	1	rs17752459	chr6:56798755	BEND6	chr6:56819773-56892138:+	-0.37	-5.28	2.01E-7	Menarche (age at onset)	
LUSC	cis	1	rs1778508	chr6:28229881	ZNF187	chr6:28234788-28245978:+	0.25	4.11	4.67E-5	Depression	
LUSC	cis	1	rs1778508	chr6:28229881	ZNF389	chr6:28129551-28137375:+	0.27	3.83	0.000144	Depression	
LUSC	cis	1	rs17818399	chr2:46826026	ATP6V1E2	chr2:46738988-46769696:-	-0.24	-4.17	3.62E-5	Height	
LUSC	cis	1	rs17848459	chr22:51012311	CPT1B	chr22:51007291-51017096:-	-0.34	-4.34	1.76E-5	Narcolepsy	
LUSC	cis	1	rs1789562	chr18:53780029	TCF4	chr18:52889562-53303185:-	0.16	3.73	0.000215	Schizophrenia	
LUSC	cis	1	rs1792695	chr18:53782900	TCF4	chr18:52889562-53303185:-	0.17	3.84	0.00014	Schizophrenia	
LUSC	cis	1	rs1794693	chr6:167405670	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs1795379	chr12:75941042	GLIPR1L2	chr12:75784889-75825591:+	-0.27	-4.69	3.52E-6	Polycystic ovary syndrome	
LUSC	cis	1	rs1796220	chr7:66062100	CCT6P1	chr7:65216092-65228661:+	0.24	3.76	0.00019	Diabetic kidney disease	
LUSC	cis	1	rs1796228	chr7:66033084	CCT6P1	chr7:65216092-65228661:+	0.25	3.86	0.000129	Diabetic kidney disease	
LUSC	cis	1	rs1799922	chr7:128415195	OPN1SW	chr7:128412545-128415844:-	0.26	4.51	8.04E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs1800662	chr10:102289078	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.24E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs180515	chr17:58024275	DHX40P1	chr17:58053385-58096336:-	0.32	6.94	1.26E-11	Multiple sclerosis	
LUSC	cis	1	rs1807282	chr2:114110036	PAX8	chr2:113973575-114036498:-	0.28	3.7	0.000241	Sleep duration;Sleep duration (oversleepers vs undersleepers)	
LUSC	cis	1	rs1814336	chr3:134200823	ANAPC13	chr3:134196547-134204865:-	0.42	8.33	8.63E-16	Height	
LUSC	cis	1	rs1814337	chr3:134200682	ANAPC13	chr3:134196547-134204865:-	0.42	8.26	1.51E-15	Height	
LUSC	cis	1	rs1815787	chr11:116921397	PCSK7	chr11:117075789-117102811:-	-0.36	-5.11	4.74E-7	Subjective well-being	
LUSC	cis	1	rs1818950	chr15:84722521	LOC388152	chr15:84867600-84898920:-	-0.26	-4.65	4.24E-6	Schizophrenia	
LUSC	cis	1	rs1819333	chr6:167373547	RNASET2	chr6:167343008-167412795:-	-0.24	-4.71	3.27E-6	Crohn's disease	
LUSC	cis	1	rs1823061	chr19:37800626	ZNF781	chr19:38158650-38183216:-	0.26	4.17	3.58E-5	Coronary artery calcification	
LUSC	cis	1	rs1823874	chr15:100357435	C15orf51	chr15:100330361-100347132:-	-0.23	-4.6	5.48E-6	IgG glycosylation	
LUSC	cis	1	rs1833896	chr5:56097669	C5orf35	chr5:56205103-56213010:+	0.83	14.41	2.61E-39	Type 2 diabetes	
LUSC	cis	1	rs1834481	chr11:112023827	IL18	chr11:112013976-112034840:-	0.24	4.36	1.61E-5	Interleukin-18 levels	
LUSC	cis	1	rs1848093	chr15:84755527	LOC388152	chr15:84867600-84898920:-	-0.27	-4.76	2.57E-6	Schizophrenia	
LUSC	cis	1	rs1849004	chr19:22142455	ZNF100	chr19:21906844-21950430:-	-0.31	-4.42	1.22E-5	Body mass index (change over time)	
LUSC	cis	1	rs1849004	chr19:22142455	ZNF429	chr19:21688437-21739068:+	-0.29	-4.13	4.31E-5	Body mass index (change over time)	
LUSC	cis	1	rs1849004	chr19:22142455	ZNF430	chr19:21203497-21241652:+	-0.26	-3.74	0.000204	Body mass index (change over time)	
LUSC	cis	1	rs1849004	chr19:22142455	ZNF43	chr19:21987753-22034830:-	-0.28	-4.07	5.54E-5	Body mass index (change over time)	
LUSC	cis	1	rs1849004	chr19:22142455	ZNF493	chr19:21579921-21610294:+	-0.24	-3.71	0.00023	Body mass index (change over time)	
LUSC	cis	1	rs1849781	chr12:43573966	ADAMTS20	chr12:43748013-43945724:-	0.22	4.35	1.69E-5	Type 2 diabetes	
LUSC	cis	1	rs1849784	chr12:43572374	ADAMTS20	chr12:43748013-43945724:-	-0.21	-4.16	3.73E-5	Type 2 diabetes	
LUSC	cis	1	rs1857964	chr6:86635994	SNHG5	chr6:86386726-86388451:-	-0.67	-12.46	5.11E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs1857965	chr6:86630776	SNHG5	chr6:86386726-86388451:-	-0.65	-12.15	8.93E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs1860463	chr7:151119332	CRYGN	chr7:151127057-151137899:-	0.28	3.83	0.000148	Coronary heart disease	
LUSC	cis	1	rs1860463	chr7:151119332	WDR86	chr7:151078207-151107740:-	0.28	4.1	4.89E-5	Coronary heart disease	
LUSC	cis	1	rs1861444	chr2:37464511	CEBPZ	chr2:37428778-37458740:-	0.18	4.08	5.3E-5	Chronic lymphocytic leukemia	
LUSC	cis	1	rs1862619	chr5:56098256	C5orf35	chr5:56205103-56213010:+	0.83	14.29	8.56E-39	Type 2 diabetes	
LUSC	cis	1	rs1863913	chr3:134200205	ANAPC13	chr3:134196547-134204865:-	0.43	8.57	1.48E-16	Height	
LUSC	cis	1	rs1874883	chr3:134205071	ANAPC13	chr3:134196547-134204865:-	0.43	8.75	3.85E-17	Height	
LUSC	cis	1	rs1875124	chr12:58196802	FAM119B	chr12:58166383-58176323:+	0.52	9.13	1.99E-18	Multiple sclerosis	
LUSC	cis	1	rs1875124	chr12:58196802	TSFM	chr12:58176536-58191367:+	-0.41	-8.91	1.08E-17	Multiple sclerosis	
LUSC	cis	1	rs1875124	chr12:58196802	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.39	1.4E-5	Multiple sclerosis	
LUSC	cis	1	rs1877316	chr17:61766880	FTSJ3	chr17:61896795-61905031:-	0.32	6.28	7.82E-10	Body mass index	
LUSC	cis	1	rs1880376	chr3:134270347	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs1880377	chr3:134270468	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs1881123	chr7:1084706	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.87E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs1881245	chr2:73649928	ALMS1P	chr2:73872046-73912692:+	0.41	7.59	1.69E-13	Metabolite levels	
LUSC	cis	1	rs1881245	chr2:73649928	NAT8	chr2:73867850-73869537:-	0.24	4.16	3.83E-5	Metabolite levels	
LUSC	cis	1	rs1882099	chr4:1352685	CRIPAK	chr4:1385340-1389782:+	0.29	4.72	3.04E-6	Systolic blood pressure	
LUSC	cis	1	rs1882140	chr12:91479826	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs1886644	chr1:85350658	MCOLN3	chr1:85483766-85514169:-	-0.21	-3.95	8.94E-5	Glucose homeostasis traits	
LUSC	cis	1	rs1886682	chr1:92977275	EVI5	chr1:92974255-93257961:-	-0.31	-4.53	7.51E-6	Cholesterol, total	
LUSC	cis	1	rs1886683	chr1:92976023	EVI5	chr1:92974255-93257961:-	-0.31	-4.53	7.51E-6	Cholesterol, total	
LUSC	cis	1	rs1888997	chr20:25298988	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000236	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs1895320	chr5:159849586	SLU7	chr5:159828649-159846168:-	-0.27	-3.97	8.16E-5	Insulin-related traits	
LUSC	cis	1	rs1898355	chr10:118828369	KIAA1598	chr10:118644308-118886097:-	-0.24	-4.03	6.43E-5	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs1903330	chr6:56776985	BEND6	chr6:56819773-56892138:+	0.37	5.26	2.21E-7	Menarche (age at onset)	
LUSC	cis	1	rs190414	chr5:56116772	C5orf35	chr5:56205103-56213010:+	0.87	15.33	2.18E-43	Type 2 diabetes	
LUSC	cis	1	rs1904302	chr10:118868941	KIAA1598	chr10:118644308-118886097:-	0.24	3.78	0.00018	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs1911155	chr15:84787635	GOLGA6L5	chr15:85047738-85060078:-	-0.16	-3.77	0.000181	Schizophrenia	
LUSC	cis	1	rs1911155	chr15:84787635	LOC388152	chr15:84867600-84898920:-	-0.27	-4.81	2.07E-6	Schizophrenia	
LUSC	cis	1	rs1911552	chr6:86638024	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs1911553	chr6:86630892	SNHG5	chr6:86386726-86388451:-	-0.65	-12.21	4.99E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs1917130	chr3:134313773	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.17	2.75E-15	Height	
LUSC	cis	1	rs1919948	chr7:143762843	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7	9.0E-12	Obesity-related traits	
LUSC	cis	1	rs1919948	chr7:143762843	OR2A9P	chr7:143991573-143997832:+;chr7	-0.22	-4.08	5.22E-5	Obesity-related traits	
LUSC	cis	1	rs1919949	chr7:143767723	ARHGEF35	chr7:143883677-143892736:-	-0.36	-7.23	1.97E-12	Obesity-related traits	
LUSC	cis	1	rs1919949	chr7:143767723	OR2A9P	chr7:143991573-143997832:+;chr7	-0.23	-4.28	2.25E-5	Obesity-related traits	
LUSC	cis	1	rs1919950	chr7:143767898	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7.18	2.71E-12	Obesity-related traits	
LUSC	cis	1	rs1919950	chr7:143767898	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.32	1.89E-5	Obesity-related traits	
LUSC	cis	1	rs1919951	chr7:143768891	ARHGEF35	chr7:143883677-143892736:-	-0.38	-7.7	8.07E-14	Obesity-related traits	
LUSC	cis	1	rs1919951	chr7:143768891	OR2A9P	chr7:143991573-143997832:+;chr7	-0.26	-4.69	3.5E-6	Obesity-related traits	
LUSC	cis	1	rs1920790	chr12:91492788	KERA	chr12:91444273-91452131:-	0.24	3.91	0.000106	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs1925148	chr6:56095672	COL21A1	chr6:55921389-56258892:-	0.19	3.8	0.000161	Pulse pressure	
LUSC	cis	1	rs1933182	chr1:109999838	SYPL2	chr1:110009100-110024763:+	-0.25	-5.52	5.72E-8	Chronic kidney disease	
LUSC	cis	1	rs1936365	chr6:28268452	ZNF187	chr6:28234788-28245978:+	0.22	3.7	0.000237	Depression	
LUSC	cis	1	rs1950500	chr14:24830850	ADCY4	chr14:24787571-24804277:-	-0.17	-4.25	2.62E-5	Height	
LUSC	cis	1	rs1950500	chr14:24830850	NYNRIN	chr14:24867992-24888493:+	-0.16	-4.1	4.87E-5	Height	
LUSC	cis	1	rs1952012	chr14:50098896	RPL36AL	chr14:50085407-50087349:-	0.21	4.53	7.5E-6	Carotid intima media thickness	
LUSC	cis	1	rs1953126	chr9:123640500	LOC253039	chr9:123605320-123616644:+	-0.34	-6.34	5.36E-10	Rheumatoid arthritis	
LUSC	cis	1	rs1957977	chr14:50090603	RPL36AL	chr14:50085407-50087349:-	0.21	4.61	5.15E-6	Carotid intima media thickness	
LUSC	cis	1	rs1961779	chr12:91483139	KERA	chr12:91444273-91452131:-	0.24	3.94	9.5E-5	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs1962716	chr6:86648436	SNHG5	chr6:86386726-86388451:-	-0.66	-12.03	2.82E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs1966423	chr2:202216661	ALS2CR12	chr2:202153148-202222101:-	-0.21	-3.99	7.61E-5	Basal cell carcinoma	
LUSC	cis	1	rs1966887	chr8:38468811	PLEKHA2	chr8:38758753-38831428:+	-0.21	-3.72	0.000222	Pancreatic cancer	
LUSC	cis	1	rs1968225	chr7:65874773	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs1979	chr6:26377591	BTN3A2	chr6:26365398-26378546:+	-0.9	-14.91	1.65E-41	Schizophrenia	
LUSC	cis	1	rs1981798	chr7:65954903	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.09	2.33E-9	Aortic root size	
LUSC	cis	1	rs1982861	chr3:49577665	AMT	chr3:49454212-49460012:-	0.2	4.79	2.28E-6	Menarche (age at onset)	
LUSC	cis	1	rs198811	chr6:26128446	BTN3A2	chr6:26365398-26378546:+	-0.17	-3.8	0.000166	Schizophrenia	
LUSC	cis	1	rs199347	chr7:23293746	GPNMB	chr7:23286316-23314728:+	-0.26	-5.3	1.76E-7	Parkinson's disease	
LUSC	cis	1	rs199348	chr7:23293098	GPNMB	chr7:23286316-23314728:+	-0.26	-5.43	9.1E-8	Parkinson's disease	
LUSC	cis	1	rs199351	chr7:23300049	GPNMB	chr7:23286316-23314728:+	-0.25	-5.07	5.79E-7	Parkinson's disease	
LUSC	cis	1	rs199357	chr7:23288309	GPNMB	chr7:23286316-23314728:+	0.23	4.77	2.49E-6	Parkinson's disease	
LUSC	cis	1	rs1994157	chr3:41897482	ULK4	chr3:41288091-42003660:-	0.63	9.45	1.49E-19	Diastolic blood pressure	
LUSC	cis	1	rs1995688	chr6:86632319	SNHG5	chr6:86386726-86388451:-	-0.65	-12.21	4.99E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs1997243	chr7:1083777	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.33	1.55E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs1998207	chr14:94957714	SERPINA9	chr14:94929060-94942670:-	-0.27	-4.93	1.11E-6	Obesity-related traits	
LUSC	cis	1	rs1999852	chr6:86705738	SNHG5	chr6:86386726-86388451:-	-0.67	-12.63	1.03E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs2000614	chr11:116915742	PCSK7	chr11:117075789-117102811:-	-0.37	-5.12	4.56E-7	Protein quantitative trait loci	
LUSC	cis	1	rs2000615	chr11:116915819	PCSK7	chr11:117075789-117102811:-	-0.37	-5.08	5.51E-7	Protein quantitative trait loci	
LUSC	cis	1	rs2000616	chr11:116916529	PCSK7	chr11:117075789-117102811:-	-0.36	-5.1	4.84E-7	Protein quantitative trait loci	
LUSC	cis	1	rs2003284	chr10:102202338	SEC31B	chr10:102246403-102289636:-	-0.26	-7.76	5.29E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2003301	chr7:66147656	NCRNA00174	chr7:65841032-65865395:-	0.25	5.49	6.51E-8	Aortic root size	
LUSC	cis	1	rs2006751	chr11:43670501	HSD17B12	chr11:43702143-43878160:+	-0.46	-8.15	3.19E-15	Forced vital capacity	
LUSC	cis	1	rs2007981	chr19:18567555	LRRC25	chr19:18501955-18508421:-	-0.12	-4.09	5.07E-5	Breast cancer	
LUSC	cis	1	rs2010648	chr14:35604892	PPP2R3C	chr14:35554679-35591679:-	0.32	5.59	3.86E-8	Atopic dermatitis	
LUSC	cis	1	rs2013288	chr17:61785904	FTSJ3	chr17:61896795-61905031:-	0.33	6.57	1.33E-10	Body mass index	
LUSC	cis	1	rs2013815	chr6:167373812	RNASET2	chr6:167343008-167412795:-	0.25	4.83	1.84E-6	Crohn's disease	
LUSC	cis	1	rs2015336	chr17:18073610	LOC220594	chr17:18414577-18445234:-	-0.29	-4.32	1.88E-5	Obesity-related traits	
LUSC	cis	1	rs2015336	chr17:18073610	MYO15A	chr17:18012020-18083115:+	0.2	3.71	0.000234	Obesity-related traits	
LUSC	cis	1	rs2017962	chr19:22208751	ZNF257	chr19:22235266-22273901:+	0.26	3.95	9.11E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs2019097	chr2:202193463	CFLAR	chr2:201980816-202029001:+	-0.25	-3.86	0.000129	Rheumatoid arthritis	
LUSC	cis	1	rs2019097	chr2:202193463	PPIL3	chr2:201735680-201753999:-	-0.53	-6.55	1.53E-10	Rheumatoid arthritis	
LUSC	cis	1	rs2019814	chr11:93168885	C11orf75	chr11:93211641-93276546:-	-0.28	-4.5	8.46E-6	Pulmonary function decline	
LUSC	cis	1	rs2019814	chr11:93168885	CCDC67	chr11:93063156-93171634:+	-0.29	-4.79	2.23E-6	Pulmonary function decline	
LUSC	cis	1	rs201983168	chr1:150314981	HORMAD1	chr1:150670542-150693352:-	-0.36	-3.73	0.000216	Eye morphology	
LUSC	cis	1	rs2031494	chr1:92965969	EVI5	chr1:92974255-93257961:-	-0.32	-4.56	6.66E-6	Cholesterol, total	
LUSC	cis	1	rs2036264	chr7:65799904	NCRNA00174	chr7:65841032-65865395:-	0.29	6.08	2.42E-9	Aortic root size	
LUSC	cis	1	rs2041837	chr2:37468564	CEBPZ	chr2:37428778-37458740:-	-0.17	-3.79	0.000168	Chronic lymphocytic leukemia	
LUSC	cis	1	rs2041840	chr2:37467264	CEBPZ	chr2:37428778-37458740:-	-0.17	-3.8	0.000163	Chronic lymphocytic leukemia	
LUSC	cis	1	rs2042133	chr7:65931922	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs2042947	chr19:12693103	GCDH	chr19:13001974-13010782:+	-0.21	-4.21	3.06E-5	Bipolar disorder	
LUSC	cis	1	rs2045554	chr3:48494542	ATRIP	chr3:48488141-48507708:+	-0.18	-3.86	0.00013	Longevity	
LUSC	cis	1	rs2045554	chr3:48494542	TREX1	chr3:48501186-48509043:+	0.37	8.07	5.97E-15	Longevity	
LUSC	cis	1	rs2046323	chr17:65849927	LOC440461	chr17:66194801-66196436:+	0.25	3.81	0.000159	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs2047134	chr2:225347713	FAM124B	chr2:225243416-225266711:-	0.2	3.86	0.00013	Acute graft versus host disease in bone marrow transplantation (recipient effect)	
LUSC	cis	1	rs2050265	chr1:11879699	CLCN6	chr1:11866207-11907674:+	0.21	4.38	1.47E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs205243	chr22:34890448	HMGXB4	chr22:35653445-35691799:+	0.32	3.93	9.66E-5	Immune reponse to smallpox (secreted TNF-alpha)	
LUSC	cis	1	rs2055682	chr7:66260289	NCRNA00174	chr7:65841032-65865395:-	-0.26	-5.51	5.92E-8	Aortic root size	
LUSC	cis	1	rs2056603	chr3:134312749	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs2056604	chr3:134312648	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs2058059	chr7:72311817	TYW1B	chr7:72023729-72298813:-	-0.37	-5.38	1.15E-7	Subcutaneous adipose tissue	
LUSC	cis	1	rs2058805	chr12:109998591	MYO1H	chr12:109826524-109886176:+	0.24	4.42	1.2E-5	HDL cholesterol	
LUSC	cis	1	rs2062078	chr8:130734461	GSDMC	chr8:130760443-130799134:-	-0.26	-5.43	8.93E-8	Infant length;Height	
LUSC	cis	1	rs2064088	chr22:39053382	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs2066575	chr13:50656582	DLEU2	chr13:50556688-50699677:-	0.26	4.68	3.81E-6	Height	
LUSC	cis	1	rs2069502	chr12:58144665	FAM119B	chr12:58166383-58176323:+	-0.52	-8.89	1.31E-17	Multiple sclerosis	
LUSC	cis	1	rs2069502	chr12:58144665	TSFM	chr12:58176536-58191367:+	0.37	7.82	3.51E-14	Multiple sclerosis	
LUSC	cis	1	rs2069502	chr12:58144665	XRCC6BP1	chr12:58335445-58351051:+	0.22	4.35	1.67E-5	Multiple sclerosis	
LUSC	cis	1	rs2069940	chr20:33759272	GDF5	chr20:33897002-34042568:-	0.3	4.16	3.83E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs2069940	chr20:33759272	PROCR	chr20:33758727-33765164:+	-0.29	-3.76	0.000191	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs2070180	chr3:121351338	IQCB1	chr3:121488610-121553926:-	-0.2	-4.08	5.24E-5	Cognitive performance	
LUSC	cis	1	rs2072052	chr12:58146719	FAM119B	chr12:58166383-58176323:+	0.52	8.74	3.97E-17	Multiple sclerosis	
LUSC	cis	1	rs2072052	chr12:58146719	TSFM	chr12:58176536-58191367:+	-0.38	-8	9.44E-15	Multiple sclerosis	
LUSC	cis	1	rs2072052	chr12:58146719	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.22	2.89E-5	Multiple sclerosis	
LUSC	cis	1	rs2072796	chr22:39064230	CBY1	chr22:39052658-39069853:+	0.21	3.84	0.000141	Resting heart rate	
LUSC	cis	1	rs2072798	chr22:39148483	CBY1	chr22:39052658-39069853:+	0.24	4.57	6.28E-6	Resting heart rate	
LUSC	cis	1	rs2073604	chr22:51008925	CPT1B	chr22:51007291-51017096:-	-0.34	-4.39	1.39E-5	Narcolepsy	
LUSC	cis	1	rs2073605	chr22:51008850	CPT1B	chr22:51007291-51017096:-	-0.34	-4.37	1.53E-5	Narcolepsy	
LUSC	cis	1	rs2074018	chr11:2309634	C11orf21	chr11:2317507-2323143:-	0.36	7.08	5.29E-12	Obesity-related traits	
LUSC	cis	1	rs2076028	chr22:39150450	CBY1	chr22:39052658-39069853:+	0.24	4.52	7.85E-6	Resting heart rate	
LUSC	cis	1	rs2077593	chr7:65892530	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.2	1.21E-9	Aortic root size	
LUSC	cis	1	rs2077808	chr1:45988115	CCDC163P	chr1:45960581-45965646:-	-0.75	-18.03	9.6E-56	Homocysteine levels	
LUSC	cis	1	rs2077808	chr1:45988115	MMACHC	chr1:45965856-45976737:+	-0.15	-3.85	0.000136	Homocysteine levels	
LUSC	cis	1	rs2078089	chr19:22209753	ZNF257	chr19:22235266-22273901:+	0.26	3.95	9.11E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs2080303	chr2:202165206	ALS2CR12	chr2:202153148-202222101:-	-0.27	-4.75	2.75E-6	Basal cell carcinoma	
LUSC	cis	1	rs2080303	chr2:202165206	PPIL3	chr2:201735680-201753999:-	-0.27	-4.61	5.23E-6	Basal cell carcinoma	
LUSC	cis	1	rs2087647	chr7:65593188	NCRNA00174	chr7:65841032-65865395:-	0.3	6.34	5.45E-10	Aortic root size	
LUSC	cis	1	rs2098297	chr14:75619118	MLH3	chr14:75480467-75518235:-	-0.27	-5.75	1.64E-8	Height	
LUSC	cis	1	rs2103876	chr1:12053100	C1orf187	chr1:11751781-11780336:+	0.19	4.22	2.9E-5	Platelet count	
LUSC	cis	1	rs2113078	chr5:56087190	C5orf35	chr5:56205103-56213010:+	0.86	14.93	1.28E-41	Type 2 diabetes	
LUSC	cis	1	rs2113079	chr5:56157951	C5orf35	chr5:56205103-56213010:+	0.88	15.56	2.02E-44	Type 2 diabetes	
LUSC	cis	1	rs2116081	chr8:125697673	LOC157381	chr8:125951884-125963337:+	0.17	3.76	0.000195	Cognitive function	
LUSC	cis	1	rs2118862	chr4:154657782	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2120019	chr15:75334184	SCAMP5	chr15:75287901-75313836:+	0.26	4.23	2.79E-5	Blood trace element (Zn levels)	
LUSC	cis	1	rs2126129	chr2:212548	SH3YL1	chr2:218138-264810:-	-0.49	-8.79	2.68E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs2127905	chr11:117026374	PCSK7	chr11:117075789-117102811:-	-0.39	-5.39	1.12E-7	Protein quantitative trait loci	
LUSC	cis	1	rs2128792	chr17:65857177	LOC440461	chr17:66194801-66196436:+	0.25	3.85	0.000133	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs2128834	chr3:41862645	ULK4	chr3:41288091-42003660:-	0.57	9.21	1.01E-18	Diastolic blood pressure	
LUSC	cis	1	rs2128835	chr3:41862873	ULK4	chr3:41288091-42003660:-	0.58	8.97	6.79E-18	Diastolic blood pressure	
LUSC	cis	1	rs2130392	chr4:185639169	MLF1IP	chr4:185615220-185655286:-	-0.49	-10.47	3.13E-23	Kawasaki disease	
LUSC	cis	1	rs2134688	chr1:150816886	HORMAD1	chr1:150670542-150693352:-	0.46	5.06	6.03E-7	Congenital left-sided heart lesions	
LUSC	cis	1	rs2135509	chr4:17917818	NCAPG	chr4:17812525-17846485:+	-0.19	-4.07	5.44E-5	Height	
LUSC	cis	1	rs2140270	chr3:49439440	AMT	chr3:49454212-49460012:-	-0.2	-4.82	1.89E-6	Menarche (age at onset)	
LUSC	cis	1	rs2140270	chr3:49439440	TREX1	chr3:48501186-48509043:+	0.2	3.76	0.000193	Menarche (age at onset)	
LUSC	cis	1	rs2143062	chr6:27353852	ZNF391	chr6:27356524-27369227:+	0.3	5.97	4.66E-9	Glomerular filtration rate (creatinine)	
LUSC	cis	1	rs2143950	chr14:35572357	PPP2R3C	chr14:35554679-35591679:-	0.33	5.71	2.03E-8	Atopic dermatitis	
LUSC	cis	1	rs2147712	chr14:50091684	RPL36AL	chr14:50085407-50087349:-	0.22	4.67	3.97E-6	Carotid intima media thickness	
LUSC	cis	1	rs2149085	chr6:167371110	RNASET2	chr6:167343008-167412795:-	0.24	4.82	1.92E-6	Crohn's disease	
LUSC	cis	1	rs2149090	chr6:167372764	RNASET2	chr6:167343008-167412795:-	0.25	4.83	1.84E-6	Crohn's disease	
LUSC	cis	1	rs2149091	chr6:167372786	RNASET2	chr6:167343008-167412795:-	0.25	4.83	1.84E-6	Crohn's disease	
LUSC	cis	1	rs2149423	chr13:36772381	SOHLH2	chr13:36742347-36871992:-	0.25	4.53	7.45E-6	Glucose homeostasis traits	
LUSC	cis	1	rs2152916	chr10:97392265	ENTPD1	chr10:97471536-97637022:+	0.18	5.25	2.32E-7	Blood metabolite levels	
LUSC	cis	1	rs2153904	chr1:205642790	PM20D1	chr1:205797154-205819245:-	-0.28	-4.38	1.46E-5	Prostate-specific antigen levels	
LUSC	cis	1	rs2154536	chr21:38492147	PIGP	chr21:38437664-38445458:-	-0.33	-6.3	6.7E-10	Eye color traits	
LUSC	cis	1	rs2155583	chr11:116915217	PCSK7	chr11:117075789-117102811:-	-0.36	-5.01	7.57E-7	Protein quantitative trait loci	
LUSC	cis	1	rs2157710	chr22:23457486	RTDR1	chr22:23401594-23484241:-	-0.25	-4.66	4.2E-6	Bone mineral density	
LUSC	cis	1	rs2159584	chr4:17620568	MED28	chr4:17616273-17629791:+	0.18	3.71	0.000231	Parasitemia in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs2160392	chr2:37527393	CEBPZ	chr2:37428778-37458740:-	-0.17	-3.82	0.000152	Chronic lymphocytic leukemia	
LUSC	cis	1	rs2160395	chr2:37479862	CEBPZ	chr2:37428778-37458740:-	-0.16	-3.7	0.000242	Chronic lymphocytic leukemia	
LUSC	cis	1	rs2166663	chr6:86593896	SNHG5	chr6:86386726-86388451:-	-0.68	-12.89	8.6E-33	Response to antipsychotic treatment	
LUSC	cis	1	rs2169748	chr2:28957753	TRMT61B	chr2:29072690-29093175:-	0.24	5.01	7.55E-7	Body mass index	
LUSC	cis	1	rs2169751	chr2:28966758	TRMT61B	chr2:29072690-29093175:-	-0.25	-5.17	3.43E-7	Body mass index	
LUSC	cis	1	rs2170998	chr15:77007159	ETFA	chr15:76508629-76603810:-	0.27	3.71	0.000232	Recalcitrant atopic dermatitis	
LUSC	cis	1	rs2175366	chr19:22128279	ZNF257	chr19:22235266-22273901:+	0.29	4.51	8.27E-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs2177268	chr3:49439725	AMT	chr3:49454212-49460012:-	-0.2	-4.82	1.91E-6	Menarche (age at onset)	
LUSC	cis	1	rs2177268	chr3:49439725	TREX1	chr3:48501186-48509043:+	0.2	3.8	0.000166	Menarche (age at onset)	
LUSC	cis	1	rs2177601	chr3:134245434	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs2182652	chr10:7735876	ATP5C1	chr10:7830093-7849755:+	-0.18	-3.78	0.000177	Ovarian reserve	
LUSC	cis	1	rs2184000	chr20:25395878	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2193172	chr12:15332342	GUCY2C	chr12:14765570-14849519:-	0.26	3.72	0.000222	Glomerular filtration rate (creatinine)	
LUSC	cis	1	rs2196098	chr3:85505246	CADM2	chr3:85008133-86117948:+	0.3	4.55	6.81E-6	Longevity (90 years and older)	
LUSC	cis	1	rs2205802	chr22:39046327	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs2210913	chr1:157668993	FCRL3	chr1:157646278-157670775:-	0.29	9.44	1.73E-19	Type 1 diabetes autoantibodies	
LUSC	cis	1	rs2214047	chr22:30556101	RFPL1S	chr22:29833006-29838118:-	0.4	3.93	9.68E-5	LDL cholesterol	
LUSC	cis	1	rs2220626	chr7:65546062	NCRNA00174	chr7:65841032-65865395:-	0.28	5.98	4.46E-9	Aortic root size	
LUSC	cis	1	rs2224949	chr14:50096560	RPL36AL	chr14:50085407-50087349:-	-0.2	-4.56	6.48E-6	Carotid intima media thickness	
LUSC	cis	1	rs2227336	chr17:38174855	GSDMA	chr17:38119226-38134019:+	-0.43	-8.81	2.38E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs2229384	chr6:49425521	CENPQ	chr6:49431096-49460820:+	0.36	8.47	3.12E-16	Homocysteine levels	
LUSC	cis	1	rs2229384	chr6:49425521	MUT	chr6:49398994-49431031:-	-0.21	-3.84	0.000141	Homocysteine levels	
LUSC	cis	1	rs2233551	chr11:76814471	CLNS1A	chr11:77327197-77348851:-	0.34	4.04	6.22E-5	Cognitive performance	
LUSC	cis	1	rs2233551	chr11:76814471	INTS4	chr11:77589768-77705717:-	0.37	4.11	4.65E-5	Cognitive performance	
LUSC	cis	1	rs2233551	chr11:76814471	PRKRIR	chr11:76061004-76091880:-	0.33	3.88	0.000121	Cognitive performance	
LUSC	cis	1	rs2233551	chr11:76814471	RSF1	chr11:77377275-77531880:-	0.29	3.94	9.32E-5	Cognitive performance	
LUSC	cis	1	rs2235230	chr22:39124467	CBY1	chr22:39052658-39069853:+	-0.23	-4.11	4.64E-5	Resting heart rate	
LUSC	cis	1	rs2236246	chr14:104379206	TDRD9	chr14:104394817-104519002:+	-0.26	-4.49	8.76E-6	Bipolar disorder	
LUSC	cis	1	rs2236247	chr14:104378087	TDRD9	chr14:104394817-104519002:+	0.22	4.03	6.61E-5	Bipolar disorder	
LUSC	cis	1	rs2239557	chr14:74551970	LIN52	chr14:74551656-74667117:+	0.28	6.22	1.07E-9	Common traits (Other)	
LUSC	cis	1	rs2239557	chr14:74551970	PTGR2	chr14:74318534-74352166:+	-0.23	-4.47	9.71E-6	Common traits (Other)	
LUSC	cis	1	rs2242150	chr3:48505964	ATRIP	chr3:48488141-48507708:+	-0.2	-4.25	2.62E-5	Longevity	
LUSC	cis	1	rs2242150	chr3:48505964	TREX1	chr3:48501186-48509043:+	0.39	8.54	1.82E-16	Longevity	
LUSC	cis	1	rs2242471	chr4:76878716	NAAA	chr4:76831809-76862166:-	0.26	5.46	7.58E-8	Longevity	
LUSC	cis	1	rs2242473	chr4:76878956	NAAA	chr4:76831809-76862166:-	0.26	5.46	7.58E-8	Longevity	
LUSC	cis	1	rs2242474	chr4:76878982	NAAA	chr4:76831809-76862166:-	0.26	5.46	7.58E-8	Longevity	
LUSC	cis	1	rs224329	chr20:34019579	CEP250	chr20:34042996-34099802:+	0.15	3.76	0.000188	Height	
LUSC	cis	1	rs224329	chr20:34019579	CPNE1	chr20:34213968-34262539:-	-0.29	-5.1	4.93E-7	Height	
LUSC	cis	1	rs224329	chr20:34019579	UQCC	chr20:33890383-33999833:-	-0.28	-5.1	4.89E-7	Height	
LUSC	cis	1	rs2245717	chr20:43995880	SYS1	chr20:43991701-44004724:+	0.21	3.89	0.000113	Psoriasis	
LUSC	cis	1	rs2246833	chr10:91005854	LIPA	chr10:90973328-91174382:-	0.22	6.02	3.59E-9	Fibrinogen levels	
LUSC	cis	1	rs2246942	chr10:91004886	LIPA	chr10:90973328-91174382:-	0.22	6.1	2.26E-9	Fibrinogen levels	
LUSC	cis	1	rs2247753	chr22:30022936	NIPSNAP1	chr22:29950800-29977144:-	0.27	4.59	5.68E-6	Lipid traits	
LUSC	cis	1	rs2248393	chr20:33926103	CEP250	chr20:34042996-34099802:+	0.15	3.97	8.39E-5	Height	
LUSC	cis	1	rs2248393	chr20:33926103	CPNE1	chr20:34213968-34262539:-	-0.27	-4.68	3.74E-6	Height	
LUSC	cis	1	rs2248393	chr20:33926103	UQCC	chr20:33890383-33999833:-	-0.31	-5.66	2.57E-8	Height	
LUSC	cis	1	rs2248637	chr20:43997240	SYS1	chr20:43991701-44004724:+	-0.21	-3.81	0.00016	Psoriasis	
LUSC	cis	1	rs2250644	chr10:91008879	LIPA	chr10:90973328-91174382:-	0.23	6.15	1.63E-9	Fibrinogen levels	
LUSC	cis	1	rs2251115	chr6:49446509	CENPQ	chr6:49431096-49460820:+	-0.37	-8.5	2.48E-16	Homocysteine levels	
LUSC	cis	1	rs2251115	chr6:49446509	MUT	chr6:49398994-49431031:-	0.22	3.98	8.12E-5	Homocysteine levels	
LUSC	cis	1	rs2251900	chr4:154654145	TLR2	chr4:154605441-154627240:+	-0.2	-3.84	0.000138	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2251994	chr4:154654097	TLR2	chr4:154605441-154627240:+	-0.2	-4.05	5.97E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2251997	chr4:154654067	TLR2	chr4:154605441-154627240:+	0.19	3.83	0.000144	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2257420	chr20:25275890	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257432	chr20:25271086	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.000208	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257496	chr20:25279315	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257808	chr20:25266450	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.8	0.000165	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257809	chr20:25266476	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.8	0.000165	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257982	chr20:25269630	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.000208	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257985	chr20:25269743	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.000208	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257988	chr20:25270003	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.000208	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2257991	chr20:25270339	ENTPD6	chr20:25176339-25207360:+	0.21	3.91	0.000108	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258066	chr20:25271326	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.00021	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258135	chr20:25272323	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.00021	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258201	chr20:25272490	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.00021	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258563	chr20:25273435	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.72	0.000221	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258617	chr20:25274318	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258769	chr20:25276680	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258879	chr20:25279213	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2258884	chr20:25279539	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2259837	chr20:25280205	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2259873	chr20:25280781	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2259926	chr20:25281733	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2259928	chr20:25281834	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2259956	chr20:25282433	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2263434	chr4:154658312	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2265186	chr10:30691743	LOC220930	chr10:31605458-31608024:-	-0.19	-3.83	0.000148	Inflammatory bowel disease	
LUSC	cis	1	rs2265186	chr10:30691743	MTPAP	chr10:30598731-30663377:-	-0.3	-5.3	1.81E-7	Inflammatory bowel disease	
LUSC	cis	1	rs2267002	chr22:23456702	RTDR1	chr22:23401594-23484241:-	-0.24	-4.54	7.28E-6	Bone mineral density	
LUSC	cis	1	rs2267003	chr22:23457098	RTDR1	chr22:23401594-23484241:-	-0.24	-4.5	8.48E-6	Bone mineral density	
LUSC	cis	1	rs2267393	chr22:39101619	CBY1	chr22:39052658-39069853:+	0.21	3.93	9.65E-5	Resting heart rate	
LUSC	cis	1	rs2267394	chr22:39101633	CBY1	chr22:39052658-39069853:+	0.21	3.93	9.65E-5	Resting heart rate	
LUSC	cis	1	rs2267395	chr22:39113903	CBY1	chr22:39052658-39069853:+	0.23	4.19	3.35E-5	Resting heart rate	
LUSC	cis	1	rs2268617	chr14:75608728	MLH3	chr14:75480467-75518235:-	0.28	6.03	3.31E-9	Height	
LUSC	cis	1	rs2269186	chr14:104379912	TDRD9	chr14:104394817-104519002:+	0.26	4.52	7.94E-6	Bipolar disorder	
LUSC	cis	1	rs2269381	chr22:51020069	CPT1B	chr22:51007291-51017096:-	-0.32	-3.83	0.000147	Narcolepsy	
LUSC	cis	1	rs2269382	chr22:51018911	CPT1B	chr22:51007291-51017096:-	-0.33	-3.98	8.13E-5	Narcolepsy	
LUSC	cis	1	rs2269384	chr22:51011115	CPT1B	chr22:51007291-51017096:-	-0.34	-4.34	1.77E-5	Narcolepsy	
LUSC	cis	1	rs2269385	chr22:51010939	CPT1B	chr22:51007291-51017096:-	-0.34	-4.34	1.77E-5	Narcolepsy	
LUSC	cis	1	rs2269558	chr16:682250	WFIKKN1	chr16:679239-684116:+	0.34	6.44	2.86E-10	Height	
LUSC	cis	1	rs2271404	chr2:112003867	BCL2L11	chr2:111878491-111926022:+	-0.3	-3.88	0.000118	Atopic dermatitis	
LUSC	cis	1	rs2272006	chr3:41997059	ULK4	chr3:41288091-42003660:-	-0.65	-10.21	3.02E-22	Diastolic blood pressure	
LUSC	cis	1	rs2272390	chr2:202195311	PPIL3	chr2:201735680-201753999:-	-0.51	-5.2	2.94E-7	Rheumatoid arthritis	
LUSC	cis	1	rs2273694	chr10:102256496	SEC31B	chr10:102246403-102289636:-	-0.28	-8.62	1.03E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2273695	chr10:102259568	SEC31B	chr10:102246403-102289636:-	-0.26	-8.2	2.29E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2273	chr4:76889388	NAAA	chr4:76831809-76862166:-	0.26	5.71	1.98E-8	Longevity	
LUSC	cis	1	rs2275426	chr1:46487552	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.93	1.37E-11	Body mass index	
LUSC	cis	1	rs2275540	chr10:128797717	FAM196A	chr10:128933690-128994422:-	0.21	3.81	0.000158	Response to cytidine analogues (gemcitabine)	
LUSC	cis	1	rs2276547	chr2:28975107	TRMT61B	chr2:29072690-29093175:-	-0.26	-5.23	2.56E-7	Body mass index	
LUSC	cis	1	rs2277862	chr20:34152782	CPNE1	chr20:34213968-34262539:-	-0.61	-7.97	1.16E-14	Cholesterol, total	
LUSC	cis	1	rs2278086	chr2:86281905	LOC90784	chr2:86247339-86250991:-	-0.39	-3.94	9.19E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LUSC	cis	1	rs2278238	chr19:18576484	LRRC25	chr19:18501955-18508421:-	-0.11	-3.73	0.000217	Breast cancer	
LUSC	cis	1	rs2278238	chr19:18576484	SSBP4	chr19:18530221-18545371:+	-0.19	-3.75	0.000197	Breast cancer	
LUSC	cis	1	rs2278842	chr10:102056745	PKD2L1	chr10:102047903-102090243:-	0.28	4.47	9.9E-6	Obesity-related traits	
LUSC	cis	1	rs2279077	chr3:48474249	ATRIP	chr3:48488141-48507708:+	0.19	3.85	0.000136	Longevity	
LUSC	cis	1	rs2279077	chr3:48474249	TREX1	chr3:48501186-48509043:+	-0.42	-9.18	1.37E-18	Longevity	
LUSC	cis	1	rs2279144	chr19:39201781	LGALS7B	chr19:39279850-39282393:+	0.19	4.04	6.35E-5	Heart rate	
LUSC	cis	1	rs2281019	chr22:39064378	CBY1	chr22:39052658-39069853:+	0.21	3.83	0.000147	Resting heart rate	
LUSC	cis	1	rs2281020	chr22:39064406	CBY1	chr22:39052658-39069853:+	0.21	3.83	0.000147	Resting heart rate	
LUSC	cis	1	rs2281021	chr22:39064667	CBY1	chr22:39052658-39069853:+	0.21	3.83	0.000147	Resting heart rate	
LUSC	cis	1	rs2284073	chr22:39105948	CBY1	chr22:39052658-39069853:+	0.22	3.99	7.62E-5	Resting heart rate	
LUSC	cis	1	rs2285946	chr7:21583329	DNAH11	chr7:21582833-21941455:+	-0.53	-10.02	1.5E-21	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs2285947	chr7:21584088	DNAH11	chr7:21582833-21941455:+	0.55	10.46	3.36E-23	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs2285949	chr7:21584243	DNAH11	chr7:21582833-21941455:+	-0.54	-10.27	1.79E-22	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs2285950	chr7:21584432	DNAH11	chr7:21582833-21941455:+	0.55	10.57	1.3E-23	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs2286614	chr11:64068310	C11orf20	chr11:64067863-64072238:+	-0.34	-4.6	5.36E-6	Mean platelet volume	
LUSC	cis	1	rs2286684	chr7:66129830	NCRNA00174	chr7:65841032-65865395:-	0.25	5.39	1.09E-7	Aortic root size	
LUSC	cis	1	rs2288073	chr2:24413298	C2orf84	chr2:24397531-24414566:+	-0.38	-6.85	2.26E-11	Venous thromboembolism (SNP x SNP interaction)	
LUSC	cis	1	rs2288344	chr15:56122347	NEDD4	chr15:56119131-56285835:-	0.24	4.31	1.94E-5	Keloid	
LUSC	cis	1	rs2290822	chr3:48473204	ATRIP	chr3:48488141-48507708:+	0.18	3.82	0.000153	Longevity	
LUSC	cis	1	rs2290822	chr3:48473204	TREX1	chr3:48501186-48509043:+	-0.4	-8.82	2.18E-17	Longevity	
LUSC	cis	1	rs2290850	chr11:47807774	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.04	6.32E-5	Subjective well-being	
LUSC	cis	1	rs2290911	chr2:224919	SH3YL1	chr2:218138-264810:-	-0.52	-9.25	7.59E-19	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs2291361	chr12:56717805	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs2291361	chr12:56717805	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs2292239	chr12:56482180	RPS26	chr12:56435686-56438005:+	0.57	12.46	4.73E-31	Cognitive function	
LUSC	cis	1	rs2294008	chr8:143761931	LOC100133669	chr8:144063448-144099807:-	0.23	3.78	0.000176	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2294008	chr8:143761931	LY6K	chr8:143781529-143785582:+	0.25	5.03	6.82E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2294008	chr8:143761931	PSCA	chr8:143761875-143764142:+	0.46	10.04	1.18E-21	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2294010	chr8:143762430	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2294010	chr8:143762430	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2294010	chr8:143762430	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2294296	chr22:39053049	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs229527	chr22:37581485	C1QTNF6	chr22:37576206-37594341:-	-0.16	-3.7	0.000245	Type 1 diabetes	
LUSC	cis	1	rs2295700	chr20:33591627	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.47E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs2295770	chr10:102239829	SEC31B	chr10:102246403-102289636:-	-0.27	-8.09	5.16E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2295772	chr10:102265183	SEC31B	chr10:102246403-102289636:-	-0.28	-8.41	4.74E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2295773	chr10:102265815	SEC31B	chr10:102246403-102289636:-	-0.28	-8.5	2.41E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2295774	chr10:102265847	SEC31B	chr10:102246403-102289636:-	-0.29	-8.54	1.83E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2295776	chr10:102295629	SEC31B	chr10:102246403-102289636:-	-0.28	-8.38	5.89E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2295779	chr10:102296061	SEC31B	chr10:102246403-102289636:-	-0.28	-8.52	2.16E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2295780	chr10:102305965	SEC31B	chr10:102246403-102289636:-	-0.28	-8.2	2.33E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2296691	chr10:97370989	ENTPD1	chr10:97471536-97637022:+	0.17	5.22	2.72E-7	Blood metabolite levels	
LUSC	cis	1	rs2297496	chr20:25295787	ENTPD6	chr20:25176339-25207360:+	0.2	3.86	0.000132	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2297497	chr20:25297909	ENTPD6	chr20:25176339-25207360:+	0.22	4.14	4.16E-5	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2298074	chr10:102247526	SEC31B	chr10:102246403-102289636:-	-0.27	-8.06	6.36E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2298075	chr10:102247408	SEC31B	chr10:102246403-102289636:-	-0.27	-8.01	8.91E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2300601	chr14:75639571	MLH3	chr14:75480467-75518235:-	0.27	5.67	2.47E-8	Height	
LUSC	cis	1	rs2301889	chr7:98931105	CYP3A5	chr7:99245818-99332821:-	0.47	5.59	3.89E-8	Blood metabolite levels	
LUSC	cis	1	rs2302138	chr14:74363305	LIN52	chr14:74551656-74667117:+	0.29	4.32	1.91E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs2303695	chr19:18562624	LRRC25	chr19:18501955-18508421:-	-0.12	-4.15	3.91E-5	Breast cancer	
LUSC	cis	1	rs2303695	chr19:18562624	SSBP4	chr19:18530221-18545371:+	-0.19	-3.82	0.000152	Breast cancer	
LUSC	cis	1	rs2303759	chr19:49869051	CCDC155	chr19:49891506-49921246:+	-0.25	-4.42	1.23E-5	Multiple sclerosis	
LUSC	cis	1	rs2303759	chr19:49869051	DKKL1	chr19:49867042-49878371:+	-0.48	-8.15	3.2E-15	Multiple sclerosis	
LUSC	cis	1	rs2304641	chr1:85513398	MCOLN2	chr1:85391267-85462796:-	-0.24	-4.05	5.92E-5	Serum sulfate level	
LUSC	cis	1	rs2304668	chr2:239168448	LOC151174	chr2:239133754-239140318:-	0.33	3.85	0.000135	Irritable bowel syndrome	
LUSC	cis	1	rs2305815	chr1:150956947	HORMAD1	chr1:150670542-150693352:-	-0.4	-4.14	4.09E-5	Congenital left-sided heart lesions	
LUSC	cis	1	rs2306937	chr1:113246506	ST7L	chr1:113066142-113162405:-	0.25	4.08	5.28E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs2306940	chr1:113241052	ST7L	chr1:113066142-113162405:-	0.23	3.75	0.0002	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs2312462	chr3:49601255	AMT	chr3:49454212-49460012:-	0.18	4.37	1.5E-5	Menarche (age at onset)	
LUSC	cis	1	rs2324843	chr6:86617501	SNHG5	chr6:86386726-86388451:-	-0.67	-12.37	1.16E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs2333194	chr14:73767214	HEATR4	chr14:73945193-74025651:-	-0.31	-6.03	3.23E-9	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs2336384	chr1:12046063	C1orf187	chr1:11751781-11780336:+	-0.18	-3.91	0.000104	Platelet count	
LUSC	cis	1	rs2349075	chr2:202223566	ALS2CR12	chr2:202153148-202222101:-	-0.21	-3.99	7.79E-5	Basal cell carcinoma	
LUSC	cis	1	rs2351002	chr15:89869329	LOC283761	chr15:90048162-90067265:-	0.2	3.88	0.000121	Menopause (age at onset)	
LUSC	cis	1	rs2356501	chr6:118942371	C6orf204	chr6:118786239-119031238:-	-0.24	-3.77	0.000181	Renal cell carcinoma	
LUSC	cis	1	rs2356559	chr1:45981512	CCDC163P	chr1:45960581-45965646:-	-0.72	-17	5.9E-51	Homocysteine levels	
LUSC	cis	1	rs2356561	chr1:45980862	CCDC163P	chr1:45960581-45965646:-	-0.71	-16.81	4.13E-50	Homocysteine levels	
LUSC	cis	1	rs2359155	chr19:21671869	ZNF708	chr19:21473963-21512212:-	-0.25	-4.35	1.64E-5	Pain	
LUSC	cis	1	rs2359820	chr19:22208114	ZNF100	chr19:21906844-21950430:-	-0.3	-4.29	2.19E-5	Body mass index (change over time)	
LUSC	cis	1	rs2359820	chr19:22208114	ZNF43	chr19:21987753-22034830:-	-0.28	-4.06	5.7E-5	Body mass index (change over time)	
LUSC	cis	1	rs2359821	chr19:22208314	ZNF257	chr19:22235266-22273901:+	0.26	3.95	9.11E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs2362450	chr3:48461313	ATRIP	chr3:48488141-48507708:+	0.18	3.86	0.000127	Longevity	
LUSC	cis	1	rs2362450	chr3:48461313	TREX1	chr3:48501186-48509043:+	-0.37	-8.19	2.52E-15	Longevity	
LUSC	cis	1	rs2362452	chr3:48418214	TREX1	chr3:48501186-48509043:+	0.39	8.63	9.47E-17	Longevity	
LUSC	cis	1	rs2363286	chr7:1091625	ZFAND2A	chr7:1192544-1199855:-	-0.35	-5.19	3.16E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs2363731	chr2:88521793	THNSL2	chr2:88469835-88486145:+	-0.71	-8.45	3.67E-16	Plasma clusterin levels	
LUSC	cis	1	rs2365764	chr17:65857714	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs236918	chr11:117091609	PCSK7	chr11:117075789-117102811:-	0.34	4.57	6.09E-6	Protein quantitative trait loci	
LUSC	cis	1	rs2369962	chr3:132729728	TMEM108	chr3:132757171-133116618:+	0.2	4.55	6.74E-6	IgE grass sensitization	
LUSC	cis	1	rs2370578	chr3:134199612	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.19E-16	Height	
LUSC	cis	1	rs2370641	chr3:134222161	ANAPC13	chr3:134196547-134204865:-	0.42	8.54	1.78E-16	Height	
LUSC	cis	1	rs2370642	chr3:134222136	ANAPC13	chr3:134196547-134204865:-	0.43	8.61	1.09E-16	Height	
LUSC	cis	1	rs2371244	chr7:143757611	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.46	4.12E-13	Obesity-related traits	
LUSC	cis	1	rs2371244	chr7:143757611	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.49	8.97E-6	Obesity-related traits	
LUSC	cis	1	rs2371247	chr7:143764179	ARHGEF35	chr7:143883677-143892736:-	-0.35	-6.99	9.6E-12	Obesity-related traits	
LUSC	cis	1	rs2371247	chr7:143764179	OR2A9P	chr7:143991573-143997832:+;chr7	-0.23	-4.1	4.78E-5	Obesity-related traits	
LUSC	cis	1	rs2371248	chr7:143764189	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7	9.0E-12	Obesity-related traits	
LUSC	cis	1	rs2371248	chr7:143764189	OR2A9P	chr7:143991573-143997832:+;chr7	-0.22	-4.08	5.22E-5	Obesity-related traits	
LUSC	cis	1	rs2373865	chr3:134291556	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.14	3.45E-15	Height	
LUSC	cis	1	rs2378078	chr20:32714728	TRPC4AP	chr20:33590215-33680618:-	-0.22	-3.95	8.93E-5	Tanning;Skin sensitivity to sun;Red vs. non-red hair color;Freckles;Burning and freckling	
LUSC	cis	1	rs2387880	chr20:25377787	ENTPD6	chr20:25176339-25207360:+	0.2	3.71	0.000232	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2387881	chr20:25378172	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.00024	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2387884	chr20:25379069	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2391159	chr1:92971951	EVI5	chr1:92974255-93257961:-	-0.31	-4.36	1.59E-5	Cholesterol, total	
LUSC	cis	1	rs2391160	chr1:92992797	EVI5	chr1:92974255-93257961:-	-0.31	-4.57	6.31E-6	Cholesterol, total	
LUSC	cis	1	rs2393593	chr6:26285683	BTN3A2	chr6:26365398-26378546:+	0.22	5.03	6.85E-7	Educational attainment	
LUSC	cis	1	rs239935	chr6:167411788	RNASET2	chr6:167343008-167412795:-	-0.23	-4.36	1.56E-5	Crohn's disease	
LUSC	cis	1	rs2403205	chr14:104143385	C14orf153	chr14:104029299-104057227:+	0.15	3.86	0.000131	Body mass index	
LUSC	cis	1	rs2403205	chr14:104143385	CKB	chr14:103985996-103989170:-	0.19	3.71	0.000235	Body mass index	
LUSC	cis	1	rs2405430	chr4:154658391	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2413544	chr22:39059404	CBY1	chr22:39052658-39069853:+	0.22	3.97	8.21E-5	Resting heart rate	
LUSC	cis	1	rs2413545	chr22:39092524	CBY1	chr22:39052658-39069853:+	0.22	3.95	8.86E-5	Resting heart rate	
LUSC	cis	1	rs2413546	chr22:39107001	CBY1	chr22:39052658-39069853:+	0.23	4.12	4.47E-5	Resting heart rate	
LUSC	cis	1	rs2413547	chr22:39107338	CBY1	chr22:39052658-39069853:+	0.23	4.12	4.47E-5	Resting heart rate	
LUSC	cis	1	rs2415255	chr15:75332412	SCAMP5	chr15:75287901-75313836:+	0.26	4.23	2.79E-5	Blood trace element (Zn levels)	
LUSC	cis	1	rs2420168	chr7:65630631	NCRNA00174	chr7:65841032-65865395:-	0.3	6.44	2.98E-10	Aortic root size	
LUSC	cis	1	rs2420591	chr7:65912381	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs2420820	chr7:66091907	NCRNA00174	chr7:65841032-65865395:-	0.27	5.74	1.72E-8	Aortic root size	
LUSC	cis	1	rs2420824	chr7:66131116	NCRNA00174	chr7:65841032-65865395:-	0.25	5.42	9.65E-8	Aortic root size	
LUSC	cis	1	rs2421332	chr2:61876965	C2orf74	chr2:61372243-61391964:+	-0.29	-4.57	6.15E-6	Homeostasis model assessment of beta-cell function (interaction)	
LUSC	cis	1	rs242271	chr6:88082029	C6orf164	chr6:88032306-88109459:+	-0.23	-4.26	2.47E-5	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs2424700	chr20:25266513	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.8	0.000165	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2424704	chr20:25273929	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.92	0.0001	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2425027	chr20:33849390	MMP24	chr20:33814539-33864804:+	-0.27	-3.75	0.0002	Attention deficit hyperactivity disorder	
LUSC	cis	1	rs2425065	chr20:33926268	CEP250	chr20:34042996-34099802:+	0.16	4.22	2.88E-5	Height	
LUSC	cis	1	rs2425065	chr20:33926268	CPNE1	chr20:34213968-34262539:-	-0.27	-4.77	2.45E-6	Height	
LUSC	cis	1	rs2425065	chr20:33926268	UQCC	chr20:33890383-33999833:-	-0.28	-5.16	3.61E-7	Height	
LUSC	cis	1	rs2425066	chr20:33927006	CEP250	chr20:34042996-34099802:+	0.16	4.22	2.94E-5	Height	
LUSC	cis	1	rs2425066	chr20:33927006	CPNE1	chr20:34213968-34262539:-	-0.27	-4.77	2.4E-6	Height	
LUSC	cis	1	rs2425066	chr20:33927006	UQCC	chr20:33890383-33999833:-	-0.28	-5.2	2.99E-7	Height	
LUSC	cis	1	rs2432195	chr5:56120413	C5orf35	chr5:56205103-56213010:+	0.85	14.64	2.54E-40	Type 2 diabetes	
LUSC	cis	1	rs2447208	chr15:43933895	CATSPER2	chr15:43922774-43959900:-	-0.27	-4.04	6.17E-5	Tumor biomarkers	
LUSC	cis	1	rs2447211	chr15:43936351	CATSPER2	chr15:43922774-43959900:-	-0.29	-4.3	2.08E-5	Tumor biomarkers	
LUSC	cis	1	rs2448704	chr6:49453672	CENPQ	chr6:49431096-49460820:+	0.39	9.08	2.87E-18	Homocysteine levels	
LUSC	cis	1	rs2448707	chr6:49446951	CENPQ	chr6:49431096-49460820:+	0.41	9.06	3.28E-18	Folate pathway vitamin levels	
LUSC	cis	1	rs2448707	chr6:49446951	MUT	chr6:49398994-49431031:-	-0.29	-5.18	3.27E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs2458413	chr8:105359432	TM7SF4	chr8:105352054-105368916:+	0.18	4.12	4.45E-5	Paget's disease	
LUSC	cis	1	rs2458414	chr8:105355840	TM7SF4	chr8:105352054-105368916:+	0.18	4.27	2.39E-5	Paget's disease	
LUSC	cis	1	rs2463825	chr11:62094493	TMEM138	chr11:61129856-61136680:+	-0.27	-3.74	0.000208	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs246454	chr5:96123264	ERAP1	chr5:96096515-96149837:-	-0.46	-11.15	8.33E-26	Ankylosing spondylitis	
LUSC	cis	1	rs246454	chr5:96123264	ERAP2	chr5:96211644-96255398:+	0.38	7.31	1.18E-12	Ankylosing spondylitis	
LUSC	cis	1	rs2470134	chr15:43849886	TUBGCP4	chr15:43663313-43698238:+	-0.28	-3.93	9.59E-5	Tumor biomarkers	
LUSC	cis	1	rs2471884	chr11:117010320	PCSK7	chr11:117075789-117102811:-	-0.35	-4.77	2.46E-6	Protein quantitative trait loci	
LUSC	cis	1	rs2482930	chr20:25334115	ENTPD6	chr20:25176339-25207360:+	0.2	3.73	0.000212	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs2486447	chr1:46545724	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.27	1.5E-12	Body mass index	
LUSC	cis	1	rs2489034	chr10:102319192	SEC31B	chr10:102246403-102289636:-	-0.28	-8.23	1.78E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489035	chr10:102319395	SEC31B	chr10:102246403-102289636:-	-0.28	-8.23	1.88E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489036	chr10:102319581	SEC31B	chr10:102246403-102289636:-	-0.28	-8.13	3.71E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489037	chr10:102319918	SEC31B	chr10:102246403-102289636:-	0.26	7.6	1.57E-13	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489039	chr10:102328036	SEC31B	chr10:102246403-102289636:-	-0.27	-7.78	4.49E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489040	chr10:102331298	SEC31B	chr10:102246403-102289636:-	-0.29	-8.73	4.26E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489043	chr10:102334327	SEC31B	chr10:102246403-102289636:-	-0.28	-8.67	6.65E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489045	chr10:102344754	SEC31B	chr10:102246403-102289636:-	-0.29	-8.54	1.85E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489046	chr10:102346282	SEC31B	chr10:102246403-102289636:-	-0.29	-9.11	2.28E-18	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489047	chr10:102347028	SEC31B	chr10:102246403-102289636:-	-0.29	-8.78	2.88E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489048	chr10:102348497	SEC31B	chr10:102246403-102289636:-	-0.29	-8.5	2.5E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489049	chr10:102350732	SEC31B	chr10:102246403-102289636:-	-0.28	-8.51	2.25E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489050	chr10:102350898	SEC31B	chr10:102246403-102289636:-	-0.29	-8.47	3.06E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489051	chr10:102351785	SEC31B	chr10:102246403-102289636:-	0.28	8.52	2.1E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2489053	chr10:102353341	SEC31B	chr10:102246403-102289636:-	-0.3	-9.17	1.46E-18	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2494112	chr1:201787833	SHISA4	chr1:201858032-201861426:+	-0.14	-3.74	0.000203	Body mass index	
LUSC	cis	1	rs2495734	chr10:102338686	SEC31B	chr10:102246403-102289636:-	-0.29	-8.67	6.79E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495736	chr10:102338410	SEC31B	chr10:102246403-102289636:-	-0.29	-8.44	3.74E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495737	chr10:102338344	SEC31B	chr10:102246403-102289636:-	-0.29	-8.69	6.12E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495741	chr10:102331795	SEC31B	chr10:102246403-102289636:-	-0.28	-8.5	2.4E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495742	chr10:102331364	SEC31B	chr10:102246403-102289636:-	-0.28	-8.4	5.18E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495743	chr10:102329739	SEC31B	chr10:102246403-102289636:-	-0.28	-8.25	1.54E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495745	chr10:102329075	SEC31B	chr10:102246403-102289636:-	-0.28	-8.59	1.29E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495747	chr10:102328247	SEC31B	chr10:102246403-102289636:-	-0.27	-7.97	1.19E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495750	chr10:102327708	SEC31B	chr10:102246403-102289636:-	-0.27	-7.71	7.36E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495751	chr10:102327260	SEC31B	chr10:102246403-102289636:-	-0.27	-7.78	4.49E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495752	chr10:102326115	SEC31B	chr10:102246403-102289636:-	-0.28	-7.83	3.26E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495753	chr10:102325640	SEC31B	chr10:102246403-102289636:-	-0.28	-7.58	1.84E-13	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495754	chr10:102324812	SEC31B	chr10:102246403-102289636:-	-0.28	-7.83	3.26E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495755	chr10:102324649	SEC31B	chr10:102246403-102289636:-	-0.28	-7.58	1.84E-13	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495758	chr10:102321900	SEC31B	chr10:102246403-102289636:-	-0.28	-7.57	1.95E-13	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495759	chr10:102320363	SEC31B	chr10:102246403-102289636:-	-0.27	-7.24	1.77E-12	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2495760	chr10:102318771	SEC31B	chr10:102246403-102289636:-	-0.29	-8.02	8.26E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs2501962	chr6:49453636	CENPQ	chr6:49431096-49460820:+	0.41	9.04	3.87E-18	Folate pathway vitamin levels	
LUSC	cis	1	rs2501962	chr6:49453636	MUT	chr6:49398994-49431031:-	-0.29	-5.19	3.15E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs2501963	chr6:49454281	CENPQ	chr6:49431096-49460820:+	0.41	9.14	1.88E-18	Folate pathway vitamin levels	
LUSC	cis	1	rs2501963	chr6:49454281	MUT	chr6:49398994-49431031:-	-0.3	-5.22	2.7E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs2502757	chr9:136586954	SARDH	chr9:136528686-136605077:-	-0.27	-6.45	2.73E-10	Asthma	
LUSC	cis	1	rs2513071	chr11:62098387	TMEM138	chr11:61129856-61136680:+	-0.27	-3.74	0.000208	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs2513074	chr11:62100880	TMEM138	chr11:61129856-61136680:+	-0.27	-3.74	0.000208	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs2513093	chr11:116806687	PCSK7	chr11:117075789-117102811:-	-0.32	-4.5	8.74E-6	Protein quantitative trait loci	
LUSC	cis	1	rs2513095	chr11:116806269	PCSK7	chr11:117075789-117102811:-	-0.33	-4.56	6.54E-6	Protein quantitative trait loci	
LUSC	cis	1	rs2524005	chr6:29899677	HCG4	chr6:29758809-29760850:-	-0.36	-6.15	1.65E-9	Bipolar disorder and schizophrenia	
LUSC	cis	1	rs2524005	chr6:29899677	TRIM31	chr6:30070674-30080867:-	-0.25	-4.23	2.83E-5	Bipolar disorder and schizophrenia	
LUSC	cis	1	rs2524005	chr6:29899677	ZFP57	chr6:29640171-29648887:-	0.62	10.87	9.62E-25	Bipolar disorder and schizophrenia	
LUSC	cis	1	rs252887	chr5:56166188	C5orf35	chr5:56205103-56213010:+	0.86	14.43	2.12E-39	Type 2 diabetes	
LUSC	cis	1	rs252898	chr5:56188931	C5orf35	chr5:56205103-56213010:+	0.87	14.2	2.05E-38	Type 2 diabetes	
LUSC	cis	1	rs252902	chr5:56116085	C5orf35	chr5:56205103-56213010:+	0.87	15.43	8.02E-44	Type 2 diabetes	
LUSC	cis	1	rs252904	chr5:56118733	C5orf35	chr5:56205103-56213010:+	0.88	15.57	1.83E-44	Type 2 diabetes	
LUSC	cis	1	rs252909	chr5:56121131	C5orf35	chr5:56205103-56213010:+	0.84	14.6	3.95E-40	Type 2 diabetes	
LUSC	cis	1	rs252910	chr5:56192983	C5orf35	chr5:56205103-56213010:+	0.88	14.43	2.19E-39	Type 2 diabetes	
LUSC	cis	1	rs252915	chr5:56121754	C5orf35	chr5:56205103-56213010:+	-0.84	-14.58	4.44E-40	Type 2 diabetes	
LUSC	cis	1	rs252916	chr5:56121788	C5orf35	chr5:56205103-56213010:+	0.84	14.62	2.98E-40	Type 2 diabetes	
LUSC	cis	1	rs252919	chr5:56124111	C5orf35	chr5:56205103-56213010:+	0.84	14.58	4.64E-40	Type 2 diabetes	
LUSC	cis	1	rs252921	chr5:56137787	C5orf35	chr5:56205103-56213010:+	0.85	14.68	1.65E-40	Type 2 diabetes	
LUSC	cis	1	rs252922	chr5:56136343	C5orf35	chr5:56205103-56213010:+	0.84	14.27	1.04E-38	Type 2 diabetes	
LUSC	cis	1	rs2530664	chr22:30038152	CCDC157	chr22:30752627-30772816:+	0.22	3.82	0.000149	Lipid traits	
LUSC	cis	1	rs2530664	chr22:30038152	NIPSNAP1	chr22:29950800-29977144:-	0.27	4.55	6.87E-6	Lipid traits	
LUSC	cis	1	rs2531848	chr22:30032484	CCDC157	chr22:30752627-30772816:+	0.22	3.78	0.000177	Lipid traits	
LUSC	cis	1	rs2531848	chr22:30032484	NIPSNAP1	chr22:29950800-29977144:-	0.27	4.64	4.59E-6	Lipid traits	
LUSC	cis	1	rs2531849	chr22:30037900	CCDC157	chr22:30752627-30772816:+	0.22	3.82	0.000149	Lipid traits	
LUSC	cis	1	rs2531849	chr22:30037900	NIPSNAP1	chr22:29950800-29977144:-	0.27	4.55	6.87E-6	Lipid traits	
LUSC	cis	1	rs2533288	chr7:66056711	CCT6P1	chr7:65216092-65228661:+	0.25	3.86	0.000129	Diabetic kidney disease	
LUSC	cis	1	rs2541161	chr9:131884802	CRAT	chr9:131857075-131873070:-	-0.25	-5.19	3.16E-7	Blood metabolite ratios	
LUSC	cis	1	rs2541164	chr9:131876908	CRAT	chr9:131857075-131873070:-	0.28	5.73	1.79E-8	Blood metabolite ratios	
LUSC	cis	1	rs2548664	chr5:56133555	C5orf35	chr5:56205103-56213010:+	0.84	14.22	1.74E-38	Type 2 diabetes	
LUSC	cis	1	rs2548665	chr5:56131805	C5orf35	chr5:56205103-56213010:+	0.85	14.46	1.55E-39	Type 2 diabetes	
LUSC	cis	1	rs2562456	chr19:21666210	ZNF708	chr19:21473963-21512212:-	0.25	4.27	2.35E-5	Pain	
LUSC	cis	1	rs2572910	chr8:143770135	LY6K	chr8:143781529-143785582:+	0.26	5.15	3.74E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2572910	chr8:143770135	PSCA	chr8:143761875-143764142:+	0.47	10.23	2.49E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2579916	chr4:154659972	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2579917	chr4:154652648	TLR2	chr4:154605441-154627240:+	-0.2	-3.74	0.000207	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2585179	chr8:143774193	LY6K	chr8:143781529-143785582:+	0.26	5.15	3.81E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2585179	chr8:143774193	PSCA	chr8:143761875-143764142:+	0.47	10.21	3.0E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs259346	chr1:95728746	RWDD3	chr1:95583479-95712773:+	0.33	3.72	0.000223	Stearic acid (18:0) plasma levels	
LUSC	cis	1	rs2602836	chr4:100014805	ADH4	chr4:100044835-100065449:-	0.21	4.17	3.67E-5	HDL cholesterol	
LUSC	cis	1	rs2605582	chr11:93163799	C11orf75	chr11:93211641-93276546:-	-0.26	-4.3	2.07E-5	Pulmonary function decline	
LUSC	cis	1	rs2605582	chr11:93163799	CCDC67	chr11:93063156-93171634:+	-0.28	-4.71	3.24E-6	Pulmonary function decline	
LUSC	cis	1	rs2605583	chr11:93164957	C11orf75	chr11:93211641-93276546:-	-0.27	-4.27	2.31E-5	Pulmonary function decline	
LUSC	cis	1	rs2605583	chr11:93164957	CCDC67	chr11:93063156-93171634:+	-0.27	-4.51	8.34E-6	Pulmonary function decline	
LUSC	cis	1	rs2606325	chr4:154652681	TLR2	chr4:154605441-154627240:+	-0.2	-3.74	0.000207	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606327	chr4:154653629	TLR2	chr4:154605441-154627240:+	-0.2	-3.97	8.19E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606328	chr4:154653864	TLR2	chr4:154605441-154627240:+	-0.2	-4.21	3.06E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606329	chr4:154654643	TLR2	chr4:154605441-154627240:+	-0.2	-3.91	0.000104	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606332	chr4:154655372	TLR2	chr4:154605441-154627240:+	-0.2	-3.95	9.06E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606335	chr4:154656536	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606337	chr4:154656845	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606341	chr4:154658702	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2606342	chr4:154659980	TLR2	chr4:154605441-154627240:+	-0.19	-3.88	0.00012	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs2608216	chr11:93149172	C11orf75	chr11:93211641-93276546:-	-0.27	-4.3	2.05E-5	Pulmonary function decline	
LUSC	cis	1	rs2608216	chr11:93149172	CCDC67	chr11:93063156-93171634:+	-0.27	-4.59	5.64E-6	Pulmonary function decline	
LUSC	cis	1	rs2614811	chr15:43913487	CATSPER2	chr15:43922774-43959900:-	-0.25	-3.78	0.000177	Tumor biomarkers	
LUSC	cis	1	rs2617170	chr12:10560957	KLRC1	chr12:10594863-10606984:-	0.18	3.9	0.000108	Behcet's disease	
LUSC	cis	1	rs2617170	chr12:10560957	KLRC2	chr12:10579193-10588592:-	-0.17	-3.71	0.000233	Behcet's disease	
LUSC	cis	1	rs2629540	chr10:126426148	METTL10	chr10:126447406-126480439:-	0.27	4.3	2.05E-5	Cocaine dependence	
LUSC	cis	1	rs2637678	chr6:116787378	FAM26F	chr6:116782556-116784933:+	0.16	4.44	1.11E-5	Ulcerative colitis	
LUSC	cis	1	rs2644128	chr1:201793440	SHISA4	chr1:201858032-201861426:+	0.14	3.7	0.000242	Body mass index	
LUSC	cis	1	rs26510	chr5:96125910	ERAP1	chr5:96096515-96149837:-	-0.46	-11.26	3.1E-26	Ankylosing spondylitis	
LUSC	cis	1	rs26510	chr5:96125910	ERAP2	chr5:96211644-96255398:+	0.37	7.19	2.46E-12	Ankylosing spondylitis	
LUSC	cis	1	rs2651807	chr11:2378840	C11orf21	chr11:2317507-2323143:-	-0.2	-4.69	3.53E-6	Bacteremia	
LUSC	cis	1	rs2655310	chr4:130017919	C4orf33	chr4:130014829-130033842:+	-0.39	-7.89	2.03E-14	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs2658778	chr11:93148948	C11orf75	chr11:93211641-93276546:-	-0.27	-4.36	1.6E-5	Pulmonary function decline	
LUSC	cis	1	rs2658778	chr11:93148948	CCDC67	chr11:93063156-93171634:+	-0.28	-4.72	3.15E-6	Pulmonary function decline	
LUSC	cis	1	rs2658779	chr11:93163137	C11orf75	chr11:93211641-93276546:-	0.25	4.13	4.26E-5	Pulmonary function decline	
LUSC	cis	1	rs2658779	chr11:93163137	CCDC67	chr11:93063156-93171634:+	0.27	4.67	4.01E-6	Pulmonary function decline	
LUSC	cis	1	rs2658781	chr11:93166368	C11orf75	chr11:93211641-93276546:-	0.25	4.17	3.57E-5	Pulmonary function decline	
LUSC	cis	1	rs2658781	chr11:93166368	CCDC67	chr11:93063156-93171634:+	0.24	4.22	2.97E-5	Pulmonary function decline	
LUSC	cis	1	rs2658782	chr11:93166731	C11orf75	chr11:93211641-93276546:-	-0.26	-4.24	2.67E-5	Pulmonary function decline	
LUSC	cis	1	rs2658782	chr11:93166731	CCDC67	chr11:93063156-93171634:+	-0.27	-4.6	5.39E-6	Pulmonary function decline	
LUSC	cis	1	rs2659889	chr7:66217112	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.36	1.3E-7	Aortic root size	
LUSC	cis	1	rs2659906	chr7:66165310	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.47	7.14E-8	Aortic root size	
LUSC	cis	1	rs2659909	chr7:66160279	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.49	6.73E-8	Aortic root size	
LUSC	cis	1	rs2659912	chr7:66157999	NCRNA00174	chr7:65841032-65865395:-	-0.26	-5.67	2.46E-8	Aortic root size	
LUSC	cis	1	rs2659915	chr7:66153101	NCRNA00174	chr7:65841032-65865395:-	-0.24	-5.3	1.74E-7	Aortic root size	
LUSC	cis	1	rs2665826	chr17:61944924	FTSJ3	chr17:61896795-61905031:-	0.33	6.47	2.5E-10	Body mass index	
LUSC	cis	1	rs2667011	chr2:160867059	LY75	chr2:160625141-160761262:-	-0.28	-4.84	1.79E-6	Bilirubin levels	
LUSC	cis	1	rs267736	chr1:150945607	HORMAD1	chr1:150670542-150693352:-	-0.43	-4.72	3.17E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs2707831	chr7:66062511	CCT6P1	chr7:65216092-65228661:+	0.24	3.76	0.00019	Diabetic kidney disease	
LUSC	cis	1	rs2707836	chr7:66160435	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.46	7.77E-8	Aortic root size	
LUSC	cis	1	rs2707844	chr7:66059509	CCT6P1	chr7:65216092-65228661:+	0.24	3.79	0.000169	Diabetic kidney disease	
LUSC	cis	1	rs2707845	chr7:66198798	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.48	7.03E-8	Aortic root size	
LUSC	cis	1	rs2707850	chr7:66203870	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.48	7.03E-8	Aortic root size	
LUSC	cis	1	rs2707854	chr7:66212597	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.48	7.03E-8	Aortic root size	
LUSC	cis	1	rs2707856	chr7:66211010	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.5	6.21E-8	Aortic root size	
LUSC	cis	1	rs2717562	chr8:143776668	LY6K	chr8:143781529-143785582:+	0.26	5.15	3.81E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2717562	chr8:143776668	PSCA	chr8:143761875-143764142:+	0.47	10.21	3.0E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2734839	chr11:113286490	TTC12	chr11:113185251-113244016:+	-0.25	-4.58	5.99E-6	Information processing speed	
LUSC	cis	1	rs2736371	chr8:11105529	AMAC1L2	chr8:11188495-11189695:+	0.23	4.07	5.59E-5	Retinal vascular caliber	
LUSC	cis	1	rs2741435	chr20:43988198	SYS1	chr20:43991701-44004724:+	0.21	3.77	0.000183	Psoriasis	
LUSC	cis	1	rs2743414	chr20:43991566	SYS1	chr20:43991701-44004724:+	0.21	3.75	0.000199	Psoriasis	
LUSC	cis	1	rs2743419	chr20:43992645	SYS1	chr20:43991701-44004724:+	0.22	3.93	9.61E-5	Psoriasis	
LUSC	cis	1	rs2743423	chr20:43993539	SYS1	chr20:43991701-44004724:+	0.22	3.93	9.61E-5	Psoriasis	
LUSC	cis	1	rs2743424	chr20:43993934	SYS1	chr20:43991701-44004724:+	0.21	3.75	0.000199	Psoriasis	
LUSC	cis	1	rs27529	chr5:96126308	ERAP1	chr5:96096515-96149837:-	-0.44	-10.83	1.46E-24	Ankylosing spondylitis	
LUSC	cis	1	rs27529	chr5:96126308	ERAP2	chr5:96211644-96255398:+	0.38	7.54	2.36E-13	Ankylosing spondylitis	
LUSC	cis	1	rs2757042	chr6:167371234	RNASET2	chr6:167343008-167412795:-	0.25	4.84	1.75E-6	Crohn's disease	
LUSC	cis	1	rs2757047	chr6:167374489	RNASET2	chr6:167343008-167412795:-	0.25	4.83	1.84E-6	Crohn's disease	
LUSC	cis	1	rs2769347	chr6:167371737	RNASET2	chr6:167343008-167412795:-	0.25	4.88	1.43E-6	Crohn's disease	
LUSC	cis	1	rs2769352	chr6:167378619	RNASET2	chr6:167343008-167412795:-	0.25	4.89	1.39E-6	Crohn's disease	
LUSC	cis	1	rs2769354	chr6:167379771	RNASET2	chr6:167343008-167412795:-	0.25	4.93	1.15E-6	Crohn's disease	
LUSC	cis	1	rs27710	chr5:96126197	ERAP1	chr5:96096515-96149837:-	0.46	11.36	1.26E-26	Ankylosing spondylitis	
LUSC	cis	1	rs27710	chr5:96126197	ERAP2	chr5:96211644-96255398:+	-0.37	-7.24	1.79E-12	Ankylosing spondylitis	
LUSC	cis	1	rs27964	chr5:50152467	PARP8	chr5:49961733-50138169:+	0.18	3.71	0.000233	Myopia (pathological)	
LUSC	cis	1	rs280604	chr4:129921170	C4orf33	chr4:130014829-130033842:+	-0.38	-7.46	4.2E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs2812972	chr6:86669880	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.42E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs2816815	chr6:86691656	SNHG5	chr6:86386726-86388451:-	-0.69	-12.95	4.49E-33	Response to antipsychotic treatment	
LUSC	cis	1	rs2816821	chr6:86657084	SNHG5	chr6:86386726-86388451:-	-0.67	-12.58	1.56E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs2817953	chr6:121186786	GJA1	chr6:121756745-121770872:+	-0.17	-3.8	0.000162	Peak creatinine levels in vancomycin therapy	
LUSC	cis	1	rs2835607	chr21:38491973	PIGP	chr21:38437664-38445458:-	-0.33	-6.33	5.63E-10	Eye color traits	
LUSC	cis	1	rs2835608	chr21:38493455	PIGP	chr21:38437664-38445458:-	-0.33	-6.3	6.7E-10	Eye color traits	
LUSC	cis	1	rs28360661	chr21:40681972	PSMG1	chr21:40547390-40555440:-	-0.2	-3.86	0.00013	Cognitive function	
LUSC	cis	1	rs28365850	chr14:35591316	PPP2R3C	chr14:35554679-35591679:-	0.33	5.7	2.12E-8	Atopic dermatitis	
LUSC	cis	1	rs28376729	chr14:30495417	COCH	chr14:31343741-31364259:+	0.33	3.92	0.000102	Body mass index	
LUSC	cis	1	rs28379681	chr7:1070539	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs2838009	chr21:42694284	FAM3B	chr21:42676177-42729654:+	-0.23	-4.05	6.04E-5	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
LUSC	cis	1	rs28391259	chr4:107014012	TBCK	chr4:106967233-107237861:-	0.29	5.34	1.48E-7	Airflow obstruction	
LUSC	cis	1	rs2839181	chr21:47685939	C21orf57	chr21:47706267-47717664:+	-0.42	-7.74	5.85E-14	Testicular germ cell tumor	
LUSC	cis	1	rs2839186	chr21:47690068	C21orf57	chr21:47706267-47717664:+	-0.43	-7.92	1.68E-14	Testicular germ cell tumor	
LUSC	cis	1	rs2839337	chr21:47987167	C21orf56	chr21:47581063-47604373:-	0.31	5.18	3.25E-7	Lymphocyte counts	
LUSC	cis	1	rs28399702	chr14:35625217	PPP2R3C	chr14:35554679-35591679:-	0.31	5.47	7.22E-8	Atopic dermatitis	
LUSC	cis	1	rs28399710	chr7:1070631	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs28409322	chr3:134252385	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs28428724	chr4:75711826	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs28463311	chr17:61919643	FTSJ3	chr17:61896795-61905031:-	0.33	6.29	7.23E-10	Body mass index	
LUSC	cis	1	rs28468623	chr7:98922812	CYP3A5	chr7:99245818-99332821:-	0.47	5.63	3.08E-8	Blood metabolite levels	
LUSC	cis	1	rs28508557	chr15:36287359	ATPBD4	chr15:35663171-35838404:-	-0.21	-3.71	0.00023	Attention deficit hyperactivity disorder	
LUSC	cis	1	rs28513831	chr8:124189208	FAM83A	chr8:124191287-124222317:+	-0.27	-4.43	1.19E-5	Urinary uromodulin levels	
LUSC	cis	1	rs28522614	chr10:102323141	SEC31B	chr10:102246403-102289636:-	-0.28	-7.73	6.59E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs28528096	chr7:1070912	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs28537152	chr8:124189071	FAM83A	chr8:124191287-124222317:+	-0.27	-4.43	1.19E-5	Urinary uromodulin levels	
LUSC	cis	1	rs28542077	chr8:124190896	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs2854218	chr17:61942940	FTSJ3	chr17:61896795-61905031:-	0.36	6.92	1.44E-11	Body mass index	
LUSC	cis	1	rs2854218	chr17:61942940	MAP3K3	chr17:61699775-61773669:+	0.17	3.92	9.96E-5	Body mass index	
LUSC	cis	1	rs2854219	chr17:61942682	FTSJ3	chr17:61896795-61905031:-	0.35	6.76	3.99E-11	Body mass index	
LUSC	cis	1	rs2854219	chr17:61942682	MAP3K3	chr17:61699775-61773669:+	0.16	3.73	0.000217	Body mass index	
LUSC	cis	1	rs2854223	chr17:61939014	FTSJ3	chr17:61896795-61905031:-	0.33	6.52	1.82E-10	Body mass index	
LUSC	cis	1	rs28565322	chr18:12614183	SPIRE1	chr18:12446512-12657912:-	-0.31	-3.7	0.000241	Immune response to smallpox vaccine (IL-6)	
LUSC	cis	1	rs2856	chr20:25433536	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.78	0.000177	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs28588043	chr1:170966012	FMO6P	chr1:171106879-171130702:+	0.28	3.79	0.000172	Number of children (6+ vs. 0 or 1)	
LUSC	cis	1	rs28595532	chr4:119716950	SEC24D	chr4:119643979-119759827:-	0.43	5.34	1.44E-7	Cannabis dependence	
LUSC	cis	1	rs2859998	chr8:59324162	UBXN2B	chr8:59323823-59364059:+	-0.24	-4.27	2.35E-5	Narcolepsy with cataplexy	
LUSC	cis	1	rs28600316	chr4:75711790	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs28600861	chr8:124189063	FAM83A	chr8:124191287-124222317:+	-0.27	-4.43	1.19E-5	Urinary uromodulin levels	
LUSC	cis	1	rs28600971	chr4:119712728	SEC24D	chr4:119643979-119759827:-	0.43	5.16	3.64E-7	Cannabis dependence	
LUSC	cis	1	rs28605789	chr6:118889952	C6orf204	chr6:118786239-119031238:-	-0.24	-3.84	0.000142	Renal cell carcinoma	
LUSC	cis	1	rs28608578	chr4:75713550	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs28624331	chr8:124190768	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs28624565	chr4:75713287	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs28626045	chr14:75589195	MLH3	chr14:75480467-75518235:-	0.26	5.63	3.08E-8	Height	
LUSC	cis	1	rs2862961	chr11:43656535	HSD17B12	chr11:43702143-43878160:+	0.45	8.04	7.3E-15	Forced vital capacity	
LUSC	cis	1	rs2862963	chr11:43640115	HSD17B12	chr11:43702143-43878160:+	0.45	7.86	2.62E-14	Forced vital capacity	
LUSC	cis	1	rs2862985	chr10:102062809	PKD2L1	chr10:102047903-102090243:-	0.25	4.17	3.57E-5	Obesity-related traits	
LUSC	cis	1	rs2862996	chr11:43653833	HSD17B12	chr11:43702143-43878160:+	-0.44	-7.86	2.68E-14	Forced vital capacity	
LUSC	cis	1	rs28647657	chr4:75713724	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs28660477	chr15:56145267	NEDD4	chr15:56119131-56285835:-	0.24	4.41	1.25E-5	Keloid	
LUSC	cis	1	rs28661978	chr3:156579739	LEKR1	chr3:156544076-156763918:+	-0.39	-6.28	7.66E-10	Bone mineral density	
LUSC	cis	1	rs28664971	chr17:28437410	EFCAB5	chr17:28256874-28435469:+	0.28	5.29	1.85E-7	Coffee consumption (cups per day)	
LUSC	cis	1	rs28670850	chr8:124189125	FAM83A	chr8:124191287-124222317:+	-0.27	-4.43	1.19E-5	Urinary uromodulin levels	
LUSC	cis	1	rs28683528	chr12:123845351	ABCB9	chr12:123413540-123459752:-	0.3	4.25	2.54E-5	Educational attainment;Height;Head circumference (infant)	
LUSC	cis	1	rs28683528	chr12:123845351	CDK2AP1	chr12:123745542-123756687:-	-0.26	-3.88	0.000119	Educational attainment;Height;Head circumference (infant)	
LUSC	cis	1	rs28694222	chr8:124195017	FAM83A	chr8:124191287-124222317:+	-0.25	-3.97	8.33E-5	Urinary uromodulin levels	
LUSC	cis	1	rs28702390	chr3:41889920	ULK4	chr3:41288091-42003660:-	0.63	9.45	1.49E-19	Diastolic blood pressure	
LUSC	cis	1	rs28733681	chr3:41863444	ULK4	chr3:41288091-42003660:-	0.58	8.97	6.79E-18	Diastolic blood pressure	
LUSC	cis	1	rs2874121	chr17:61731024	FTSJ3	chr17:61896795-61905031:-	0.33	6.46	2.54E-10	Body mass index	
LUSC	cis	1	rs2874490	chr3:156635513	LEKR1	chr3:156544076-156763918:+	-0.35	-5.83	9.98E-9	Bone mineral density	
LUSC	cis	1	rs2874491	chr3:156649111	LEKR1	chr3:156544076-156763918:+	-0.34	-5.64	3.0E-8	Bone mineral density	
LUSC	cis	1	rs2878677	chr1:12053264	C1orf187	chr1:11751781-11780336:+	-0.18	-4.09	5.01E-5	Platelet count	
LUSC	cis	1	rs2879657	chr15:36287611	ATPBD4	chr15:35663171-35838404:-	-0.21	-3.73	0.000218	Attention deficit hyperactivity disorder	
LUSC	cis	1	rs28824259	chr3:48425675	TREX1	chr3:48501186-48509043:+	-0.44	-9.78	1.02E-20	Longevity	
LUSC	cis	1	rs2885510	chr3:48418226	ATRIP	chr3:48488141-48507708:+	-0.18	-3.76	0.000189	Longevity	
LUSC	cis	1	rs2885510	chr3:48418226	TREX1	chr3:48501186-48509043:+	0.42	9.31	4.71E-19	Longevity	
LUSC	cis	1	rs2887797	chr3:134202506	ANAPC13	chr3:134196547-134204865:-	0.42	8.36	7.23E-16	Height	
LUSC	cis	1	rs28881240	chr3:132728810	TMEM108	chr3:132757171-133116618:+	0.2	4.56	6.42E-6	IgE grass sensitization	
LUSC	cis	1	rs2888674	chr7:150510915	TMEM176A	chr7:150497854-150502208:+	0.13	4.31	1.97E-5	Forced expiratory volume in 1 second (environmental interaction)	
LUSC	cis	1	rs28897193	chr4:107005529	TBCK	chr4:106967233-107237861:-	0.28	5.33	1.54E-7	Airflow obstruction	
LUSC	cis	1	rs2889873	chr20:33646841	PROCR	chr20:33758727-33765164:+	-0.33	-4.21	3.01E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs2896463	chr14:103490892	MARK3	chr14:103851701-103970164:+	-0.33	-4	7.45E-5	Large B-cell lymphoma	
LUSC	cis	1	rs2911130	chr5:96183427	ERAP1	chr5:96096515-96149837:-	-0.26	-5.7	2.1E-8	Urate levels (BMI interaction)	
LUSC	cis	1	rs2911131	chr5:96185949	ERAP1	chr5:96096515-96149837:-	0.26	5.71	2.04E-8	Urate levels (BMI interaction)	
LUSC	cis	1	rs2911132	chr5:96186988	ERAP1	chr5:96096515-96149837:-	-0.26	-5.6	3.65E-8	Urate levels (BMI interaction)	
LUSC	cis	1	rs2920292	chr8:143765699	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.48E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920292	chr8:143765699	PSCA	chr8:143761875-143764142:+	0.47	10.15	4.97E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920293	chr8:143765414	LY6K	chr8:143781529-143785582:+	0.26	5.27	2.07E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920293	chr8:143765414	PSCA	chr8:143761875-143764142:+	0.47	10.16	4.59E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920294	chr8:143765326	LY6K	chr8:143781529-143785582:+	0.25	5.1	4.87E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920294	chr8:143765326	PSCA	chr8:143761875-143764142:+	0.46	10.03	1.32E-21	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920295	chr8:143764937	LY6K	chr8:143781529-143785582:+	0.25	5.06	6.03E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920295	chr8:143764937	PSCA	chr8:143761875-143764142:+	0.46	9.97	2.25E-21	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920296	chr8:143763109	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920296	chr8:143763109	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920296	chr8:143763109	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920297	chr8:143763083	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920297	chr8:143763083	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920297	chr8:143763083	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920298	chr8:143763043	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920298	chr8:143763043	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920298	chr8:143763043	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2920781	chr15:43924682	CATSPER2	chr15:43922774-43959900:-	-0.29	-4.3	2.08E-5	Tumor biomarkers	
LUSC	cis	1	rs2926702	chr8:71167994	XKR9	chr8:71581600-71648176:+	0.38	4.51	8.0E-6	Non-small cell lung cancer	
LUSC	cis	1	rs2927072	chr15:43922398	CATSPER2	chr15:43922774-43959900:-	-0.29	-4.3	2.08E-5	Tumor biomarkers	
LUSC	cis	1	rs2932538	chr1:113216543	ST7L	chr1:113066142-113162405:-	-0.23	-3.83	0.000146	Systolic blood pressure;Hypertension;Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs2935183	chr17:45607572	C17orf57	chr17:45401142-45518675:+	-0.28	-6.22	1.08E-9	Multiple sclerosis or amyotrophic lateral sclerosis	
LUSC	cis	1	rs2951308	chr7:143767149	ARHGEF35	chr7:143883677-143892736:-	0.34	6.94	1.29E-11	Obesity-related traits	
LUSC	cis	1	rs2951308	chr7:143767149	OR2A9P	chr7:143991573-143997832:+;chr7	0.23	4.21	3.0E-5	Obesity-related traits	
LUSC	cis	1	rs2951353	chr7:143761116	ARHGEF35	chr7:143883677-143892736:-	-0.35	-6.99	9.6E-12	Obesity-related traits	
LUSC	cis	1	rs2951353	chr7:143761116	OR2A9P	chr7:143991573-143997832:+;chr7	-0.23	-4.1	4.78E-5	Obesity-related traits	
LUSC	cis	1	rs2951354	chr7:143761001	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7	9.0E-12	Obesity-related traits	
LUSC	cis	1	rs2951354	chr7:143761001	OR2A9P	chr7:143991573-143997832:+;chr7	-0.22	-4.08	5.22E-5	Obesity-related traits	
LUSC	cis	1	rs2951360	chr7:143757349	ARHGEF35	chr7:143883677-143892736:-	-0.36	-7.38	7.27E-13	Obesity-related traits	
LUSC	cis	1	rs2951360	chr7:143757349	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.48	9.5E-6	Obesity-related traits	
LUSC	cis	1	rs2951363	chr7:143754724	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.59	1.69E-13	Obesity-related traits	
LUSC	cis	1	rs2951363	chr7:143754724	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.52	7.93E-6	Obesity-related traits	
LUSC	cis	1	rs2951364	chr7:143754483	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.56	2.16E-13	Obesity-related traits	
LUSC	cis	1	rs2951364	chr7:143754483	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.48	9.3E-6	Obesity-related traits	
LUSC	cis	1	rs2951368	chr7:143752821	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.56	2.16E-13	Obesity-related traits	
LUSC	cis	1	rs2951368	chr7:143752821	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.48	9.3E-6	Obesity-related traits	
LUSC	cis	1	rs2951369	chr7:143752638	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.56	2.16E-13	Obesity-related traits	
LUSC	cis	1	rs2951369	chr7:143752638	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.48	9.3E-6	Obesity-related traits	
LUSC	cis	1	rs2951372	chr7:143749503	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.6	1.61E-13	Obesity-related traits	
LUSC	cis	1	rs2951372	chr7:143749503	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.47	9.99E-6	Obesity-related traits	
LUSC	cis	1	rs2961115	chr7:143753371	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.56	2.16E-13	Obesity-related traits	
LUSC	cis	1	rs2961115	chr7:143753371	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.48	9.3E-6	Obesity-related traits	
LUSC	cis	1	rs2961117	chr7:143755253	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7.16	3.0E-12	Obesity-related traits	
LUSC	cis	1	rs2961117	chr7:143755253	OR2A9P	chr7:143991573-143997832:+;chr7	-0.23	-4.26	2.42E-5	Obesity-related traits	
LUSC	cis	1	rs2961118	chr7:143755443	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.64	1.19E-13	Obesity-related traits	
LUSC	cis	1	rs2961118	chr7:143755443	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.54	7.0E-6	Obesity-related traits	
LUSC	cis	1	rs2961119	chr7:143755852	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.61	1.51E-13	Obesity-related traits	
LUSC	cis	1	rs2961119	chr7:143755852	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.51	8.2E-6	Obesity-related traits	
LUSC	cis	1	rs2961120	chr7:143756585	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.56	2.1E-13	Obesity-related traits	
LUSC	cis	1	rs2961120	chr7:143756585	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.53	7.37E-6	Obesity-related traits	
LUSC	cis	1	rs2961125	chr7:143761770	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7	9.0E-12	Obesity-related traits	
LUSC	cis	1	rs2961125	chr7:143761770	OR2A9P	chr7:143991573-143997832:+;chr7	-0.22	-4.08	5.22E-5	Obesity-related traits	
LUSC	cis	1	rs2961126	chr7:143762736	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7	9.0E-12	Obesity-related traits	
LUSC	cis	1	rs2961126	chr7:143762736	OR2A9P	chr7:143991573-143997832:+;chr7	-0.22	-4.08	5.22E-5	Obesity-related traits	
LUSC	cis	1	rs2961128	chr7:143763483	ARHGEF35	chr7:143883677-143892736:-	-0.35	-7	9.0E-12	Obesity-related traits	
LUSC	cis	1	rs2961128	chr7:143763483	OR2A9P	chr7:143991573-143997832:+;chr7	-0.22	-4.08	5.22E-5	Obesity-related traits	
LUSC	cis	1	rs2961132	chr7:143768128	ARHGEF35	chr7:143883677-143892736:-	-0.36	-7.27	1.47E-12	Obesity-related traits	
LUSC	cis	1	rs2961132	chr7:143768128	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.37	1.54E-5	Obesity-related traits	
LUSC	cis	1	rs2961134	chr7:143771062	ARHGEF35	chr7:143883677-143892736:-	-0.38	-7.96	1.24E-14	Obesity-related traits	
LUSC	cis	1	rs2961134	chr7:143771062	OR2A9P	chr7:143991573-143997832:+;chr7	-0.24	-4.51	8.09E-6	Obesity-related traits	
LUSC	cis	1	rs2961144	chr7:143747870	ARHGEF35	chr7:143883677-143892736:-	0.37	7.57	1.94E-13	Obesity-related traits	
LUSC	cis	1	rs2961144	chr7:143747870	OR2A9P	chr7:143991573-143997832:+;chr7	0.24	4.4	1.32E-5	Obesity-related traits	
LUSC	cis	1	rs2976388	chr8:143760256	LOC100133669	chr8:144063448-144099807:-	0.23	3.72	0.000227	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976388	chr8:143760256	LY6K	chr8:143781529-143785582:+	0.31	6.15	1.68E-9	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976388	chr8:143760256	PSCA	chr8:143761875-143764142:+	0.46	9.68	2.49E-20	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976392	chr8:143762932	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976392	chr8:143762932	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976392	chr8:143762932	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976394	chr8:143763622	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976394	chr8:143763622	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976394	chr8:143763622	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976396	chr8:143764001	LOC100133669	chr8:144063448-144099807:-	-0.23	-3.85	0.000136	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976396	chr8:143764001	LY6K	chr8:143781529-143785582:+	-0.28	-5.72	1.93E-8	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976396	chr8:143764001	PSCA	chr8:143761875-143764142:+	-0.46	-10.19	3.43E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976398	chr8:143764879	LY6K	chr8:143781529-143785582:+	0.25	5.11	4.69E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2976398	chr8:143764879	PSCA	chr8:143761875-143764142:+	0.46	10.04	1.23E-21	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2978982	chr8:143763490	LOC100133669	chr8:144063448-144099807:-	0.22	3.71	0.000228	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2978982	chr8:143763490	LY6K	chr8:143781529-143785582:+	0.26	5.17	3.49E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2978982	chr8:143763490	PSCA	chr8:143761875-143764142:+	0.46	10.1	7.6E-22	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
LUSC	cis	1	rs2985684	chr14:50101682	RPL36AL	chr14:50085407-50087349:-	0.21	4.53	7.5E-6	Carotid intima media thickness	
LUSC	cis	1	rs2985687	chr14:50100386	RPL36AL	chr14:50085407-50087349:-	0.21	4.53	7.5E-6	Carotid intima media thickness	
LUSC	cis	1	rs2985696	chr14:50094913	RPL36AL	chr14:50085407-50087349:-	0.22	4.72	3.12E-6	Carotid intima media thickness	
LUSC	cis	1	rs2985697	chr14:50092902	RPL36AL	chr14:50085407-50087349:-	0.21	4.67	3.91E-6	Carotid intima media thickness	
LUSC	cis	1	rs2993259	chr1:46001550	CCDC163P	chr1:45960581-45965646:-	-0.74	-18.02	1.1E-55	Homocysteine levels	
LUSC	cis	1	rs2993259	chr1:46001550	MMACHC	chr1:45965856-45976737:+	-0.15	-3.89	0.000115	Homocysteine levels	
LUSC	cis	1	rs3002702	chr20:25268920	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.74	0.000208	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs3007030	chr14:50086563	RPL36AL	chr14:50085407-50087349:-	0.23	4.84	1.75E-6	Carotid intima media thickness	
LUSC	cis	1	rs3007031	chr14:50102269	RPL36AL	chr14:50085407-50087349:-	0.21	4.56	6.52E-6	Carotid intima media thickness	
LUSC	cis	1	rs30187	chr5:96124330	ERAP1	chr5:96096515-96149837:-	-0.46	-11.24	3.91E-26	Ankylosing spondylitis	
LUSC	cis	1	rs30187	chr5:96124330	ERAP2	chr5:96211644-96255398:+	0.37	7.18	2.72E-12	Ankylosing spondylitis	
LUSC	cis	1	rs3020282	chr8:6328628	XKR5	chr8:6666043-6693037:-	-0.38	-3.96	8.77E-5	Cytomegalovirus antibody response	
LUSC	cis	1	rs30379	chr5:96122260	ERAP1	chr5:96096515-96149837:-	-0.46	-11.14	9.07E-26	Ankylosing spondylitis	
LUSC	cis	1	rs30379	chr5:96122260	ERAP2	chr5:96211644-96255398:+	0.38	7.4	6.26E-13	Ankylosing spondylitis	
LUSC	cis	1	rs30380	chr5:96122281	ERAP1	chr5:96096515-96149837:-	-0.46	-11.14	9.07E-26	Ankylosing spondylitis	
LUSC	cis	1	rs30380	chr5:96122281	ERAP2	chr5:96211644-96255398:+	0.38	7.4	6.26E-13	Ankylosing spondylitis	
LUSC	cis	1	rs3091242	chr1:25674785	RHCE	chr1:25688741-25756683:-	0.31	5.69	2.22E-8	Erythrocyte sedimentation rate	
LUSC	cis	1	rs3091242	chr1:25674785	RHD	chr1:25598981-25656935:+	-0.58	-10.87	1.0E-24	Erythrocyte sedimentation rate	
LUSC	cis	1	rs3091242	chr1:25674785	TMEM50A	chr1:25664811-25688850:+	0.17	3.83	0.000143	Erythrocyte sedimentation rate	
LUSC	cis	1	rs3099459	chr5:56137170	C5orf35	chr5:56205103-56213010:+	0.84	14.23	1.53E-38	Type 2 diabetes	
LUSC	cis	1	rs3099899	chr4:129917368	C4orf33	chr4:130014829-130033842:+	-0.39	-7.51	2.96E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs3101443	chr15:43912372	CATSPER2	chr15:43922774-43959900:-	-0.27	-4.06	5.71E-5	Tumor biomarkers	
LUSC	cis	1	rs3105369	chr4:130022448	C4orf33	chr4:130014829-130033842:+	-0.37	-7.49	3.38E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs3113489	chr4:129961179	C4orf33	chr4:130014829-130033842:+	-0.36	-7	8.85E-12	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs316312	chr7:65596491	CCT6P1	chr7:65216092-65228661:+	0.23	3.73	0.000211	Diabetic kidney disease	
LUSC	cis	1	rs316331	chr7:65604622	CCT6P1	chr7:65216092-65228661:+	-0.25	-3.69	0.000246	Diabetic kidney disease	
LUSC	cis	1	rs316331	chr7:65604622	LOC493754	chr7:65993446-66057363:-	-0.38	-4.18	3.53E-5	Diabetic kidney disease	
LUSC	cis	1	rs317689	chr12:69727190	LYZ	chr12:69742134-69748013:+	-0.17	-5.33	1.53E-7	Response to diuretic therapy	
LUSC	cis	1	rs3180872	chr22:51017394	CPT1B	chr22:51007291-51017096:-	-0.36	-4.83	1.84E-6	Narcolepsy	
LUSC	cis	1	rs3213445	chr22:51015838	CPT1B	chr22:51007291-51017096:-	-0.35	-4.53	7.52E-6	Narcolepsy	
LUSC	cis	1	rs3213446	chr22:51015674	CPT1B	chr22:51007291-51017096:-	-0.38	-4.9	1.3E-6	Narcolepsy	
LUSC	cis	1	rs3213762	chr17:38178627	GSDMA	chr17:38119226-38134019:+	-0.45	-8.89	1.23E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs3214041	chr3:48454468	ATRIP	chr3:48488141-48507708:+	0.19	3.92	0.000103	Longevity	
LUSC	cis	1	rs3214041	chr3:48454468	TREX1	chr3:48501186-48509043:+	-0.41	-9.07	3.17E-18	Longevity	
LUSC	cis	1	rs33322	chr5:56175226	C5orf35	chr5:56205103-56213010:+	0.85	13.94	2.9E-37	Type 2 diabetes	
LUSC	cis	1	rs33325	chr5:56142547	C5orf35	chr5:56205103-56213010:+	0.87	15.26	4.72E-43	Type 2 diabetes	
LUSC	cis	1	rs33326	chr5:56142601	C5orf35	chr5:56205103-56213010:+	0.87	15.22	6.85E-43	Type 2 diabetes	
LUSC	cis	1	rs33955793	chr3:12544829	TSEN2	chr3:12525931-12581122:+	0.53	5.31	1.65E-7	Prostate cancer (gene x gene interaction)	
LUSC	cis	1	rs33988592	chr3:121415610	IQCB1	chr3:121488610-121553926:-	0.21	4.37	1.53E-5	Cognitive performance	
LUSC	cis	1	rs34086988	chr3:121352745	IQCB1	chr3:121488610-121553926:-	0.2	4.15	3.93E-5	Cognitive performance	
LUSC	cis	1	rs34102169	chr1:46424864	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.2	2.41E-12	Body mass index	
LUSC	cis	1	rs34106666	chr6:86676258	SNHG5	chr6:86386726-86388451:-	-0.66	-12.16	8.14E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs34128973	chr11:47851376	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.11	4.67E-5	Subjective well-being	
LUSC	cis	1	rs34171762	chr19:18559410	LRRC25	chr19:18501955-18508421:-	-0.11	-3.81	0.000154	Breast cancer	
LUSC	cis	1	rs34174778	chr20:33544277	PROCR	chr20:33758727-33765164:+	-0.32	-4.05	5.88E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs34180334	chr7:97615725	MGC72080	chr7:97503667-97601638:-	0.35	3.84	0.000141	Sudden cardiac arrest	
LUSC	cis	1	rs34237279	chr15:75361121	SCAMP5	chr15:75287901-75313836:+	0.23	3.72	0.000223	Blood trace element (Zn levels)	
LUSC	cis	1	rs34256197	chr19:18606472	SSBP4	chr19:18530221-18545371:+	-0.19	-3.76	0.000192	Breast cancer	
LUSC	cis	1	rs34281561	chr6:86701872	SNHG5	chr6:86386726-86388451:-	-0.68	-12.38	1.03E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs34292685	chr11:64049021	C11orf20	chr11:64067863-64072238:+	-0.32	-4.34	1.71E-5	Mean platelet volume	
LUSC	cis	1	rs34311452	chr7:151113143	CRYGN	chr7:151127057-151137899:-	0.28	3.7	0.000245	Coronary heart disease	
LUSC	cis	1	rs34311452	chr7:151113143	WDR86	chr7:151078207-151107740:-	0.27	3.99	7.81E-5	Coronary heart disease	
LUSC	cis	1	rs34324835	chr7:74132305	GATSL1	chr7:74379083-74438803:+	-0.25	-4.09	5.15E-5	Menarche (age at onset)	
LUSC	cis	1	rs34333482	chr6:116855952	FAM26F	chr6:116782556-116784933:+	0.15	4.23	2.86E-5	Pelvic organ prolapse (moderate/severe)	
LUSC	cis	1	rs34396223	chr1:95697828	RWDD3	chr1:95583479-95712773:+	0.42	4.66	4.09E-6	Stearic acid (18:0) plasma levels	
LUSC	cis	1	rs344081	chr3:156555984	LEKR1	chr3:156544076-156763918:+	-0.4	-6.55	1.52E-10	Bone mineral density	
LUSC	cis	1	rs344088	chr3:156561361	LEKR1	chr3:156544076-156763918:+	-0.39	-6.44	2.97E-10	Bone mineral density	
LUSC	cis	1	rs344090	chr3:156563140	LEKR1	chr3:156544076-156763918:+	-0.39	-6.44	2.97E-10	Bone mineral density	
LUSC	cis	1	rs34409160	chr2:28943865	TRMT61B	chr2:29072690-29093175:-	0.25	5.17	3.4E-7	Body mass index	
LUSC	cis	1	rs34428306	chr1:152184316	FLG	chr1:152274651-152297679:-	0.24	4.82	1.9E-6	Inflammatory skin disease	
LUSC	cis	1	rs3448	chr3:49396751	AMT	chr3:49454212-49460012:-	0.2	4.82	1.89E-6	Menarche (age at onset)	
LUSC	cis	1	rs3448	chr3:49396751	TREX1	chr3:48501186-48509043:+	-0.2	-3.76	0.000193	Menarche (age at onset)	
LUSC	cis	1	rs34570071	chr15:85280212	LOC388152	chr15:84867600-84898920:-	-0.23	-4.06	5.7E-5	Schizophrenia	
LUSC	cis	1	rs34581302	chr6:86705948	SNHG5	chr6:86386726-86388451:-	-0.67	-12.54	2.44E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs34583567	chr15:67983281	IQCH	chr15:67547188-67794139:+	0.21	3.73	0.000218	Motion sickness	
LUSC	cis	1	rs34610643	chr17:40574388	CNTD1	chr17:40950854-40963604:+	0.17	3.71	0.000227	Crohn's disease	
LUSC	cis	1	rs34622557	chr6:86630852	SNHG5	chr6:86386726-86388451:-	-0.65	-12.21	4.99E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs34625843	chr14:93793329	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs34636547	chr11:48590103	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.72	0.00022	HDL cholesterol	
LUSC	cis	1	rs34645895	chr20:25368373	ENTPD6	chr20:25176339-25207360:+	0.2	3.79	0.000167	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs34656763	chr1:212728389	LQK1	chr1:213029947-213031480:-	-0.35	-5.66	2.56E-8	Loneliness;Loneliness (linear analysis);Loneliness (multivariate analysis)	
LUSC	cis	1	rs34746918	chr19:18539744	LRRC25	chr19:18501955-18508421:-	-0.12	-4.17	3.64E-5	Breast cancer	
LUSC	cis	1	rs34746918	chr19:18539744	SSBP4	chr19:18530221-18545371:+	-0.2	-3.92	0.000102	Breast cancer	
LUSC	cis	1	rs34751999	chr15:84758419	LOC388152	chr15:84867600-84898920:-	-0.27	-4.76	2.57E-6	Schizophrenia	
LUSC	cis	1	rs34812189	chr6:56806727	BEND6	chr6:56819773-56892138:+	-0.41	-5.72	1.89E-8	Menarche (age at onset)	
LUSC	cis	1	rs34848593	chr1:113240106	ST7L	chr1:113066142-113162405:-	0.25	4.09	5.13E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs34852683	chr6:86702330	SNHG5	chr6:86386726-86388451:-	-0.65	-12.09	1.59E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs34872586	chr17:65863466	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs34897410	chr2:239182123	LOC151174	chr2:239133754-239140318:-	0.34	3.94	9.47E-5	Irritable bowel syndrome	
LUSC	cis	1	rs34900908	chr15:85257599	LOC388152	chr15:84867600-84898920:-	-0.24	-4.3	2.04E-5	Schizophrenia	
LUSC	cis	1	rs34910028	chr11:47758449	C1QTNF4	chr11:47611216-47615961:-	-0.21	-3.88	0.000119	Subjective well-being	
LUSC	cis	1	rs34949904	chr22:24695298	POM121L9P	chr22:24647589-24661490:+	-0.28	-6.7	6.02E-11	Gut microbiome composition (summer)	
LUSC	cis	1	rs34964872	chr14:104448435	TDRD9	chr14:104394817-104519002:+	0.25	4.39	1.41E-5	Bipolar disorder	
LUSC	cis	1	rs35006492	chr4:129878342	C4orf33	chr4:130014829-130033842:+	0.37	7.07	5.7E-12	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs35056702	chr6:109736326	AKD1	chr6:109814059-110012415:-	-0.17	-4.01	7.1E-5	Height	
LUSC	cis	1	rs35056702	chr6:109736326	SMPD2	chr6:109761931-109765121:+	0.23	4.27	2.4E-5	Height	
LUSC	cis	1	rs35060985	chr11:43693110	HSD17B12	chr11:43702143-43878160:+	-0.49	-8.93	9.4E-18	Forced vital capacity	
LUSC	cis	1	rs35105361	chr7:128383768	OPN1SW	chr7:128412545-128415844:-	0.26	4.53	7.51E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs35106985	chr10:102307542	SEC31B	chr10:102246403-102289636:-	-0.27	-8.21	2.17E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs35149210	chr7:65929925	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs35202312	chr6:56788937	BEND6	chr6:56819773-56892138:+	-0.35	-5.09	5.06E-7	Menarche (age at onset)	
LUSC	cis	1	rs35243555	chr17:65876477	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs35297609	chr15:84772896	LOC388152	chr15:84867600-84898920:-	-0.27	-4.87	1.5E-6	Schizophrenia	
LUSC	cis	1	rs35303215	chr22:24801535	POM121L9P	chr22:24647589-24661490:+	-0.3	-7.11	4.35E-12	Gut microbiome composition (summer)	
LUSC	cis	1	rs35316992	chr15:85248133	LOC388152	chr15:84867600-84898920:-	-0.24	-4.32	1.93E-5	Schizophrenia	
LUSC	cis	1	rs35318583	chr7:97622729	MGC72080	chr7:97503667-97601638:-	0.37	4.11	4.71E-5	Sudden cardiac arrest	
LUSC	cis	1	rs35385043	chr6:86648546	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs35395156	chr15:67962763	IQCH	chr15:67547188-67794139:+	0.21	3.78	0.000176	Motion sickness	
LUSC	cis	1	rs35398388	chr19:37740358	ZNF781	chr19:38158650-38183216:-	0.24	3.87	0.000123	Coronary artery calcification	
LUSC	cis	1	rs35419329	chr6:86702291	SNHG5	chr6:86386726-86388451:-	-0.67	-12.34	1.59E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs35435780	chr17:79579602	TSPAN10	chr17:79609349-79615778:+	0.46	9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs35481514	chr7:97620097	MGC72080	chr7:97503667-97601638:-	0.37	4.01	7.08E-5	Sudden cardiac arrest	
LUSC	cis	1	rs35522482	chr22:39063015	CBY1	chr22:39052658-39069853:+	0.21	3.84	0.000141	Resting heart rate	
LUSC	cis	1	rs35524990	chr15:85258203	LOC388152	chr15:84867600-84898920:-	-0.24	-4.3	2.04E-5	Schizophrenia	
LUSC	cis	1	rs35527216	chr6:56791278	BEND6	chr6:56819773-56892138:+	-0.38	-5.44	8.39E-8	Menarche (age at onset)	
LUSC	cis	1	rs35552264	chr20:33544973	PROCR	chr20:33758727-33765164:+	-0.33	-4.12	4.41E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs35565791	chr22:39063011	CBY1	chr22:39052658-39069853:+	0.21	3.84	0.000141	Resting heart rate	
LUSC	cis	1	rs35624992	chr11:47615798	C1QTNF4	chr11:47611216-47615961:-	-0.25	-4.65	4.22E-6	Subjective well-being	
LUSC	cis	1	rs35630683	chr15:85349231	LOC388152	chr15:84867600-84898920:-	-0.23	-4.08	5.19E-5	Schizophrenia	
LUSC	cis	1	rs35648189	chr15:84740748	LOC388152	chr15:84867600-84898920:-	-0.27	-4.76	2.57E-6	Schizophrenia	
LUSC	cis	1	rs35658069	chr15:84780146	LOC388152	chr15:84867600-84898920:-	-0.27	-4.77	2.41E-6	Schizophrenia	
LUSC	cis	1	rs35718987	chr3:134272783	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs35726233	chr15:85337800	LOC388152	chr15:84867600-84898920:-	-0.24	-4.3	2.1E-5	Schizophrenia	
LUSC	cis	1	rs35736167	chr15:75332002	SCAMP5	chr15:75287901-75313836:+	0.26	4.23	2.79E-5	Blood trace element (Zn levels)	
LUSC	cis	1	rs35760725	chr6:86648985	SNHG5	chr6:86386726-86388451:-	-0.67	-12.6	1.29E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs35761942	chr6:86629504	SNHG5	chr6:86386726-86388451:-	-0.66	-11.98	4.52E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs35797755	chr6:86706554	SNHG5	chr6:86386726-86388451:-	-0.67	-12.63	1.03E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs35808647	chr15:85377441	LOC388152	chr15:84867600-84898920:-	-0.22	-3.93	9.91E-5	Schizophrenia	
LUSC	cis	1	rs35835884	chr10:127708468	UROS	chr10:127477148-127511837:-	-0.26	-5.49	6.51E-8	Visceral fat	
LUSC	cis	1	rs35902101	chr11:47795169	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.02	6.78E-5	Subjective well-being	
LUSC	cis	1	rs35949897	chr12:15346379	GUCY2C	chr12:14765570-14849519:-	0.27	3.88	0.000121	Glomerular filtration rate (creatinine)	
LUSC	cis	1	rs35949897	chr12:15346379	RERG	chr12:15260718-15374304:-	0.23	3.93	9.94E-5	Glomerular filtration rate (creatinine)	
LUSC	cis	1	rs35960805	chr15:85343980	LOC388152	chr15:84867600-84898920:-	-0.24	-4.3	2.1E-5	Schizophrenia	
LUSC	cis	1	rs35988617	chr3:121432902	IQCB1	chr3:121488610-121553926:-	0.21	4.37	1.53E-5	Cognitive performance	
LUSC	cis	1	rs36033486	chr15:85319692	LOC388152	chr15:84867600-84898920:-	-0.23	-4.24	2.71E-5	Schizophrenia	
LUSC	cis	1	rs36035949	chr6:109736614	AKD1	chr6:109814059-110012415:-	-0.17	-3.93	9.6E-5	Height	
LUSC	cis	1	rs36035949	chr6:109736614	SMPD2	chr6:109761931-109765121:+	0.25	4.51	8.2E-6	Height	
LUSC	cis	1	rs36044436	chr7:74089819	GATSL1	chr7:74379083-74438803:+	-0.24	-3.83	0.000147	Menarche (age at onset)	
LUSC	cis	1	rs36096931	chr6:86693134	SNHG5	chr6:86386726-86388451:-	-0.66	-12.19	6.11E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs36123022	chr3:12552980	TSEN2	chr3:12525931-12581122:+	0.52	5.26	2.23E-7	Prostate cancer (gene x gene interaction)	
LUSC	cis	1	rs36216559	chr2:262335	SH3YL1	chr2:218138-264810:-	-0.51	-9.08	3.03E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs364283	chr6:167383750	RNASET2	chr6:167343008-167412795:-	-0.25	-4.84	1.76E-6	Crohn's disease	
LUSC	cis	1	rs364451	chr6:167384756	RNASET2	chr6:167343008-167412795:-	-0.25	-4.87	1.52E-6	Crohn's disease	
LUSC	cis	1	rs365189	chr6:167384545	RNASET2	chr6:167343008-167412795:-	-0.25	-4.93	1.15E-6	Crohn's disease	
LUSC	cis	1	rs3730729	chr18:51804702	POLI	chr18:51795849-51824602:+	-0.23	-3.83	0.000143	Psoriasis	
LUSC	cis	1	rs3731714	chr2:202060820	PPIL3	chr2:201735680-201753999:-	0.22	3.84	0.000141	Trans fatty acid levels	
LUSC	cis	1	rs3732408	chr3:121421179	IQCB1	chr3:121488610-121553926:-	0.21	4.37	1.53E-5	Cognitive performance	
LUSC	cis	1	rs3735148	chr7:65971009	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.13E-9	Aortic root size	
LUSC	cis	1	rs37379	chr5:35045826	RAD1	chr5:34905367-34918383:-	0.3	3.7	0.000243	Urinary metabolites (H-NMR features)	
LUSC	cis	1	rs3738483	chr1:150801466	HORMAD1	chr1:150670542-150693352:-	0.46	4.97	9.52E-7	Congenital left-sided heart lesions	
LUSC	cis	1	rs3742500	chr14:24611978	FAM158A	chr14:24608175-24610797:-	-0.32	-6.98	9.86E-12	IgG glycosylation	
LUSC	cis	1	rs3742773	chr14:75579643	MLH3	chr14:75480467-75518235:-	0.26	5.64	2.87E-8	Height	
LUSC	cis	1	rs3742778	chr14:75538217	MLH3	chr14:75480467-75518235:-	-0.25	-5.3	1.74E-7	Height	
LUSC	cis	1	rs3742780	chr14:75505008	MLH3	chr14:75480467-75518235:-	0.26	5.59	3.84E-8	Height	
LUSC	cis	1	rs3745859	chr19:39196745	LGALS7B	chr19:39279850-39282393:+	0.2	4.19	3.27E-5	Heart rate	
LUSC	cis	1	rs3745937	chr19:42071289	CEACAM21	chr19:42055886-42093196:+	0.53	15.39	1.19E-43	Schizophrenia	
LUSC	cis	1	rs3747113	chr22:24717518	POM121L9P	chr22:24647589-24661490:+	0.25	6.2	1.2E-9	Gut microbiome composition (summer)	
LUSC	cis	1	rs3747170	chr22:39067331	CBY1	chr22:39052658-39069853:+	0.21	3.82	0.000154	Resting heart rate	
LUSC	cis	1	rs3747172	chr22:39067524	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs3747174	chr22:39069181	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs3748656	chr1:113236681	ST7L	chr1:113066142-113162405:-	0.25	4.13	4.37E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs3750626	chr10:102266316	SEC31B	chr10:102246403-102289636:-	-0.29	-8.6	1.21E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3750627	chr10:102275642	SEC31B	chr10:102246403-102289636:-	-0.26	-7.85	2.79E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3750629	chr10:102275727	SEC31B	chr10:102246403-102289636:-	-0.29	-8.82	2.19E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3750630	chr10:102275780	SEC31B	chr10:102246403-102289636:-	-0.28	-8.58	1.32E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3750633	chr10:102308214	SEC31B	chr10:102246403-102289636:-	-0.27	-8.11	4.38E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3750719	chr10:102248950	SEC31B	chr10:102246403-102289636:-	-0.27	-8.05	6.67E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3750720	chr10:102248884	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.13E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3751237	chr12:27963507	LOC100133893	chr12:27915599-27924209:-	0.31	4.79	2.28E-6	Type 2 diabetes	
LUSC	cis	1	rs3754210	chr1:150954261	HORMAD1	chr1:150670542-150693352:-	-0.34	-3.84	0.000142	Congenital left-sided heart lesions	
LUSC	cis	1	rs3759843	chr15:40453075	C15orf56	chr15:40542868-40545110:-	0.25	3.82	0.00015	Chronic lymphocytic leukemia	
LUSC	cis	1	rs3761117	chr20:25388070	ENTPD6	chr20:25176339-25207360:+	0.2	3.72	0.000219	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs3761454	chr22:39066820	CBY1	chr22:39052658-39069853:+	0.21	3.82	0.000154	Resting heart rate	
LUSC	cis	1	rs3761959	chr1:157669278	FCRL3	chr1:157646278-157670775:-	0.29	9.61	4.14E-20	Type 1 diabetes autoantibodies	
LUSC	cis	1	rs3763695	chr10:102269206	SEC31B	chr10:102246403-102289636:-	-0.28	-8.4	5.2E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs376551	chr6:167384923	RNASET2	chr6:167343008-167412795:-	-0.25	-4.93	1.14E-6	Crohn's disease	
LUSC	cis	1	rs376574	chr6:167389956	RNASET2	chr6:167343008-167412795:-	-0.25	-4.88	1.48E-6	Crohn's disease	
LUSC	cis	1	rs3770752	chr2:37576136	CEBPZ	chr2:37428778-37458740:-	0.25	5.48	6.99E-8	Schizophrenia	
LUSC	cis	1	rs3771175	chr2:102960210	IL1RL1	chr2:102927962-102968497:+	-0.24	-3.76	0.000192	Asthma	
LUSC	cis	1	rs3772128	chr3:121345094	IQCB1	chr3:121488610-121553926:-	0.2	4.11	4.69E-5	Cognitive performance	
LUSC	cis	1	rs3772130	chr3:121344140	IQCB1	chr3:121488610-121553926:-	0.2	4.13	4.3E-5	Cognitive performance	
LUSC	cis	1	rs3774372	chr3:41877414	ULK4	chr3:41288091-42003660:-	0.66	9.79	9.49E-21	Diastolic blood pressure	
LUSC	cis	1	rs3774808	chr3:48481647	ATRIP	chr3:48488141-48507708:+	0.19	3.83	0.000143	Longevity	
LUSC	cis	1	rs3774808	chr3:48481647	TREX1	chr3:48501186-48509043:+	-0.42	-9.17	1.48E-18	Longevity	
LUSC	cis	1	rs3775422	chr4:90654664	MMRN1	chr4:90816003-90875778:+	0.25	3.8	0.000166	Parkinson's disease	
LUSC	cis	1	rs3775423	chr4:90657491	MMRN1	chr4:90816003-90875778:+	0.25	3.8	0.000166	Parkinson's disease	
LUSC	cis	1	rs3777722	chr6:167352104	RNASET2	chr6:167343008-167412795:-	0.32	3.7	0.000242	Spontaneous preterm birth (preterm birth)	
LUSC	cis	1	rs3778909	chr7:66255646	NCRNA00174	chr7:65841032-65865395:-	-0.26	-5.6	3.7E-8	Aortic root size	
LUSC	cis	1	rs3781001	chr10:127706028	UROS	chr10:127477148-127511837:-	-0.27	-5.57	4.38E-8	Visceral fat	
LUSC	cis	1	rs3782130	chr12:58161898	FAM119B	chr12:58166383-58176323:+	0.53	9.23	8.75E-19	Multiple sclerosis	
LUSC	cis	1	rs3782130	chr12:58161898	TSFM	chr12:58176536-58191367:+	-0.4	-8.55	1.69E-16	Multiple sclerosis	
LUSC	cis	1	rs3782130	chr12:58161898	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.31	1.97E-5	Multiple sclerosis	
LUSC	cis	1	rs3782894	chr12:110026024	MYO1H	chr12:109826524-109886176:+	0.24	4.32	1.88E-5	HDL cholesterol	
LUSC	cis	1	rs3783890	chr14:93790276	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs3786835	chr19:39155880	LGALS7B	chr19:39279850-39282393:+	0.2	4.11	4.74E-5	Heart rate	
LUSC	cis	1	rs3786839	chr19:39182565	LGALS7B	chr19:39279850-39282393:+	0.21	4.38	1.49E-5	Heart rate	
LUSC	cis	1	rs3786845	chr19:39195083	LGALS7B	chr19:39279850-39282393:+	0.2	4.19	3.31E-5	Heart rate	
LUSC	cis	1	rs3786848	chr19:39207329	LGALS7B	chr19:39279850-39282393:+	0.19	4.03	6.46E-5	Heart rate	
LUSC	cis	1	rs3786851	chr19:39215333	LGALS7B	chr19:39279850-39282393:+	0.2	4.19	3.29E-5	Heart rate	
LUSC	cis	1	rs3788347	chr22:23467804	RTDR1	chr22:23401594-23484241:-	-0.24	-4.51	8.24E-6	Bone mineral density	
LUSC	cis	1	rs3788544	chr22:39064966	CBY1	chr22:39052658-39069853:+	0.21	3.82	0.000152	Resting heart rate	
LUSC	cis	1	rs3788545	chr22:39065172	CBY1	chr22:39052658-39069853:+	0.21	3.72	0.00022	Resting heart rate	
LUSC	cis	1	rs3790012	chr13:36773489	SOHLH2	chr13:36742347-36871992:-	0.25	4.44	1.12E-5	Glucose homeostasis traits	
LUSC	cis	1	rs3791185	chr1:107600869	PRMT6	chr1:107599267-107601907:+	0.27	4.29	2.15E-5	AIDS	
LUSC	cis	1	rs3791220	chr2:227066	SH3YL1	chr2:218138-264810:-	-0.51	-9.11	2.3E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs3791221	chr2:226933	SH3YL1	chr2:218138-264810:-	-0.51	-9.26	6.79E-19	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs3791223	chr2:222336	SH3YL1	chr2:218138-264810:-	-0.5	-9.08	2.88E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs3791224	chr2:221981	SH3YL1	chr2:218138-264810:-	-0.5	-9.02	4.84E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs3792574	chr7:134254029	AKR1B15	chr7:134233849-134264300:+	0.2	4.07	5.48E-5	Longevity	
LUSC	cis	1	rs3793706	chr10:102269085	SEC31B	chr10:102246403-102289636:-	0.28	8.62	1.03E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3793771	chr10:102222957	SEC31B	chr10:102246403-102289636:-	-0.27	-8.19	2.44E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3793772	chr10:102222825	SEC31B	chr10:102246403-102289636:-	-0.26	-7.92	1.67E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs3795819	chr1:113234179	ST7L	chr1:113066142-113162405:-	-0.26	-4.23	2.83E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs3800812	chr7:66223461	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.36	1.3E-7	Aortic root size	
LUSC	cis	1	rs3806988	chr6:49431569	CENPQ	chr6:49431096-49460820:+	-0.34	-7.2	2.38E-12	Folate pathway vitamin levels	
LUSC	cis	1	rs3806988	chr6:49431569	MUT	chr6:49398994-49431031:-	0.38	6.65	8.09E-11	Folate pathway vitamin levels	
LUSC	cis	1	rs3809868	chr17:45750596	C17orf57	chr17:45401142-45518675:+	-0.29	-6.46	2.52E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs3813227	chr2:73651967	ALMS1P	chr2:73872046-73912692:+	-0.41	-7.48	3.66E-13	Metabolite levels	
LUSC	cis	1	rs3813227	chr2:73651967	NAT8	chr2:73867850-73869537:-	-0.23	-3.86	0.000127	Metabolite levels	
LUSC	cis	1	rs3814184	chr10:69966251	PBLD	chr10:70042417-70092684:-	0.33	5.32	1.57E-7	Optic nerve measurement (disc area)	
LUSC	cis	1	rs3817181	chr17:61776538	FTSJ3	chr17:61896795-61905031:-	0.34	6.42	3.22E-10	Body mass index	
LUSC	cis	1	rs3820541	chr1:150848681	HORMAD1	chr1:150670542-150693352:-	-0.49	-4.93	1.12E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs3820543	chr1:150812858	HORMAD1	chr1:150670542-150693352:-	-0.5	-4.96	1.0E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs3823114	chr6:49431720	CENPQ	chr6:49431096-49460820:+	-0.4	-8.84	1.92E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs3823114	chr6:49431720	MUT	chr6:49398994-49431031:-	0.3	5.39	1.09E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs3825079	chr12:58203354	FAM119B	chr12:58166383-58176323:+	0.52	9.16	1.54E-18	Multiple sclerosis	
LUSC	cis	1	rs3825079	chr12:58203354	TSFM	chr12:58176536-58191367:+	-0.4	-8.65	7.88E-17	Multiple sclerosis	
LUSC	cis	1	rs3825079	chr12:58203354	XRCC6BP1	chr12:58335445-58351051:+	-0.21	-4.16	3.77E-5	Multiple sclerosis	
LUSC	cis	1	rs3825932	chr15:79235446	CTSH	chr15:79214092-79237420:-	0.21	5.12	4.39E-7	Type 1 diabetes	
LUSC	cis	1	rs3826331	chr17:38150492	GSDMA	chr17:38119226-38134019:+	0.45	9.05	3.82E-18	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs3827066	chr20:44586023	WFDC3	chr20:44402847-44420547:-	-0.57	-7.57	1.97E-13	Abdominal aortic aneurysm	
LUSC	cis	1	rs3827316	chr22:23468538	RTDR1	chr22:23401594-23484241:-	-0.25	-4.77	2.43E-6	Bone mineral density	
LUSC	cis	1	rs3827357	chr22:39079413	CBY1	chr22:39052658-39069853:+	0.23	4.18	3.53E-5	Resting heart rate	
LUSC	cis	1	rs3828165	chr2:220889	SH3YL1	chr2:218138-264810:-	-0.5	-9.08	2.85E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs3829218	chr11:58331309	CNTF	chr11:58390146-58393203:+	0.37	4.67	3.9E-6	Lymphoma	
LUSC	cis	1	rs3829218	chr11:58331309	ZFP91-CNTF	chr11:58346587-58393203:+	0.27	3.83	0.000143	Lymphoma	
LUSC	cis	1	rs3846055	chr3:134203973	ANAPC13	chr3:134196547-134204865:-	0.43	8.61	1.12E-16	Height	
LUSC	cis	1	rs3846056	chr3:134227292	ANAPC13	chr3:134196547-134204865:-	0.42	8.41	4.72E-16	Height	
LUSC	cis	1	rs3846926	chr6:56092186	COL21A1	chr6:55921389-56258892:-	0.19	3.8	0.000161	Pulse pressure	
LUSC	cis	1	rs3847669	chr12:75949158	GLIPR1L2	chr12:75784889-75825591:+	-0.26	-4.6	5.52E-6	Polycystic ovary syndrome	
LUSC	cis	1	rs3850639	chr1:172253634	VAMP4	chr1:171669298-171711214:-	0.19	3.85	0.000135	Height	
LUSC	cis	1	rs3850640	chr1:172253765	VAMP4	chr1:171669298-171711214:-	-0.19	-3.83	0.000148	Height	
LUSC	cis	1	rs385113	chr6:167403971	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs3857051	chr4:90643697	MMRN1	chr4:90816003-90875778:+	0.26	4.06	5.82E-5	Parkinson's disease	
LUSC	cis	1	rs3857053	chr4:90645674	MMRN1	chr4:90816003-90875778:+	0.25	3.82	0.000153	Parkinson's disease	
LUSC	cis	1	rs3857688	chr7:66127806	NCRNA00174	chr7:65841032-65865395:-	0.25	5.39	1.09E-7	Aortic root size	
LUSC	cis	1	rs3858534	chr12:75947084	GLIPR1L2	chr12:75784889-75825591:+	-0.26	-4.52	7.66E-6	Polycystic ovary syndrome	
LUSC	cis	1	rs385863	chr6:167386615	RNASET2	chr6:167343008-167412795:-	-0.25	-4.91	1.28E-6	Crohn's disease	
LUSC	cis	1	rs386548	chr6:167385533	RNASET2	chr6:167343008-167412795:-	0.25	4.87	1.56E-6	Crohn's disease	
LUSC	cis	1	rs3866330	chr3:49582994	AMT	chr3:49454212-49460012:-	0.21	5.04	6.66E-7	Menarche (age at onset)	
LUSC	cis	1	rs3870339	chr3:49536863	AMT	chr3:49454212-49460012:-	0.21	4.92	1.22E-6	Menarche (age at onset)	
LUSC	cis	1	rs3870341	chr3:49584745	AMT	chr3:49454212-49460012:-	0.21	5.04	6.66E-7	Menarche (age at onset)	
LUSC	cis	1	rs387676	chr7:65598220	LOC493754	chr7:65993446-66057363:-	0.32	3.71	0.000228	Diabetic kidney disease	
LUSC	cis	1	rs3886938	chr8:130737546	GSDMC	chr8:130760443-130799134:-	0.26	5.25	2.34E-7	Infant length;Height	
LUSC	cis	1	rs389946	chr6:167407268	RNASET2	chr6:167343008-167412795:-	-0.25	-4.82	1.89E-6	Crohn's disease	
LUSC	cis	1	rs389956	chr6:167407254	RNASET2	chr6:167343008-167412795:-	-0.25	-4.82	1.89E-6	Crohn's disease	
LUSC	cis	1	rs3905330	chr3:49550774	AMT	chr3:49454212-49460012:-	0.21	5	7.97E-7	Menarche (age at onset)	
LUSC	cis	1	rs390966	chr2:71255691	OR7E91P	chr2:71251205-71257058:+	-0.29	-4.64	4.49E-6	Erythema nodosum in inflammatory bowel disease	
LUSC	cis	1	rs391396	chr4:130037653	C4orf33	chr4:130014829-130033842:+	-0.37	-7.52	2.67E-13	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs3915733	chr14:104147353	C14orf153	chr14:104029299-104057227:+	0.15	3.88	0.00012	Body mass index	
LUSC	cis	1	rs3915733	chr14:104147353	CKB	chr14:103985996-103989170:-	0.19	3.73	0.000214	Body mass index	
LUSC	cis	1	rs3917839	chr1:169560485	SLC19A2	chr1:169433151-169455208:-	0.34	3.78	0.000177	Hippocampal atrophy	
LUSC	cis	1	rs3917851	chr1:169559635	SLC19A2	chr1:169433151-169455208:-	0.38	4.32	1.88E-5	Hippocampal atrophy	
LUSC	cis	1	rs3931020	chr1:75235317	CRYZ	chr1:75171175-75199092:-	-0.3	-5.63	3.13E-8	Resistin levels	
LUSC	cis	1	rs3932818	chr3:134206069	ANAPC13	chr3:134196547-134204865:-	0.43	8.77	3.29E-17	Height	
LUSC	cis	1	rs3934103	chr3:41977214	ULK4	chr3:41288091-42003660:-	-0.62	-9.49	1.14E-19	Diastolic blood pressure	
LUSC	cis	1	rs3935543	chr17:79579874	TSPAN10	chr17:79609349-79615778:+	0.46	9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs393558	chr6:167397750	RNASET2	chr6:167343008-167412795:-	-0.24	-4.79	2.28E-6	Crohn's disease	
LUSC	cis	1	rs3935969	chr17:65881959	LOC440461	chr17:66194801-66196436:+	0.26	4.06	5.8E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs393727	chr6:167398632	RNASET2	chr6:167343008-167412795:-	-0.24	-4.78	2.3E-6	Crohn's disease	
LUSC	cis	1	rs394522	chr6:167398071	RNASET2	chr6:167343008-167412795:-	-0.24	-4.79	2.28E-6	Crohn's disease	
LUSC	cis	1	rs396508	chr16:20682354	ACSM1	chr16:20634559-20709066:-	-0.34	-6.17	1.45E-9	Schizophrenia	
LUSC	cis	1	rs397119	chr20:25440187	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.89	0.000114	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs397119	chr20:25440187	FAM182A	chr20:26035250-26067552:+	-0.2	-3.91	0.000106	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs397713	chr6:167386714	RNASET2	chr6:167343008-167412795:-	-0.25	-4.88	1.48E-6	Crohn's disease	
LUSC	cis	1	rs398036	chr20:25439850	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.89	0.000115	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs398036	chr20:25439850	FAM182A	chr20:26035250-26067552:+	-0.2	-3.92	0.000102	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs3981131	chr7:65951677	NCRNA00174	chr7:65841032-65865395:-	-0.3	-6.26	8.53E-10	Aortic root size	
LUSC	cis	1	rs398278	chr6:167388169	RNASET2	chr6:167343008-167412795:-	-0.25	-4.82	1.93E-6	Crohn's disease	
LUSC	cis	1	rs3999544	chr6:26285867	BTN3A2	chr6:26365398-26378546:+	0.23	5.11	4.78E-7	Educational attainment	
LUSC	cis	1	rs400063	chr6:167386592	RNASET2	chr6:167343008-167412795:-	-0.25	-4.98	8.88E-7	Crohn's disease	
LUSC	cis	1	rs400176	chr6:167406238	RNASET2	chr6:167343008-167412795:-	-0.25	-4.82	1.89E-6	Crohn's disease	
LUSC	cis	1	rs400837	chr6:167411008	RNASET2	chr6:167343008-167412795:-	-0.25	-4.79	2.25E-6	Crohn's disease	
LUSC	cis	1	rs401166	chr20:25446308	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.92	0.0001	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs401166	chr20:25446308	FAM182A	chr20:26035250-26067552:+	-0.19	-3.82	0.000152	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs40200	chr5:35045745	RAD1	chr5:34905367-34918383:-	0.31	3.89	0.000114	Urinary metabolites (H-NMR features)	
LUSC	cis	1	rs402749	chr6:167386104	RNASET2	chr6:167343008-167412795:-	-0.25	-4.88	1.48E-6	Crohn's disease	
LUSC	cis	1	rs4037	chr10:97365820	ENTPD1	chr10:97471536-97637022:+	0.16	4.87	1.5E-6	Blood metabolite levels	
LUSC	cis	1	rs404222	chr6:167402150	RNASET2	chr6:167343008-167412795:-	-0.25	-4.74	2.82E-6	Crohn's disease	
LUSC	cis	1	rs404394	chr20:25447896	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.92	0.0001	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs404394	chr20:25447896	FAM182A	chr20:26035250-26067552:+	-0.19	-3.82	0.000152	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs405553	chr6:167395058	RNASET2	chr6:167343008-167412795:-	-0.24	-4.78	2.36E-6	Crohn's disease	
LUSC	cis	1	rs406095	chr6:167409087	RNASET2	chr6:167343008-167412795:-	-0.25	-4.79	2.25E-6	Crohn's disease	
LUSC	cis	1	rs406900	chr6:88085447	C6orf164	chr6:88032306-88109459:+	-0.23	-4.26	2.45E-5	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs4073846	chr1:46462881	CCDC163P	chr1:45960581-45965646:-	0.34	6.91	1.53E-11	Body mass index	
LUSC	cis	1	rs4074170	chr17:28381141	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.87	8.27E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs4074493	chr1:231172281	CAPN9	chr1:230883130-230937749:+	-0.2	-3.94	9.27E-5	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs4074494	chr1:231172249	CAPN9	chr1:230883130-230937749:+	-0.2	-3.92	0.000101	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs4074915	chr17:79579230	TSPAN10	chr17:79609349-79615778:+	-0.45	-9.27	6.46E-19	Eye color traits	
LUSC	cis	1	rs4074916	chr17:79579248	TSPAN10	chr17:79609349-79615778:+	-0.46	-9.61	4.09E-20	Eye color traits	
LUSC	cis	1	rs407515	chr6:167407544	RNASET2	chr6:167343008-167412795:-	-0.25	-4.79	2.25E-6	Crohn's disease	
LUSC	cis	1	rs4075623	chr17:28386526	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.86	8.8E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs4075892	chr1:231171807	CAPN9	chr1:230883130-230937749:+	-0.2	-3.85	0.000135	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs4076006	chr1:46438076	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.17	2.97E-12	Body mass index	
LUSC	cis	1	rs4078160	chr10:52565940	ASAH2B	chr10:52499696-52514567:+	-0.41	-5.22	2.64E-7	Urate levels in lean individuals	
LUSC	cis	1	rs408040	chr6:167398903	RNASET2	chr6:167343008-167412795:-	-0.24	-4.79	2.28E-6	Crohn's disease	
LUSC	cis	1	rs408080	chr6:167392522	RNASET2	chr6:167343008-167412795:-	-0.25	-4.84	1.79E-6	Crohn's disease	
LUSC	cis	1	rs408087	chr6:167398952	RNASET2	chr6:167343008-167412795:-	-0.25	-4.86	1.58E-6	Crohn's disease	
LUSC	cis	1	rs408918	chr6:167399282	RNASET2	chr6:167343008-167412795:-	-0.24	-4.57	6.32E-6	Crohn's disease	
LUSC	cis	1	rs409356	chr6:167405226	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs4118325	chr1:107577832	PRMT6	chr1:107599267-107601907:+	0.24	3.95	8.94E-5	AIDS	
LUSC	cis	1	rs41266839	chr6:26409890	BTN3A2	chr6:26365398-26378546:+	-0.88	-11	3.07E-25	Schizophrenia	
LUSC	cis	1	rs41274152	chr7:128399231	OPN1SW	chr7:128412545-128415844:-	0.26	4.5	8.5E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs41275472	chr1:11876300	CLCN6	chr1:11866207-11907674:+	0.22	4.56	6.56E-6	QRS complex (12-leadsum)	
LUSC	cis	1	rs41276626	chr1:120262112	ZNF697	chr1:120162000-120190390:-	-0.34	-4.81	2.05E-6	Height	
LUSC	cis	1	rs41294396	chr11:64078581	C11orf20	chr11:64067863-64072238:+	-0.34	-4.67	3.97E-6	Mean platelet volume	
LUSC	cis	1	rs413232	chr6:167400972	RNASET2	chr6:167343008-167412795:-	-0.24	-4.79	2.28E-6	Crohn's disease	
LUSC	cis	1	rs4134386	chr1:46395089	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.03	7.18E-12	Body mass index	
LUSC	cis	1	rs414013	chr6:88085866	C6orf164	chr6:88032306-88109459:+	-0.23	-4.26	2.45E-5	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs4140574	chr6:56099424	COL21A1	chr6:55921389-56258892:-	0.19	3.88	0.00012	Pulse pressure	
LUSC	cis	1	rs4140575	chr6:56099222	COL21A1	chr6:55921389-56258892:-	0.19	3.79	0.000173	Pulse pressure	
LUSC	cis	1	rs4144829	chr4:17903654	NCAPG	chr4:17812525-17846485:+	-0.19	-4.28	2.25E-5	Height	
LUSC	cis	1	rs41455648	chr4:119718030	SEC24D	chr4:119643979-119759827:-	0.35	4.53	7.36E-6	Cannabis dependence	
LUSC	cis	1	rs415842	chr6:167406681	RNASET2	chr6:167343008-167412795:-	-0.25	-4.82	1.89E-6	Crohn's disease	
LUSC	cis	1	rs415890	chr6:167406633	RNASET2	chr6:167343008-167412795:-	0.24	4.74	2.79E-6	Crohn's disease	
LUSC	cis	1	rs416131	chr6:167406544	RNASET2	chr6:167343008-167412795:-	0.25	4.75	2.64E-6	Crohn's disease	
LUSC	cis	1	rs419603	chr7:65597341	CCT6P1	chr7:65216092-65228661:+	0.23	3.74	0.000209	Diabetic kidney disease	
LUSC	cis	1	rs420259	chr16:23634026	DCTN5	chr16:23652807-23681182:+	-0.22	-4.19	3.32E-5	Bipolar disorder	
LUSC	cis	1	rs421214	chr6:167396629	RNASET2	chr6:167343008-167412795:-	-0.24	-4.79	2.28E-6	Crohn's disease	
LUSC	cis	1	rs422094	chr6:167397033	RNASET2	chr6:167343008-167412795:-	-0.24	-4.79	2.28E-6	Crohn's disease	
LUSC	cis	1	rs422424	chr20:25445446	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.92	0.0001	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs422424	chr20:25445446	FAM182A	chr20:26035250-26067552:+	-0.19	-3.82	0.000152	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs422562	chr6:167406318	RNASET2	chr6:167343008-167412795:-	-0.25	-4.95	1.05E-6	Crohn's disease	
LUSC	cis	1	rs422694	chr6:167406074	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs422780	chr6:167406209	RNASET2	chr6:167343008-167412795:-	-0.25	-4.82	1.89E-6	Crohn's disease	
LUSC	cis	1	rs422844	chr20:25445591	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.92	0.000103	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs422844	chr20:25445591	FAM182A	chr20:26035250-26067552:+	-0.19	-3.74	0.000205	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4237643	chr11:43648368	HSD17B12	chr11:43702143-43878160:+	0.44	7.8	3.83E-14	Forced vital capacity	
LUSC	cis	1	rs4239227	chr17:28389103	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.86	8.8E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs4241407	chr3:49600319	AMT	chr3:49454212-49460012:-	0.21	4.85	1.64E-6	Menarche (age at onset)	
LUSC	cis	1	rs4243043	chr15:77178540	ETFA	chr15:76508629-76603810:-	0.3	3.83	0.000146	Recalcitrant atopic dermatitis	
LUSC	cis	1	rs4244338	chr10:102272802	SEC31B	chr10:102246403-102289636:-	-0.28	-8.39	5.47E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4253311	chr4:187174683	F11	chr4:187187118-187210835:+	-0.17	-3.88	0.000122	Plasma renin activity levels;Blood metabolite levels	
LUSC	cis	1	rs4253766	chr22:46623905	PKDREJ	chr22:46651561-46659219:-	-0.59	-7.61	1.45E-13	Cholesterol, total;LDL cholesterol	
LUSC	cis	1	rs4253772	chr22:46627603	PKDREJ	chr22:46651561-46659219:-	-0.59	-6.98	1.02E-11	Cholesterol, total;LDL cholesterol	
LUSC	cis	1	rs4256922	chr10:52568616	ASAH2B	chr10:52499696-52514567:+	-0.41	-5.14	4.05E-7	Urate levels in lean individuals	
LUSC	cis	1	rs4263408	chr4:39785276	RPL9	chr4:39455747-39460568:-	-0.34	-6.22	1.11E-9	Plasma amyloid beta peptide concentrations (ABx-40)	
LUSC	cis	1	rs4267943	chr6:49439805	CENPQ	chr6:49431096-49460820:+	0.43	9.21	1.02E-18	Folate pathway vitamin levels	
LUSC	cis	1	rs4267943	chr6:49439805	MUT	chr6:49398994-49431031:-	-0.26	-4.29	2.13E-5	Folate pathway vitamin levels	
LUSC	cis	1	rs4272382	chr8:8433488	ERI1	chr8:8860314-8890849:+	-0.42	-4.42	1.2E-5	Response to cytidine analogues (gemcitabine)	
LUSC	cis	1	rs4279493	chr7:66226620	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.36	1.3E-7	Aortic root size	
LUSC	cis	1	rs4280164	chr14:24771285	ADCY4	chr14:24787571-24804277:-	0.19	4.12	4.39E-5	Parent of origin effect on language impairment (paternal)	
LUSC	cis	1	rs4280164	chr14:24771285	DHRS1	chr14:24759806-24769039:-	-0.23	-4.21	3.08E-5	Parent of origin effect on language impairment (paternal)	
LUSC	cis	1	rs4282209	chr4:76919536	NAAA	chr4:76831809-76862166:-	-0.24	-5.12	4.43E-7	Longevity	
LUSC	cis	1	rs4282551	chr8:124185916	FAM83A	chr8:124191287-124222317:+	-0.25	-3.8	0.000161	Urinary uromodulin levels	
LUSC	cis	1	rs429083	chr6:167383972	RNASET2	chr6:167343008-167412795:-	-0.25	-4.84	1.76E-6	Crohn's disease	
LUSC	cis	1	rs4297570	chr13:36755179	SOHLH2	chr13:36742347-36871992:-	-0.24	-4.28	2.29E-5	Glucose homeostasis traits	
LUSC	cis	1	rs430097	chr6:167405073	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs430293	chr6:167404958	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs430477	chr6:167389851	RNASET2	chr6:167343008-167412795:-	-0.25	-4.88	1.48E-6	Crohn's disease	
LUSC	cis	1	rs4309773	chr3:134277301	ANAPC13	chr3:134196547-134204865:-	0.42	8.41	4.96E-16	Height	
LUSC	cis	1	rs431328	chr19:22222236	ZNF257	chr19:22235266-22273901:+	0.25	3.97	8.41E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs4318247	chr17:65882172	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs43184	chr5:56141777	C5orf35	chr5:56205103-56213010:+	0.87	15.19	9.05E-43	Type 2 diabetes	
LUSC	cis	1	rs4322591	chr14:75600697	MLH3	chr14:75480467-75518235:-	0.27	5.79	1.25E-8	Height	
LUSC	cis	1	rs4323544	chr9:123647377	LOC253039	chr9:123605320-123616644:+	-0.32	-6.07	2.58E-9	Rheumatoid arthritis	
LUSC	cis	1	rs4328498	chr17:28344276	EFCAB5	chr17:28256874-28435469:+	-0.29	-5.57	4.26E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs4334685	chr3:134304335	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs433598	chr16:20680206	ACSM1	chr16:20634559-20709066:-	0.36	6.63	9.1E-11	Schizophrenia	
LUSC	cis	1	rs433852	chr19:49117104	SEC1	chr19:49141296-49185501:+	-0.29	-4.51	8.06E-6	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease	
LUSC	cis	1	rs4350617	chr17:28423088	EFCAB5	chr17:28256874-28435469:+	0.32	6.13	1.82E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs4355180	chr20:23831427	CST2	chr20:23804404-23807312:-	-0.35	-5.21	2.8E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs4356975	chr4:69972463	UGT2B7	chr4:69962193-69978704:+	-0.2	-3.99	7.79E-5	Obesity-related traits	
LUSC	cis	1	rs436039	chr19:22214873	ZNF257	chr19:22235266-22273901:+	0.26	3.95	9.11E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs4363822	chr15:67992583	IQCH	chr15:67547188-67794139:+	0.22	3.89	0.000116	Motion sickness	
LUSC	cis	1	rs436707	chr6:167388843	RNASET2	chr6:167343008-167412795:-	-0.25	-4.88	1.48E-6	Crohn's disease	
LUSC	cis	1	rs4367113	chr3:134287975	ANAPC13	chr3:134196547-134204865:-	0.41	8.06	6.2E-15	Height	
LUSC	cis	1	rs4368544	chr3:134300014	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.09	4.93E-15	Height	
LUSC	cis	1	rs4372836	chr2:28973883	TRMT61B	chr2:29072690-29093175:-	-0.26	-5.36	1.27E-7	Body mass index	
LUSC	cis	1	rs4375281	chr1:92987575	EVI5	chr1:92974255-93257961:-	-0.31	-4.49	9.08E-6	Cholesterol, total	
LUSC	cis	1	rs4375701	chr17:45712218	C17orf57	chr17:45401142-45518675:+	0.28	6.37	4.57E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs4376778	chr1:46288846	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.12	3.9E-12	Body mass index	
LUSC	cis	1	rs4377946	chr8:124185887	FAM83A	chr8:124191287-124222317:+	-0.25	-3.8	0.000161	Urinary uromodulin levels	
LUSC	cis	1	rs4378192	chr1:231173379	CAPN9	chr1:230883130-230937749:+	-0.21	-3.98	7.83E-5	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs4391665	chr1:115921680	NGF	chr1:115828537-115880857:-	0.2	3.75	0.000201	Non-alcoholic fatty liver disease	
LUSC	cis	1	rs439237	chr6:167391392	RNASET2	chr6:167343008-167412795:-	-0.25	-4.88	1.48E-6	Crohn's disease	
LUSC	cis	1	rs439295	chr3:156572455	LEKR1	chr3:156544076-156763918:+	-0.39	-6.48	2.28E-10	Bone mineral density	
LUSC	cis	1	rs439553	chr6:167391212	RNASET2	chr6:167343008-167412795:-	-0.25	-4.95	1.02E-6	Crohn's disease	
LUSC	cis	1	rs4404834	chr7:151116702	WDR86	chr7:151078207-151107740:-	0.27	4	7.25E-5	Coronary heart disease	
LUSC	cis	1	rs4407214	chr2:29118258	TRMT61B	chr2:29072690-29093175:-	0.21	3.92	0.000103	Breast cancer (estrogen-receptor negative);Breast cancer	
LUSC	cis	1	rs4417907	chr3:134291363	ANAPC13	chr3:134196547-134204865:-	0.41	8.14	3.63E-15	Height	
LUSC	cis	1	rs4423247	chr12:91476875	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs4423809	chr3:134300107	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.15	3.18E-15	Height	
LUSC	cis	1	rs4431687	chr9:130111697	SLC2A8	chr9:130159465-130170161:+	-0.28	-4.86	1.57E-6	Metabolite levels (HVA)	
LUSC	cis	1	rs4431687	chr9:130111697	ZNF79	chr9:130186653-130207650:+	-0.21	-3.71	0.000235	Metabolite levels (HVA)	
LUSC	cis	1	rs444988	chr6:167389674	RNASET2	chr6:167343008-167412795:-	-0.25	-4.84	1.79E-6	Crohn's disease	
LUSC	cis	1	rs4460622	chr1:231173033	CAPN9	chr1:230883130-230937749:+	-0.2	-3.96	8.51E-5	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs4465649	chr17:28394747	EFCAB5	chr17:28256874-28435469:+	-0.29	-5.41	1.02E-7	Coffee consumption (cups per day)	
LUSC	cis	1	rs4465650	chr17:28396721	EFCAB5	chr17:28256874-28435469:+	0.27	5.13	4.16E-7	Coffee consumption (cups per day)	
LUSC	cis	1	rs4466058	chr4:129923879	C4orf33	chr4:130014829-130033842:+	-0.38	-7.31	1.17E-12	Chronic obstructive pulmonary disease (moderate to severe)	
LUSC	cis	1	rs4469291	chr6:49440614	CENPQ	chr6:49431096-49460820:+	-0.41	-9.04	3.88E-18	Folate pathway vitamin levels	
LUSC	cis	1	rs4469291	chr6:49440614	MUT	chr6:49398994-49431031:-	0.29	5.13	4.19E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs447722	chr20:25443510	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.92	0.0001	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs447722	chr20:25443510	FAM182A	chr20:26035250-26067552:+	-0.19	-3.82	0.000152	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs448060	chr6:167382622	RNASET2	chr6:167343008-167412795:-	-0.25	-4.93	1.15E-6	Crohn's disease	
LUSC	cis	1	rs448396	chr20:25440269	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.92	0.0001	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs448396	chr20:25440269	FAM182A	chr20:26035250-26067552:+	-0.19	-3.82	0.000152	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4486677	chr12:8669116	CLEC4D	chr12:8666136-8674958:+	0.31	6.3	6.99E-10	Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	
LUSC	cis	1	rs4490383	chr3:48484683	ATRIP	chr3:48488141-48507708:+	0.19	4.05	5.98E-5	Longevity	
LUSC	cis	1	rs4490383	chr3:48484683	TREX1	chr3:48501186-48509043:+	-0.39	-8.54	1.83E-16	Longevity	
LUSC	cis	1	rs449043	chr21:42700410	FAM3B	chr21:42676177-42729654:+	-0.2	-3.8	0.000167	Elevated serum carcinoembryonic antigen levels;Tumor biomarkers	
LUSC	cis	1	rs4490669	chr6:56789465	BEND6	chr6:56819773-56892138:+	-0.36	-5.32	1.57E-7	Menarche (age at onset)	
LUSC	cis	1	rs4493873	chr8:92075643	SLC26A7	chr8:92221722-92410380:+	0.24	4.52	7.97E-6	Migraine - clinic-based	
LUSC	cis	1	rs4494330	chr11:5372718	OR51B5	chr11:5363816-5526882:-	0.21	3.93	9.82E-5	Fetal hemoglobin levels	
LUSC	cis	1	rs4497901	chr2:239969	SH3YL1	chr2:218138-264810:-	-0.51	-9.08	2.95E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs4498009	chr3:134198008	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.19E-16	Height	
LUSC	cis	1	rs4509261	chr7:128382285	OPN1SW	chr7:128412545-128415844:-	0.25	4.43	1.18E-5	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs453329	chr20:25440593	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.89	0.000115	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs453329	chr20:25440593	FAM182A	chr20:26035250-26067552:+	-0.2	-3.91	0.000104	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4533340	chr17:28277951	EFCAB5	chr17:28256874-28435469:+	0.32	6.1	2.22E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs4535272	chr3:134299916	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.09	4.93E-15	Height	
LUSC	cis	1	rs4545281	chr1:46360054	CCDC163P	chr1:45960581-45965646:-	-0.33	-7.03	7.04E-12	Body mass index	
LUSC	cis	1	rs45469101	chr20:61875007	BIRC7	chr20:61867276-61871853:+	0.32	4.14	4.09E-5	Response to cytadine analogues (cytosine arabinoside)	
LUSC	cis	1	rs4549034	chr2:28972579	TRMT61B	chr2:29072690-29093175:-	-0.26	-5.36	1.27E-7	Body mass index	
LUSC	cis	1	rs4553849	chr2:1855567	MYT1L	chr2:1792887-2335045:-	0.4	4.81	2.03E-6	Gut microbiota (functional units)	
LUSC	cis	1	rs45559033	chr14:74341124	LIN52	chr14:74551656-74667117:+	0.29	4.37	1.5E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs4560868	chr9:115985499	CDC26	chr9:116029290-116037869:-	0.38	7.98	1.12E-14	Hematology traits	
LUSC	cis	1	rs4565964	chr12:43575002	ADAMTS20	chr12:43748013-43945724:-	-0.21	-4.17	3.57E-5	Type 2 diabetes	
LUSC	cis	1	rs4568579	chr8:92072144	SLC26A7	chr8:92221722-92410380:+	0.24	4.44	1.11E-5	Migraine - clinic-based	
LUSC	cis	1	rs4569324	chr17:65872750	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs4572812	chr3:134291177	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.14	3.45E-15	Height	
LUSC	cis	1	rs4575590	chr17:28361969	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.79	1.29E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs4581755	chr17:28427898	EFCAB5	chr17:28256874-28435469:+	0.32	6.11	2.04E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs458196	chr22:29978026	NIPSNAP1	chr22:29950800-29977144:-	0.27	4.65	4.22E-6	Lipid traits	
LUSC	cis	1	rs4594164	chr14:35509571	PPP2R3C	chr14:35554679-35591679:-	0.31	5.41	1.02E-7	Atopic dermatitis	
LUSC	cis	1	rs459498	chr21:42795027	MX1	chr21:42792520-42831140:+	-0.23	-4.18	3.42E-5	IgG glycosylation	
LUSC	cis	1	rs4604732	chr1:247623872	LOC148824	chr1:247687982-247694106:-	0.31	5.07	5.6E-7	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
LUSC	cis	1	rs4604805	chr10:102261409	SEC31B	chr10:102246403-102289636:-	-0.29	-8.86	1.66E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4604928	chr11:117044203	PCSK7	chr11:117075789-117102811:-	-0.36	-4.95	1.02E-6	Protein quantitative trait loci	
LUSC	cis	1	rs4628584	chr10:4972697	C10orf18	chr10:5726801-5806943:+	0.28	3.77	0.000181	Height	
LUSC	cis	1	rs4640348	chr2:28965479	TRMT61B	chr2:29072690-29093175:-	-0.25	-5.17	3.43E-7	Body mass index	
LUSC	cis	1	rs4643294	chr15:85250253	LOC388152	chr15:84867600-84898920:-	-0.24	-4.32	1.93E-5	Schizophrenia	
LUSC	cis	1	rs4646536	chr12:58157988	FAM119B	chr12:58166383-58176323:+	0.52	9.16	1.54E-18	Multiple sclerosis	
LUSC	cis	1	rs4646536	chr12:58157988	TSFM	chr12:58176536-58191367:+	-0.38	-8.36	6.99E-16	Multiple sclerosis	
LUSC	cis	1	rs4646536	chr12:58157988	XRCC6BP1	chr12:58335445-58351051:+	-0.19	-3.89	0.000114	Multiple sclerosis	
LUSC	cis	1	rs464783	chr21:42796480	MX1	chr21:42792520-42831140:+	0.24	4.51	8.14E-6	IgG glycosylation	
LUSC	cis	1	rs4657039	chr1:161462728	FCGR2C	chr1:161551129-161570031:+	-0.12	-3.77	0.000182	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia	
LUSC	cis	1	rs465742	chr22:29959335	NIPSNAP1	chr22:29950800-29977144:-	-0.28	-4.51	8.21E-6	Lipid traits	
LUSC	cis	1	rs4660306	chr1:45978675	CCDC163P	chr1:45960581-45965646:-	0.74	17.83	7.94E-55	Homocysteine levels	
LUSC	cis	1	rs4660306	chr1:45978675	MMACHC	chr1:45965856-45976737:+	0.16	4.11	4.61E-5	Homocysteine levels	
LUSC	cis	1	rs4660317	chr1:46326226	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.15	3.31E-12	Body mass index	
LUSC	cis	1	rs4660319	chr1:46341623	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.15	3.31E-12	Body mass index	
LUSC	cis	1	rs4660321	chr1:46366760	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.17	2.93E-12	Body mass index	
LUSC	cis	1	rs4660870	chr1:45995231	CCDC163P	chr1:45960581-45965646:-	-0.71	-16.83	3.44E-50	Homocysteine levels	
LUSC	cis	1	rs4660898	chr1:46402171	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.03	7.37E-12	Body mass index	
LUSC	cis	1	rs4660910	chr1:46548402	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.61E-13	Body mass index	
LUSC	cis	1	rs4663300	chr2:239181491	LOC151174	chr2:239133754-239140318:-	0.33	3.81	0.000157	Irritable bowel syndrome	
LUSC	cis	1	rs4663866	chr2:239150815	LOC151174	chr2:239133754-239140318:-	0.33	3.88	0.000119	Irritable bowel syndrome	
LUSC	cis	1	rs4663867	chr2:239159964	LOC151174	chr2:239133754-239140318:-	0.34	3.98	7.95E-5	Irritable bowel syndrome	
LUSC	cis	1	rs4663868	chr2:239161091	LOC151174	chr2:239133754-239140318:-	0.34	3.98	7.95E-5	Irritable bowel syndrome	
LUSC	cis	1	rs4666118	chr2:28951698	TRMT61B	chr2:29072690-29093175:-	-0.26	-5.37	1.25E-7	Body mass index	
LUSC	cis	1	rs4666119	chr2:28975690	TRMT61B	chr2:29072690-29093175:-	-0.25	-5.15	3.82E-7	Body mass index	
LUSC	cis	1	rs468795	chr22:29955450	NIPSNAP1	chr22:29950800-29977144:-	-0.26	-4.33	1.8E-5	Lipid traits	
LUSC	cis	1	rs468852	chr22:29956156	NIPSNAP1	chr22:29950800-29977144:-	-0.27	-4.52	7.68E-6	Lipid traits	
LUSC	cis	1	rs4690071	chr4:3086753	C4orf44	chr4:3250767-3265839:+	-0.18	-3.7	0.000241	Parental longevity (mother's age at death)	
LUSC	cis	1	rs469758	chr5:96121715	ERAP1	chr5:96096515-96149837:-	-0.46	-11.05	2.04E-25	Ankylosing spondylitis	
LUSC	cis	1	rs469758	chr5:96121715	ERAP2	chr5:96211644-96255398:+	0.39	7.47	3.85E-13	Ankylosing spondylitis	
LUSC	cis	1	rs4698432	chr4:15964763	FGFBP2	chr4:15961864-15964859:-	0.41	7.94	1.47E-14	QT interval	
LUSC	cis	1	rs4698433	chr4:15964863	FGFBP2	chr4:15961864-15964859:-	-0.4	-7.69	8.26E-14	QT interval	
LUSC	cis	1	rs470119	chr22:50966914	TYMP	chr22:50964184-50968514:-	-0.21	-5.58	4.05E-8	Mean corpuscular hemoglobin	
LUSC	cis	1	rs4705972	chr5:132179237	SLC22A5	chr5:131705401-131731302:+	-0.28	-3.76	0.000193	Apolipoprotein A-IV levels	
LUSC	cis	1	rs4706254	chr6:86602813	SNHG5	chr6:86386726-86388451:-	-0.68	-12.9	7.41E-33	Response to antipsychotic treatment	
LUSC	cis	1	rs4707239	chr6:86610717	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs4710147	chr6:167374239	RNASET2	chr6:167343008-167412795:-	0.25	4.83	1.84E-6	Crohn's disease	
LUSC	cis	1	rs4715129	chr6:49415043	CENPQ	chr6:49431096-49460820:+	-0.4	-8.69	6.13E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs4715129	chr6:49415043	MUT	chr6:49398994-49431031:-	0.31	5.5	6.14E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs4715130	chr6:49416825	CENPQ	chr6:49431096-49460820:+	-0.37	-8.12	4.17E-15	Folate pathway vitamin levels	
LUSC	cis	1	rs4715130	chr6:49416825	MUT	chr6:49398994-49431031:-	0.32	5.57	4.21E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs4715134	chr6:49488287	CENPQ	chr6:49431096-49460820:+	0.18	3.85	0.000133	Brain structure	
LUSC	cis	1	rs471569	chr1:170103379	C1orf156	chr1:169761675-169764031:-	-0.19	-3.72	0.000223	Methotrexate phramacokinetics (acute lymphoblastic leukemia)	
LUSC	cis	1	rs4717292	chr7:65895598	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.16E-9	Aortic root size	
LUSC	cis	1	rs4717300	chr7:65947380	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs4717310	chr7:66161007	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.54	5.07E-8	Aortic root size	
LUSC	cis	1	rs4717319	chr7:66242593	NCRNA00174	chr7:65841032-65865395:-	-0.26	-5.6	3.7E-8	Aortic root size	
LUSC	cis	1	rs4718307	chr7:65610988	NCRNA00174	chr7:65841032-65865395:-	0.3	6.31	6.3E-10	Aortic root size	
LUSC	cis	1	rs4718343	chr7:65874288	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs4718344	chr7:65874381	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs4718357	chr7:65960878	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.22	1.09E-9	Aortic root size	
LUSC	cis	1	rs4726669	chr7:143758191	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.46	4.12E-13	Obesity-related traits	
LUSC	cis	1	rs4726669	chr7:143758191	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.49	8.97E-6	Obesity-related traits	
LUSC	cis	1	rs4727443	chr7:99593346	TRIM4	chr7:99488037-99517154:-	-0.3	-5.25	2.3E-7	Interstitial lung disease	
LUSC	cis	1	rs4728142	chr7:128573967	IRF5	chr7:128577769-128590086:+	0.36	7.9	2.0E-14	Systemic lupus erythematosus;Ulcerative colitis;Inflammatory bowel disease	
LUSC	cis	1	rs473073	chr10:131429646	MGMT	chr10:131265454-131565783:+	0.35	7.36	8.38E-13	Response to temozolomide	
LUSC	cis	1	rs4731742	chr7:130754812	MKLN1	chr7:130794855-131181397:+	-0.25	-3.84	0.00014	Cutaneous malignant melanoma	
LUSC	cis	1	rs473188	chr11:116812029	PCSK7	chr11:117075789-117102811:-	-0.32	-4.47	9.94E-6	Protein quantitative trait loci	
LUSC	cis	1	rs4732038	chr7:134250322	AKR1B15	chr7:134233849-134264300:+	0.19	4.04	6.25E-5	Longevity	
LUSC	cis	1	rs4733384	chr8:29985381	MBOAT4	chr8:29989188-30002200:-	0.38	4.84	1.76E-6	Migraine	
LUSC	cis	1	rs473771	chr10:131408155	MGMT	chr10:131265454-131565783:+	0.36	7.55	2.24E-13	Response to temozolomide	
LUSC	cis	1	rs4743130	chr9:100546040	CTSL2	chr9:99794940-99822167:-	-0.2	-3.73	0.000219	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs4750759	chr10:131436603	MGMT	chr10:131265454-131565783:+	-0.35	-7.32	1.08E-12	Response to temozolomide	
LUSC	cis	1	rs4752028	chr10:118834991	KIAA1598	chr10:118644308-118886097:-	-0.25	-4.03	6.38E-5	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs4752797	chr11:47874364	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.11	4.67E-5	Subjective well-being	
LUSC	cis	1	rs4752856	chr11:47648042	C1QTNF4	chr11:47611216-47615961:-	-0.21	-3.91	0.000107	Subjective well-being	
LUSC	cis	1	rs4752857	chr11:47655752	C1QTNF4	chr11:47611216-47615961:-	-0.23	-4.21	3.09E-5	Subjective well-being	
LUSC	cis	1	rs4752873	chr11:47857520	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.09	4.97E-5	Subjective well-being	
LUSC	cis	1	rs4755726	chr11:43642130	HSD17B12	chr11:43702143-43878160:+	-0.45	-7.79	4.37E-14	Forced vital capacity	
LUSC	cis	1	rs4757676	chr11:18640477	SPTY2D1	chr11:18627949-18656020:-	-0.23	-3.84	0.000138	Cholesterol, total	
LUSC	cis	1	rs4759229	chr12:56474480	RPS26	chr12:56435686-56438005:+	-0.58	-12.45	5.63E-31	Cognitive function	
LUSC	cis	1	rs4763555	chr12:10721456	CSDA	chr12:10851678-10875953:-	-0.24	-4.41	1.31E-5	Cognitive function	
LUSC	cis	1	rs4763879	chr12:9910164	CLECL1	chr12:9868457-9885860:-	-0.18	-4.61	5.26E-6	Type 1 diabetes	
LUSC	cis	1	rs4768036	chr12:43577852	ADAMTS20	chr12:43748013-43945724:-	-0.22	-4.42	1.24E-5	Type 2 diabetes	
LUSC	cis	1	rs4769671	chr13:29621461	SLC7A1	chr13:30083552-30169825:-	0.44	3.76	0.00019	Methotrexate phramacokinetics (acute lymphoblastic leukemia)	
LUSC	cis	1	rs477692	chr10:131426022	MGMT	chr10:131265454-131565783:+	0.35	7.36	8.19E-13	Response to temozolomide	
LUSC	cis	1	rs4788196	chr16:29967434	LOC595101	chr16:30278914-30346695:-	-0.26	-4.23	2.82E-5	Pubertal anthropometrics	
LUSC	cis	1	rs4789693	chr17:80421870	HEXDC	chr17:80376252-80400515:+	0.22	5.08	5.38E-7	Glucocorticoid-induced osteonecrosis	
LUSC	cis	1	rs4790908	chr17:65852907	LOC440461	chr17:66194801-66196436:+	0.25	3.85	0.000134	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs4794016	chr17:45725931	C17orf57	chr17:45401142-45518675:+	-0.28	-6.25	9.08E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs4794048	chr17:45763073	C17orf57	chr17:45401142-45518675:+	0.29	6.55	1.5E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs4794202	chr17:45930539	SCRN2	chr17:45915049-45918699:-	-0.45	-7.01	8.36E-12	Alzheimer's disease (cognitive decline)	
LUSC	cis	1	rs479478	chr10:131428959	MGMT	chr10:131265454-131565783:+	0.35	7.33	1.0E-12	Response to temozolomide	
LUSC	cis	1	rs4794823	chr17:38166265	GSDMA	chr17:38119226-38134019:+	-0.44	-8.9	1.16E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs4794824	chr17:38179290	GSDMA	chr17:38119226-38134019:+	-0.44	-8.81	2.38E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs4795412	chr17:38150604	GSDMA	chr17:38119226-38134019:+	-0.44	-9.01	4.91E-18	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs4795415	chr17:38157995	GSDMA	chr17:38119226-38134019:+	-0.44	-8.99	5.71E-18	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs4795416	chr17:38158133	GSDMA	chr17:38119226-38134019:+	-0.44	-8.99	5.71E-18	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs4795418	chr17:38164851	GSDMA	chr17:38119226-38134019:+	-0.44	-8.9	1.16E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs4795525	chr17:28388487	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.86	8.8E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs4803480	chr19:42066279	CEACAM21	chr19:42055886-42093196:+	0.52	15.21	7.33E-43	Schizophrenia	
LUSC	cis	1	rs4805834	chr19:33453659	SLC7A9	chr19:33321421-33360683:-	-0.37	-5.29	1.87E-7	Creatinine levels	
LUSC	cis	1	rs480643	chr10:131400308	MGMT	chr10:131265454-131565783:+	0.37	7.67	1.02E-13	Response to temozolomide	
LUSC	cis	1	rs4808133	chr19:18608518	SSBP4	chr19:18530221-18545371:+	-0.19	-3.75	0.000198	Breast cancer	
LUSC	cis	1	rs4808134	chr19:18608579	SSBP4	chr19:18530221-18545371:+	-0.19	-3.75	0.000198	Breast cancer	
LUSC	cis	1	rs4808801	chr19:18571141	LRRC25	chr19:18501955-18508421:-	-0.12	-4.25	2.6E-5	Breast cancer	
LUSC	cis	1	rs4812048	chr20:57587771	TH1L	chr20:57556311-57570186:+	-0.38	-5.93	5.69E-9	Mean platelet volume	
LUSC	cis	1	rs4813563	chr20:25365340	ENTPD6	chr20:25176339-25207360:+	0.2	3.75	0.000197	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4813566	chr20:25386465	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815404	chr20:25301845	ENTPD6	chr20:25176339-25207360:+	0.2	3.85	0.000136	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815405	chr20:25317492	ENTPD6	chr20:25176339-25207360:+	0.2	3.76	0.000194	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815408	chr20:25346678	ENTPD6	chr20:25176339-25207360:+	0.2	3.75	0.000197	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815409	chr20:25346697	ENTPD6	chr20:25176339-25207360:+	0.2	3.79	0.000167	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815411	chr20:25350223	ENTPD6	chr20:25176339-25207360:+	0.21	3.99	7.74E-5	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815412	chr20:25350325	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.78	0.000179	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815421	chr20:25386509	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4815426	chr20:25405186	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs4820345	chr22:39091151	CBY1	chr22:39052658-39069853:+	0.21	3.87	0.000123	Resting heart rate	
LUSC	cis	1	rs4820539	chr22:23477970	RTDR1	chr22:23401594-23484241:-	0.23	4.54	7.25E-6	Bone mineral density	
LUSC	cis	1	rs4821808	chr22:39065739	CBY1	chr22:39052658-39069853:+	0.21	3.82	0.000154	Resting heart rate	
LUSC	cis	1	rs4821809	chr22:39065743	CBY1	chr22:39052658-39069853:+	0.21	3.82	0.000154	Resting heart rate	
LUSC	cis	1	rs4821810	chr22:39072098	CBY1	chr22:39052658-39069853:+	0.21	3.9	0.000108	Resting heart rate	
LUSC	cis	1	rs4821811	chr22:39075145	CBY1	chr22:39052658-39069853:+	0.22	4.07	5.44E-5	Resting heart rate	
LUSC	cis	1	rs4821812	chr22:39075235	CBY1	chr22:39052658-39069853:+	0.22	4.06	5.66E-5	Resting heart rate	
LUSC	cis	1	rs4821816	chr22:39113134	CBY1	chr22:39052658-39069853:+	0.23	4.17	3.57E-5	Resting heart rate	
LUSC	cis	1	rs4822357	chr22:23473231	RTDR1	chr22:23401594-23484241:-	-0.23	-4.5	8.39E-6	Bone mineral density	
LUSC	cis	1	rs4822358	chr22:23474795	RTDR1	chr22:23401594-23484241:-	-0.23	-4.4	1.32E-5	Bone mineral density	
LUSC	cis	1	rs4822360	chr22:23482460	RTDR1	chr22:23401594-23484241:-	-0.23	-4.35	1.65E-5	Bone mineral density	
LUSC	cis	1	rs4822361	chr22:23482718	RTDR1	chr22:23401594-23484241:-	0.23	4.52	7.96E-6	Bone mineral density	
LUSC	cis	1	rs4822362	chr22:23482744	RTDR1	chr22:23401594-23484241:-	-0.24	-4.52	7.65E-6	Bone mineral density	
LUSC	cis	1	rs4839524	chr1:116800201	ATP1A1	chr1:116915004-116947394:+	0.26	4.85	1.66E-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
LUSC	cis	1	rs4841017	chr8:8577093	FLJ10661	chr8:8086092-8102386:+	0.24	4.2	3.2E-5	Obesity-related traits	
LUSC	cis	1	rs4846083	chr1:12045555	C1orf187	chr1:11751781-11780336:+	0.19	4.2	3.22E-5	Platelet count	
LUSC	cis	1	rs4846085	chr1:12050634	C1orf187	chr1:11751781-11780336:+	0.19	4.09	5.09E-5	Platelet count	
LUSC	cis	1	rs4847181	chr1:93028792	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs4852715	chr2:71088070	CD207	chr2:71057348-71062953:-	-0.28	-3.7	0.000239	IgG glycosylation	
LUSC	cis	1	rs4854569	chr3:132715932	TMEM108	chr3:132757171-133116618:+	0.22	5	8.1E-7	IgE grass sensitization	
LUSC	cis	1	rs4854673	chr3:132713144	TMEM108	chr3:132757171-133116618:+	0.21	4.86	1.62E-6	IgE grass sensitization	
LUSC	cis	1	rs4854676	chr3:132738563	TMEM108	chr3:132757171-133116618:+	0.19	4.5	8.44E-6	IgE grass sensitization	
LUSC	cis	1	rs4854677	chr3:132738709	TMEM108	chr3:132757171-133116618:+	0.2	4.75	2.7E-6	IgE grass sensitization	
LUSC	cis	1	rs4855695	chr3:108851484	MORC1	chr3:108677089-108836993:-	-0.16	-3.82	0.000154	Colorectal cancer (diet interaction)	
LUSC	cis	1	rs485576	chr10:131425496	MGMT	chr10:131265454-131565783:+	0.35	7.36	7.95E-13	Response to temozolomide	
LUSC	cis	1	rs4858793	chr3:48415007	ATRIP	chr3:48488141-48507708:+	-0.22	-4.39	1.4E-5	Longevity	
LUSC	cis	1	rs4858793	chr3:48415007	CDC25A	chr3:48198668-48229801:-	-0.16	-4.36	1.57E-5	Longevity	
LUSC	cis	1	rs4858793	chr3:48415007	TREX1	chr3:48501186-48509043:+	0.42	8.76	3.6E-17	Longevity	
LUSC	cis	1	rs4859413	chr4:76898250	NAAA	chr4:76831809-76862166:-	0.27	5.84	9.58E-9	Longevity	
LUSC	cis	1	rs4859581	chr4:76906974	NAAA	chr4:76831809-76862166:-	-0.27	-6.01	3.61E-9	Longevity	
LUSC	cis	1	rs4859582	chr4:76907213	NAAA	chr4:76831809-76862166:-	-0.27	-5.93	5.79E-9	Longevity	
LUSC	cis	1	rs4862406	chr4:185629339	MLF1IP	chr4:185615220-185655286:-	0.49	10.01	1.57E-21	Kawasaki disease	
LUSC	cis	1	rs4862406	chr4:185629339	UFSP2	chr4:186320694-186347139:-	-0.21	-3.77	0.000184	Kawasaki disease	
LUSC	cis	1	rs4869313	chr5:96223880	ERAP2	chr5:96211644-96255398:+	-0.87	-23.81	4.98E-83	Pediatric autoimmune diseases	
LUSC	cis	1	rs4881994	chr11:48498139	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.89	0.000116	HDL cholesterol	
LUSC	cis	1	rs4882010	chr11:48559173	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.9	0.000111	HDL cholesterol	
LUSC	cis	1	rs4882015	chr11:48565573	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.89	0.000113	HDL cholesterol	
LUSC	cis	1	rs4882016	chr11:48570125	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.86	0.00013	HDL cholesterol	
LUSC	cis	1	rs4882017	chr11:48570182	C1QTNF4	chr11:47611216-47615961:-	0.19	3.8	0.000163	HDL cholesterol	
LUSC	cis	1	rs4882096	chr11:48534102	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.77	0.000186	HDL cholesterol	
LUSC	cis	1	rs4882111	chr11:48558447	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.9	0.000111	HDL cholesterol	
LUSC	cis	1	rs4882117	chr11:48565468	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.89	0.000113	HDL cholesterol	
LUSC	cis	1	rs4882120	chr11:48573529	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.81	0.000157	HDL cholesterol	
LUSC	cis	1	rs4882123	chr11:48575739	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.81	0.000157	HDL cholesterol	
LUSC	cis	1	rs4882129	chr11:48588774	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.72	0.00022	HDL cholesterol	
LUSC	cis	1	rs4882130	chr11:48588954	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.72	0.00022	HDL cholesterol	
LUSC	cis	1	rs4882132	chr11:48593125	AGBL2	chr11:47681145-47736302:-	-0.22	-4.23	2.81E-5	HDL cholesterol	
LUSC	cis	1	rs4886831	chr15:77106801	ETFA	chr15:76508629-76603810:-	0.31	4.08	5.36E-5	Recalcitrant atopic dermatitis	
LUSC	cis	1	rs4886832	chr15:77121196	ETFA	chr15:76508629-76603810:-	0.32	4.11	4.76E-5	Recalcitrant atopic dermatitis	
LUSC	cis	1	rs4887783	chr16:74700743	RFWD3	chr16:74655298-74700779:-	-0.23	-5.23	2.52E-7	Testicular germ cell tumor	
LUSC	cis	1	rs4888262	chr16:74670458	RFWD3	chr16:74655298-74700779:-	-0.23	-5.32	1.61E-7	Testicular germ cell tumor	
LUSC	cis	1	rs4888264	chr16:74681632	RFWD3	chr16:74655298-74700779:-	-0.24	-5.65	2.71E-8	Testicular germ cell tumor	
LUSC	cis	1	rs4888265	chr16:74683737	RFWD3	chr16:74655298-74700779:-	-0.24	-5.64	2.89E-8	Testicular germ cell tumor	
LUSC	cis	1	rs4889775	chr17:78592287	NPTX1	chr17:78440633-78450404:-	-0.24	-4.59	5.6E-6	Obesity	
LUSC	cis	1	rs4899544	chr14:75546556	MLH3	chr14:75480467-75518235:-	0.28	5.94	5.63E-9	Height	
LUSC	cis	1	rs4899546	chr14:75594946	MLH3	chr14:75480467-75518235:-	0.26	5.63	3.09E-8	Height	
LUSC	cis	1	rs4903275	chr14:75512509	MLH3	chr14:75480467-75518235:-	0.26	5.53	5.32E-8	Height	
LUSC	cis	1	rs4903279	chr14:75546583	MLH3	chr14:75480467-75518235:-	0.28	5.94	5.63E-9	Height	
LUSC	cis	1	rs4903281	chr14:75554361	MLH3	chr14:75480467-75518235:-	0.27	5.87	8.12E-9	Height	
LUSC	cis	1	rs4903284	chr14:75592483	MLH3	chr14:75480467-75518235:-	0.28	5.91	6.41E-9	Height	
LUSC	cis	1	rs4903289	chr14:75623988	MLH3	chr14:75480467-75518235:-	-0.28	-6.05	2.97E-9	Height	
LUSC	cis	1	rs4906205	chr14:102932447	ZNF839	chr14:102783714-102809044:+	-0.21	-3.95	9.0E-5	QT interval	
LUSC	cis	1	rs4910755	chr11:5372751	OR51B5	chr11:5363816-5526882:-	-0.2	-3.7	0.000245	Fetal hemoglobin levels	
LUSC	cis	1	rs4911178	chr20:33952620	CEP250	chr20:34042996-34099802:+	-0.15	-3.87	0.000123	Height	
LUSC	cis	1	rs4911178	chr20:33952620	CPNE1	chr20:34213968-34262539:-	0.27	4.83	1.88E-6	Height	
LUSC	cis	1	rs4911178	chr20:33952620	UQCC	chr20:33890383-33999833:-	0.27	5.05	6.27E-7	Height	
LUSC	cis	1	rs4911180	chr20:33972948	CEP250	chr20:34042996-34099802:+	-0.15	-3.94	9.4E-5	Height	
LUSC	cis	1	rs4911180	chr20:33972948	CPNE1	chr20:34213968-34262539:-	0.29	4.89	1.4E-6	Height	
LUSC	cis	1	rs4911180	chr20:33972948	UQCC	chr20:33890383-33999833:-	0.29	5.13	4.15E-7	Height	
LUSC	cis	1	rs4911491	chr20:33947285	CEP250	chr20:34042996-34099802:+	-0.16	-4.22	2.88E-5	Height	
LUSC	cis	1	rs4911491	chr20:33947285	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.45E-6	Height	
LUSC	cis	1	rs4911491	chr20:33947285	UQCC	chr20:33890383-33999833:-	0.28	5.16	3.61E-7	Height	
LUSC	cis	1	rs4911492	chr20:33951799	CEP250	chr20:34042996-34099802:+	-0.16	-4.21	3.0E-5	Height	
LUSC	cis	1	rs4911492	chr20:33951799	CPNE1	chr20:34213968-34262539:-	0.27	4.78	2.29E-6	Height	
LUSC	cis	1	rs4911492	chr20:33951799	UQCC	chr20:33890383-33999833:-	0.28	5.2	3.03E-7	Height	
LUSC	cis	1	rs4911494	chr20:33971914	CEP250	chr20:34042996-34099802:+	-0.15	-4.04	6.25E-5	Height	
LUSC	cis	1	rs4911494	chr20:33971914	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.45E-6	Height	
LUSC	cis	1	rs4911494	chr20:33971914	UQCC	chr20:33890383-33999833:-	0.28	5.18	3.33E-7	Height	
LUSC	cis	1	rs4911496	chr20:33972053	CEP250	chr20:34042996-34099802:+	0.15	3.98	8.02E-5	Height	
LUSC	cis	1	rs4911496	chr20:33972053	CPNE1	chr20:34213968-34262539:-	-0.26	-4.5	8.67E-6	Height	
LUSC	cis	1	rs4911496	chr20:33972053	UQCC	chr20:33890383-33999833:-	-0.25	-4.66	4.2E-6	Height	
LUSC	cis	1	rs4917385	chr10:105003721	C10orf32	chr10:104613967-104624718:+	-0.21	-4.13	4.28E-5	Systemic lupus erythematosus	
LUSC	cis	1	rs4917385	chr10:105003721	CALHM2	chr10:105206545-105212658:-	-0.17	-3.93	9.74E-5	Systemic lupus erythematosus	
LUSC	cis	1	rs4917901	chr10:102201773	SEC31B	chr10:102246403-102289636:-	-0.26	-7.76	5.29E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919464	chr10:102221195	SEC31B	chr10:102246403-102289636:-	-0.27	-7.99	1.03E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919465	chr10:102221703	SEC31B	chr10:102246403-102289636:-	-0.27	-7.99	1.03E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919466	chr10:102241213	SEC31B	chr10:102246403-102289636:-	-0.27	-8.17	2.91E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919468	chr10:102288343	SEC31B	chr10:102246403-102289636:-	-0.29	-8.31	1.03E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919469	chr10:102298855	SEC31B	chr10:102246403-102289636:-	-0.28	-8.37	6.33E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919470	chr10:102298920	SEC31B	chr10:102246403-102289636:-	-0.29	-8.32	9.74E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919471	chr10:102299239	SEC31B	chr10:102246403-102289636:-	-0.28	-8.44	3.73E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919472	chr10:102315864	SEC31B	chr10:102246403-102289636:-	-0.28	-7.99	1.02E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs4919690	chr10:104616500	C10orf32	chr10:104613967-104624718:+	0.41	8.3	1.08E-15	Arsenic metabolism	
LUSC	cis	1	rs4925540	chr1:247214878	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs4932148	chr15:90394356	AP3S2	chr15:90373832-90456222:-	-0.6	-10.18	3.64E-22	Type 2 diabetes	
LUSC	cis	1	rs494003	chr11:65542298	CTSW	chr11:65647284-65651212:+	-0.24	-5.31	1.65E-7	Systemic lupus erythematosus	
LUSC	cis	1	rs494003	chr11:65542298	SNX32	chr11:65601410-65621170:+	0.44	6.82	2.69E-11	Systemic lupus erythematosus	
LUSC	cis	1	rs4949874	chr1:76161889	ACADM	chr1:76190043-76229353:+	0.21	3.87	0.000125	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs4951261	chr1:205717823	PM20D1	chr1:205797154-205819245:-	0.32	6.23	1.04E-9	Menarche (age at onset)	
LUSC	cis	1	rs4955485	chr3:134295843	ANAPC13	chr3:134196547-134204865:-	0.41	8.02	8.13E-15	Height	
LUSC	cis	1	rs4955555	chr3:134286427	ANAPC13	chr3:134196547-134204865:-	0.41	8.05	6.68E-15	Height	
LUSC	cis	1	rs496584	chr15:43831923	TUBGCP4	chr15:43663313-43698238:+	0.26	3.73	0.000212	Tumor biomarkers	
LUSC	cis	1	rs4970696	chr1:92968853	EVI5	chr1:92974255-93257961:-	-0.32	-4.56	6.66E-6	Cholesterol, total	
LUSC	cis	1	rs4970698	chr1:92972933	EVI5	chr1:92974255-93257961:-	-0.32	-4.6	5.42E-6	Cholesterol, total	
LUSC	cis	1	rs4970705	chr1:92971828	EVI5	chr1:92974255-93257961:-	0.33	4.71	3.19E-6	Cholesterol, total	
LUSC	cis	1	rs4970708	chr1:92986514	EVI5	chr1:92974255-93257961:-	-0.31	-4.49	9.08E-6	Cholesterol, total	
LUSC	cis	1	rs4970709	chr1:92988592	EVI5	chr1:92974255-93257961:-	-0.31	-4.49	9.08E-6	Cholesterol, total	
LUSC	cis	1	rs4970710	chr1:92988717	EVI5	chr1:92974255-93257961:-	-0.31	-4.49	9.08E-6	Cholesterol, total	
LUSC	cis	1	rs4970712	chr1:92993547	EVI5	chr1:92974255-93257961:-	0.27	4.06	5.84E-5	Cholesterol, total	
LUSC	cis	1	rs4970941	chr1:151068546	HORMAD1	chr1:150670542-150693352:-	0.3	4.59	5.75E-6	Body mass index	
LUSC	cis	1	rs4971316	chr1:247210903	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs4971319	chr1:247211565	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs4974483	chr3:134219001	ANAPC13	chr3:134196547-134204865:-	0.43	8.65	8.22E-17	Height	
LUSC	cis	1	rs4974484	chr3:134219019	ANAPC13	chr3:134196547-134204865:-	0.42	8.55	1.72E-16	Height	
LUSC	cis	1	rs4974493	chr3:134219993	ANAPC13	chr3:134196547-134204865:-	0.43	8.7	5.34E-17	Height	
LUSC	cis	1	rs4974559	chr4:1380848	CRIPAK	chr4:1385340-1389782:+	-0.25	-4.65	4.29E-6	Systolic blood pressure	
LUSC	cis	1	rs4975794	chr5:2015330	MRPL36	chr5:1798500-1799956:-	0.21	4.26	2.44E-5	Gut microbiome composition (winter)	
LUSC	cis	1	rs4988359	chr11:112025915	IL18	chr11:112013976-112034840:-	-0.25	-4.52	7.74E-6	Interleukin-18 levels	
LUSC	cis	1	rs5008830	chr3:122030462	CSTA	chr3:122044011-122060813:+	-0.19	-3.79	0.000172	Serum parathyroid hormone levels	
LUSC	cis	1	rs501220	chr6:25873025	BTN3A2	chr6:26365398-26378546:+	-0.47	-8.11	4.3E-15	Homocysteine levels	
LUSC	cis	1	rs5029726	chr3:132740108	TMEM108	chr3:132757171-133116618:+	0.2	4.69	3.51E-6	IgE grass sensitization	
LUSC	cis	1	rs503660	chr10:131418999	MGMT	chr10:131265454-131565783:+	0.34	7.25	1.71E-12	Response to temozolomide	
LUSC	cis	1	rs506274	chr10:131409392	MGMT	chr10:131265454-131565783:+	0.37	7.9	2.01E-14	Response to temozolomide	
LUSC	cis	1	rs508303	chr10:131424996	MGMT	chr10:131265454-131565783:+	-0.35	-7.5	3.23E-13	Response to temozolomide	
LUSC	cis	1	rs510988	chr11:116813804	PCSK7	chr11:117075789-117102811:-	-0.33	-4.61	5.29E-6	Protein quantitative trait loci	
LUSC	cis	1	rs511676	chr11:116824884	PCSK7	chr11:117075789-117102811:-	-0.33	-4.63	4.69E-6	Protein quantitative trait loci	
LUSC	cis	1	rs513736	chr10:131406489	MGMT	chr10:131265454-131565783:+	0.35	7.4	6.08E-13	Response to temozolomide	
LUSC	cis	1	rs516704	chr10:131419879	MGMT	chr10:131265454-131565783:+	0.34	7.11	4.26E-12	Response to temozolomide	
LUSC	cis	1	rs520146	chr11:102690131	MMP12	chr11:102733465-102745712:-	0.26	3.7	0.000237	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs522891	chr10:131430916	MGMT	chr10:131265454-131565783:+	-0.35	-7.3	1.22E-12	Response to temozolomide	
LUSC	cis	1	rs530466	chr10:131427717	MGMT	chr10:131265454-131565783:+	0.36	7.67	1.01E-13	Response to temozolomide	
LUSC	cis	1	rs531572	chr10:131427569	MGMT	chr10:131265454-131565783:+	-0.38	-8.16	3.12E-15	Response to temozolomide	
LUSC	cis	1	rs533928	chr1:150884271	HORMAD1	chr1:150670542-150693352:-	0.44	4.59	5.6E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs538969	chr10:131410608	MGMT	chr10:131265454-131565783:+	0.37	7.85	2.75E-14	Response to temozolomide	
LUSC	cis	1	rs543030	chr19:6081667	FUT5	chr19:5865838-5904025:-	0.38	4.01	7.17E-5	Bipolar disorder and schizophrenia	
LUSC	cis	1	rs543725	chr11:57483039	MED19	chr11:57471182-57479673:-	-0.21	-4.37	1.55E-5	Schizophrenia	
LUSC	cis	1	rs548390	chr10:131417427	MGMT	chr10:131265454-131565783:+	0.34	7.1	4.54E-12	Response to temozolomide	
LUSC	cis	1	rs553371	chr10:131413676	MGMT	chr10:131265454-131565783:+	0.34	7.23	1.92E-12	Response to temozolomide	
LUSC	cis	1	rs554792	chr10:131423181	MGMT	chr10:131265454-131565783:+	0.34	7.3	1.26E-12	Response to temozolomide	
LUSC	cis	1	rs55634130	chr4:119655093	SEC24D	chr4:119643979-119759827:-	0.39	4.31	1.95E-5	Cannabis dependence	
LUSC	cis	1	rs55656112	chr1:172189764	VAMP4	chr1:171669298-171711214:-	0.19	3.71	0.000231	Height	
LUSC	cis	1	rs55674647	chr17:61794195	FTSJ3	chr17:61896795-61905031:-	0.35	6.66	7.68E-11	Body mass index	
LUSC	cis	1	rs55674647	chr17:61794195	MAP3K3	chr17:61699775-61773669:+	0.16	3.71	0.000236	Body mass index	
LUSC	cis	1	rs55696836	chr20:33549887	PROCR	chr20:33758727-33765164:+	-0.33	-4.16	3.74E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs55697388	chr6:118891544	C6orf204	chr6:118786239-119031238:-	-0.24	-3.87	0.000126	Renal cell carcinoma	
LUSC	cis	1	rs55702511	chr4:154665978	TLR2	chr4:154605441-154627240:+	-0.2	-4.01	7.08E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs55722886	chr4:154668335	TLR2	chr4:154605441-154627240:+	-0.21	-4.12	4.48E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs55734215	chr20:33585437	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.47E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs55753056	chr2:243929	SH3YL1	chr2:218138-264810:-	-0.51	-9.08	2.85E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs55786720	chr6:56783647	BEND6	chr6:56819773-56892138:+	-0.35	-5.02	7.26E-7	Menarche (age at onset)	
LUSC	cis	1	rs55792703	chr4:154668278	TLR2	chr4:154605441-154627240:+	-0.21	-4.12	4.48E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs55834832	chr11:48562583	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.86	0.000129	HDL cholesterol	
LUSC	cis	1	rs55835850	chr2:28949296	TRMT61B	chr2:29072690-29093175:-	0.25	5.11	4.72E-7	Body mass index	
LUSC	cis	1	rs55838400	chr3:122032293	CSTA	chr3:122044011-122060813:+	-0.18	-3.72	0.000219	Serum parathyroid hormone levels	
LUSC	cis	1	rs55857306	chr1:11895795	CLCN6	chr1:11866207-11907674:+	0.26	5.12	4.52E-7	QRS complex (12-leadsum)	
LUSC	cis	1	rs55868506	chr17:61851686	FTSJ3	chr17:61896795-61905031:-	0.33	6.53	1.73E-10	Body mass index	
LUSC	cis	1	rs558764	chr10:131426957	MGMT	chr10:131265454-131565783:+	-0.33	-7.04	6.71E-12	Response to temozolomide	
LUSC	cis	1	rs55879323	chr1:152168740	FLG	chr1:152274651-152297679:-	-0.26	-6.09	2.32E-9	Inflammatory skin disease	
LUSC	cis	1	rs55879323	chr1:152168740	HRNR	chr1:152184558-152196669:-	0.22	4.87	1.55E-6	Inflammatory skin disease	
LUSC	cis	1	rs55885592	chr14:104126024	C14orf153	chr14:104029299-104057227:+	0.15	3.81	0.000159	Body mass index	
LUSC	cis	1	rs55905547	chr20:57589995	TH1L	chr20:57556311-57570186:+	-0.36	-5.57	4.23E-8	Mean platelet volume	
LUSC	cis	1	rs55909363	chr20:33549407	PROCR	chr20:33758727-33765164:+	-0.33	-4.15	4.01E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs55913793	chr3:134285968	ANAPC13	chr3:134196547-134204865:-	0.41	8.05	6.68E-15	Height	
LUSC	cis	1	rs55914901	chr19:50528346	SIGLEC16	chr19:50472912-50479075:+	0.68	7.18	2.67E-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs55936726	chr2:258210	SH3YL1	chr2:218138-264810:-	-0.51	-9.04	4.14E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs55939964	chr17:65869297	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs55946144	chr20:33629610	GDF5	chr20:33897002-34042568:-	0.28	3.79	0.000173	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs55946144	chr20:33629610	PROCR	chr20:33758727-33765164:+	-0.33	-4.37	1.55E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs55946380	chr2:268293	SH3YL1	chr2:218138-264810:-	-0.51	-9.03	4.25E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs55962025	chr4:3112109	C4orf44	chr4:3250767-3265839:+	-0.19	-3.79	0.000172	Parental longevity (mother's age at death)	
LUSC	cis	1	rs55962648	chr7:65625751	NCRNA00174	chr7:65841032-65865395:-	0.3	6.44	2.98E-10	Aortic root size	
LUSC	cis	1	rs55971458	chr17:28427016	EFCAB5	chr17:28256874-28435469:+	0.32	6.13	1.82E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs55976357	chr5:132194565	SLC22A5	chr5:131705401-131731302:+	-0.28	-3.82	0.000153	Apolipoprotein A-IV levels	
LUSC	cis	1	rs55998153	chr1:179453824	TDRD5	chr1:179561025-179660398:+	-0.39	-4.2	3.24E-5	Multiple sclerosis (age of onset)	
LUSC	cis	1	rs56013339	chr3:12543198	TSEN2	chr3:12525931-12581122:+	0.53	5.31	1.65E-7	Prostate cancer (gene x gene interaction)	
LUSC	cis	1	rs56030203	chr6:56783857	BEND6	chr6:56819773-56892138:+	-0.35	-5.02	7.26E-7	Menarche (age at onset)	
LUSC	cis	1	rs56040780	chr16:28861881	EIF3CL	chr16:28699879-28747052:+;chr16	0.3	5.61	3.38E-8	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LUSC	cis	1	rs56057198	chr17:61733332	FTSJ3	chr17:61896795-61905031:-	0.35	6.68	6.75E-11	Body mass index	
LUSC	cis	1	rs56097052	chr5:132194430	SLC22A5	chr5:131705401-131731302:+	-0.26	-3.79	0.00017	Apolipoprotein A-IV levels	
LUSC	cis	1	rs56098064	chr14:50105849	RPL36AL	chr14:50085407-50087349:-	0.2	4.46	1.03E-5	Carotid intima media thickness	
LUSC	cis	1	rs56101873	chr1:119474790	WARS2	chr1:119573841-119683295:-	0.29	3.85	0.000137	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs56113315	chr19:39184166	LGALS7B	chr19:39279850-39282393:+	0.2	4.15	3.99E-5	Heart rate	
LUSC	cis	1	rs56121764	chr3:41883975	ULK4	chr3:41288091-42003660:-	0.62	9.36	3.28E-19	Diastolic blood pressure	
LUSC	cis	1	rs56127630	chr3:49438036	AMT	chr3:49454212-49460012:-	-0.2	-4.79	2.2E-6	Menarche (age at onset)	
LUSC	cis	1	rs56127630	chr3:49438036	TREX1	chr3:48501186-48509043:+	0.2	3.79	0.000168	Menarche (age at onset)	
LUSC	cis	1	rs56145559	chr2:73623439	ALMS1P	chr2:73872046-73912692:+	0.43	7.84	3.0E-14	Schizophrenia	
LUSC	cis	1	rs56145559	chr2:73623439	NAT8	chr2:73867850-73869537:-	0.25	4.31	1.99E-5	Schizophrenia	
LUSC	cis	1	rs56153133	chr1:11885647	CLCN6	chr1:11866207-11907674:+	0.22	4.41	1.3E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs56154726	chr2:73721767	ALMS1P	chr2:73872046-73912692:+	0.4	7.33	1.01E-12	Metabolite levels	
LUSC	cis	1	rs56154726	chr2:73721767	NAT8	chr2:73867850-73869537:-	0.26	4.52	7.95E-6	Metabolite levels	
LUSC	cis	1	rs56157864	chr5:132267859	SLC22A5	chr5:131705401-131731302:+	-0.28	-3.87	0.000124	Apolipoprotein A-IV levels	
LUSC	cis	1	rs56158380	chr3:41885588	ULK4	chr3:41288091-42003660:-	0.62	9.36	3.28E-19	Diastolic blood pressure	
LUSC	cis	1	rs56167434	chr2:282137	SH3YL1	chr2:218138-264810:-	-0.51	-8.72	4.63E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs56190030	chr1:11887382	CLCN6	chr1:11866207-11907674:+	0.2	4.21	3.11E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs56207540	chr3:41976627	ULK4	chr3:41288091-42003660:-	0.61	8.32	9.58E-16	Diastolic blood pressure	
LUSC	cis	1	rs562179	chr11:116805204	PCSK7	chr11:117075789-117102811:-	-0.32	-4.56	6.47E-6	Protein quantitative trait loci	
LUSC	cis	1	rs56232929	chr4:154665700	TLR2	chr4:154605441-154627240:+	-0.2	-3.98	8.04E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs56280226	chr17:28429575	EFCAB5	chr17:28256874-28435469:+	0.31	5.98	4.27E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs56306402	chr20:33937704	CEP250	chr20:34042996-34099802:+	-0.15	-4.04	6.33E-5	Height	
LUSC	cis	1	rs56306402	chr20:33937704	CPNE1	chr20:34213968-34262539:-	0.27	4.81	2.06E-6	Height	
LUSC	cis	1	rs56306402	chr20:33937704	UQCC	chr20:33890383-33999833:-	0.28	5.13	4.28E-7	Height	
LUSC	cis	1	rs56314138	chr3:121356656	IQCB1	chr3:121488610-121553926:-	0.2	4.17	3.57E-5	Cognitive performance	
LUSC	cis	1	rs56317427	chr10:81861934	C10orf57	chr10:81838426-81852306:+	0.48	4.76	2.6E-6	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs56317427	chr10:81861934	PLAC9	chr10:81892258-81904784:+	-0.29	-4	7.3E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs56321614	chr2:268191	SH3YL1	chr2:218138-264810:-	-0.5	-8.63	9.03E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs56322409	chr10:97395962	ENTPD1	chr10:97471536-97637022:+	0.17	5.08	5.39E-7	Blood metabolite levels	
LUSC	cis	1	rs56331473	chr4:154668052	TLR2	chr4:154605441-154627240:+	-0.21	-4.11	4.63E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs56363533	chr20:33626005	GDF5	chr20:33897002-34042568:-	0.28	3.8	0.000165	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs56363533	chr20:33626005	PROCR	chr20:33758727-33765164:+	-0.33	-4.31	1.99E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs56383601	chr17:61929968	FTSJ3	chr17:61896795-61905031:-	0.34	6.47	2.4E-10	Body mass index	
LUSC	cis	1	rs56392198	chr1:179451124	TDRD5	chr1:179561025-179660398:+	-0.39	-4.2	3.24E-5	Multiple sclerosis (age of onset)	
LUSC	cis	1	rs565974	chr10:131423274	MGMT	chr10:131265454-131565783:+	0.34	7.3	1.26E-12	Response to temozolomide	
LUSC	cis	1	rs56660916	chr14:104126137	C14orf153	chr14:104029299-104057227:+	0.15	3.81	0.000159	Body mass index	
LUSC	cis	1	rs56672945	chr2:73622663	ALMS1P	chr2:73872046-73912692:+	0.44	7.91	1.83E-14	Metabolite levels	
LUSC	cis	1	rs56672945	chr2:73622663	NAT8	chr2:73867850-73869537:-	0.27	4.49	9.13E-6	Metabolite levels	
LUSC	cis	1	rs56763150	chr6:24482999	GPLD1	chr6:24428405-24489850:-	0.41	5.39	1.08E-7	Hematological and biochemical traits	
LUSC	cis	1	rs567700	chr10:131423126	MGMT	chr10:131265454-131565783:+	0.34	7.3	1.26E-12	Response to temozolomide	
LUSC	cis	1	rs56776628	chr3:41866856	ULK4	chr3:41288091-42003660:-	0.6	9.3	4.95E-19	Diastolic blood pressure	
LUSC	cis	1	rs568617	chr11:65653242	CTSW	chr11:65647284-65651212:+	-0.61	-16.36	4.74E-48	Crohn's disease	
LUSC	cis	1	rs568617	chr11:65653242	SNX32	chr11:65601410-65621170:+	0.57	9.3	5.23E-19	Crohn's disease	
LUSC	cis	1	rs56864281	chr15:85357649	LOC388152	chr15:84867600-84898920:-	-0.23	-4.08	5.19E-5	Schizophrenia	
LUSC	cis	1	rs56884994	chr1:247211057	ZNF670	chr1:247200087-247242069:-	-0.22	-4.21	3.1E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs56922390	chr17:38157021	GSDMA	chr17:38119226-38134019:+	-0.44	-8.99	5.71E-18	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs569235	chr10:131411620	MGMT	chr10:131265454-131565783:+	0.36	7.63	1.28E-13	Response to temozolomide	
LUSC	cis	1	rs57012996	chr11:47194924	MADD	chr11:47290927-47351582:+	0.45	5.32	1.57E-7	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs57025426	chr10:102205868	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.18E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs57075379	chr14:35577801	PPP2R3C	chr14:35554679-35591679:-	0.32	5.7	2.11E-8	Atopic dermatitis	
LUSC	cis	1	rs57137641	chr12:56741228	PAN2	chr12:56710718-56727825:-	0.36	3.79	0.000173	Psoriasis vulgaris	
LUSC	cis	1	rs57218990	chr14:104128007	C14orf153	chr14:104029299-104057227:+	0.15	3.95	8.92E-5	Body mass index	
LUSC	cis	1	rs57218990	chr14:104128007	CKB	chr14:103985996-103989170:-	0.19	3.75	0.000201	Body mass index	
LUSC	cis	1	rs57307201	chr17:40572793	CNTD1	chr17:40950854-40963604:+	0.17	3.73	0.000211	Crohn's disease	
LUSC	cis	1	rs57322232	chr8:124193532	FAM83A	chr8:124191287-124222317:+	-0.28	-4.49	8.76E-6	Urinary uromodulin levels	
LUSC	cis	1	rs57411618	chr17:28273052	EFCAB5	chr17:28256874-28435469:+	0.31	5.86	8.74E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs5744249	chr11:112025306	IL18	chr11:112013976-112034840:-	-0.25	-4.52	7.74E-6	Interleukin-18 levels	
LUSC	cis	1	rs5744256	chr11:112022848	IL18	chr11:112013976-112034840:-	-0.25	-4.52	7.74E-6	Interleukin-18 levels	
LUSC	cis	1	rs5744258	chr11:112021767	IL18	chr11:112013976-112034840:-	-0.25	-4.52	7.74E-6	Interleukin-18 levels	
LUSC	cis	1	rs5750659	chr22:39068789	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs5750662	chr22:39072472	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs5750664	chr22:39072769	CBY1	chr22:39052658-39069853:+	0.23	4.18	3.41E-5	Resting heart rate	
LUSC	cis	1	rs5750668	chr22:39079964	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.84E-5	Resting heart rate	
LUSC	cis	1	rs5750669	chr22:39080638	CBY1	chr22:39052658-39069853:+	0.22	4.01	6.91E-5	Resting heart rate	
LUSC	cis	1	rs5750671	chr22:39094619	CBY1	chr22:39052658-39069853:+	0.22	4.09	5.17E-5	Resting heart rate	
LUSC	cis	1	rs5750672	chr22:39104168	CBY1	chr22:39052658-39069853:+	-0.21	-3.83	0.000146	Resting heart rate	
LUSC	cis	1	rs5750673	chr22:39110124	CBY1	chr22:39052658-39069853:+	0.24	4.32	1.89E-5	Resting heart rate	
LUSC	cis	1	rs5750677	chr22:39147715	CBY1	chr22:39052658-39069853:+	0.24	4.55	6.68E-6	Resting heart rate	
LUSC	cis	1	rs5751255	chr22:42648408	CYP2D6	chr22:42522502-42526883:-	-0.43	-9.87	5.06E-21	Cognitive function	
LUSC	cis	1	rs5751589	chr22:23475762	RTDR1	chr22:23401594-23484241:-	0.24	4.51	8.07E-6	Bone mineral density	
LUSC	cis	1	rs57542652	chr2:228088	SH3YL1	chr2:218138-264810:-	-0.51	-8.81	2.29E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs5756813	chr22:38175477	TRIOBP	chr22:38082344-38172562:+	-0.2	-4.12	4.56E-5	Optic cup area;Vertical cup-disc ratio	
LUSC	cis	1	rs5757187	chr22:39021522	CBY1	chr22:39052658-39069853:+	-0.2	-3.7	0.000236	Resting heart rate	
LUSC	cis	1	rs5757193	chr22:39034867	CBY1	chr22:39052658-39069853:+	-0.22	-4	7.32E-5	Resting heart rate	
LUSC	cis	1	rs5757196	chr22:39039855	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs5757200	chr22:39043491	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs5757203	chr22:39044152	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs5757204	chr22:39046700	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs5757208	chr22:39049230	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs5757211	chr22:39051705	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs5757213	chr22:39053888	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs5757226	chr22:39070550	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs5757231	chr22:39071658	CBY1	chr22:39052658-39069853:+	-0.23	-4.23	2.75E-5	Resting heart rate	
LUSC	cis	1	rs5757232	chr22:39071677	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs5757234	chr22:39072686	CBY1	chr22:39052658-39069853:+	0.21	3.91	0.000105	Resting heart rate	
LUSC	cis	1	rs5757253	chr22:39104320	CBY1	chr22:39052658-39069853:+	0.22	3.98	8.03E-5	Resting heart rate	
LUSC	cis	1	rs5758659	chr22:42622003	CYP2D6	chr22:42522502-42526883:-	-0.42	-9.64	3.43E-20	Cognitive function	
LUSC	cis	1	rs5758660	chr22:42623718	CYP2D6	chr22:42522502-42526883:-	-0.43	-9.77	1.12E-20	Cognitive function	
LUSC	cis	1	rs5758677	chr22:42643039	CYP2D6	chr22:42522502-42526883:-	-0.43	-9.9	3.95E-21	Cognitive function	
LUSC	cis	1	rs5759595	chr22:23471624	RTDR1	chr22:23401594-23484241:-	-0.24	-4.66	4.12E-6	Bone mineral density	
LUSC	cis	1	rs5759596	chr22:23475750	RTDR1	chr22:23401594-23484241:-	-0.23	-4.4	1.32E-5	Bone mineral density	
LUSC	cis	1	rs5759598	chr22:23480962	RTDR1	chr22:23401594-23484241:-	-0.23	-4.35	1.64E-5	Bone mineral density	
LUSC	cis	1	rs5760216	chr22:24539734	SUSD2	chr22:24577444-24585074:+	0.45	6.1	2.23E-9	Amyotrophic lateral sclerosis	
LUSC	cis	1	rs5760220	chr22:24542480	SUSD2	chr22:24577444-24585074:+	0.47	6.55	1.5E-10	Amyotrophic lateral sclerosis	
LUSC	cis	1	rs5760229	chr22:24560254	SUSD2	chr22:24577444-24585074:+	0.47	6.45	2.74E-10	Amyotrophic lateral sclerosis	
LUSC	cis	1	rs5763305	chr22:29930195	NIPSNAP1	chr22:29950800-29977144:-	-0.25	-4.15	3.98E-5	Lipid traits	
LUSC	cis	1	rs5763854	chr22:30577589	RFPL1S	chr22:29833006-29838118:-	-0.38	-3.73	0.000219	LDL cholesterol	
LUSC	cis	1	rs5770917	chr22:51017353	CPT1B	chr22:51007291-51017096:-	-0.37	-4.69	3.5E-6	Narcolepsy	
LUSC	cis	1	rs5770922	chr22:51023408	CPT1B	chr22:51007291-51017096:-	-0.34	-4.09	5.13E-5	Narcolepsy	
LUSC	cis	1	rs5770924	chr22:51024542	CPT1B	chr22:51007291-51017096:-	-0.34	-4.13	4.24E-5	Narcolepsy	
LUSC	cis	1	rs577227	chr10:131404528	MGMT	chr10:131265454-131565783:+	0.37	7.68	9.34E-14	Response to temozolomide	
LUSC	cis	1	rs578056	chr11:65514874	CTSW	chr11:65647284-65651212:+	-0.25	-5.36	1.3E-7	Systemic lupus erythematosus	
LUSC	cis	1	rs578056	chr11:65514874	SNX32	chr11:65601410-65621170:+	0.43	6.75	4.31E-11	Systemic lupus erythematosus	
LUSC	cis	1	rs57832572	chr12:8668281	CLEC4D	chr12:8666136-8674958:+	0.31	6.16	1.59E-9	Response to radiotherapy in prostate cancer (toxicity, urinary frequency)	
LUSC	cis	1	rs57902736	chr8:124189893	FAM83A	chr8:124191287-124222317:+	-0.24	-3.73	0.000213	Urinary uromodulin levels	
LUSC	cis	1	rs57912102	chr19:22136043	ZNF100	chr19:21906844-21950430:-	-0.3	-4.31	1.98E-5	Body mass index (change over time)	
LUSC	cis	1	rs57912102	chr19:22136043	ZNF429	chr19:21688437-21739068:+	-0.28	-4.02	6.72E-5	Body mass index (change over time)	
LUSC	cis	1	rs57912102	chr19:22136043	ZNF430	chr19:21203497-21241652:+	-0.26	-3.71	0.000234	Body mass index (change over time)	
LUSC	cis	1	rs57912102	chr19:22136043	ZNF43	chr19:21987753-22034830:-	-0.28	-3.99	7.65E-5	Body mass index (change over time)	
LUSC	cis	1	rs579890	chr11:116798963	PCSK7	chr11:117075789-117102811:-	-0.36	-4.8	2.09E-6	Protein quantitative trait loci	
LUSC	cis	1	rs580745	chr10:131414401	MGMT	chr10:131265454-131565783:+	0.34	7.25	1.69E-12	Response to temozolomide	
LUSC	cis	1	rs58122682	chr17:65876915	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs58177772	chr8:124188067	FAM83A	chr8:124191287-124222317:+	-0.27	-4.33	1.8E-5	Urinary uromodulin levels	
LUSC	cis	1	rs58204112	chr14:74359417	LIN52	chr14:74551656-74667117:+	0.28	4.3	2.06E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs583583	chr1:147083114	ACP6	chr1:147119168-147142634:-	0.22	3.81	0.000158	Schizophrenia (negative symptoms)	
LUSC	cis	1	rs58416181	chr15:85264461	LOC388152	chr15:84867600-84898920:-	-0.23	-4.11	4.67E-5	Schizophrenia	
LUSC	cis	1	rs58461606	chr2:267367	SH3YL1	chr2:218138-264810:-	-0.51	-9.06	3.45E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs58479700	chr6:24483199	GPLD1	chr6:24428405-24489850:-	0.41	5.39	1.08E-7	Hematological and biochemical traits	
LUSC	cis	1	rs58551145	chr17:65837235	LOC440461	chr17:66194801-66196436:+	0.26	3.91	0.000107	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs58741168	chr8:124191852	FAM83A	chr8:124191287-124222317:+	-0.25	-4.11	4.75E-5	Urinary uromodulin levels	
LUSC	cis	1	rs58749629	chr20:44571317	WFDC3	chr20:44402847-44420547:-	-0.55	-7.18	2.78E-12	Abdominal aortic aneurysm	
LUSC	cis	1	rs58852079	chr12:56706922	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs58852079	chr12:56706922	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs588918	chr11:116856642	PCSK7	chr11:117075789-117102811:-	-0.28	-4.03	6.39E-5	Protein quantitative trait loci	
LUSC	cis	1	rs591058	chr11:102711338	MMP12	chr11:102733465-102745712:-	-0.18	-3.88	0.000117	Cerebrospinal fluid levels of Alzheimer's disease-related proteins	
LUSC	cis	1	rs59226697	chr22:25870037	CRYBB2	chr22:25615612-25627836:+	0.6	5.04	6.48E-7	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs59244547	chr3:156582997	LEKR1	chr3:156544076-156763918:+	-0.39	-6.28	7.66E-10	Bone mineral density	
LUSC	cis	1	rs59274738	chr17:28437635	EFCAB5	chr17:28256874-28435469:+	0.32	6.1	2.25E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs59295315	chr12:56708576	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs59295315	chr12:56708576	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs59363432	chr14:74397545	LIN52	chr14:74551656-74667117:+	0.27	4.02	6.77E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs594074	chr6:6552994	LY86	chr6:6588934-6655216:+	0.14	4.39	1.4E-5	Diabetic kidney disease	
LUSC	cis	1	rs59428599	chr10:4970849	C10orf18	chr10:5726801-5806943:+	0.28	3.72	0.000223	Height	
LUSC	cis	1	rs59448251	chr14:24928452	SDR39U1	chr14:24908974-24912064:-	-0.38	-3.9	0.000111	Smooth-surface caries	
LUSC	cis	1	rs59601467	chr8:124193488	FAM83A	chr8:124191287-124222317:+	-0.25	-3.96	8.79E-5	Urinary uromodulin levels	
LUSC	cis	1	rs59682592	chr5:132196800	SLC22A5	chr5:131705401-131731302:+	-0.28	-3.82	0.000153	Apolipoprotein A-IV levels	
LUSC	cis	1	rs59713276	chr14:93738204	COX8C	chr14:93813537-93814700:+	-0.24	-3.74	0.000203	Body mass index	
LUSC	cis	1	rs59784306	chr20:61859596	BIRC7	chr20:61867276-61871853:+	0.31	4.06	5.7E-5	Response to cytadine analogues (cytosine arabinoside)	
LUSC	cis	1	rs59834873	chr8:124188824	FAM83A	chr8:124191287-124222317:+	-0.27	-4.43	1.19E-5	Urinary uromodulin levels	
LUSC	cis	1	rs59907625	chr19:6079598	FUT5	chr19:5865838-5904025:-	0.43	4.22	2.97E-5	Bipolar disorder and schizophrenia	
LUSC	cis	1	rs59925331	chr17:38169273	GSDMA	chr17:38119226-38134019:+	-0.44	-8.88	1.4E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs59937473	chr2:271797	SH3YL1	chr2:218138-264810:-	-0.51	-8.98	6.32E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs59947468	chr2:86289436	LOC90784	chr2:86247339-86250991:-	-0.39	-3.94	9.19E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LUSC	cis	1	rs59950564	chr17:65860859	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs5995610	chr22:39064681	CBY1	chr22:39052658-39069853:+	0.21	3.83	0.000147	Resting heart rate	
LUSC	cis	1	rs5996946	chr22:25875988	CRYBB2	chr22:25615612-25627836:+	0.74	8.41	4.92E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs6001182	chr22:39047443	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs6001184	chr22:39052116	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs6001185	chr22:39052155	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs6001188	chr22:39062194	CBY1	chr22:39052658-39069853:+	0.22	3.99	7.76E-5	Resting heart rate	
LUSC	cis	1	rs6001191	chr22:39074452	CBY1	chr22:39052658-39069853:+	0.23	4.18	3.41E-5	Resting heart rate	
LUSC	cis	1	rs6001204	chr22:39100239	CBY1	chr22:39052658-39069853:+	0.22	4.06	5.66E-5	Resting heart rate	
LUSC	cis	1	rs6001214	chr22:39149155	CBY1	chr22:39052658-39069853:+	0.25	4.61	5.12E-6	Resting heart rate	
LUSC	cis	1	rs6003518	chr22:23471533	RTDR1	chr22:23401594-23484241:-	-0.24	-4.65	4.25E-6	Bone mineral density	
LUSC	cis	1	rs6004667	chr22:25874464	CRYBB2	chr22:25615612-25627836:+	-0.78	-8.94	8.95E-18	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs6004668	chr22:25874502	CRYBB2	chr22:25615612-25627836:+	-0.76	-8.6	1.21E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs6004669	chr22:25875803	CRYBB2	chr22:25615612-25627836:+	0.75	8.54	1.88E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs6004671	chr22:25879474	CRYBB2	chr22:25615612-25627836:+	0.74	8.43	4.08E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs6004672	chr22:25881013	CRYBB2	chr22:25615612-25627836:+	0.76	8.57	1.48E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs6004673	chr22:25885353	CRYBB2	chr22:25615612-25627836:+	0.72	8.54	1.9E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs6011691	chr20:61867454	BIRC7	chr20:61867276-61871853:+	0.3	3.92	0.000101	Response to cytadine analogues (cytosine arabinoside)	
LUSC	cis	1	rs601338	chr19:49206674	FUT2	chr19:49199228-49209190:+	-0.27	-5.39	1.13E-7	Blood metabolite levels;Blood metabolite ratios	
LUSC	cis	1	rs60144605	chr1:76359699	ACADM	chr1:76190043-76229353:+	-0.27	-3.7	0.000244	Attention function in attention deficit hyperactive disorder	
LUSC	cis	1	rs60149603	chr2:285421	SH3YL1	chr2:218138-264810:-	-0.5	-8.55	1.72E-16	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs602128	chr11:102713465	MMP12	chr11:102733465-102745712:-	-0.19	-4.04	6.28E-5	Cerebrospinal fluid levels of Alzheimer's disease-related proteins	
LUSC	cis	1	rs60228607	chr8:130735460	GSDMC	chr8:130760443-130799134:-	0.26	5.28	1.96E-7	Infant length;Height	
LUSC	cis	1	rs60251819	chr6:24468648	GPLD1	chr6:24428405-24489850:-	0.44	5.52	5.69E-8	Hematological and biochemical traits	
LUSC	cis	1	rs602848	chr6:131446791	SAMD3	chr6:130465463-130686570:-	0.18	4.08	5.21E-5	Migraine - clinic-based;Migraine with aura	
LUSC	cis	1	rs6028	chr1:169551682	F5	chr1:169481192-169555769:-	-0.28	-5.88	7.86E-9	Activated partial thromboplastin time	
LUSC	cis	1	rs60362869	chr8:124189971	FAM83A	chr8:124191287-124222317:+	-0.26	-4.28	2.28E-5	Urinary uromodulin levels	
LUSC	cis	1	rs6037095	chr20:25335687	ENTPD6	chr20:25176339-25207360:+	0.2	3.86	0.000128	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6037099	chr20:25356876	ENTPD6	chr20:25176339-25207360:+	0.2	3.79	0.000167	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6037105	chr20:25374199	ENTPD6	chr20:25176339-25207360:+	0.2	3.79	0.000167	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6037121	chr20:25428311	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.71	0.000232	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs60393576	chr1:228993972	WNT3A	chr1:228194752-228248961:+	0.21	3.72	0.000227	Basal cell carcinoma	
LUSC	cis	1	rs60425110	chr15:75333000	SCAMP5	chr15:75287901-75313836:+	0.26	4.23	2.79E-5	Blood trace element (Zn levels)	
LUSC	cis	1	rs60432293	chr17:65860407	LOC440461	chr17:66194801-66196436:+	0.25	3.99	7.59E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs60479377	chr2:86283948	LOC90784	chr2:86247339-86250991:-	-0.38	-3.81	0.000156	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LUSC	cis	1	rs60482539	chr15:56180297	NEDD4	chr15:56119131-56285835:-	0.25	4.44	1.12E-5	Keloid	
LUSC	cis	1	rs60484953	chr2:221560	SH3YL1	chr2:218138-264810:-	-0.5	-9.07	3.17E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs6049191	chr20:23847165	CST2	chr20:23804404-23807312:-	-0.31	-4.87	1.55E-6	Response to TNF antagonist treatment	
LUSC	cis	1	rs6049196	chr20:23848349	CST2	chr20:23804404-23807312:-	-0.31	-4.87	1.55E-6	Response to TNF antagonist treatment	
LUSC	cis	1	rs6050542	chr20:25318879	ENTPD6	chr20:25176339-25207360:+	0.21	3.87	0.000126	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050544	chr20:25320228	ENTPD6	chr20:25176339-25207360:+	0.2	3.84	0.000139	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050547	chr20:25326012	ENTPD6	chr20:25176339-25207360:+	0.2	3.76	0.000194	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050559	chr20:25329915	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.76	0.000194	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050561	chr20:25334855	ENTPD6	chr20:25176339-25207360:+	0.21	3.9	0.000109	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050562	chr20:25336186	ENTPD6	chr20:25176339-25207360:+	0.2	3.86	0.000128	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050564	chr20:25344231	ENTPD6	chr20:25176339-25207360:+	0.2	3.79	0.000167	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050598	chr20:25397257	ENTPD6	chr20:25176339-25207360:+	-0.21	-4	7.41E-5	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050599	chr20:25400240	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050602	chr20:25401203	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050609	chr20:25411751	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050617	chr20:25421648	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.71	0.000232	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050626	chr20:25428261	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050629	chr20:25430680	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.71	0.000232	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050630	chr20:25430745	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.71	0.000232	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050631	chr20:25431749	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.7	0.000236	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6050632	chr20:25432601	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.71	0.000232	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6051080	chr20:25975674	FAM182B	chr20:25744102-25848786:-	0.39	6.98	9.98E-12	Colorectal or endometrial cancer	
LUSC	cis	1	rs6051080	chr20:25975674	LOC100134868	chr20:25990435-26002424:+	-0.28	-5.09	5.04E-7	Colorectal or endometrial cancer	
LUSC	cis	1	rs60512868	chr3:48483445	ATRIP	chr3:48488141-48507708:+	0.19	4.05	6.08E-5	Longevity	
LUSC	cis	1	rs60512868	chr3:48483445	TREX1	chr3:48501186-48509043:+	-0.39	-8.54	1.77E-16	Longevity	
LUSC	cis	1	rs6051708	chr20:3262493	ITPA	chr20:3190056-3204504:+	-0.29	-4.21	3.02E-5	IFN-related cytopenia	
LUSC	cis	1	rs6051762	chr20:3321590	ITPA	chr20:3190056-3204504:+	-0.25	-3.71	0.000234	IFN-related cytopenia	
LUSC	cis	1	rs6058352	chr20:30269179	COX4I2	chr20:30225691-30232800:+	0.2	4.11	4.66E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6058465	chr20:30397691	COX4I2	chr20:30225691-30232800:+	0.19	3.98	7.86E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6058468	chr20:30406448	COX4I2	chr20:30225691-30232800:+	0.2	4.2	3.2E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060401	chr20:34005214	CEP250	chr20:34042996-34099802:+	-0.15	-3.79	0.00017	Height	
LUSC	cis	1	rs6060401	chr20:34005214	CPNE1	chr20:34213968-34262539:-	0.29	5.02	7.46E-7	Height	
LUSC	cis	1	rs6060401	chr20:34005214	UQCC	chr20:33890383-33999833:-	0.28	5.01	7.58E-7	Height	
LUSC	cis	1	rs6060402	chr20:34005240	CEP250	chr20:34042996-34099802:+	-0.15	-3.79	0.000169	Height	
LUSC	cis	1	rs6060402	chr20:34005240	CPNE1	chr20:34213968-34262539:-	0.29	5.03	7.08E-7	Height	
LUSC	cis	1	rs6060402	chr20:34005240	UQCC	chr20:33890383-33999833:-	0.28	5.06	6.08E-7	Height	
LUSC	cis	1	rs6060599	chr20:30257754	COX4I2	chr20:30225691-30232800:+	0.2	4.18	3.42E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060621	chr20:30261562	COX4I2	chr20:30225691-30232800:+	0.2	4.2	3.22E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060716	chr20:30274847	COX4I2	chr20:30225691-30232800:+	0.2	4.14	4.12E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060857	chr20:30300222	COX4I2	chr20:30225691-30232800:+	0.21	4.39	1.41E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060915	chr20:30330306	COX4I2	chr20:30225691-30232800:+	0.21	4.33	1.8E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060919	chr20:30331922	COX4I2	chr20:30225691-30232800:+	0.2	4.12	4.39E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060922	chr20:30333909	COX4I2	chr20:30225691-30232800:+	0.2	4.03	6.37E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060932	chr20:30350545	COX4I2	chr20:30225691-30232800:+	0.2	4.03	6.37E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060933	chr20:30351903	COX4I2	chr20:30225691-30232800:+	0.19	4.03	6.58E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060944	chr20:30372114	COX4I2	chr20:30225691-30232800:+	0.2	4.12	4.51E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060950	chr20:30378031	COX4I2	chr20:30225691-30232800:+	0.2	4.19	3.36E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6060962	chr20:30397847	COX4I2	chr20:30225691-30232800:+	0.19	4.01	7.11E-5	Subcortical brain region volumes	
LUSC	cis	1	rs606458	chr11:64546391	COX8A	chr11:63742079-63744014:+	-0.23	-3.7	0.000243	Urate levels	
LUSC	cis	1	rs606458	chr11:64546391	POLA2	chr11:65029432-65065087:+	-0.29	-4.22	2.93E-5	Urate levels	
LUSC	cis	1	rs60693825	chr14:35514456	PPP2R3C	chr14:35554679-35591679:-	0.32	5.76	1.51E-8	Atopic dermatitis	
LUSC	cis	1	rs6070692	chr20:57586374	TH1L	chr20:57556311-57570186:+	-0.38	-5.86	8.5E-9	Mean platelet volume	
LUSC	cis	1	rs6070696	chr20:57597645	TH1L	chr20:57556311-57570186:+	-0.34	-5.5	6.11E-8	Mean platelet volume	
LUSC	cis	1	rs6070697	chr20:57599402	TH1L	chr20:57556311-57570186:+	-0.36	-5.69	2.28E-8	Mean platelet volume	
LUSC	cis	1	rs6076336	chr20:25319212	ENTPD6	chr20:25176339-25207360:+	0.2	3.86	0.000128	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6076345	chr20:25381895	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs607987	chr11:30223574	C11orf46	chr11:30344649-30359978:+	-0.18	-3.84	0.000139	Body mass index	
LUSC	cis	1	rs60827294	chr8:124187842	FAM83A	chr8:124191287-124222317:+	-0.27	-4.33	1.8E-5	Urinary uromodulin levels	
LUSC	cis	1	rs6083804	chr20:25317060	ENTPD6	chr20:25176339-25207360:+	0.21	3.87	0.000126	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6083805	chr20:25317356	ENTPD6	chr20:25176339-25207360:+	0.2	3.85	0.000136	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6083809	chr20:25329309	ENTPD6	chr20:25176339-25207360:+	0.2	3.77	0.000186	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6083813	chr20:25337671	ENTPD6	chr20:25176339-25207360:+	0.2	3.9	0.000111	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6083825	chr20:25366424	ENTPD6	chr20:25176339-25207360:+	0.2	3.79	0.000167	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6083828	chr20:25369918	ENTPD6	chr20:25176339-25207360:+	0.2	3.76	0.00019	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6083862	chr20:25411086	FAM182B	chr20:25744102-25848786:-	-0.2	-3.75	0.000197	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs60843830	chr2:286756	SH3YL1	chr2:218138-264810:-	-0.49	-8.27	1.38E-15	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs60844734	chr2:73623205	ALMS1P	chr2:73872046-73912692:+	0.44	7.91	1.83E-14	Metabolite levels	
LUSC	cis	1	rs60844734	chr2:73623205	NAT8	chr2:73867850-73869537:-	0.27	4.49	9.13E-6	Metabolite levels	
LUSC	cis	1	rs6087698	chr20:33948919	CEP250	chr20:34042996-34099802:+	-0.16	-4.21	3.0E-5	Height	
LUSC	cis	1	rs6087698	chr20:33948919	CPNE1	chr20:34213968-34262539:-	0.27	4.78	2.29E-6	Height	
LUSC	cis	1	rs6087698	chr20:33948919	UQCC	chr20:33890383-33999833:-	0.28	5.2	3.03E-7	Height	
LUSC	cis	1	rs6087702	chr20:33995945	CEP250	chr20:34042996-34099802:+	-0.16	-4.19	3.28E-5	Height	
LUSC	cis	1	rs6087702	chr20:33995945	CPNE1	chr20:34213968-34262539:-	0.27	4.64	4.42E-6	Height	
LUSC	cis	1	rs6087702	chr20:33995945	UQCC	chr20:33890383-33999833:-	0.28	5.06	5.98E-7	Height	
LUSC	cis	1	rs6087703	chr20:33996433	CEP250	chr20:34042996-34099802:+	-0.15	-4.01	7.0E-5	Height	
LUSC	cis	1	rs6087703	chr20:33996433	CPNE1	chr20:34213968-34262539:-	0.27	4.66	4.11E-6	Height	
LUSC	cis	1	rs6087703	chr20:33996433	UQCC	chr20:33890383-33999833:-	0.27	4.97	9.59E-7	Height	
LUSC	cis	1	rs6087704	chr20:34001058	CEP250	chr20:34042996-34099802:+	-0.15	-3.96	8.72E-5	Height	
LUSC	cis	1	rs6087704	chr20:34001058	CPNE1	chr20:34213968-34262539:-	0.27	4.73	3.0E-6	Height	
LUSC	cis	1	rs6087704	chr20:34001058	UQCC	chr20:33890383-33999833:-	0.28	5.16	3.63E-7	Height	
LUSC	cis	1	rs6087705	chr20:34001250	CEP250	chr20:34042996-34099802:+	-0.15	-3.85	0.000137	Height	
LUSC	cis	1	rs6087705	chr20:34001250	CPNE1	chr20:34213968-34262539:-	0.28	4.95	1.04E-6	Height	
LUSC	cis	1	rs6087705	chr20:34001250	UQCC	chr20:33890383-33999833:-	0.3	5.5	6.1E-8	Height	
LUSC	cis	1	rs6087771	chr20:30306724	COX4I2	chr20:30225691-30232800:+	0.21	4.33	1.82E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6087779	chr20:30370566	COX4I2	chr20:30225691-30232800:+	0.2	4.11	4.67E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6087782	chr20:30391580	COX4I2	chr20:30225691-30232800:+	0.2	4.1	4.91E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6088799	chr20:33934301	CEP250	chr20:34042996-34099802:+	-0.16	-4.22	2.88E-5	Height	
LUSC	cis	1	rs6088799	chr20:33934301	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.45E-6	Height	
LUSC	cis	1	rs6088799	chr20:33934301	UQCC	chr20:33890383-33999833:-	0.28	5.16	3.61E-7	Height	
LUSC	cis	1	rs6088812	chr20:33974163	CEP250	chr20:34042996-34099802:+	-0.15	-4.04	6.25E-5	Height	
LUSC	cis	1	rs6088812	chr20:33974163	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.45E-6	Height	
LUSC	cis	1	rs6088812	chr20:33974163	UQCC	chr20:33890383-33999833:-	0.28	5.18	3.33E-7	Height	
LUSC	cis	1	rs6088813	chr20:33975181	CEP250	chr20:34042996-34099802:+	-0.15	-4.04	6.25E-5	Height	
LUSC	cis	1	rs6088813	chr20:33975181	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.45E-6	Height	
LUSC	cis	1	rs6088813	chr20:33975181	UQCC	chr20:33890383-33999833:-	0.28	5.18	3.33E-7	Height	
LUSC	cis	1	rs6088815	chr20:33976474	CEP250	chr20:34042996-34099802:+	-0.15	-4.02	6.83E-5	Height	
LUSC	cis	1	rs6088815	chr20:33976474	CPNE1	chr20:34213968-34262539:-	0.27	4.66	4.07E-6	Height	
LUSC	cis	1	rs6088815	chr20:33976474	UQCC	chr20:33890383-33999833:-	0.27	5.03	7.0E-7	Height	
LUSC	cis	1	rs6088816	chr20:33982435	CEP250	chr20:34042996-34099802:+	-0.16	-4.2	3.18E-5	Height	
LUSC	cis	1	rs6088816	chr20:33982435	CPNE1	chr20:34213968-34262539:-	0.27	4.64	4.59E-6	Height	
LUSC	cis	1	rs6088816	chr20:33982435	UQCC	chr20:33890383-33999833:-	0.28	5.03	7.06E-7	Height	
LUSC	cis	1	rs6088820	chr20:33987298	CEP250	chr20:34042996-34099802:+	-0.16	-4.19	3.28E-5	Height	
LUSC	cis	1	rs6088820	chr20:33987298	CPNE1	chr20:34213968-34262539:-	0.27	4.64	4.42E-6	Height	
LUSC	cis	1	rs6088820	chr20:33987298	UQCC	chr20:33890383-33999833:-	0.28	5.06	5.98E-7	Height	
LUSC	cis	1	rs6088821	chr20:33987576	CEP250	chr20:34042996-34099802:+	-0.15	-4.01	7.0E-5	Height	
LUSC	cis	1	rs6088821	chr20:33987576	CPNE1	chr20:34213968-34262539:-	0.27	4.66	4.11E-6	Height	
LUSC	cis	1	rs6088821	chr20:33987576	UQCC	chr20:33890383-33999833:-	0.27	4.97	9.59E-7	Height	
LUSC	cis	1	rs6088823	chr20:33994265	CEP250	chr20:34042996-34099802:+	-0.15	-4.01	7.0E-5	Height	
LUSC	cis	1	rs6088823	chr20:33994265	CPNE1	chr20:34213968-34262539:-	0.27	4.66	4.11E-6	Height	
LUSC	cis	1	rs6088823	chr20:33994265	UQCC	chr20:33890383-33999833:-	0.27	4.97	9.59E-7	Height	
LUSC	cis	1	rs6088825	chr20:33995972	CEP250	chr20:34042996-34099802:+	-0.16	-4.2	3.18E-5	Height	
LUSC	cis	1	rs6088825	chr20:33995972	CPNE1	chr20:34213968-34262539:-	0.27	4.64	4.59E-6	Height	
LUSC	cis	1	rs6088825	chr20:33995972	UQCC	chr20:33890383-33999833:-	0.28	5.03	7.06E-7	Height	
LUSC	cis	1	rs60932020	chr4:75712138	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs60957376	chr15:85280792	LOC388152	chr15:84867600-84898920:-	-0.22	-4.01	7.11E-5	Schizophrenia	
LUSC	cis	1	rs60967688	chr17:28437052	EFCAB5	chr17:28256874-28435469:+	0.3	5.78	1.32E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs60982898	chr6:49385806	CENPQ	chr6:49431096-49460820:+	-0.39	-8.75	3.62E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs60982898	chr6:49385806	MUT	chr6:49398994-49431031:-	0.31	5.43	9.04E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs61032876	chr4:90641403	MMRN1	chr4:90816003-90875778:+	0.25	4.01	7.04E-5	Parkinson's disease	
LUSC	cis	1	rs61037750	chr11:43681372	HSD17B12	chr11:43702143-43878160:+	-0.46	-8.11	4.26E-15	Forced vital capacity	
LUSC	cis	1	rs6107033	chr20:25363591	ENTPD6	chr20:25176339-25207360:+	0.2	3.74	0.000203	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6107045	chr20:25441936	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.76	0.00019	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6107045	chr20:25441936	FAM182A	chr20:26035250-26067552:+	-0.19	-3.76	0.000193	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6107046	chr20:25442049	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.76	0.00019	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6107046	chr20:25442049	FAM182A	chr20:26035250-26067552:+	-0.19	-3.76	0.000193	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6107047	chr20:25442097	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.76	0.00019	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6107047	chr20:25442097	FAM182A	chr20:26035250-26067552:+	-0.19	-3.76	0.000193	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs61102033	chr1:46382441	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.08	5.06E-12	Body mass index	
LUSC	cis	1	rs6115146	chr20:25304507	ENTPD6	chr20:25176339-25207360:+	0.21	3.87	0.000126	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6115153	chr20:25325567	ENTPD6	chr20:25176339-25207360:+	0.2	3.77	0.000186	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6115168	chr20:25372891	ENTPD6	chr20:25176339-25207360:+	0.2	3.79	0.000167	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6115182	chr20:25410259	ENTPD6	chr20:25176339-25207360:+	0.2	3.7	0.000239	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6115191	chr20:25440478	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.76	0.00019	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6115191	chr20:25440478	FAM182A	chr20:26035250-26067552:+	-0.19	-3.76	0.000193	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6119650	chr20:30258480	COX4I2	chr20:30225691-30232800:+	0.2	4.23	2.85E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6119652	chr20:30259445	COX4I2	chr20:30225691-30232800:+	0.2	4.2	3.22E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6120974	chr20:34126827	CPNE1	chr20:34213968-34262539:-	-0.6	-7.68	8.9E-14	Triglycerides	
LUSC	cis	1	rs6121038	chr20:30254773	COX4I2	chr20:30225691-30232800:+	0.21	4.23	2.79E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6121172	chr20:30296095	COX4I2	chr20:30225691-30232800:+	0.21	4.39	1.41E-5	Subcortical brain region volumes	
LUSC	cis	1	rs6121243	chr20:30415094	COX4I2	chr20:30225691-30232800:+	0.2	4.08	5.27E-5	Subcortical brain region volumes	
LUSC	cis	1	rs61280878	chr6:24468741	GPLD1	chr6:24428405-24489850:-	0.45	5.75	1.62E-8	Hematological and biochemical traits	
LUSC	cis	1	rs613089	chr1:147081187	ACP6	chr1:147119168-147142634:-	-0.25	-4.21	3.03E-5	Schizophrenia (negative symptoms)	
LUSC	cis	1	rs6132677	chr20:23840242	CST2	chr20:23804404-23807312:-	-0.35	-5.39	1.1E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs6132678	chr20:23842323	CST2	chr20:23804404-23807312:-	-0.36	-5.41	1.02E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs6132679	chr20:23842400	CST2	chr20:23804404-23807312:-	-0.36	-5.41	1.02E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs6132835	chr20:25434667	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.82	0.000152	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6132835	chr20:25434667	FAM182A	chr20:26035250-26067552:+	-0.2	-3.87	0.000125	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs61360320	chr17:61800392	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.97E-10	Body mass index	
LUSC	cis	1	rs61375994	chr14:93758073	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs6138139	chr20:23827431	CST2	chr20:23804404-23807312:-	-0.35	-5.27	2.12E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs6138148	chr20:23846726	CST2	chr20:23804404-23807312:-	-0.31	-4.87	1.55E-6	Response to TNF antagonist treatment	
LUSC	cis	1	rs6138149	chr20:23846840	CST2	chr20:23804404-23807312:-	-0.31	-4.87	1.55E-6	Response to TNF antagonist treatment	
LUSC	cis	1	rs6138150	chr20:23847009	CST2	chr20:23804404-23807312:-	-0.35	-5.37	1.26E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs6138151	chr20:23847180	CST2	chr20:23804404-23807312:-	-0.36	-5.5	6.14E-8	Response to TNF antagonist treatment	
LUSC	cis	1	rs6138572	chr20:25435934	FAM182A	chr20:26035250-26067552:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6138575	chr20:25438952	FAM182A	chr20:26035250-26067552:+	-0.2	-3.83	0.000143	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs6141546	chr20:33949282	CEP250	chr20:34042996-34099802:+	-0.16	-4.21	3.0E-5	Height	
LUSC	cis	1	rs6141546	chr20:33949282	CPNE1	chr20:34213968-34262539:-	0.27	4.78	2.29E-6	Height	
LUSC	cis	1	rs6141546	chr20:33949282	UQCC	chr20:33890383-33999833:-	0.28	5.2	3.03E-7	Height	
LUSC	cis	1	rs6141548	chr20:33971085	CEP250	chr20:34042996-34099802:+	-0.16	-4.07	5.55E-5	Height	
LUSC	cis	1	rs6141548	chr20:33971085	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.41E-6	Height	
LUSC	cis	1	rs6141548	chr20:33971085	UQCC	chr20:33890383-33999833:-	0.28	5.18	3.26E-7	Height	
LUSC	cis	1	rs6141549	chr20:33974051	CEP250	chr20:34042996-34099802:+	-0.15	-4.04	6.25E-5	Height	
LUSC	cis	1	rs6141549	chr20:33974051	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.45E-6	Height	
LUSC	cis	1	rs6141549	chr20:33974051	UQCC	chr20:33890383-33999833:-	0.28	5.18	3.33E-7	Height	
LUSC	cis	1	rs61422480	chr8:124188940	FAM83A	chr8:124191287-124222317:+	-0.27	-4.43	1.19E-5	Urinary uromodulin levels	
LUSC	cis	1	rs6142358	chr20:33960308	CEP250	chr20:34042996-34099802:+	0.16	4.24	2.73E-5	Height	
LUSC	cis	1	rs6142358	chr20:33960308	CPNE1	chr20:34213968-34262539:-	-0.28	-4.92	1.17E-6	Height	
LUSC	cis	1	rs6142358	chr20:33960308	UQCC	chr20:33890383-33999833:-	-0.28	-4.99	8.43E-7	Height	
LUSC	cis	1	rs6142359	chr20:33960450	CEP250	chr20:34042996-34099802:+	-0.16	-4.21	3.0E-5	Height	
LUSC	cis	1	rs6142359	chr20:33960450	CPNE1	chr20:34213968-34262539:-	0.27	4.78	2.29E-6	Height	
LUSC	cis	1	rs6142359	chr20:33960450	UQCC	chr20:33890383-33999833:-	0.28	5.2	3.03E-7	Height	
LUSC	cis	1	rs6142360	chr20:33960486	CEP250	chr20:34042996-34099802:+	-0.15	-4	7.24E-5	Height	
LUSC	cis	1	rs6142360	chr20:33960486	CPNE1	chr20:34213968-34262539:-	0.29	5.1	4.81E-7	Height	
LUSC	cis	1	rs6142360	chr20:33960486	UQCC	chr20:33890383-33999833:-	0.28	5.05	6.16E-7	Height	
LUSC	cis	1	rs6142369	chr20:33973315	CEP250	chr20:34042996-34099802:+	-0.15	-3.85	0.000132	Height	
LUSC	cis	1	rs6142369	chr20:33973315	CPNE1	chr20:34213968-34262539:-	0.27	4.81	2.07E-6	Height	
LUSC	cis	1	rs6142369	chr20:33973315	UQCC	chr20:33890383-33999833:-	0.28	5.14	4.01E-7	Height	
LUSC	cis	1	rs6142370	chr20:33973378	CEP250	chr20:34042996-34099802:+	-0.15	-4.04	6.25E-5	Height	
LUSC	cis	1	rs6142370	chr20:33973378	CPNE1	chr20:34213968-34262539:-	0.27	4.77	2.45E-6	Height	
LUSC	cis	1	rs6142370	chr20:33973378	UQCC	chr20:33890383-33999833:-	0.28	5.18	3.33E-7	Height	
LUSC	cis	1	rs6142373	chr20:33983314	CEP250	chr20:34042996-34099802:+	-0.16	-4.19	3.28E-5	Height	
LUSC	cis	1	rs6142373	chr20:33983314	CPNE1	chr20:34213968-34262539:-	0.27	4.64	4.42E-6	Height	
LUSC	cis	1	rs6142373	chr20:33983314	UQCC	chr20:33890383-33999833:-	0.28	5.06	5.98E-7	Height	
LUSC	cis	1	rs6142374	chr20:33985568	CEP250	chr20:34042996-34099802:+	-0.15	-4.01	7.0E-5	Height	
LUSC	cis	1	rs6142374	chr20:33985568	CPNE1	chr20:34213968-34262539:-	0.27	4.66	4.11E-6	Height	
LUSC	cis	1	rs6142374	chr20:33985568	UQCC	chr20:33890383-33999833:-	0.27	4.97	9.59E-7	Height	
LUSC	cis	1	rs6142376	chr20:33992761	CEP250	chr20:34042996-34099802:+	-0.16	-4.2	3.18E-5	Height	
LUSC	cis	1	rs6142376	chr20:33992761	CPNE1	chr20:34213968-34262539:-	0.27	4.64	4.59E-6	Height	
LUSC	cis	1	rs6142376	chr20:33992761	UQCC	chr20:33890383-33999833:-	0.28	5.03	7.06E-7	Height	
LUSC	cis	1	rs6142379	chr20:33999267	CEP250	chr20:34042996-34099802:+	-0.15	-3.96	8.72E-5	Height	
LUSC	cis	1	rs6142379	chr20:33999267	CPNE1	chr20:34213968-34262539:-	0.27	4.73	3.0E-6	Height	
LUSC	cis	1	rs6142379	chr20:33999267	UQCC	chr20:33890383-33999833:-	0.28	5.16	3.63E-7	Height	
LUSC	cis	1	rs6151429	chr22:51063477	ARSA	chr22:51063450-51066607:-	-0.9	-12.24	4.07E-30	Blood metabolite levels	
LUSC	cis	1	rs615199	chr6:117113653	GPRC6A	chr6:117113248-117150198:-	-0.22	-4.08	5.23E-5	C-reactive protein levels	
LUSC	cis	1	rs61524473	chr15:45646283	GATM	chr15:45653324-45670980:-	-0.3	-5.26	2.23E-7	Metabolite levels (small molecules and protein measures)	
LUSC	cis	1	rs617219	chr5:78429594	BHMT	chr5:78407604-78428112:+	-0.23	-4.02	6.75E-5	Betaine levels in individuals undergoing cardiac evaluation	
LUSC	cis	1	rs61776516	chr1:12047028	C1orf187	chr1:11751781-11780336:+	0.19	4.05	5.98E-5	Platelet count	
LUSC	cis	1	rs617819	chr11:102714716	MMP12	chr11:102733465-102745712:-	-0.17	-3.76	0.000194	Cerebrospinal fluid levels of Alzheimer's disease-related proteins	
LUSC	cis	1	rs61783200	chr1:46297403	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.1	4.66E-12	Body mass index	
LUSC	cis	1	rs61783220	chr1:46335312	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.15	3.31E-12	Body mass index	
LUSC	cis	1	rs61806205	chr1:119482315	WARS2	chr1:119573841-119683295:-	0.29	3.93	9.94E-5	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs61818802	chr1:113181739	ST7L	chr1:113066142-113162405:-	0.25	4.03	6.48E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs61819219	chr1:151084375	HORMAD1	chr1:150670542-150693352:-	0.3	4.7	3.42E-6	Body mass index	
LUSC	cis	1	rs61820166	chr1:150556036	HORMAD1	chr1:150670542-150693352:-	-0.42	-4.5	8.65E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs61820166	chr1:150556036	MRPS21	chr1:150266269-150280818:+	0.3	3.7	0.000238	Congenital left-sided heart lesions	
LUSC	cis	1	rs61824933	chr1:228992953	WNT3A	chr1:228194752-228248961:+	0.22	3.97	8.25E-5	Basal cell carcinoma	
LUSC	cis	1	rs61826828	chr1:174015261	SERPINC1	chr1:173872943-173886516:-	0.32	4.7	3.49E-6	Schizophrenia	
LUSC	cis	1	rs61852630	chr1:247210193	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.73E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs61852637	chr1:247219636	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs61871790	chr10:97391223	ENTPD1	chr10:97471536-97637022:+	0.17	5.16	3.65E-7	Blood metabolite levels	
LUSC	cis	1	rs61871792	chr10:97397586	ENTPD1	chr10:97471536-97637022:+	0.18	5.32	1.63E-7	Blood metabolite levels	
LUSC	cis	1	rs61871793	chr10:97407738	ENTPD1	chr10:97471536-97637022:+	0.19	5.54	5.05E-8	Blood metabolite levels	
LUSC	cis	1	rs61886892	chr11:18738575	SERGEF	chr11:17809599-18034637:-	0.25	3.89	0.000114	Diabetic kidney disease	
LUSC	cis	1	rs61897843	chr11:47187549	MADD	chr11:47290927-47351582:+	0.49	5.63	3.03E-8	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs61897851	chr11:47201981	MADD	chr11:47290927-47351582:+	0.45	5.31	1.7E-7	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs61897852	chr11:47203155	MADD	chr11:47290927-47351582:+	0.45	5.32	1.57E-7	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs61897853	chr11:47217906	MADD	chr11:47290927-47351582:+	0.45	5.37	1.25E-7	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs61897855	chr11:47231040	MADD	chr11:47290927-47351582:+	0.46	5.42	9.35E-8	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs61897858	chr11:47235263	MADD	chr11:47290927-47351582:+	0.46	5.53	5.18E-8	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs61995780	chr14:104120612	C14orf153	chr14:104029299-104057227:+	0.15	3.85	0.000137	Body mass index	
LUSC	cis	1	rs62019464	chr15:85294469	LOC388152	chr15:84867600-84898920:-	-0.23	-4.23	2.85E-5	Schizophrenia	
LUSC	cis	1	rs62019469	chr15:85321220	LOC388152	chr15:84867600-84898920:-	-0.23	-4.24	2.71E-5	Schizophrenia	
LUSC	cis	1	rs62021219	chr15:85256159	LOC388152	chr15:84867600-84898920:-	-0.24	-4.3	2.04E-5	Schizophrenia	
LUSC	cis	1	rs62026530	chr15:84775840	LOC388152	chr15:84867600-84898920:-	-0.27	-4.81	2.07E-6	Schizophrenia	
LUSC	cis	1	rs62070270	chr17:28263980	EFCAB5	chr17:28256874-28435469:+	0.32	5.95	5.24E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs62070312	chr17:28438877	EFCAB5	chr17:28256874-28435469:+	0.32	6.1	2.25E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs62084213	chr17:65842016	LOC440461	chr17:66194801-66196436:+	0.26	4	7.48E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62084214	chr17:65843325	LOC440461	chr17:66194801-66196436:+	0.26	4	7.48E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62084238	chr17:65856573	LOC440461	chr17:66194801-66196436:+	0.26	3.97	8.19E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62084240	chr17:65859233	LOC440461	chr17:66194801-66196436:+	0.25	3.88	0.00012	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62084246	chr17:65867911	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62084248	chr17:65874541	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62084249	chr17:65874998	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62084251	chr17:65878736	LOC440461	chr17:66194801-66196436:+	0.25	3.9	0.00011	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs62104262	chr19:9996578	ZNF266	chr19:9523272-9546234:-	0.21	3.99	7.63E-5	Menarche (age at onset)	
LUSC	cis	1	rs62112907	chr19:22209569	ZNF100	chr19:21906844-21950430:-	-0.29	-4.19	3.38E-5	Body mass index (change over time)	
LUSC	cis	1	rs62112907	chr19:22209569	ZNF43	chr19:21987753-22034830:-	-0.27	-3.94	9.22E-5	Body mass index (change over time)	
LUSC	cis	1	rs62112917	chr19:22226580	ZNF100	chr19:21906844-21950430:-	-0.3	-4.13	4.29E-5	Body mass index (change over time)	
LUSC	cis	1	rs62112917	chr19:22226580	ZNF43	chr19:21987753-22034830:-	-0.3	-4.16	3.77E-5	Body mass index (change over time)	
LUSC	cis	1	rs62114497	chr2:214837	SH3YL1	chr2:218138-264810:-	-0.48	-8.59	1.26E-16	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs62114501	chr2:231741	SH3YL1	chr2:218138-264810:-	-0.5	-8.79	2.86E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs62114505	chr2:242426	SH3YL1	chr2:218138-264810:-	-0.52	-9.22	9.68E-19	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs62114544	chr2:269679	SH3YL1	chr2:218138-264810:-	-0.51	-9.03	4.25E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs62114548	chr2:274672	SH3YL1	chr2:218138-264810:-	-0.5	-8.73	4.3E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs62114762	chr19:24233868	LOC100101266	chr19:24344995-24346249:-	0.29	3.74	0.000204	Response to taxane treatment (placlitaxel)	
LUSC	cis	1	rs62121818	chr19:39167760	LGALS7B	chr19:39279850-39282393:+	0.2	4.27	2.4E-5	Heart rate	
LUSC	cis	1	rs62136099	chr19:46847901	AP2S1	chr19:47341423-47354203:-	-0.19	-3.75	0.0002	Crohn's disease;Inflammatory bowel disease	
LUSC	cis	1	rs62136864	chr2:46829124	ATP6V1E2	chr2:46738988-46769696:-	-0.25	-4.21	3.0E-5	Height	
LUSC	cis	1	rs62151652	chr2:73700131	ALMS1P	chr2:73872046-73912692:+	0.39	7.37	7.88E-13	Metabolite levels	
LUSC	cis	1	rs62151652	chr2:73700131	NAT8	chr2:73867850-73869537:-	0.26	4.54	7.24E-6	Metabolite levels	
LUSC	cis	1	rs62211529	chr20:33959315	CEP250	chr20:34042996-34099802:+	-0.15	-4.03	6.55E-5	Height	
LUSC	cis	1	rs62211529	chr20:33959315	CPNE1	chr20:34213968-34262539:-	0.27	4.82	1.94E-6	Height	
LUSC	cis	1	rs62211529	chr20:33959315	UQCC	chr20:33890383-33999833:-	0.28	5.16	3.65E-7	Height	
LUSC	cis	1	rs62259933	chr3:49469703	AMT	chr3:49454212-49460012:-	-0.21	-4.87	1.51E-6	Menarche (age at onset)	
LUSC	cis	1	rs62259933	chr3:49469703	TREX1	chr3:48501186-48509043:+	0.23	4.31	1.99E-5	Menarche (age at onset)	
LUSC	cis	1	rs62259944	chr3:49430883	AMT	chr3:49454212-49460012:-	-0.18	-4.1	4.76E-5	Menarche (age at onset)	
LUSC	cis	1	rs62259944	chr3:49430883	KLHDC8B	chr3:49209068-49213918:+	0.23	3.7	0.000237	Menarche (age at onset)	
LUSC	cis	1	rs62259947	chr3:49439924	AMT	chr3:49454212-49460012:-	-0.19	-4.5	8.44E-6	Menarche (age at onset)	
LUSC	cis	1	rs62261249	chr3:49594060	AMT	chr3:49454212-49460012:-	-0.18	-3.96	8.73E-5	Menarche (age at onset)	
LUSC	cis	1	rs62268732	chr3:121370455	IQCB1	chr3:121488610-121553926:-	0.22	4.5	8.5E-6	Cognitive performance	
LUSC	cis	1	rs62269547	chr3:134214042	ANAPC13	chr3:134196547-134204865:-	0.42	8.6	1.16E-16	Height	
LUSC	cis	1	rs62271513	chr3:134298412	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.11	4.26E-15	Height	
LUSC	cis	1	rs62271514	chr3:134298554	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.15	3.18E-15	Height	
LUSC	cis	1	rs62271515	chr3:134300507	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs62321365	chr4:107013723	TBCK	chr4:106967233-107237861:-	0.28	5.24	2.43E-7	Airflow obstruction	
LUSC	cis	1	rs62325083	chr4:154661775	TLR2	chr4:154605441-154627240:+	-0.19	-3.93	9.76E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs62325085	chr4:154663283	TLR2	chr4:154605441-154627240:+	-0.19	-3.93	9.76E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs62325092	chr4:154668674	TLR2	chr4:154605441-154627240:+	-0.21	-4.16	3.83E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs62325093	chr4:154669733	TLR2	chr4:154605441-154627240:+	-0.21	-4.09	5.12E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs62325105	chr4:154673846	TLR2	chr4:154605441-154627240:+	-0.2	-3.96	8.55E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs62402013	chr6:26915000	BTN3A2	chr6:26365398-26378546:+	0.21	4.38	1.47E-5	Schizophrenia	
LUSC	cis	1	rs62402013	chr6:26915000	C6orf41	chr6:26924772-26991752:+	-0.16	-3.82	0.000149	Schizophrenia	
LUSC	cis	1	rs62422220	chr6:118923731	C6orf204	chr6:118786239-119031238:-	-0.23	-3.7	0.000244	Renal cell carcinoma	
LUSC	cis	1	rs62422224	chr6:118941116	C6orf204	chr6:118786239-119031238:-	-0.24	-3.71	0.000231	Renal cell carcinoma	
LUSC	cis	1	rs62422227	chr6:118957200	C6orf204	chr6:118786239-119031238:-	-0.23	-3.7	0.000245	Renal cell carcinoma	
LUSC	cis	1	rs62422228	chr6:118957276	C6orf204	chr6:118786239-119031238:-	-0.23	-3.7	0.000238	Renal cell carcinoma	
LUSC	cis	1	rs62422229	chr6:118959288	C6orf204	chr6:118786239-119031238:-	-0.23	-3.7	0.000245	Renal cell carcinoma	
LUSC	cis	1	rs62422235	chr6:118971913	C6orf204	chr6:118786239-119031238:-	-0.25	-3.88	0.00012	Renal cell carcinoma	
LUSC	cis	1	rs62422236	chr6:118972633	C6orf204	chr6:118786239-119031238:-	-0.25	-3.88	0.00012	Renal cell carcinoma	
LUSC	cis	1	rs62424198	chr6:118827247	C6orf204	chr6:118786239-119031238:-	-0.23	-3.71	0.000228	Renal cell carcinoma	
LUSC	cis	1	rs62424199	chr6:118827252	C6orf204	chr6:118786239-119031238:-	-0.24	-3.84	0.000138	Renal cell carcinoma	
LUSC	cis	1	rs62466793	chr7:66191517	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.39	1.13E-7	Aortic root size	
LUSC	cis	1	rs62466794	chr7:66191579	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.39	1.13E-7	Aortic root size	
LUSC	cis	1	rs62479588	chr7:128405521	OPN1SW	chr7:128412545-128415844:-	0.27	4.66	4.02E-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth)	
LUSC	cis	1	rs62521826	chr8:124186668	FAM83A	chr8:124191287-124222317:+	-0.24	-3.73	0.000213	Urinary uromodulin levels	
LUSC	cis	1	rs62625008	chr1:95702582	RWDD3	chr1:95583479-95712773:+	0.41	4.48	9.54E-6	Stearic acid (18:0) plasma levels	
LUSC	cis	1	rs62663261	chr6:118900553	C6orf204	chr6:118786239-119031238:-	-0.24	-3.73	0.000214	Renal cell carcinoma	
LUSC	cis	1	rs641018	chr11:65655393	CTSW	chr11:65647284-65651212:+	-0.6	-16.2	2.71E-47	Crohn's disease	
LUSC	cis	1	rs641018	chr11:65655393	SNX32	chr11:65601410-65621170:+	0.56	9.17	1.45E-18	Crohn's disease	
LUSC	cis	1	rs641862	chr13:110790232	ANKRD10	chr13:111530888-111567416:-	0.4	4.77	2.46E-6	Obesity-related traits	
LUSC	cis	1	rs641862	chr13:110790232	ARHGEF7	chr13:111767624-111958080:+	0.51	5.19	3.05E-7	Obesity-related traits	
LUSC	cis	1	rs641862	chr13:110790232	CARKD	chr13:111267881-111292340:+	0.49	4.64	4.55E-6	Obesity-related traits	
LUSC	cis	1	rs641862	chr13:110790232	ING1	chr13:111365083-111373420:+	0.62	5.62	3.31E-8	Obesity-related traits	
LUSC	cis	1	rs641862	chr13:110790232	RAB20	chr13:111175414-111214071:-	0.33	4.19	3.32E-5	Obesity-related traits	
LUSC	cis	1	rs6422512	chr1:93024844	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs6429567	chr1:45956700	CCDC163P	chr1:45960581-45965646:-	-0.76	-18.15	2.73E-56	Homocysteine levels	
LUSC	cis	1	rs6429567	chr1:45956700	MMACHC	chr1:45965856-45976737:+	-0.15	-4	7.21E-5	Homocysteine levels	
LUSC	cis	1	rs6429569	chr1:46001330	CCDC163P	chr1:45960581-45965646:-	-0.71	-17.17	9.47E-52	Homocysteine levels	
LUSC	cis	1	rs6429582	chr1:46321843	CCDC163P	chr1:45960581-45965646:-	0.34	7.29	1.29E-12	Body mass index	
LUSC	cis	1	rs6435079	chr2:202200331	ALS2CR12	chr2:202153148-202222101:-	-0.22	-4.15	4.01E-5	Basal cell carcinoma	
LUSC	cis	1	rs6435081	chr2:202220623	ALS2CR12	chr2:202153148-202222101:-	-0.21	-3.97	8.2E-5	Basal cell carcinoma	
LUSC	cis	1	rs6439379	chr3:132736063	TMEM108	chr3:132757171-133116618:+	0.2	4.74	2.84E-6	IgE grass sensitization	
LUSC	cis	1	rs6439381	chr3:132736382	TMEM108	chr3:132757171-133116618:+	0.22	5.31	1.73E-7	IgE grass sensitization	
LUSC	cis	1	rs6439484	chr3:134249899	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs6439487	chr3:134260860	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs6439649	chr3:136371691	PCCB	chr3:135969167-136056737:+	-0.2	-4.25	2.63E-5	Schizophrenia	
LUSC	cis	1	rs6442117	chr3:48419897	ATRIP	chr3:48488141-48507708:+	-0.19	-3.82	0.000152	Longevity	
LUSC	cis	1	rs6442117	chr3:48419897	TREX1	chr3:48501186-48509043:+	0.44	9.7	2.04E-20	Longevity	
LUSC	cis	1	rs6442118	chr3:48440047	TREX1	chr3:48501186-48509043:+	-0.44	-9.73	1.56E-20	Longevity	
LUSC	cis	1	rs6442119	chr3:48440178	ATRIP	chr3:48488141-48507708:+	0.2	4.03	6.55E-5	Longevity	
LUSC	cis	1	rs6442119	chr3:48440178	TREX1	chr3:48501186-48509043:+	-0.4	-8.85	1.77E-17	Longevity	
LUSC	cis	1	rs6442120	chr3:48464503	ATRIP	chr3:48488141-48507708:+	0.19	3.83	0.000143	Longevity	
LUSC	cis	1	rs6442120	chr3:48464503	TREX1	chr3:48501186-48509043:+	-0.42	-9.17	1.48E-18	Longevity	
LUSC	cis	1	rs6442123	chr3:48500286	ATRIP	chr3:48488141-48507708:+	0.21	4.2	3.15E-5	Longevity	
LUSC	cis	1	rs6442123	chr3:48500286	TREX1	chr3:48501186-48509043:+	-0.39	-8.5	2.43E-16	Longevity	
LUSC	cis	1	rs6446262	chr3:49401153	AMT	chr3:49454212-49460012:-	0.19	4.5	8.44E-6	Menarche (age at onset)	
LUSC	cis	1	rs6446268	chr3:49445695	AMT	chr3:49454212-49460012:-	-0.2	-4.82	1.94E-6	Menarche (age at onset)	
LUSC	cis	1	rs6446275	chr3:49466871	AMT	chr3:49454212-49460012:-	-0.21	-4.91	1.27E-6	Menarche (age at onset)	
LUSC	cis	1	rs6446275	chr3:49466871	TREX1	chr3:48501186-48509043:+	0.23	4.32	1.93E-5	Menarche (age at onset)	
LUSC	cis	1	rs6450408	chr5:56098146	C5orf35	chr5:56205103-56213010:+	0.86	14.3	7.68E-39	Type 2 diabetes	
LUSC	cis	1	rs6450409	chr5:56101399	C5orf35	chr5:56205103-56213010:+	0.85	14.83	3.52E-41	Type 2 diabetes	
LUSC	cis	1	rs6453429	chr5:78371861	BHMT	chr5:78407604-78428112:+	0.35	4.77	2.42E-6	Urinary metabolites	
LUSC	cis	1	rs6454513	chr6:86720049	SNHG5	chr6:86386726-86388451:-	0.67	12.75	3.02E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs6456617	chr6:24480769	GPLD1	chr6:24428405-24489850:-	0.42	5.22	2.67E-7	Hematological and biochemical traits	
LUSC	cis	1	rs6458685	chr6:49379536	CENPQ	chr6:49431096-49460820:+	-0.38	-8.7	5.55E-17	Homocysteine levels	
LUSC	cis	1	rs6458688	chr6:49406056	CENPQ	chr6:49431096-49460820:+	-0.38	-8.71	5.11E-17	Homocysteine levels	
LUSC	cis	1	rs6458688	chr6:49406056	MUT	chr6:49398994-49431031:-	0.21	3.75	0.000196	Homocysteine levels	
LUSC	cis	1	rs6458690	chr6:49411619	CENPQ	chr6:49431096-49460820:+	-0.38	-8.5	2.42E-16	Folate pathway vitamin levels	
LUSC	cis	1	rs6458690	chr6:49411619	MUT	chr6:49398994-49431031:-	0.32	5.64	2.99E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs6458694	chr6:49445306	CENPQ	chr6:49431096-49460820:+	-0.41	-9.04	3.88E-18	Folate pathway vitamin levels	
LUSC	cis	1	rs6458694	chr6:49445306	MUT	chr6:49398994-49431031:-	0.29	5.13	4.19E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs6460292	chr7:65810075	NCRNA00174	chr7:65841032-65865395:-	0.29	6.11	2.13E-9	Aortic root size	
LUSC	cis	1	rs6460295	chr7:65882728	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs6460296	chr7:65895139	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.16E-9	Aortic root size	
LUSC	cis	1	rs6464573	chr7:143748098	ARHGEF35	chr7:143883677-143892736:-	0.35	7.34	9.44E-13	Obesity-related traits	
LUSC	cis	1	rs6464573	chr7:143748098	OR2A9P	chr7:143991573-143997832:+;chr7	0.23	4.37	1.56E-5	Obesity-related traits	
LUSC	cis	1	rs6464574	chr7:143748257	ARHGEF35	chr7:143883677-143892736:-	-0.39	-8.04	7.3E-15	Obesity-related traits	
LUSC	cis	1	rs6464574	chr7:143748257	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.54	7.16E-6	Obesity-related traits	
LUSC	cis	1	rs6468131	chr8:29981020	MBOAT4	chr8:29989188-30002200:-	-0.31	-4.04	6.34E-5	Migraine	
LUSC	cis	1	rs646867	chr1:25709258	RHCE	chr1:25688741-25756683:-	0.33	6.27	8.29E-10	Erythrocyte sedimentation rate	
LUSC	cis	1	rs646867	chr1:25709258	RHD	chr1:25598981-25656935:+	-0.56	-10.52	2.02E-23	Erythrocyte sedimentation rate	
LUSC	cis	1	rs646867	chr1:25709258	TMEM50A	chr1:25664811-25688850:+	0.16	3.77	0.000182	Erythrocyte sedimentation rate	
LUSC	cis	1	rs6470765	chr8:130736697	GSDMC	chr8:130760443-130799134:-	0.26	5.25	2.34E-7	Infant length;Height	
LUSC	cis	1	rs6478484	chr9:123652380	LOC253039	chr9:123605320-123616644:+	-0.32	-6.07	2.59E-9	Rheumatoid arthritis	
LUSC	cis	1	rs6478486	chr9:123655329	LOC253039	chr9:123605320-123616644:+	-0.32	-6.11	2.12E-9	Rheumatoid arthritis	
LUSC	cis	1	rs6478867	chr9:131903923	CRAT	chr9:131857075-131873070:-	-0.24	-4.68	3.74E-6	Blood metabolite ratios	
LUSC	cis	1	rs6480314	chr10:69967447	PBLD	chr10:70042417-70092684:-	-0.31	-5.21	2.82E-7	Optic nerve measurement (disc area)	
LUSC	cis	1	rs6485438	chr11:43686618	HSD17B12	chr11:43702143-43878160:+	-0.46	-8.3	1.06E-15	Forced vital capacity	
LUSC	cis	1	rs6485443	chr11:43696316	HSD17B12	chr11:43702143-43878160:+	0.48	8.87	1.44E-17	Forced vital capacity	
LUSC	cis	1	rs6485872	chr11:48579710	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.73	0.000218	HDL cholesterol	
LUSC	cis	1	rs6485875	chr11:48581034	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.72	0.00022	HDL cholesterol	
LUSC	cis	1	rs6487679	chr12:9371332	PZP	chr12:9301437-9360966:-	0.25	4.21	3.11E-5	Non-alcoholic fatty liver disease histology (AST)	
LUSC	cis	1	rs6490605	chr13:21285009	IFT88	chr13:21141208-21265574:+	0.18	3.72	0.000221	Dental caries	
LUSC	cis	1	rs6503530	chr17:38161823	GSDMA	chr17:38119226-38134019:+	-0.44	-8.9	1.16E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs6503877	chr17:56841948	RAD51C	chr17:56769963-56811690:+	0.29	6.17	1.5E-9	Cognitive test performance	
LUSC	cis	1	rs6503882	chr17:56915761	RAD51C	chr17:56769963-56811690:+	0.3	6.35	5.17E-10	Cognitive test performance	
LUSC	cis	1	rs6504168	chr17:61697469	FTSJ3	chr17:61896795-61905031:-	0.33	6.48	2.26E-10	Body mass index	
LUSC	cis	1	rs6504169	chr17:61709145	FTSJ3	chr17:61896795-61905031:-	0.33	6.42	3.41E-10	Body mass index	
LUSC	cis	1	rs6504169	chr17:61709145	TCAM1P	chr17:61934376-61941738:+	-0.22	-3.73	0.000211	Body mass index	
LUSC	cis	1	rs6504170	chr17:61709168	FTSJ3	chr17:61896795-61905031:-	0.32	6.25	9.24E-10	Body mass index	
LUSC	cis	1	rs6504171	chr17:61710010	FTSJ3	chr17:61896795-61905031:-	0.33	6.45	2.73E-10	Body mass index	
LUSC	cis	1	rs6504173	chr17:61735056	FTSJ3	chr17:61896795-61905031:-	0.33	6.45	2.82E-10	Body mass index	
LUSC	cis	1	rs6504182	chr17:61823672	FTSJ3	chr17:61896795-61905031:-	0.34	6.74	4.47E-11	Body mass index	
LUSC	cis	1	rs6504542	chr17:65836642	LOC440461	chr17:66194801-66196436:+	0.25	3.93	9.78E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs6505152	chr17:28331466	EFCAB5	chr17:28256874-28435469:+	-0.3	-5.74	1.66E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs6505158	chr17:28403348	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.87	8.2E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs6508710	chr19:37749886	ZNF781	chr19:38158650-38183216:-	0.26	4.07	5.43E-5	Coronary artery calcification	
LUSC	cis	1	rs6511313	chr19:22215905	ZNF100	chr19:21906844-21950430:-	-0.25	-3.7	0.00024	Body mass index (change over time)	
LUSC	cis	1	rs6532078	chr4:76920809	NAAA	chr4:76831809-76862166:-	-0.24	-5.12	4.43E-7	Longevity	
LUSC	cis	1	rs6539029	chr12:102640056	CHPT1	chr12:102091417-102123424:+	-0.3	-4.48	9.38E-6	Height	
LUSC	cis	1	rs6545883	chr2:61772257	AHSA2	chr2:61404553-61414058:+	-0.14	-4.83	1.83E-6	Tuberculosis	
LUSC	cis	1	rs6545883	chr2:61772257	C2orf74	chr2:61372243-61391964:+	0.5	8.97	6.94E-18	Tuberculosis	
LUSC	cis	1	rs6547872	chr2:28978074	TRMT61B	chr2:29072690-29093175:-	-0.25	-5.19	3.05E-7	Body mass index	
LUSC	cis	1	rs6563380	chr13:36770422	SOHLH2	chr13:36742347-36871992:-	0.24	4.24	2.66E-5	Glucose homeostasis traits	
LUSC	cis	1	rs656980	chr11:65656282	CTSW	chr11:65647284-65651212:+	-0.6	-16.2	2.71E-47	Crohn's disease	
LUSC	cis	1	rs656980	chr11:65656282	SNX32	chr11:65601410-65621170:+	0.56	9.17	1.45E-18	Crohn's disease	
LUSC	cis	1	rs6570043	chr6:136134098	PDE7B	chr6:136172834-136516708:+	0.27	5.35	1.37E-7	Phosphorus levels	
LUSC	cis	1	rs6579208	chr20:33598612	PROCR	chr20:33758727-33765164:+	-0.31	-4.21	3.06E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs6579210	chr20:33605802	PROCR	chr20:33758727-33765164:+	-0.32	-4.22	2.87E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs6579211	chr20:33605857	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.46E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs6579234	chr20:33983485	CEP250	chr20:34042996-34099802:+	-0.16	-4.19	3.28E-5	Height	
LUSC	cis	1	rs6579234	chr20:33983485	CPNE1	chr20:34213968-34262539:-	0.27	4.64	4.42E-6	Height	
LUSC	cis	1	rs6579234	chr20:33983485	UQCC	chr20:33890383-33999833:-	0.28	5.06	5.98E-7	Height	
LUSC	cis	1	rs6579245	chr20:34125271	CPNE1	chr20:34213968-34262539:-	-0.6	-7.69	8.39E-14	Cholesterol, total	
LUSC	cis	1	rs6581155	chr12:58178162	FAM119B	chr12:58166383-58176323:+	0.53	9.45	1.55E-19	Multiple sclerosis	
LUSC	cis	1	rs6581155	chr12:58178162	TSFM	chr12:58176536-58191367:+	-0.37	-8.19	2.5E-15	Multiple sclerosis	
LUSC	cis	1	rs6581155	chr12:58178162	XRCC6BP1	chr12:58335445-58351051:+	-0.19	-3.95	9.05E-5	Multiple sclerosis	
LUSC	cis	1	rs6584379	chr10:102224490	SEC31B	chr10:102246403-102289636:-	-0.27	-7.99	1.03E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs6584383	chr10:102303065	SEC31B	chr10:102246403-102289636:-	-0.27	-7.95	1.39E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs6589576	chr11:116735788	PCSK7	chr11:117075789-117102811:-	0.31	4.4	1.33E-5	Protein quantitative trait loci	
LUSC	cis	1	rs6589589	chr11:116932428	PCSK7	chr11:117075789-117102811:-	-0.36	-5.07	5.79E-7	Protein quantitative trait loci	
LUSC	cis	1	rs6593585	chr1:76140273	ACADM	chr1:76190043-76229353:+	0.22	4	7.23E-5	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs6593	chr14:104163282	CKB	chr14:103985996-103989170:-	0.2	3.98	7.88E-5	Body mass index	
LUSC	cis	1	rs6599176	chr3:41788492	ULK4	chr3:41288091-42003660:-	-0.66	-9.92	3.42E-21	Diastolic blood pressure	
LUSC	cis	1	rs6603033	chr15:83335875	LOC80154	chr15:82944795-82975797:+;chr15	-0.24	-4.78	2.39E-6	Schizophrenia	
LUSC	cis	1	rs6603975	chr1:92951239	EVI5	chr1:92974255-93257961:-	-0.3	-4.22	2.98E-5	Cholesterol, total	
LUSC	cis	1	rs6603979	chr1:92979354	EVI5	chr1:92974255-93257961:-	-0.31	-4.53	7.51E-6	Cholesterol, total	
LUSC	cis	1	rs6603981	chr1:92993807	EVI5	chr1:92974255-93257961:-	-0.31	-4.57	6.31E-6	Cholesterol, total	
LUSC	cis	1	rs6603982	chr1:92994033	EVI5	chr1:92974255-93257961:-	-0.31	-4.57	6.31E-6	Cholesterol, total	
LUSC	cis	1	rs6603984	chr1:93011572	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs6603985	chr1:93017159	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs6603987	chr1:93019313	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs6603990	chr1:93030735	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs66462353	chr15:56186767	NEDD4	chr15:56119131-56285835:-	0.25	4.58	6.02E-6	Keloid	
LUSC	cis	1	rs6651255	chr8:130723792	GSDMC	chr8:130760443-130799134:-	-0.23	-4.37	1.51E-5	Infant length;Height	
LUSC	cis	1	rs6651271	chr8:96047621	C8orf38	chr8:95908040-96088396:+	-0.26	-3.71	0.000228	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LUSC	cis	1	rs6651272	chr8:96047933	C8orf38	chr8:95908040-96088396:+	0.26	3.76	0.000189	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LUSC	cis	1	rs6656432	chr1:93029453	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs6656450	chr1:151089602	HORMAD1	chr1:150670542-150693352:-	0.31	4.84	1.74E-6	Body mass index	
LUSC	cis	1	rs6656992	chr1:46333068	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.15	3.31E-12	Body mass index	
LUSC	cis	1	rs6661134	chr1:93010908	EVI5	chr1:92974255-93257961:-	-0.32	-4.58	5.99E-6	Cholesterol, total	
LUSC	cis	1	rs6661910	chr1:46290632	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.79	3.39E-11	Body mass index	
LUSC	cis	1	rs6662641	chr1:46571509	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.27	1.51E-12	Body mass index	
LUSC	cis	1	rs6667191	chr1:45982844	CCDC163P	chr1:45960581-45965646:-	-0.76	-18.3	5.01E-57	Homocysteine levels	
LUSC	cis	1	rs6667191	chr1:45982844	MMACHC	chr1:45965856-45976737:+	-0.15	-3.97	8.4E-5	Homocysteine levels	
LUSC	cis	1	rs6668284	chr1:46354510	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.24	1.78E-12	Body mass index	
LUSC	cis	1	rs6668386	chr1:12047233	C1orf187	chr1:11751781-11780336:+	0.19	4.07	5.42E-5	Platelet count	
LUSC	cis	1	rs6669371	chr1:11882142	CLCN6	chr1:11866207-11907674:+	0.22	4.44	1.1E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs6669522	chr1:46397941	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.04	6.88E-12	Body mass index	
LUSC	cis	1	rs6672267	chr1:12054911	C1orf187	chr1:11751781-11780336:+	0.18	4	7.2E-5	Platelet count	
LUSC	cis	1	rs6672898	chr1:46290588	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.12	3.9E-12	Body mass index	
LUSC	cis	1	rs6674970	chr1:151116279	HORMAD1	chr1:150670542-150693352:-	0.25	3.84	0.000138	Body mass index	
LUSC	cis	1	rs66754062	chr20:23839051	CST2	chr20:23804404-23807312:-	-0.36	-5.45	8.13E-8	Response to TNF antagonist treatment	
LUSC	cis	1	rs6675726	chr1:46560643	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.66E-13	Body mass index	
LUSC	cis	1	rs6675946	chr1:46371774	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.17	2.93E-12	Body mass index	
LUSC	cis	1	rs6676190	chr1:151079317	HORMAD1	chr1:150670542-150693352:-	0.3	4.69	3.55E-6	Body mass index	
LUSC	cis	1	rs6677007	chr1:46400590	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.03	7.37E-12	Body mass index	
LUSC	cis	1	rs6679073	chr1:205756484	PM20D1	chr1:205797154-205819245:-	-0.36	-6.66	7.64E-11	Prostate-specific antigen levels	
LUSC	cis	1	rs6679	chr1:113243048	ST7L	chr1:113066142-113162405:-	0.25	4.05	5.98E-5	Diastolic blood pressure;Blood pressure	
LUSC	cis	1	rs6680380	chr1:46300189	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.1	4.66E-12	Body mass index	
LUSC	cis	1	rs6684571	chr1:107623224	PRMT6	chr1:107599267-107601907:+	0.26	3.93	9.9E-5	AIDS	
LUSC	cis	1	rs6686643	chr1:165616588	MGST3	chr1:165600450-165624853:+	0.31	5.68	2.29E-8	Total ventricular volume	
LUSC	cis	1	rs6690464	chr1:85466369	MCOLN2	chr1:85391267-85462796:-	0.2	3.86	0.000129	Serum sulfate level	
LUSC	cis	1	rs6690583	chr1:85466337	MCOLN2	chr1:85391267-85462796:-	0.2	3.9	0.00011	Serum sulfate level	
LUSC	cis	1	rs6690764	chr1:92976590	EVI5	chr1:92974255-93257961:-	-0.31	-4.53	7.51E-6	Cholesterol, total	
LUSC	cis	1	rs6692187	chr1:93035020	EVI5	chr1:92974255-93257961:-	-0.25	-3.74	0.000204	Cholesterol, total	
LUSC	cis	1	rs6695809	chr1:46285461	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.07	5.42E-12	Body mass index	
LUSC	cis	1	rs66968227	chr11:64070930	C11orf20	chr11:64067863-64072238:+	-0.34	-4.58	5.85E-6	Mean platelet volume	
LUSC	cis	1	rs6700597	chr1:46284246	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.12	4.06E-12	Body mass index	
LUSC	cis	1	rs6700792	chr1:231170013	CAPN9	chr1:230883130-230937749:+	0.19	3.71	0.000228	Carotid plaque burden (smoking interaction)	
LUSC	cis	1	rs6701614	chr1:46309420	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.1	4.66E-12	Body mass index	
LUSC	cis	1	rs6704770	chr2:232109816	ARMC9	chr2:232063342-232238606:+	0.24	5.09	5.29E-7	Food antigen IgG levels	
LUSC	cis	1	rs6705489	chr2:73648811	ALMS1P	chr2:73872046-73912692:+	0.41	7.69	8.54E-14	Metabolite levels	
LUSC	cis	1	rs6705489	chr2:73648811	NAT8	chr2:73867850-73869537:-	0.26	4.48	9.52E-6	Metabolite levels	
LUSC	cis	1	rs67073037	chr2:29119585	TRMT61B	chr2:29072690-29093175:-	0.21	3.92	0.000103	Breast cancer (estrogen-receptor negative);Breast cancer	
LUSC	cis	1	rs6707722	chr2:73654363	ALMS1P	chr2:73872046-73912692:+	0.42	7.63	1.26E-13	Metabolite levels	
LUSC	cis	1	rs6707722	chr2:73654363	NAT8	chr2:73867850-73869537:-	0.25	4.27	2.39E-5	Metabolite levels	
LUSC	cis	1	rs6707848	chr2:28988083	TRMT61B	chr2:29072690-29093175:-	-0.26	-5.37	1.26E-7	Body mass index	
LUSC	cis	1	rs6708328	chr2:24412413	C2orf84	chr2:24397531-24414566:+	0.37	6.61	1.03E-10	Venous thromboembolism (SNP x SNP interaction)	
LUSC	cis	1	rs6709534	chr2:217334	SH3YL1	chr2:218138-264810:-	-0.51	-9.09	2.78E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs6710467	chr2:127889932	BIN1	chr2:127805607-127864864:-	-0.26	-4	7.38E-5	Alzheimer's disease (late onset)	
LUSC	cis	1	rs6710959	chr2:28958603	TRMT61B	chr2:29072690-29093175:-	-0.25	-5.17	3.43E-7	Body mass index	
LUSC	cis	1	rs6711033	chr2:73746643	ALMS1P	chr2:73872046-73912692:+	0.4	7.39	6.81E-13	Metabolite levels	
LUSC	cis	1	rs6711033	chr2:73746643	NAT8	chr2:73867850-73869537:-	0.25	4.37	1.51E-5	Metabolite levels	
LUSC	cis	1	rs6711127	chr2:202213515	PPIL3	chr2:201735680-201753999:-	-0.49	-4.87	1.49E-6	Rheumatoid arthritis	
LUSC	cis	1	rs6711312	chr2:232122348	ARMC9	chr2:232063342-232238606:+	0.23	4.89	1.39E-6	Food antigen IgG levels	
LUSC	cis	1	rs6711941	chr2:202178130	PPIL3	chr2:201735680-201753999:-	-0.53	-6.35	5.13E-10	Rheumatoid arthritis	
LUSC	cis	1	rs67121560	chr20:23833294	CST2	chr20:23804404-23807312:-	-0.35	-5.22	2.67E-7	Response to TNF antagonist treatment	
LUSC	cis	1	rs6714736	chr2:202214148	ALS2CR12	chr2:202153148-202222101:-	0.22	4.03	6.49E-5	Basal cell carcinoma	
LUSC	cis	1	rs6715284	chr2:202154397	CFLAR	chr2:201980816-202029001:+	-0.26	-4.13	4.22E-5	Rheumatoid arthritis	
LUSC	cis	1	rs6715284	chr2:202154397	PPIL3	chr2:201735680-201753999:-	-0.5	-6.27	7.98E-10	Rheumatoid arthritis	
LUSC	cis	1	rs6715380	chr2:202214505	PPIL3	chr2:201735680-201753999:-	-0.47	-4.67	3.96E-6	Rheumatoid arthritis	
LUSC	cis	1	rs6720809	chr2:88528943	THNSL2	chr2:88469835-88486145:+	-0.66	-7.76	5.37E-14	Plasma clusterin levels	
LUSC	cis	1	rs6722069	chr2:88533151	THNSL2	chr2:88469835-88486145:+	-0.66	-7.58	1.8E-13	Plasma clusterin levels	
LUSC	cis	1	rs67239267	chr7:143745116	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.51	2.92E-13	Obesity-related traits	
LUSC	cis	1	rs67239267	chr7:143745116	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.54	6.98E-6	Obesity-related traits	
LUSC	cis	1	rs6724253	chr2:232121998	ARMC9	chr2:232063342-232238606:+	0.23	4.89	1.37E-6	Food antigen IgG levels	
LUSC	cis	1	rs67257959	chr19:17158145	HAUS8	chr19:17160573-17186343:-	-0.2	-4.45	1.09E-5	Selective IgA deficiency	
LUSC	cis	1	rs6732241	chr2:30479927	LBH	chr2:30454397-30482899:+	-0.24	-3.76	0.000189	Systemic lupus erythematosus	
LUSC	cis	1	rs6736866	chr2:73661986	ALMS1P	chr2:73872046-73912692:+	0.41	7.59	1.75E-13	Metabolite levels	
LUSC	cis	1	rs6736866	chr2:73661986	NAT8	chr2:73867850-73869537:-	0.27	4.66	4.14E-6	Metabolite levels	
LUSC	cis	1	rs6737085	chr2:202221441	ALS2CR12	chr2:202153148-202222101:-	-0.22	-4.06	5.7E-5	Basal cell carcinoma	
LUSC	cis	1	rs6740223	chr2:73653332	ALMS1P	chr2:73872046-73912692:+	0.42	7.63	1.26E-13	Metabolite levels	
LUSC	cis	1	rs6740223	chr2:73653332	NAT8	chr2:73867850-73869537:-	0.25	4.27	2.39E-5	Metabolite levels	
LUSC	cis	1	rs6741269	chr2:239179418	LOC151174	chr2:239133754-239140318:-	0.34	3.98	7.84E-5	Irritable bowel syndrome	
LUSC	cis	1	rs6741325	chr2:219907699	RNF25	chr2:219528588-219536781:-	0.3	3.7	0.000239	Height	
LUSC	cis	1	rs6742276	chr2:61768745	AHSA2	chr2:61404553-61414058:+	-0.15	-5.31	1.69E-7	Tuberculosis	
LUSC	cis	1	rs6742276	chr2:61768745	C2orf74	chr2:61372243-61391964:+	0.46	8.25	1.62E-15	Tuberculosis	
LUSC	cis	1	rs6745368	chr2:73809974	ALMS1P	chr2:73872046-73912692:+	0.41	7.65	1.09E-13	Metabolite levels	
LUSC	cis	1	rs6745368	chr2:73809974	NAT8	chr2:73867850-73869537:-	0.27	4.71	3.26E-6	Metabolite levels	
LUSC	cis	1	rs67505007	chr15:56196253	NEDD4	chr15:56119131-56285835:-	0.24	4.36	1.6E-5	Keloid	
LUSC	cis	1	rs67519234	chr5:132199359	SLC22A5	chr5:131705401-131731302:+	-0.28	-3.82	0.000153	Apolipoprotein A-IV levels	
LUSC	cis	1	rs6753344	chr2:73653138	ALMS1P	chr2:73872046-73912692:+	-0.4	-7.31	1.15E-12	Metabolite levels	
LUSC	cis	1	rs6753344	chr2:73653138	NAT8	chr2:73867850-73869537:-	-0.26	-4.46	1.0E-5	Metabolite levels	
LUSC	cis	1	rs67544533	chr15:75361539	SCAMP5	chr15:75287901-75313836:+	0.23	3.72	0.000223	Blood trace element (Zn levels)	
LUSC	cis	1	rs6755217	chr2:73641285	ALMS1P	chr2:73872046-73912692:+	0.43	7.85	2.83E-14	Metabolite levels	
LUSC	cis	1	rs6755217	chr2:73641285	NAT8	chr2:73867850-73869537:-	0.28	4.88	1.44E-6	Metabolite levels	
LUSC	cis	1	rs6755241	chr2:73641364	ALMS1P	chr2:73872046-73912692:+	0.43	7.87	2.34E-14	Metabolite levels	
LUSC	cis	1	rs6755241	chr2:73641364	NAT8	chr2:73867850-73869537:-	0.27	4.7	3.36E-6	Metabolite levels	
LUSC	cis	1	rs6755622	chr2:197923801	ANKRD44	chr2:197831743-198175495:-	-0.14	-3.7	0.000245	Interferon alpha levels in systemic lupus erythematosus	
LUSC	cis	1	rs6759004	chr2:202004676	CFLAR	chr2:201980816-202029001:+	-0.31	-5.6	3.56E-8	Triptolide cytotoxicity	
LUSC	cis	1	rs6759004	chr2:202004676	PPIL3	chr2:201735680-201753999:-	-0.77	-11.97	5.02E-29	Triptolide cytotoxicity	
LUSC	cis	1	rs6761514	chr2:202227549	CASP8	chr2:202098166-202152434:+	0.21	3.71	0.000228	Basal cell carcinoma	
LUSC	cis	1	rs6763088	chr3:134254989	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs6763093	chr3:134254995	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.23	1.85E-15	Height	
LUSC	cis	1	rs6763815	chr3:132725875	TMEM108	chr3:132757171-133116618:+	0.2	4.63	4.74E-6	IgE grass sensitization	
LUSC	cis	1	rs67652061	chr5:132280347	SLC22A5	chr5:131705401-131731302:+	-0.28	-3.87	0.000124	Apolipoprotein A-IV levels	
LUSC	cis	1	rs6765505	chr3:134208132	ANAPC13	chr3:134196547-134204865:-	0.42	8.56	1.58E-16	Height	
LUSC	cis	1	rs6766510	chr3:12551807	TSEN2	chr3:12525931-12581122:+	0.54	5.65	2.7E-8	Prostate cancer (gene x gene interaction)	
LUSC	cis	1	rs6766818	chr3:134226159	ANAPC13	chr3:134196547-134204865:-	0.42	8.48	2.91E-16	Height	
LUSC	cis	1	rs6766897	chr3:134191303	ANAPC13	chr3:134196547-134204865:-	0.39	7.63	1.34E-13	Height	
LUSC	cis	1	rs6768128	chr3:41865080	ULK4	chr3:41288091-42003660:-	0.6	9.2	1.13E-18	Diastolic blood pressure	
LUSC	cis	1	rs6768542	chr3:41865474	ULK4	chr3:41288091-42003660:-	0.6	9.04	3.86E-18	Diastolic blood pressure	
LUSC	cis	1	rs6768563	chr3:41865541	ULK4	chr3:41288091-42003660:-	0.59	8.99	5.95E-18	Diastolic blood pressure	
LUSC	cis	1	rs6769885	chr3:134286913	ANAPC13	chr3:134196547-134204865:-	0.41	8.06	6.2E-15	Height	
LUSC	cis	1	rs6770470	chr3:48435123	TREX1	chr3:48501186-48509043:+	-0.42	-9.31	4.88E-19	Longevity	
LUSC	cis	1	rs6772896	chr3:134203347	ANAPC13	chr3:134196547-134204865:-	0.42	8.44	3.75E-16	Height	
LUSC	cis	1	rs6776700	chr3:48496758	ATRIP	chr3:48488141-48507708:+	0.22	4.33	1.84E-5	Longevity	
LUSC	cis	1	rs6776700	chr3:48496758	TREX1	chr3:48501186-48509043:+	-0.42	-8.88	1.34E-17	Longevity	
LUSC	cis	1	rs677977	chr1:147083744	ACP6	chr1:147119168-147142634:-	-0.23	-4.02	6.89E-5	Schizophrenia (negative symptoms)	
LUSC	cis	1	rs6782563	chr3:134295959	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.02	8.13E-15	Height	
LUSC	cis	1	rs6783003	chr3:49524778	AMT	chr3:49454212-49460012:-	-0.19	-4.28	2.26E-5	Menarche (age at onset)	
LUSC	cis	1	rs6783003	chr3:49524778	KLHDC8B	chr3:49209068-49213918:+	0.24	3.86	0.000129	Menarche (age at onset)	
LUSC	cis	1	rs6783003	chr3:49524778	WDR6	chr3:49044637-49053386:+	0.19	3.88	0.00012	Menarche (age at onset)	
LUSC	cis	1	rs6784322	chr3:48422235	ATRIP	chr3:48488141-48507708:+	0.19	3.91	0.000104	Longevity	
LUSC	cis	1	rs6784322	chr3:48422235	TREX1	chr3:48501186-48509043:+	-0.41	-9.32	4.23E-19	Longevity	
LUSC	cis	1	rs6784421	chr3:156655494	LEKR1	chr3:156544076-156763918:+	0.25	5.71	2.05E-8	Multiple sclerosis (severity)	
LUSC	cis	1	rs6785027	chr3:134211649	ANAPC13	chr3:134196547-134204865:-	-0.39	-8.09	4.86E-15	Height	
LUSC	cis	1	rs6785045	chr3:49435243	AMT	chr3:49454212-49460012:-	-0.2	-4.82	1.89E-6	Menarche (age at onset)	
LUSC	cis	1	rs6785045	chr3:49435243	TREX1	chr3:48501186-48509043:+	0.2	3.76	0.000193	Menarche (age at onset)	
LUSC	cis	1	rs6787371	chr3:134254991	ANAPC13	chr3:134196547-134204865:-	0.41	8.22	1.96E-15	Height	
LUSC	cis	1	rs678815	chr11:102713777	MMP12	chr11:102733465-102745712:-	-0.19	-4.06	5.71E-5	Cerebrospinal fluid levels of Alzheimer's disease-related proteins	
LUSC	cis	1	rs6790466	chr3:134197740	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.19E-16	Height	
LUSC	cis	1	rs67927699	chr2:61187415	C2orf74	chr2:61372243-61391964:+	0.37	6.68	6.71E-11	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LUSC	cis	1	rs6793487	chr3:134299426	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.02	8.13E-15	Height	
LUSC	cis	1	rs6794300	chr3:46346640	CCR2	chr3:46395235-46402412:+	-0.1	-3.79	0.000169	Celiac disease	
LUSC	cis	1	rs6794875	chr3:48455626	ATRIP	chr3:48488141-48507708:+	0.2	4.03	6.59E-5	Longevity	
LUSC	cis	1	rs6794875	chr3:48455626	TREX1	chr3:48501186-48509043:+	-0.41	-8.99	6.07E-18	Longevity	
LUSC	cis	1	rs679620	chr11:102713620	MMP12	chr11:102733465-102745712:-	-0.18	-4	7.21E-5	Cerebrospinal fluid levels of Alzheimer's disease-related proteins	
LUSC	cis	1	rs6796491	chr3:48430465	TREX1	chr3:48501186-48509043:+	-0.44	-9.77	1.18E-20	Longevity	
LUSC	cis	1	rs6800862	chr3:134228628	ANAPC13	chr3:134196547-134204865:-	0.42	8.42	4.41E-16	Height	
LUSC	cis	1	rs6801596	chr3:134252114	ANAPC13	chr3:134196547-134204865:-	0.42	8.33	8.46E-16	Height	
LUSC	cis	1	rs6802654	chr3:134217072	ANAPC13	chr3:134196547-134204865:-	0.42	8.6	1.16E-16	Height	
LUSC	cis	1	rs6804770	chr3:134230234	ANAPC13	chr3:134196547-134204865:-	0.42	8.41	4.72E-16	Height	
LUSC	cis	1	rs6804774	chr3:48430617	TREX1	chr3:48501186-48509043:+	-0.44	-9.77	1.18E-20	Longevity	
LUSC	cis	1	rs6805609	chr3:49471522	AMT	chr3:49454212-49460012:-	-0.17	-3.72	0.000219	Menarche (age at onset)	
LUSC	cis	1	rs6805609	chr3:49471522	KLHDC8B	chr3:49209068-49213918:+	0.27	4.16	3.75E-5	Menarche (age at onset)	
LUSC	cis	1	rs6805609	chr3:49471522	TREX1	chr3:48501186-48509043:+	0.23	3.86	0.00013	Menarche (age at onset)	
LUSC	cis	1	rs6805609	chr3:49471522	WDR6	chr3:49044637-49053386:+	0.2	3.9	0.000111	Menarche (age at onset)	
LUSC	cis	1	rs6805880	chr3:41865397	ULK4	chr3:41288091-42003660:-	0.6	9.04	3.86E-18	Diastolic blood pressure	
LUSC	cis	1	rs6806417	chr3:134211446	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.33	8.75E-16	Height	
LUSC	cis	1	rs6809805	chr3:85553096	CADM2	chr3:85008133-86117948:+	0.31	4.85	1.67E-6	Longevity (90 years and older)	
LUSC	cis	1	rs6810060	chr3:48434748	TREX1	chr3:48501186-48509043:+	-0.43	-9.4	2.29E-19	Longevity	
LUSC	cis	1	rs6810295	chr3:31967967	OSBPL10	chr3:31699403-32023238:-	-0.23	-4.38	1.45E-5	Body mass index (education interaction)	
LUSC	cis	1	rs6810295	chr3:31967967	ZNF860	chr3:32023266-32033120:+	-0.25	-4.38	1.45E-5	Body mass index (education interaction)	
LUSC	cis	1	rs68171315	chr6:86707400	SNHG5	chr6:86386726-86388451:-	-0.67	-12.45	5.62E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs6818319	chr4:90642868	MMRN1	chr4:90816003-90875778:+	0.25	3.96	8.76E-5	Parkinson's disease	
LUSC	cis	1	rs6823347	chr4:106962725	TBCK	chr4:106967233-107237861:-	0.31	5.61	3.36E-8	Airflow obstruction	
LUSC	cis	1	rs6827617	chr4:76916146	NAAA	chr4:76831809-76862166:-	-0.24	-5.16	3.63E-7	Longevity	
LUSC	cis	1	rs6831256	chr4:3473139	LRPAP1	chr4:3514290-3534224:-	0.2	4.42	1.24E-5	Triglycerides;Cholesterol, total;LDL cholesterol	
LUSC	cis	1	rs6833988	chr4:10295586	SLC2A9	chr4:9827850-10041872:-	0.24	4.12	4.48E-5	Schizophrenia (age at onset)	
LUSC	cis	1	rs6846579	chr4:107011756	TBCK	chr4:106967233-107237861:-	0.28	5.18	3.37E-7	Airflow obstruction	
LUSC	cis	1	rs687672	chr11:65649984	CTSW	chr11:65647284-65651212:+	0.61	16.34	5.88E-48	Crohn's disease	
LUSC	cis	1	rs687672	chr11:65649984	SNX32	chr11:65601410-65621170:+	-0.56	-9.08	2.97E-18	Crohn's disease	
LUSC	cis	1	rs6885541	chr5:56110857	C5orf35	chr5:56205103-56213010:+	0.87	14.56	5.56E-40	Type 2 diabetes	
LUSC	cis	1	rs6901250	chr6:117114025	GPRC6A	chr6:117113248-117150198:-	0.2	3.85	0.000134	C-reactive protein levels	
LUSC	cis	1	rs6901703	chr6:24475300	GPLD1	chr6:24428405-24489850:-	-0.43	-5.68	2.33E-8	Hematological and biochemical traits	
LUSC	cis	1	rs6902429	chr6:49393500	CENPQ	chr6:49431096-49460820:+	-0.38	-8.75	3.68E-17	Homocysteine levels	
LUSC	cis	1	rs6902429	chr6:49393500	MUT	chr6:49398994-49431031:-	0.21	3.75	0.000199	Homocysteine levels	
LUSC	cis	1	rs6905391	chr6:28262686	ZNF187	chr6:28234788-28245978:+	-0.23	-3.84	0.000138	Depression	
LUSC	cis	1	rs6910233	chr6:33534726	BAK1	chr6:33540324-33548070:-	0.21	4.78	2.33E-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs6910460	chr6:24471712	GPLD1	chr6:24428405-24489850:-	0.46	5.8	1.19E-8	Hematological and biochemical traits	
LUSC	cis	1	rs6911965	chr6:24480295	GPLD1	chr6:24428405-24489850:-	-0.38	-5.11	4.61E-7	Hematological and biochemical traits	
LUSC	cis	1	rs6914463	chr6:86653415	SNHG5	chr6:86386726-86388451:-	-0.67	-12.58	1.56E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs6915187	chr6:49423547	CENPQ	chr6:49431096-49460820:+	-0.39	-8.99	5.8E-18	Homocysteine levels	
LUSC	cis	1	rs6916802	chr6:24465722	GPLD1	chr6:24428405-24489850:-	0.46	5.79	1.27E-8	Hematological and biochemical traits	
LUSC	cis	1	rs6916888	chr6:49383804	CENPQ	chr6:49431096-49460820:+	-0.38	-8.77	3.28E-17	Homocysteine levels	
LUSC	cis	1	rs6916888	chr6:49383804	MUT	chr6:49398994-49431031:-	0.21	3.73	0.000217	Homocysteine levels	
LUSC	cis	1	rs6918347	chr6:49406348	CENPQ	chr6:49431096-49460820:+	-0.38	-8.71	4.91E-17	Homocysteine levels	
LUSC	cis	1	rs6918347	chr6:49406348	MUT	chr6:49398994-49431031:-	0.21	3.76	0.000193	Homocysteine levels	
LUSC	cis	1	rs6922313	chr6:24438719	ALDH5A1	chr6:24495197-24537434:+	-0.25	-3.95	8.92E-5	Liver enzyme levels	
LUSC	cis	1	rs6922631	chr6:24438734	ALDH5A1	chr6:24495197-24537434:+	-0.25	-3.81	0.000156	Liver enzyme levels	
LUSC	cis	1	rs6923124	chr6:49419864	CENPQ	chr6:49431096-49460820:+	-0.39	-8.7	5.35E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs6923124	chr6:49419864	MUT	chr6:49398994-49431031:-	0.3	5.33	1.54E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs6923148	chr6:86767786	SNHG5	chr6:86386726-86388451:-	0.69	12.87	9.62E-33	Response to antipsychotic treatment	
LUSC	cis	1	rs6927188	chr6:42912589	GNMT	chr6:42928500-42931617:+	0.35	5.56	4.61E-8	Diabetic kidney disease	
LUSC	cis	1	rs6927188	chr6:42912589	PEX6	chr6:42931613-42946981:-	-0.59	-8.89	1.29E-17	Diabetic kidney disease	
LUSC	cis	1	rs6928435	chr6:24467366	GPLD1	chr6:24428405-24489850:-	0.45	5.75	1.62E-8	Hematological and biochemical traits	
LUSC	cis	1	rs6930076	chr6:88088654	C6orf164	chr6:88032306-88109459:+	-0.22	-4.19	3.27E-5	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs6933377	chr6:86705255	SNHG5	chr6:86386726-86388451:-	0.47	8.83	2.03E-17	Response to antipsychotic treatment	
LUSC	cis	1	rs6936048	chr6:86702608	SNHG5	chr6:86386726-86388451:-	-0.65	-11.88	1.08E-28	Response to antipsychotic treatment	
LUSC	cis	1	rs693824	chr11:65654783	CTSW	chr11:65647284-65651212:+	-0.61	-16.36	4.74E-48	Crohn's disease	
LUSC	cis	1	rs693824	chr11:65654783	SNX32	chr11:65601410-65621170:+	0.57	9.3	5.23E-19	Crohn's disease	
LUSC	cis	1	rs6940458	chr6:86644992	SNHG5	chr6:86386726-86388451:-	-0.65	-12.21	4.99E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs6945843	chr7:65734783	NCRNA00174	chr7:65841032-65865395:-	0.29	6.2	1.21E-9	Aortic root size	
LUSC	cis	1	rs6946143	chr7:65579722	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.18	1.39E-9	Aortic root size	
LUSC	cis	1	rs6948775	chr7:98945480	CYP3A5	chr7:99245818-99332821:-	0.47	5.76	1.49E-8	Blood metabolite levels	
LUSC	cis	1	rs694994	chr11:65653309	CTSW	chr11:65647284-65651212:+	-0.62	-16.41	2.77E-48	Crohn's disease	
LUSC	cis	1	rs694994	chr11:65653309	SNX32	chr11:65601410-65621170:+	0.58	9.49	1.13E-19	Crohn's disease	
LUSC	cis	1	rs6951245	chr7:1058193	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.37	1.22E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs6952407	chr7:66045512	NCRNA00174	chr7:65841032-65865395:-	0.22	4.9	1.34E-6	Cotinine glucuronidation	
LUSC	cis	1	rs6956179	chr7:65806659	NCRNA00174	chr7:65841032-65865395:-	0.29	6.04	3.08E-9	Aortic root size	
LUSC	cis	1	rs6957199	chr7:65978519	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.15	1.63E-9	Aortic root size	
LUSC	cis	1	rs6958271	chr7:65979331	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.09	2.3E-9	Aortic root size	
LUSC	cis	1	rs6958277	chr7:65979349	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.09	2.3E-9	Aortic root size	
LUSC	cis	1	rs6958484	chr7:65599446	NCRNA00174	chr7:65841032-65865395:-	0.3	6.34	5.46E-10	Aortic root size	
LUSC	cis	1	rs6958520	chr7:66151453	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.44	8.73E-8	Aortic root size	
LUSC	cis	1	rs6961155	chr7:65933295	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs6961717	chr7:65587537	NCRNA00174	chr7:65841032-65865395:-	0.3	6.32	6.04E-10	Aortic root size	
LUSC	cis	1	rs6961990	chr7:65888570	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.15E-9	Aortic root size	
LUSC	cis	1	rs6963646	chr7:65685767	NCRNA00174	chr7:65841032-65865395:-	0.29	6.28	7.47E-10	Aortic root size	
LUSC	cis	1	rs6967385	chr7:12391319	VWDE	chr7:12370509-12443852:-	-0.29	-5.35	1.39E-7	Response to taxane treatment (placlitaxel)	
LUSC	cis	1	rs6970030	chr7:65968679	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.13E-9	Aortic root size	
LUSC	cis	1	rs6970597	chr7:21583519	DNAH11	chr7:21582833-21941455:+	-0.53	-9.84	6.51E-21	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs6970985	chr7:21583597	DNAH11	chr7:21582833-21941455:+	-0.54	-10.15	4.68E-22	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
LUSC	cis	1	rs6974373	chr7:99590893	TRIM4	chr7:99488037-99517154:-	-0.3	-5.16	3.68E-7	Interstitial lung disease	
LUSC	cis	1	rs6975195	chr7:66124774	NCRNA00174	chr7:65841032-65865395:-	0.25	5.39	1.09E-7	Aortic root size	
LUSC	cis	1	rs6979382	chr7:65886375	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.21	1.15E-9	Aortic root size	
LUSC	cis	1	rs697970	chr7:65560052	NCRNA00174	chr7:65841032-65865395:-	0.28	5.86	8.57E-9	Aortic root size	
LUSC	cis	1	rs6983795	chr8:124185296	FAM83A	chr8:124191287-124222317:+	-0.25	-3.8	0.000161	Urinary uromodulin levels	
LUSC	cis	1	rs698500	chr15:83237769	LOC80154	chr15:82944795-82975797:+;chr15	0.24	4.84	1.77E-6	Schizophrenia	
LUSC	cis	1	rs6986256	chr8:130728361	GSDMC	chr8:130760443-130799134:-	0.25	5.14	3.97E-7	Infant length;Height	
LUSC	cis	1	rs6988636	chr8:124185970	FAM83A	chr8:124191287-124222317:+	-0.25	-3.86	0.000129	Urinary uromodulin levels	
LUSC	cis	1	rs7002021	chr8:124185250	FAM83A	chr8:124191287-124222317:+	-0.25	-3.8	0.000161	Urinary uromodulin levels	
LUSC	cis	1	rs7002332	chr8:124185442	FAM83A	chr8:124191287-124222317:+	-0.25	-3.8	0.000161	Urinary uromodulin levels	
LUSC	cis	1	rs7007450	chr8:71640269	XKR9	chr8:71581600-71648176:+	0.91	20.3	1.94E-66	Bone mineral density	
LUSC	cis	1	rs7007970	chr8:120647929	DSCC1	chr8:120846182-120868170:-	0.26	4.47	9.91E-6	Height	
LUSC	cis	1	rs7014578	chr8:92077568	SLC26A7	chr8:92221722-92410380:+	0.24	4.55	6.68E-6	Migraine - clinic-based	
LUSC	cis	1	rs7017914	chr8:71591203	XKR9	chr8:71581600-71648176:+	0.92	20.41	6.25E-67	Bone mineral density	
LUSC	cis	1	rs7018	chr20:25278261	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.81	0.000154	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs7020689	chr9:22972985	CDKN2A	chr9:21967752-21994490:-	-0.34	-3.92	0.0001	Cannabis use (initiation)	
LUSC	cis	1	rs7020689	chr9:22972985	CDKN2BAS	chr9:21994790-22121091:+	-0.41	-4.8	2.15E-6	Cannabis use (initiation)	
LUSC	cis	1	rs7020689	chr9:22972985	CDKN2B	chr9:22002906-22009312:-	-0.32	-3.82	0.00015	Cannabis use (initiation)	
LUSC	cis	1	rs7020976	chr9:100547972	CTSL2	chr9:99794940-99822167:-	-0.2	-3.72	0.000219	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs7020	chr20:25278600	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.83	0.000146	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs7021576	chr9:100540541	CTSL2	chr9:99794940-99822167:-	-0.2	-3.73	0.000216	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs7022397	chr9:116007677	CDC26	chr9:116029290-116037869:-	-0.35	-7.4	6.42E-13	Hematology traits	
LUSC	cis	1	rs7027030	chr9:100550455	CTSL2	chr9:99794940-99822167:-	-0.2	-3.81	0.000159	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs7027930	chr9:565917	CBWD1	chr9:121039-179075:-	-0.23	-3.74	0.000209	Pulmonary function decline	
LUSC	cis	1	rs7028661	chr9:100538470	CTSL2	chr9:99794940-99822167:-	-0.2	-3.76	0.000194	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs7029536	chr9:130110411	SLC2A8	chr9:130159465-130170161:+	-0.3	-5.2	2.93E-7	Metabolite levels (HVA)	
LUSC	cis	1	rs7029536	chr9:130110411	ZNF79	chr9:130186653-130207650:+	-0.24	-4.36	1.6E-5	Metabolite levels (HVA)	
LUSC	cis	1	rs7030241	chr9:100550375	CTSL2	chr9:99794940-99822167:-	-0.2	-3.87	0.000125	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs7032019	chr9:100548144	CTSL2	chr9:99794940-99822167:-	-0.2	-3.72	0.000219	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs7037140	chr9:123656327	LOC253039	chr9:123605320-123616644:+	-0.32	-6.08	2.51E-9	Rheumatoid arthritis	
LUSC	cis	1	rs703842	chr12:58162739	FAM119B	chr12:58166383-58176323:+	-0.5	-8.87	1.51E-17	Multiple sclerosis	
LUSC	cis	1	rs703842	chr12:58162739	TSFM	chr12:58176536-58191367:+	0.39	8.62	1.04E-16	Multiple sclerosis	
LUSC	cis	1	rs703842	chr12:58162739	XRCC6BP1	chr12:58335445-58351051:+	0.2	4.11	4.72E-5	Multiple sclerosis	
LUSC	cis	1	rs7038769	chr9:116007583	CDC26	chr9:116029290-116037869:-	-0.35	-7.4	6.42E-13	Hematology traits	
LUSC	cis	1	rs705696	chr12:56480648	RPS26	chr12:56435686-56438005:+	0.58	11.94	6.46E-29	Cognitive function	
LUSC	cis	1	rs706201	chr7:134251041	AKR1B15	chr7:134233849-134264300:+	-0.22	-4.49	8.98E-6	Longevity	
LUSC	cis	1	rs706202	chr7:134250704	AKR1B15	chr7:134233849-134264300:+	-0.22	-4.53	7.43E-6	Longevity	
LUSC	cis	1	rs7069235	chr10:118786985	KIAA1598	chr10:118644308-118886097:-	0.25	3.97	8.34E-5	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs7070776	chr10:102264672	SEC31B	chr10:102246403-102289636:-	-0.28	-8.67	7.07E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7071271	chr10:102264824	SEC31B	chr10:102246403-102289636:-	-0.28	-8.41	4.74E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7072216	chr10:100156853	PYROXD2	chr10:100143323-100174978:-	0.47	10.04	1.21E-21	Metabolite levels	
LUSC	cis	1	rs7073586	chr10:102307671	SEC31B	chr10:102246403-102289636:-	-0.27	-8.5	2.44E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7078160	chr10:118827560	KIAA1598	chr10:118644308-118886097:-	0.26	4.09	5.0E-5	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs7078799	chr10:102301447	SEC31B	chr10:102246403-102289636:-	-0.27	-8.01	9.01E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7079136	chr10:102292709	SEC31B	chr10:102246403-102289636:-	-0.28	-8.28	1.27E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7079756	chr10:102302105	SEC31B	chr10:102246403-102289636:-	-0.27	-8.31	1.01E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7080356	chr10:102266735	SEC31B	chr10:102246403-102289636:-	-0.29	-8.89	1.28E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs708152	chr11:2384348	C11orf21	chr11:2317507-2323143:-	-0.2	-4.6	5.39E-6	Bacteremia	
LUSC	cis	1	rs7084810	chr10:102297546	SEC31B	chr10:102246403-102289636:-	-0.28	-8.38	5.89E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7085439	chr10:102210100	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.16E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7088512	chr10:102303498	SEC31B	chr10:102246403-102289636:-	-0.27	-8.29	1.15E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7088827	chr10:102303865	SEC31B	chr10:102246403-102289636:-	-0.27	-8.11	4.38E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7090431	chr10:102261753	SEC31B	chr10:102246403-102289636:-	-0.28	-8.6	1.16E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs709400	chr14:104149475	C14orf153	chr14:104029299-104057227:+	0.15	3.86	0.00013	Body mass index	
LUSC	cis	1	rs709400	chr14:104149475	CKB	chr14:103985996-103989170:-	0.19	3.7	0.000238	Body mass index	
LUSC	cis	1	rs709592	chr17:38175553	GSDMA	chr17:38119226-38134019:+	-0.44	-8.92	9.9E-18	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs7095944	chr10:126302936	METTL10	chr10:126447406-126480439:-	-0.25	-4.91	1.23E-6	Asthma	
LUSC	cis	1	rs709595	chr7:65817333	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.17	1.46E-9	Aortic root size	
LUSC	cis	1	rs709597	chr7:65825983	NCRNA00174	chr7:65841032-65865395:-	0.29	6.13	1.83E-9	Aortic root size	
LUSC	cis	1	rs7099913	chr10:102314777	SEC31B	chr10:102246403-102289636:-	-0.27	-7.8	3.88E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7099965	chr10:102301165	SEC31B	chr10:102246403-102289636:-	-0.27	-8.01	9.01E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7099	chr20:43997646	SYS1	chr20:43991701-44004724:+	-0.21	-3.86	0.000127	Psoriasis	
LUSC	cis	1	rs7100386	chr10:102301417	SEC31B	chr10:102246403-102289636:-	-0.27	-8.01	9.01E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7105282	chr11:47805614	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.11	4.69E-5	Subjective well-being	
LUSC	cis	1	rs7107184	chr11:48577069	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.84	0.000137	HDL cholesterol	
LUSC	cis	1	rs710825	chr1:228990234	WNT3A	chr1:228194752-228248961:+	0.2	3.7	0.00024	Basal cell carcinoma	
LUSC	cis	1	rs7112513	chr11:117037361	PCSK7	chr11:117075789-117102811:-	-0.35	-4.96	9.64E-7	Protein quantitative trait loci	
LUSC	cis	1	rs7114963	chr11:116875983	PCSK7	chr11:117075789-117102811:-	-0.32	-4.49	9.12E-6	Protein quantitative trait loci	
LUSC	cis	1	rs7115737	chr11:43681249	HSD17B12	chr11:43702143-43878160:+	-0.45	-8.09	5.17E-15	Forced vital capacity	
LUSC	cis	1	rs7117082	chr11:133392294	JAM3	chr11:133938820-134021649:+	-0.32	-4.67	3.9E-6	Amyotrophic lateral sclerosis (sporadic)	
LUSC	cis	1	rs7120333	chr11:47817441	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.13	4.29E-5	Subjective well-being	
LUSC	cis	1	rs7121347	chr11:116867209	PCSK7	chr11:117075789-117102811:-	-0.32	-4.49	9.01E-6	Protein quantitative trait loci	
LUSC	cis	1	rs7121460	chr11:48545232	C1QTNF4	chr11:47611216-47615961:-	-0.2	-3.9	0.000112	HDL cholesterol	
LUSC	cis	1	rs7121554	chr11:112048051	IL18	chr11:112013976-112034840:-	-0.23	-4.07	5.55E-5	Interleukin-18 levels	
LUSC	cis	1	rs7121992	chr11:48592582	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.75	0.000196	HDL cholesterol	
LUSC	cis	1	rs7122944	chr11:117034619	PCSK7	chr11:117075789-117102811:-	-0.39	-5.29	1.85E-7	Protein quantitative trait loci	
LUSC	cis	1	rs7123517	chr11:117027755	PCSK7	chr11:117075789-117102811:-	-0.38	-5.2	2.91E-7	Protein quantitative trait loci	
LUSC	cis	1	rs7131094	chr11:112044917	IL18	chr11:112013976-112034840:-	-0.23	-4.07	5.55E-5	Interleukin-18 levels	
LUSC	cis	1	rs713219	chr9:131900920	CRAT	chr9:131857075-131873070:-	0.25	5.12	4.53E-7	Blood metabolite ratios	
LUSC	cis	1	rs71327718	chr3:125592857	ALG1L	chr3:125648118-125655882:-	-0.31	-5.05	6.45E-7	Metabolite levels (HVA/5-HIAA ratio)	
LUSC	cis	1	rs7134594	chr12:110000193	MYO1H	chr12:109826524-109886176:+	0.23	4.17	3.6E-5	HDL cholesterol	
LUSC	cis	1	rs71419270	chr14:93772500	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000198	Body mass index	
LUSC	cis	1	rs7142235	chr14:75559963	MLH3	chr14:75480467-75518235:-	0.27	5.75	1.58E-8	Height	
LUSC	cis	1	rs7142457	chr14:50097862	RPL36AL	chr14:50085407-50087349:-	0.21	4.53	7.5E-6	Carotid intima media thickness	
LUSC	cis	1	rs71426509	chr2:239175334	LOC151174	chr2:239133754-239140318:-	0.34	3.98	7.84E-5	Irritable bowel syndrome	
LUSC	cis	1	rs71426510	chr2:239178909	LOC151174	chr2:239133754-239140318:-	0.34	3.98	7.84E-5	Irritable bowel syndrome	
LUSC	cis	1	rs71429788	chr14:93727579	COX8C	chr14:93813537-93814700:+	-0.23	-3.76	0.000191	Body mass index	
LUSC	cis	1	rs71429789	chr14:93745184	COX8C	chr14:93813537-93814700:+	-0.24	-3.75	0.000202	Body mass index	
LUSC	cis	1	rs7143682	chr14:104413455	TDRD9	chr14:104394817-104519002:+	0.26	4.47	9.59E-6	Bipolar disorder	
LUSC	cis	1	rs7144423	chr14:35572547	PPP2R3C	chr14:35554679-35591679:-	0.31	5.39	1.1E-7	Atopic dermatitis	
LUSC	cis	1	rs7145159	chr14:75583268	MLH3	chr14:75480467-75518235:-	0.26	5.52	5.46E-8	Height	
LUSC	cis	1	rs7147118	chr14:75610170	MLH3	chr14:75480467-75518235:-	0.28	6.08	2.52E-9	Height	
LUSC	cis	1	rs7148538	chr14:74392342	LIN52	chr14:74551656-74667117:+	0.27	4.01	6.93E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs7150141	chr14:104129352	C14orf153	chr14:104029299-104057227:+	0.15	3.91	0.000106	Body mass index	
LUSC	cis	1	rs7150141	chr14:104129352	CKB	chr14:103985996-103989170:-	0.18	3.72	0.000224	Body mass index	
LUSC	cis	1	rs7150255	chr14:104912876	AHNAK2	chr14:105403591-105444694:-	-0.13	-3.8	0.00016	Gut microbiome composition (summer and winter)	
LUSC	cis	1	rs7151218	chr14:103488801	MARK3	chr14:103851701-103970164:+	-0.33	-4	7.4E-5	Large B-cell lymphoma	
LUSC	cis	1	rs7154306	chr14:35540499	PPP2R3C	chr14:35554679-35591679:-	0.31	5.55	4.65E-8	Atopic dermatitis	
LUSC	cis	1	rs71550519	chr6:56780272	BEND6	chr6:56819773-56892138:+	-0.34	-4.9	1.32E-6	Menarche (age at onset)	
LUSC	cis	1	rs7156105	chr14:75541954	MLH3	chr14:75480467-75518235:-	0.26	5.52	5.73E-8	Height	
LUSC	cis	1	rs71562227	chr6:110759274	SLC22A16	chr6:110745907-110797844:-	0.4	4.51	8.12E-6	Glucose homeostasis traits	
LUSC	cis	1	rs7156322	chr14:35544330	PPP2R3C	chr14:35554679-35591679:-	0.31	5.42	9.63E-8	Atopic dermatitis	
LUSC	cis	1	rs7156328	chr14:75532941	MLH3	chr14:75480467-75518235:-	0.27	5.81	1.13E-8	Height	
LUSC	cis	1	rs71563547	chr7:97615831	MGC72080	chr7:97503667-97601638:-	0.35	3.79	0.00017	Sudden cardiac arrest	
LUSC	cis	1	rs71564866	chr6:56771207	BEND6	chr6:56819773-56892138:+	-0.36	-5.21	2.84E-7	Menarche (age at onset)	
LUSC	cis	1	rs71564868	chr6:56798441	BEND6	chr6:56819773-56892138:+	-0.37	-5.28	2.01E-7	Menarche (age at onset)	
LUSC	cis	1	rs7157566	chr14:74649129	LIN52	chr14:74551656-74667117:+	-0.27	-5.99	4.2E-9	Common traits (Other)	
LUSC	cis	1	rs7157566	chr14:74649129	PTGR2	chr14:74318534-74352166:+	0.22	4.27	2.33E-5	Common traits (Other)	
LUSC	cis	1	rs7157940	chr14:94563193	IFI27L1	chr14:94547639-94569059:+	0.45	9.7	2.02E-20	Anthropometric traits	
LUSC	cis	1	rs7162435	chr15:56121334	NEDD4	chr15:56119131-56285835:-	-0.22	-4.15	3.95E-5	Keloid	
LUSC	cis	1	rs7164132	chr15:40675155	C15orf23	chr15:40674922-40686488:+	0.23	3.72	0.000219	Heschl's gyrus morphology	
LUSC	cis	1	rs7164132	chr15:40675155	IVD	chr15:40697686-40713512:+	-0.38	-4.32	1.94E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs71654419	chr1:95664497	RWDD3	chr1:95583479-95712773:+	0.39	4.5	8.39E-6	Stearic acid (18:0) plasma levels	
LUSC	cis	1	rs7166991	chr15:40671957	IVD	chr15:40697686-40713512:+	-0.41	-4.74	2.79E-6	Heschl's gyrus morphology	
LUSC	cis	1	rs7169404	chr15:40675443	C15orf23	chr15:40674922-40686488:+	0.23	3.72	0.000219	Heschl's gyrus morphology	
LUSC	cis	1	rs7169404	chr15:40675443	IVD	chr15:40697686-40713512:+	-0.38	-4.32	1.94E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs7175720	chr15:75348962	SCAMP5	chr15:75287901-75313836:+	-0.29	-4.66	4.08E-6	Blood trace element (Zn levels)	
LUSC	cis	1	rs717593	chr20:33652964	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7176225	chr15:56126857	NEDD4	chr15:56119131-56285835:-	0.23	4.23	2.76E-5	Keloid	
LUSC	cis	1	rs717658	chr7:150503637	TMEM176A	chr7:150497854-150502208:+	0.13	4.24	2.66E-5	Forced expiratory volume in 1 second (environmental interaction)	
LUSC	cis	1	rs7178759	chr15:77143513	ETFA	chr15:76508629-76603810:-	0.33	4.64	4.45E-6	Recalcitrant atopic dermatitis	
LUSC	cis	1	rs7187423	chr16:54090495	RBL2	chr16:53468351-53525559:+	0.39	4.04	6.25E-5	Allergic rhinitis	
LUSC	cis	1	rs7191665	chr16:74688948	RFWD3	chr16:74655298-74700779:-	-0.24	-5.65	2.71E-8	Testicular germ cell tumor	
LUSC	cis	1	rs7201320	chr16:74694058	RFWD3	chr16:74655298-74700779:-	-0.24	-5.45	7.98E-8	Testicular germ cell tumor	
LUSC	cis	1	rs720475	chr7:144074929	OR2A7	chr7:143955790-143974852:-	-0.37	-6.94	1.33E-11	Breast cancer	
LUSC	cis	1	rs7205409	chr16:642610	WFIKKN1	chr16:679239-684116:+	0.33	6.22	1.08E-9	Height	
LUSC	cis	1	rs7207021	chr17:28400516	EFCAB5	chr17:28256874-28435469:+	-0.29	-5.49	6.54E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs7208663	chr17:65885171	LOC440461	chr17:66194801-66196436:+	0.26	4.06	5.8E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs7209180	chr17:79581519	TSPAN10	chr17:79609349-79615778:+	0.46	9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs7209435	chr17:61712964	FTSJ3	chr17:61896795-61905031:-	0.33	6.45	2.73E-10	Body mass index	
LUSC	cis	1	rs7209758	chr17:61913621	FTSJ3	chr17:61896795-61905031:-	0.32	6.17	1.44E-9	Body mass index	
LUSC	cis	1	rs7210738	chr17:45757598	C17orf57	chr17:45401142-45518675:+	-0.28	-6.41	3.45E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs7211213	chr17:61769456	FTSJ3	chr17:61896795-61905031:-	0.32	6.3	6.98E-10	Body mass index	
LUSC	cis	1	rs7211777	chr17:40534075	NKIRAS2	chr17:40169594-40177654:+	0.2	4.14	4.16E-5	Crohn's disease;Multiple sclerosis	
LUSC	cis	1	rs7212497	chr17:28335949	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.87	8.13E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs7213129	chr17:79581573	TSPAN10	chr17:79609349-79615778:+	0.46	9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs7214085	chr17:38169095	GSDMA	chr17:38119226-38134019:+	-0.44	-8.88	1.4E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs7214312	chr17:61870863	FTSJ3	chr17:61896795-61905031:-	0.33	6.44	2.88E-10	Body mass index	
LUSC	cis	1	rs7214743	chr17:59498052	C17orf82	chr17:59489112-59490641:+	0.16	3.81	0.000157	Sitting height ratio	
LUSC	cis	1	rs7214758	chr17:65880538	LOC440461	chr17:66194801-66196436:+	0.25	3.86	0.00013	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs7216798	chr17:61740963	FTSJ3	chr17:61896795-61905031:-	0.32	6.31	6.53E-10	Body mass index	
LUSC	cis	1	rs7217982	chr17:61832150	FTSJ3	chr17:61896795-61905031:-	0.34	6.69	6.33E-11	Body mass index	
LUSC	cis	1	rs7218362	chr17:56888299	RAD51C	chr17:56769963-56811690:+	0.29	6.09	2.35E-9	Cognitive test performance	
LUSC	cis	1	rs7219014	chr17:37624790	PGAP3	chr17:37827376-37844310:-	-0.25	-3.97	8.27E-5	Urinary metabolites	
LUSC	cis	1	rs7220821	chr17:61704147	FTSJ3	chr17:61896795-61905031:-	0.33	6.5	2.03E-10	Body mass index	
LUSC	cis	1	rs7220892	chr17:61908316	FTSJ3	chr17:61896795-61905031:-	0.32	6.15	1.67E-9	Body mass index	
LUSC	cis	1	rs7221109	chr17:38770286	KRT24	chr17:38854244-38860002:-	0.19	4.16	3.8E-5	Type 1 diabetes	
LUSC	cis	1	rs7221743	chr17:28407876	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.79	1.26E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs7222060	chr17:61868279	FTSJ3	chr17:61896795-61905031:-	0.33	6.44	2.88E-10	Body mass index	
LUSC	cis	1	rs7222241	chr17:79574714	TSPAN10	chr17:79609349-79615778:+	0.46	9.6	4.49E-20	Eye color traits	
LUSC	cis	1	rs7222308	chr17:28277041	EFCAB5	chr17:28256874-28435469:+	0.31	5.86	8.74E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs7223412	chr17:61808172	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.97E-10	Body mass index	
LUSC	cis	1	rs7223613	chr17:79574803	TSPAN10	chr17:79609349-79615778:+	-0.46	-9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs7223672	chr17:61720565	FTSJ3	chr17:61896795-61905031:-	0.33	6.34	5.51E-10	Body mass index	
LUSC	cis	1	rs7223786	chr17:28332107	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.87	8.13E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs7223930	chr17:65842186	LOC440461	chr17:66194801-66196436:+	0.26	3.99	7.52E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs7223966	chr17:61893398	FTSJ3	chr17:61896795-61905031:-	0.32	6.22	1.09E-9	Body mass index	
LUSC	cis	1	rs7224923	chr17:65842265	LOC440461	chr17:66194801-66196436:+	0.26	4	7.48E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs7246657	chr19:37747108	ZNF781	chr19:38158650-38183216:-	-0.27	-4.6	5.55E-6	Coronary artery calcification	
LUSC	cis	1	rs7247513	chr19:12691185	GCDH	chr19:13001974-13010782:+	-0.19	-3.88	0.000118	Bipolar disorder	
LUSC	cis	1	rs7247672	chr19:37743928	ZNF781	chr19:38158650-38183216:-	0.24	3.87	0.000123	Coronary artery calcification	
LUSC	cis	1	rs7251653	chr19:18608283	SSBP4	chr19:18530221-18545371:+	-0.19	-3.79	0.000173	Breast cancer	
LUSC	cis	1	rs7251903	chr19:39184811	LGALS7B	chr19:39279850-39282393:+	0.2	4.19	3.38E-5	Heart rate	
LUSC	cis	1	rs7252589	chr19:39170908	LGALS7B	chr19:39279850-39282393:+	0.2	4.29	2.14E-5	Heart rate	
LUSC	cis	1	rs7252707	chr19:18612257	LRRC25	chr19:18501955-18508421:-	-0.11	-3.71	0.000232	Breast cancer	
LUSC	cis	1	rs725309	chr3:48418708	ATRIP	chr3:48488141-48507708:+	-0.19	-3.86	0.000129	Longevity	
LUSC	cis	1	rs725309	chr3:48418708	TREX1	chr3:48501186-48509043:+	0.42	9.26	7.15E-19	Longevity	
LUSC	cis	1	rs725310	chr3:48418571	ATRIP	chr3:48488141-48507708:+	-0.2	-4.15	4.02E-5	Longevity	
LUSC	cis	1	rs725310	chr3:48418571	TREX1	chr3:48501186-48509043:+	0.4	9.04	3.87E-18	Longevity	
LUSC	cis	1	rs7254349	chr19:24230343	LOC100101266	chr19:24344995-24346249:-	0.29	3.98	7.96E-5	Response to taxane treatment (placlitaxel)	
LUSC	cis	1	rs7255679	chr19:42063981	CEACAM21	chr19:42055886-42093196:+	0.52	15.6	1.3E-44	Schizophrenia	
LUSC	cis	1	rs7257127	chr19:23056699	ZNF492	chr19:22817126-22850472:+	-0.26	-3.71	0.000231	Bronchopulmonary dysplasia	
LUSC	cis	1	rs7258465	chr19:18533642	LRRC25	chr19:18501955-18508421:-	-0.11	-3.93	9.94E-5	Breast cancer	
LUSC	cis	1	rs725908	chr20:33968067	CEP250	chr20:34042996-34099802:+	-0.15	-3.85	0.000133	Height	
LUSC	cis	1	rs725908	chr20:33968067	CPNE1	chr20:34213968-34262539:-	0.29	5.09	5.07E-7	Height	
LUSC	cis	1	rs725908	chr20:33968067	UQCC	chr20:33890383-33999833:-	0.28	5.04	6.62E-7	Height	
LUSC	cis	1	rs72627113	chr14:74340141	LIN52	chr14:74551656-74667117:+	0.33	3.78	0.000174	Morning vs. evening chronotype	
LUSC	cis	1	rs72627117	chr14:74355233	LIN52	chr14:74551656-74667117:+	0.28	4.24	2.64E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627119	chr14:74356274	LIN52	chr14:74551656-74667117:+	0.28	4.24	2.64E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627120	chr14:74363480	LIN52	chr14:74551656-74667117:+	0.29	4.32	1.93E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627122	chr14:74368236	LIN52	chr14:74551656-74667117:+	0.28	4.21	3.01E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627123	chr14:74368331	LIN52	chr14:74551656-74667117:+	0.28	4.2	3.15E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627124	chr14:74369128	LIN52	chr14:74551656-74667117:+	0.29	4.25	2.53E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627125	chr14:74369623	LIN52	chr14:74551656-74667117:+	0.29	4.25	2.53E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627126	chr14:74370024	LIN52	chr14:74551656-74667117:+	0.29	4.3	2.04E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627127	chr14:74370098	LIN52	chr14:74551656-74667117:+	0.29	4.25	2.53E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627129	chr14:74374805	LIN52	chr14:74551656-74667117:+	0.29	4.33	1.8E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627130	chr14:74374897	LIN52	chr14:74551656-74667117:+	0.29	4.33	1.8E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs72627138	chr14:74401900	LIN52	chr14:74551656-74667117:+	0.27	4.05	6.1E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs7263203	chr20:33773375	GDF5	chr20:33897002-34042568:-	0.3	4.14	4.11E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7263203	chr20:33773375	PROCR	chr20:33758727-33765164:+	-0.3	-3.95	8.92E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7263253	chr20:33649376	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs72644213	chr10:81783660	LOC219347	chr10:81805991-81838949:-	0.5	4.97	9.5E-7	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs7265317	chr20:33768523	GDF5	chr20:33897002-34042568:-	0.3	4.1	4.84E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7265317	chr20:33768523	PROCR	chr20:33758727-33765164:+	-0.31	-4.07	5.5E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs72677306	chr4:106997678	TBCK	chr4:106967233-107237861:-	0.28	5.27	2.1E-7	Airflow obstruction	
LUSC	cis	1	rs7267979	chr20:25298087	ENTPD6	chr20:25176339-25207360:+	-0.21	-3.86	0.000131	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs7268053	chr20:25328286	ENTPD6	chr20:25176339-25207360:+	0.2	3.77	0.000186	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs7268447	chr20:33649593	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs72690918	chr8:143753696	LOC100133669	chr8:144063448-144099807:-	0.49	4.03	6.57E-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	
LUSC	cis	1	rs7269138	chr20:33570007	GDF5	chr20:33897002-34042568:-	0.27	3.7	0.000241	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7269138	chr20:33570007	PROCR	chr20:33758727-33765164:+	-0.31	-4.12	4.45E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs72692896	chr1:150048871	PRPF3	chr1:150293928-150325703:+	-0.22	-3.87	0.000125	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LUSC	cis	1	rs72692897	chr1:150049934	PRPF3	chr1:150293928-150325703:+	-0.21	-3.72	0.000226	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LUSC	cis	1	rs72692901	chr1:150056510	PRPF3	chr1:150293928-150325703:+	-0.21	-3.71	0.000228	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LUSC	cis	1	rs72694943	chr1:150111980	PRPF3	chr1:150293928-150325703:+	-0.21	-3.71	0.000232	Obesity in adult survivors of childhood cancer not exposed to cranial radiation	
LUSC	cis	1	rs7270354	chr20:44607661	WFDC3	chr20:44402847-44420547:-	-0.52	-7.18	2.77E-12	Abdominal aortic aneurysm	
LUSC	cis	1	rs7271729	chr20:33610992	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.46E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs72721182	chr1:172258325	VAMP4	chr1:171669298-171711214:-	0.2	3.87	0.000124	Height	
LUSC	cis	1	rs72725138	chr14:68387979	VTI1B	chr14:68117869-68141602:-	0.2	3.77	0.000184	Platelet count	
LUSC	cis	1	rs72731669	chr4:154662464	TLR2	chr4:154605441-154627240:+	-0.19	-3.93	9.76E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs72731670	chr4:154662471	TLR2	chr4:154605441-154627240:+	-0.19	-3.93	9.76E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs72731672	chr4:154664925	TLR2	chr4:154605441-154627240:+	-0.2	-3.9	0.000108	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs72731674	chr4:154667447	TLR2	chr4:154605441-154627240:+	-0.21	-4.19	3.32E-5	Response to statins (LDL cholesterol change)	
LUSC	cis	1	rs7273787	chr20:4098567	SMOX	chr20:4129450-4168369:+	0.21	3.89	0.000115	Height	
LUSC	cis	1	rs7274866	chr20:33608616	PROCR	chr20:33758727-33765164:+	-0.32	-4.22	2.87E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs72768397	chr1:247219411	ZNF670	chr1:247200087-247242069:-	-0.22	-4.21	3.11E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs72782294	chr2:28953390	TRMT61B	chr2:29072690-29093175:-	0.26	5.28	1.98E-7	Body mass index	
LUSC	cis	1	rs72787722	chr2:30489941	LBH	chr2:30454397-30482899:+	-0.23	-3.72	0.000224	Systemic lupus erythematosus	
LUSC	cis	1	rs72787724	chr2:30491746	LBH	chr2:30454397-30482899:+	-0.24	-3.75	0.0002	Systemic lupus erythematosus	
LUSC	cis	1	rs72823064	chr17:40569974	CNTD1	chr17:40950854-40963604:+	0.18	3.86	0.000129	Crohn's disease	
LUSC	cis	1	rs72840063	chr2:85550396	TGOLN2	chr2:85545147-85555374:-	-0.26	-5.72	1.93E-8	Ear protrusion	
LUSC	cis	1	rs72843784	chr6:26498758	BTN3A2	chr6:26365398-26378546:+	-0.87	-10.9	7.58E-25	Schizophrenia	
LUSC	cis	1	rs72848797	chr17:61934664	FTSJ3	chr17:61896795-61905031:-	0.34	6.47	2.39E-10	Body mass index	
LUSC	cis	1	rs7285549	chr22:25874580	CRYBB2	chr22:25615612-25627836:+	0.78	8.74	4.01E-17	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs72855860	chr4:75714054	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs728615	chr10:81848089	C10orf57	chr10:81838426-81852306:+	0.44	4.21	3.01E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs728615	chr10:81848089	PLAC9	chr10:81892258-81904784:+	-0.3	-4.03	6.47E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs728616	chr10:81847914	C10orf57	chr10:81838426-81852306:+	0.44	4.21	3.01E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs728616	chr10:81847914	PLAC9	chr10:81892258-81904784:+	-0.3	-4.03	6.47E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs7289577	chr22:39042214	CBY1	chr22:39052658-39069853:+	0.21	3.84	0.00014	Resting heart rate	
LUSC	cis	1	rs72922733	chr11:65520746	CTSW	chr11:65647284-65651212:+	-0.25	-5.24	2.37E-7	Systemic lupus erythematosus	
LUSC	cis	1	rs72922733	chr11:65520746	SNX32	chr11:65601410-65621170:+	0.46	6.92	1.5E-11	Systemic lupus erythematosus	
LUSC	cis	1	rs72934944	chr2:202190610	PPIL3	chr2:201735680-201753999:-	-0.53	-6.28	7.43E-10	Rheumatoid arthritis	
LUSC	cis	1	rs72934960	chr2:202204749	PPIL3	chr2:201735680-201753999:-	-0.49	-4.91	1.28E-6	Rheumatoid arthritis	
LUSC	cis	1	rs72934973	chr2:202213934	PPIL3	chr2:201735680-201753999:-	-0.49	-4.87	1.49E-6	Rheumatoid arthritis	
LUSC	cis	1	rs72934999	chr2:202223524	PPIL3	chr2:201735680-201753999:-	-0.44	-4.42	1.22E-5	Rheumatoid arthritis	
LUSC	cis	1	rs72937106	chr2:202225520	PPIL3	chr2:201735680-201753999:-	-0.44	-4.42	1.22E-5	Rheumatoid arthritis	
LUSC	cis	1	rs72937118	chr2:202229527	PPIL3	chr2:201735680-201753999:-	-0.44	-4.42	1.24E-5	Rheumatoid arthritis	
LUSC	cis	1	rs72937120	chr2:202232611	PPIL3	chr2:201735680-201753999:-	-0.46	-4.54	7.06E-6	Rheumatoid arthritis	
LUSC	cis	1	rs72952733	chr6:118834452	C6orf204	chr6:118786239-119031238:-	-0.24	-3.74	0.000208	Renal cell carcinoma	
LUSC	cis	1	rs72952761	chr6:118866758	C6orf204	chr6:118786239-119031238:-	-0.24	-3.96	8.56E-5	Renal cell carcinoma	
LUSC	cis	1	rs72952793	chr6:118892979	C6orf204	chr6:118786239-119031238:-	-0.25	-3.93	9.6E-5	Renal cell carcinoma	
LUSC	cis	1	rs72954806	chr6:118899965	C6orf204	chr6:118786239-119031238:-	-0.24	-3.73	0.000214	Renal cell carcinoma	
LUSC	cis	1	rs7298108	chr12:9376168	PZP	chr12:9301437-9360966:-	-0.25	-4.2	3.25E-5	Non-alcoholic fatty liver disease histology (AST)	
LUSC	cis	1	rs72981675	chr11:102721251	MMP12	chr11:102733465-102745712:-	-0.3	-4.48	9.31E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs72981680	chr11:102721859	MMP12	chr11:102733465-102745712:-	-0.32	-4.55	6.79E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs72981683	chr11:102722614	MMP12	chr11:102733465-102745712:-	-0.31	-4.51	8.2E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs72981698	chr11:102726540	MMP12	chr11:102733465-102745712:-	-0.32	-4.55	6.79E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs72983508	chr11:102727409	MMP12	chr11:102733465-102745712:-	-0.31	-4.52	7.74E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs72983513	chr11:102728985	MMP12	chr11:102733465-102745712:-	-0.32	-4.5	8.42E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs73018016	chr19:9997361	ZNF266	chr19:9523272-9546234:-	0.21	3.83	0.000144	Menarche (age at onset)	
LUSC	cis	1	rs7302787	chr12:15344066	GUCY2C	chr12:14765570-14849519:-	0.26	3.84	0.000142	Glomerular filtration rate (creatinine)	
LUSC	cis	1	rs73036023	chr19:32948320	DPY19L3	chr19:32896677-32975236:+	0.27	3.93	9.62E-5	Bipolar disorder	
LUSC	cis	1	rs73036771	chr1:179463925	TDRD5	chr1:179561025-179660398:+	-0.38	-4	7.3E-5	Multiple sclerosis (age of onset)	
LUSC	cis	1	rs7303	chr14:75520065	MLH3	chr14:75480467-75518235:-	0.28	5.87	8.09E-9	Height	
LUSC	cis	1	rs73069392	chr3:41787009	ULK4	chr3:41288091-42003660:-	0.6	8.89	1.26E-17	Diastolic blood pressure	
LUSC	cis	1	rs73071329	chr3:41810539	ULK4	chr3:41288091-42003660:-	0.65	10.2	3.23E-22	Diastolic blood pressure	
LUSC	cis	1	rs73074358	chr3:48427247	TREX1	chr3:48501186-48509043:+	-0.44	-9.77	1.18E-20	Longevity	
LUSC	cis	1	rs73079316	chr3:41863859	ULK4	chr3:41288091-42003660:-	0.61	9.18	1.36E-18	Diastolic blood pressure	
LUSC	cis	1	rs73079321	chr3:41863910	ULK4	chr3:41288091-42003660:-	0.6	9.26	6.88E-19	Diastolic blood pressure	
LUSC	cis	1	rs73081353	chr3:41906448	ULK4	chr3:41288091-42003660:-	0.62	9.32	4.23E-19	Diastolic blood pressure	
LUSC	cis	1	rs73081364	chr3:41913616	ULK4	chr3:41288091-42003660:-	0.62	9.32	4.23E-19	Diastolic blood pressure	
LUSC	cis	1	rs73088137	chr3:49448423	AMT	chr3:49454212-49460012:-	-0.2	-4.65	4.32E-6	Menarche (age at onset)	
LUSC	cis	1	rs73088137	chr3:49448423	TREX1	chr3:48501186-48509043:+	0.2	3.7	0.000238	Menarche (age at onset)	
LUSC	cis	1	rs73128528	chr20:44582187	WFDC3	chr20:44402847-44420547:-	-0.54	-6.5	2.0E-10	Abdominal aortic aneurysm	
LUSC	cis	1	rs7313075	chr12:102630679	CHPT1	chr12:102091417-102123424:+	-0.28	-4.31	1.98E-5	Height	
LUSC	cis	1	rs73197056	chr12:91473658	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs73197065	chr12:91477437	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs73197078	chr12:91481558	KERA	chr12:91444273-91452131:-	0.24	3.94	9.5E-5	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs7322160	chr13:61061456	TDRD3	chr13:60970591-61148012:+	0.24	4.31	1.97E-5	Menopause (age at onset)	
LUSC	cis	1	rs73224414	chr4:10297679	SLC2A9	chr4:9827850-10041872:-	0.23	4	7.25E-5	Schizophrenia (age at onset)	
LUSC	cis	1	rs73224437	chr4:10329825	SLC2A9	chr4:9827850-10041872:-	0.25	4.07	5.57E-5	Schizophrenia (age at onset)	
LUSC	cis	1	rs7332189	chr13:36755610	SOHLH2	chr13:36742347-36871992:-	-0.24	-4.27	2.39E-5	Glucose homeostasis traits	
LUSC	cis	1	rs7332932	chr13:36755636	SOHLH2	chr13:36742347-36871992:-	-0.24	-4.27	2.39E-5	Glucose homeostasis traits	
LUSC	cis	1	rs73337598	chr17:61732576	FTSJ3	chr17:61896795-61905031:-	0.32	6.25	9.4E-10	Body mass index	
LUSC	cis	1	rs73352808	chr17:65875157	LOC440461	chr17:66194801-66196436:+	0.24	3.8	0.000167	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs73395547	chr7:98922746	CYP3A5	chr7:99245818-99332821:-	0.47	5.62	3.3E-8	Blood metabolite levels	
LUSC	cis	1	rs73395557	chr7:98934424	CYP3A5	chr7:99245818-99332821:-	0.47	5.59	3.89E-8	Blood metabolite levels	
LUSC	cis	1	rs7340989	chr4:107148720	TBCK	chr4:106967233-107237861:-	0.28	5.28	1.98E-7	Airflow obstruction	
LUSC	cis	1	rs7343481	chr20:25300113	ENTPD6	chr20:25176339-25207360:+	0.21	3.87	0.000126	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs735531	chr20:33947730	CEP250	chr20:34042996-34099802:+	-0.15	-4.04	6.33E-5	Height	
LUSC	cis	1	rs735531	chr20:33947730	CPNE1	chr20:34213968-34262539:-	0.27	4.81	2.06E-6	Height	
LUSC	cis	1	rs735531	chr20:33947730	UQCC	chr20:33890383-33999833:-	0.28	5.13	4.28E-7	Height	
LUSC	cis	1	rs7356093	chr3:134238753	ANAPC13	chr3:134196547-134204865:-	0.42	8.54	1.87E-16	Height	
LUSC	cis	1	rs736344	chr12:110001195	MYO1H	chr12:109826524-109886176:+	0.23	4.23	2.86E-5	HDL cholesterol	
LUSC	cis	1	rs7364173	chr22:50681029	LOC90834	chr22:50171538-50173958:-	-0.14	-3.81	0.000156	Obesity-related traits	
LUSC	cis	1	rs7364180	chr22:42218856	LOC339674	chr22:42120359-42354945:+	0.21	3.9	0.000111	Alzheimer's disease biomarkers	
LUSC	cis	1	rs7371896	chr3:134249769	ANAPC13	chr3:134196547-134204865:-	0.41	8.27	1.4E-15	Height	
LUSC	cis	1	rs7372094	chr3:46346271	CCR2	chr3:46395235-46402412:+	-0.1	-3.83	0.000145	Celiac disease	
LUSC	cis	1	rs737245	chr14:24927382	SDR39U1	chr14:24908974-24912064:-	-0.38	-3.9	0.000111	Smooth-surface caries	
LUSC	cis	1	rs737246	chr14:24927313	SDR39U1	chr14:24908974-24912064:-	-0.37	-3.84	0.000141	Smooth-surface caries	
LUSC	cis	1	rs737247	chr14:24927197	SDR39U1	chr14:24908974-24912064:-	-0.38	-3.9	0.000111	Smooth-surface caries	
LUSC	cis	1	rs7374158	chr3:134270156	ANAPC13	chr3:134196547-134204865:-	0.41	8.23	1.88E-15	Height	
LUSC	cis	1	rs7374325	chr3:134275601	ANAPC13	chr3:134196547-134204865:-	0.42	8.42	4.36E-16	Height	
LUSC	cis	1	rs7374654	chr3:46345787	CCR2	chr3:46395235-46402412:+	-0.1	-3.83	0.000145	Celiac disease	
LUSC	cis	1	rs737693	chr11:102726142	MMP12	chr11:102733465-102745712:-	-0.32	-4.55	6.79E-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
LUSC	cis	1	rs73903009	chr20:33678732	PROCR	chr20:33758727-33765164:+	-0.3	-3.87	0.000126	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs73905019	chr20:33560314	PROCR	chr20:33758727-33765164:+	-0.32	-4.18	3.54E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs73905041	chr20:33592148	GDF5	chr20:33897002-34042568:-	0.27	3.71	0.000234	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs73905041	chr20:33592148	PROCR	chr20:33758727-33765164:+	-0.33	-4.31	1.96E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7406003	chr17:79597597	TSPAN10	chr17:79609349-79615778:+	0.46	9.47	1.33E-19	Eye color traits	
LUSC	cis	1	rs7412746	chr1:150860471	CTSS	chr1:150702554-150738305:-	-0.09	-3.83	0.000145	Melanoma	
LUSC	cis	1	rs7412746	chr1:150860471	HORMAD1	chr1:150670542-150693352:-	-0.62	-11.15	8.16E-26	Melanoma	
LUSC	cis	1	rs74210981	chr10:102287520	SEC31B	chr10:102246403-102289636:-	-0.29	-8.43	4.14E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7425670	chr2:88522028	THNSL2	chr2:88469835-88486145:+	-0.66	-7.86	2.65E-14	Plasma clusterin levels	
LUSC	cis	1	rs7426847	chr3:134267519	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.39	5.58E-16	Height	
LUSC	cis	1	rs7427165	chr3:121364624	IQCB1	chr3:121488610-121553926:-	0.2	4.09	4.97E-5	Cognitive performance	
LUSC	cis	1	rs7427492	chr3:134261654	ANAPC13	chr3:134196547-134204865:-	0.42	8.38	5.82E-16	Height	
LUSC	cis	1	rs7428326	chr3:134251184	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs7428447	chr3:132729297	TMEM108	chr3:132757171-133116618:+	0.2	4.56	6.41E-6	IgE grass sensitization	
LUSC	cis	1	rs7428	chr2:85545490	TGOLN2	chr2:85545147-85555374:-	0.26	5.71	2.02E-8	Ear protrusion	
LUSC	cis	1	rs74293240	chr6:24483896	GPLD1	chr6:24428405-24489850:-	0.42	5.48	6.86E-8	Hematological and biochemical traits	
LUSC	cis	1	rs7429866	chr3:134236306	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.54	1.79E-16	Height	
LUSC	cis	1	rs7432268	chr3:134242051	ANAPC13	chr3:134196547-134204865:-	0.42	8.54	1.87E-16	Height	
LUSC	cis	1	rs7433663	chr3:134235790	ANAPC13	chr3:134196547-134204865:-	0.42	8.47	3.02E-16	Height	
LUSC	cis	1	rs7433991	chr3:134312292	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs74347384	chr7:1072440	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7436021	chr4:76905472	NAAA	chr4:76831809-76862166:-	-0.27	-5.79	1.31E-8	Longevity	
LUSC	cis	1	rs74366004	chr7:1088630	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.87E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs74369356	chr7:1071711	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7436973	chr4:90643921	MMRN1	chr4:90816003-90875778:+	0.26	4.06	5.82E-5	Parkinson's disease	
LUSC	cis	1	rs74372131	chr10:81787214	LOC219347	chr10:81805991-81838949:-	0.41	4.09	5.05E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs74443587	chr1:169532683	SLC19A2	chr1:169433151-169455208:-	0.36	3.87	0.000123	Hippocampal atrophy	
LUSC	cis	1	rs7444	chr22:21976934	CCDC116	chr22:21987086-21991615:+	-0.28	-4.58	5.9E-6	Systemic lupus erythematosus	
LUSC	cis	1	rs74471041	chr3:49542543	AMT	chr3:49454212-49460012:-	-0.2	-4.73	2.92E-6	Menarche (age at onset)	
LUSC	cis	1	rs744937	chr10:118865472	KIAA1598	chr10:118644308-118886097:-	0.24	3.82	0.000154	Nonsyndromic cleft lip with or without cleft palate;Orofacial clefts	
LUSC	cis	1	rs74496027	chr12:56726340	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs74496027	chr12:56726340	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs74543591	chr20:33658658	PROCR	chr20:33758727-33765164:+	-0.33	-4.21	3.07E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs74544416	chr8:82657745	CHMP4C	chr8:82644688-82671746:+	-0.66	-6.3	6.85E-10	Epithelial ovarian cancer;Ovarian cancer	
LUSC	cis	1	rs74589786	chr20:61860939	BIRC7	chr20:61867276-61871853:+	0.36	4.64	4.42E-6	Response to cytadine analogues (cytosine arabinoside)	
LUSC	cis	1	rs74599371	chr20:33561495	PROCR	chr20:33758727-33765164:+	-0.33	-4.16	3.74E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs74626382	chr20:33746668	GDF5	chr20:33897002-34042568:-	0.29	3.7	0.000238	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs74626382	chr20:33746668	PROCR	chr20:33758727-33765164:+	-0.32	-3.93	9.91E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs74650218	chr10:102293830	SEC31B	chr10:102246403-102289636:-	-0.28	-8.28	1.27E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs74652290	chr7:1090109	ZFAND2A	chr7:1192544-1199855:-	-0.36	-5	7.96E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7475154	chr10:131440584	MGMT	chr10:131265454-131565783:+	-0.34	-7.14	3.58E-12	Response to temozolomide	
LUSC	cis	1	rs74758321	chr8:82667320	CHMP4C	chr8:82644688-82671746:+	-0.66	-6.23	1.01E-9	Epithelial ovarian cancer;Ovarian cancer	
LUSC	cis	1	rs7477246	chr10:102261538	SEC31B	chr10:102246403-102289636:-	-0.28	-8.34	8.11E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs74785791	chr7:1088494	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.87E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7478900	chr11:48544003	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.86	0.00013	HDL cholesterol	
LUSC	cis	1	rs7488394	chr12:91480002	KERA	chr12:91444273-91452131:-	0.24	3.92	0.000101	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs74887741	chr7:1110658	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs74898661	chr11:47225730	MADD	chr11:47290927-47351582:+	0.45	5.4	1.03E-7	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs749050	chr10:97376115	ENTPD1	chr10:97471536-97637022:+	0.17	4.97	9.52E-7	Blood metabolite levels	
LUSC	cis	1	rs7496954	chr15:83345536	LOC80154	chr15:82944795-82975797:+;chr15	-0.24	-4.96	9.68E-7	Schizophrenia	
LUSC	cis	1	rs75016635	chr7:1094121	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.11	4.71E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7503679	chr17:79583843	TSPAN10	chr17:79609349-79615778:+	0.46	9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs7503807	chr17:78591111	NPTX1	chr17:78440633-78450404:-	0.23	4.48	9.19E-6	Obesity	
LUSC	cis	1	rs75063298	chr10:102213600	SEC31B	chr10:102246403-102289636:-	-0.26	-7.74	6.18E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7511868	chr1:161463331	FCGR2C	chr1:161551129-161570031:+	-0.12	-3.9	0.000108	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia	
LUSC	cis	1	rs7511962	chr1:247212122	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs7512150	chr1:247212326	ZNF670	chr1:247200087-247242069:-	-0.22	-4.21	3.1E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs7515491	chr1:46355079	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.52	2.85E-13	Body mass index	
LUSC	cis	1	rs7515577	chr1:93009438	EVI5	chr1:92974255-93257961:-	-0.31	-4.5	8.71E-6	Cholesterol, total	
LUSC	cis	1	rs75165171	chr20:33651453	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs75167249	chr19:22128655	ZNF100	chr19:21906844-21950430:-	-0.28	-4.05	6.01E-5	Body mass index (change over time)	
LUSC	cis	1	rs75167249	chr19:22128655	ZNF43	chr19:21987753-22034830:-	-0.26	-3.8	0.000165	Body mass index (change over time)	
LUSC	cis	1	rs7517566	chr1:150850035	HORMAD1	chr1:150670542-150693352:-	0.46	4.71	3.27E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs7517	chr1:150596411	HORMAD1	chr1:150670542-150693352:-	0.42	4.37	1.55E-5	Congenital left-sided heart lesions	
LUSC	cis	1	rs7518038	chr1:76154430	ACADM	chr1:76190043-76229353:+	0.21	3.91	0.000105	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs75181745	chr2:88520408	THNSL2	chr2:88469835-88486145:+	-0.71	-8.45	3.63E-16	Plasma clusterin levels	
LUSC	cis	1	rs751837	chr14:103484825	MARK3	chr14:103851701-103970164:+	0.27	4.07	5.59E-5	Large B-cell lymphoma	
LUSC	cis	1	rs7519795	chr1:247212126	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs7520516	chr1:150659695	HORMAD1	chr1:150670542-150693352:-	0.48	5.13	4.26E-7	Congenital left-sided heart lesions	
LUSC	cis	1	rs7522601	chr1:46419021	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.17	2.97E-12	Body mass index	
LUSC	cis	1	rs7522705	chr1:45992300	CCDC163P	chr1:45960581-45965646:-	0.62	14.08	6.88E-38	Homocysteine levels	
LUSC	cis	1	rs7524495	chr1:46266932	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.16	3.16E-12	Body mass index	
LUSC	cis	1	rs752621	chr17:61901880	FTSJ3	chr17:61896795-61905031:-	0.33	6.28	7.54E-10	Body mass index	
LUSC	cis	1	rs75278386	chr15:40678312	C15orf23	chr15:40674922-40686488:+	0.24	3.78	0.000178	Heschl's gyrus morphology	
LUSC	cis	1	rs75278386	chr15:40678312	IVD	chr15:40697686-40713512:+	-0.37	-4.26	2.45E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs7528684	chr1:157670816	FCRL3	chr1:157646278-157670775:-	0.28	9.11	2.25E-18	Type 1 diabetes autoantibodies	
LUSC	cis	1	rs7528914	chr1:169539133	SLC19A2	chr1:169433151-169455208:-	0.36	4	7.26E-5	Hippocampal atrophy	
LUSC	cis	1	rs7529204	chr1:150845380	HORMAD1	chr1:150670542-150693352:-	-0.49	-4.93	1.12E-6	Congenital left-sided heart lesions	
LUSC	cis	1	rs75309929	chr2:88524377	THNSL2	chr2:88469835-88486145:+	-0.66	-7.69	8.51E-14	Plasma clusterin levels	
LUSC	cis	1	rs753129	chr4:56668431	EXOC1	chr4:56719816-56771244:+	0.28	4.67	4.0E-6	Psychosis in Alzheimer's disease	
LUSC	cis	1	rs7533888	chr1:76160449	ACADM	chr1:76190043-76229353:+	0.22	3.94	9.3E-5	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs7534467	chr1:45988691	CCDC163P	chr1:45960581-45965646:-	-0.75	-18.03	9.6E-56	Homocysteine levels	
LUSC	cis	1	rs7534467	chr1:45988691	MMACHC	chr1:45965856-45976737:+	-0.15	-3.85	0.000136	Homocysteine levels	
LUSC	cis	1	rs7534485	chr1:168720621	DPT	chr1:168664707-168698428:-	0.17	4.32	1.9E-5	Diisocyanate-induced asthma	
LUSC	cis	1	rs7534754	chr1:76185308	ACADM	chr1:76190043-76229353:+	0.21	3.75	0.0002	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs7535475	chr1:161463587	FCGR2C	chr1:161551129-161570031:+	0.13	4.28	2.3E-5	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia	
LUSC	cis	1	rs7536557	chr1:45992114	CCDC163P	chr1:45960581-45965646:-	-0.71	-16.97	7.58E-51	Homocysteine levels	
LUSC	cis	1	rs7537765	chr1:11887303	CLCN6	chr1:11866207-11907674:+	-0.2	-4.22	2.88E-5	QRS complex (12-leadsum)	
LUSC	cis	1	rs7539932	chr1:46292354	CCDC163P	chr1:45960581-45965646:-	-0.34	-7.1	4.66E-12	Body mass index	
LUSC	cis	1	rs7540325	chr1:46338217	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.15	3.31E-12	Body mass index	
LUSC	cis	1	rs75408336	chr1:179459485	TDRD5	chr1:179561025-179660398:+	-0.39	-4.16	3.81E-5	Multiple sclerosis (age of onset)	
LUSC	cis	1	rs7543089	chr1:107591693	PRMT6	chr1:107599267-107601907:+	0.27	4.26	2.44E-5	AIDS	
LUSC	cis	1	rs7546304	chr1:151114484	HORMAD1	chr1:150670542-150693352:-	0.3	4.62	5.01E-6	Body mass index	
LUSC	cis	1	rs7546342	chr1:247213292	ZNF670	chr1:247200087-247242069:-	-0.22	-4.21	3.1E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs75488469	chr7:1102122	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.11	4.65E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7548962	chr1:76139266	ACADM	chr1:76190043-76229353:+	0.22	4.01	7.01E-5	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs7549410	chr1:247214167	ZNF670	chr1:247200087-247242069:-	-0.22	-4.24	2.72E-5	Response to taxane treatment (docetaxel)	
LUSC	cis	1	rs7550746	chr1:46351719	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.3	1.23E-12	Body mass index	
LUSC	cis	1	rs7551732	chr1:89139041	GBP3	chr1:89472367-89488549:-	0.18	3.71	0.00023	Height	
LUSC	cis	1	rs7551874	chr1:12048130	C1orf187	chr1:11751781-11780336:+	0.19	4.09	5.09E-5	Platelet count	
LUSC	cis	1	rs7552404	chr1:76135946	ACADM	chr1:76190043-76229353:+	0.21	3.84	0.000137	Blood metabolite levels;Acylcarnitine levels	
LUSC	cis	1	rs7552722	chr1:115921355	NGF	chr1:115828537-115880857:-	0.21	3.94	9.35E-5	Non-alcoholic fatty liver disease	
LUSC	cis	1	rs7552801	chr1:115921424	NGF	chr1:115828537-115880857:-	0.21	3.94	9.35E-5	Non-alcoholic fatty liver disease	
LUSC	cis	1	rs75535620	chr20:33601498	PROCR	chr20:33758727-33765164:+	-0.33	-4.24	2.65E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs75537616	chr20:33592588	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.47E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs75539640	chr1:169548301	SLC19A2	chr1:169433151-169455208:-	0.35	3.85	0.000135	Hippocampal atrophy	
LUSC	cis	1	rs7556436	chr1:46363880	CCDC163P	chr1:45960581-45965646:-	0.37	7.77	4.83E-14	Body mass index	
LUSC	cis	1	rs7556615	chr1:46461369	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.24	1.82E-12	Body mass index	
LUSC	cis	1	rs7558944	chr2:73810909	ALMS1P	chr2:73872046-73912692:+	0.4	7.45	4.34E-13	Metabolite levels	
LUSC	cis	1	rs7558944	chr2:73810909	NAT8	chr2:73867850-73869537:-	0.27	4.71	3.29E-6	Metabolite levels	
LUSC	cis	1	rs7560328	chr2:202164837	ALS2CR12	chr2:202153148-202222101:-	-0.22	-4.15	4.02E-5	Melanoma;Esophageal squamous cell carcinoma	
LUSC	cis	1	rs7560357	chr2:99247820	UNC50	chr2:99225042-99234975:+	0.23	3.79	0.000168	Bipolar disorder	
LUSC	cis	1	rs7562170	chr2:28943516	TRMT61B	chr2:29072690-29093175:-	0.25	5.06	5.98E-7	Body mass index	
LUSC	cis	1	rs75635914	chr20:33555815	PROCR	chr20:33758727-33765164:+	-0.33	-4.15	4.01E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7564890	chr2:73641853	ALMS1P	chr2:73872046-73912692:+	0.42	7.78	4.53E-14	Metabolite levels	
LUSC	cis	1	rs7564890	chr2:73641853	NAT8	chr2:73867850-73869537:-	0.26	4.45	1.06E-5	Metabolite levels	
LUSC	cis	1	rs7566279	chr2:281178	SH3YL1	chr2:218138-264810:-	-0.5	-8.81	2.34E-17	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs756631	chr22:23463183	RTDR1	chr22:23401594-23484241:-	-0.24	-4.64	4.54E-6	Bone mineral density	
LUSC	cis	1	rs7572722	chr2:73724675	ALMS1P	chr2:73872046-73912692:+	0.4	7.35	8.62E-13	Metabolite levels	
LUSC	cis	1	rs7572722	chr2:73724675	NAT8	chr2:73867850-73869537:-	0.26	4.51	8.01E-6	Metabolite levels	
LUSC	cis	1	rs75754909	chr12:56726349	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs75754909	chr12:56726349	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs757608	chr17:59497277	C17orf82	chr17:59489112-59490641:+	0.16	3.71	0.000233	Sitting height ratio	
LUSC	cis	1	rs7576245	chr2:73829678	ALMS1P	chr2:73872046-73912692:+	0.41	7.6	1.56E-13	Metabolite levels	
LUSC	cis	1	rs7576245	chr2:73829678	NAT8	chr2:73867850-73869537:-	0.24	4.12	4.54E-5	Metabolite levels	
LUSC	cis	1	rs7578199	chr2:242192848	SEPT2	chr2:242254723-242293439:+	0.22	3.92	0.000102	Chronic lymphocytic leukemia	
LUSC	cis	1	rs7579277	chr2:28996295	TRMT61B	chr2:29072690-29093175:-	-0.25	-5.29	1.89E-7	Body mass index	
LUSC	cis	1	rs7580240	chr2:29114372	TRMT61B	chr2:29072690-29093175:-	0.22	3.97	8.19E-5	Breast cancer (estrogen-receptor negative);Breast cancer	
LUSC	cis	1	rs7580825	chr2:73635148	ALMS1P	chr2:73872046-73912692:+	0.44	8.02	8.28E-15	Metabolite levels	
LUSC	cis	1	rs7580825	chr2:73635148	NAT8	chr2:73867850-73869537:-	0.28	4.69	3.5E-6	Metabolite levels	
LUSC	cis	1	rs7581224	chr2:84709215	DNAH6	chr2:84743579-85046711:+	0.23	4.77	2.4E-6	Coronary artery calcification	
LUSC	cis	1	rs75824619	chr20:61856471	BIRC7	chr20:61867276-61871853:+	0.37	4.78	2.31E-6	Response to cytadine analogues (cytosine arabinoside)	
LUSC	cis	1	rs7582606	chr2:73813945	ALMS1P	chr2:73872046-73912692:+	0.41	7.62	1.39E-13	Metabolite levels	
LUSC	cis	1	rs7582606	chr2:73813945	NAT8	chr2:73867850-73869537:-	0.28	4.87	1.49E-6	Metabolite levels	
LUSC	cis	1	rs7583255	chr2:73797996	ALMS1P	chr2:73872046-73912692:+	0.4	7.54	2.33E-13	Metabolite levels	
LUSC	cis	1	rs7583255	chr2:73797996	NAT8	chr2:73867850-73869537:-	0.27	4.73	2.9E-6	Metabolite levels	
LUSC	cis	1	rs7584535	chr2:232106857	ARMC9	chr2:232063342-232238606:+	0.24	5.1	5.04E-7	Food antigen IgG levels	
LUSC	cis	1	rs7584575	chr2:73666402	ALMS1P	chr2:73872046-73912692:+	0.39	7.26	1.59E-12	Metabolite levels	
LUSC	cis	1	rs7584575	chr2:73666402	NAT8	chr2:73867850-73869537:-	0.24	4.17	3.55E-5	Metabolite levels	
LUSC	cis	1	rs7585004	chr2:73666645	ALMS1P	chr2:73872046-73912692:+	0.4	7.33	9.72E-13	Metabolite levels	
LUSC	cis	1	rs7585004	chr2:73666645	NAT8	chr2:73867850-73869537:-	0.23	3.86	0.00013	Metabolite levels	
LUSC	cis	1	rs758598	chr17:59492714	C17orf82	chr17:59489112-59490641:+	0.16	3.85	0.000135	Sitting height ratio	
LUSC	cis	1	rs758599	chr17:59492268	C17orf82	chr17:59489112-59490641:+	0.16	3.83	0.000148	Sitting height ratio	
LUSC	cis	1	rs7586463	chr2:73798476	ALMS1P	chr2:73872046-73912692:+	0.41	7.7	7.86E-14	Metabolite levels	
LUSC	cis	1	rs7586463	chr2:73798476	NAT8	chr2:73867850-73869537:-	0.27	4.78	2.37E-6	Metabolite levels	
LUSC	cis	1	rs75866240	chr20:33558839	PROCR	chr20:33758727-33765164:+	-0.33	-4.15	4.01E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs75889859	chr14:35539054	PPP2R3C	chr14:35554679-35591679:-	0.32	5.73	1.83E-8	Atopic dermatitis	
LUSC	cis	1	rs7589728	chr2:88518440	THNSL2	chr2:88469835-88486145:+	-0.71	-8.45	3.63E-16	Plasma clusterin levels	
LUSC	cis	1	rs75913297	chr10:81789845	LOC219347	chr10:81805991-81838949:-	0.42	4.35	1.66E-5	Chronic obstructive pulmonary disease-related biomarkers	
LUSC	cis	1	rs7591472	chr2:201889751	CFLAR	chr2:201980816-202029001:+	-0.27	-5.15	3.92E-7	Triptolide cytotoxicity	
LUSC	cis	1	rs7591472	chr2:201889751	PPIL3	chr2:201735680-201753999:-	-0.76	-12.84	1.33E-32	Triptolide cytotoxicity	
LUSC	cis	1	rs7594511	chr2:73681639	ALMS1P	chr2:73872046-73912692:+	0.39	7.35	8.5E-13	Metabolite levels	
LUSC	cis	1	rs7594511	chr2:73681639	NAT8	chr2:73867850-73869537:-	0.26	4.52	7.92E-6	Metabolite levels	
LUSC	cis	1	rs7595075	chr2:264019	SH3YL1	chr2:218138-264810:-	-0.51	-9.01	5.01E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs7596362	chr2:61204688	C2orf74	chr2:61372243-61391964:+	0.36	6.48	2.25E-10	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LUSC	cis	1	rs7598396	chr2:73652628	ALMS1P	chr2:73872046-73912692:+	0.4	7.6	1.54E-13	Metabolite levels	
LUSC	cis	1	rs7598396	chr2:73652628	NAT8	chr2:73867850-73869537:-	0.26	4.7	3.46E-6	Metabolite levels	
LUSC	cis	1	rs7598419	chr2:73798223	ALMS1P	chr2:73872046-73912692:+	0.41	7.62	1.41E-13	Metabolite levels	
LUSC	cis	1	rs7598419	chr2:73798223	NAT8	chr2:73867850-73869537:-	0.27	4.73	2.94E-6	Metabolite levels	
LUSC	cis	1	rs7598876	chr2:28974466	TRMT61B	chr2:29072690-29093175:-	-0.26	-5.36	1.27E-7	Body mass index	
LUSC	cis	1	rs7605824	chr2:280819	SH3YL1	chr2:218138-264810:-	0.54	9.68	2.45E-20	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs7607014	chr2:73730174	ALMS1P	chr2:73872046-73912692:+	-0.38	-7.32	1.08E-12	Metabolite levels	
LUSC	cis	1	rs7607014	chr2:73730174	NAT8	chr2:73867850-73869537:-	-0.23	-4.17	3.67E-5	Metabolite levels	
LUSC	cis	1	rs76081054	chr2:86285037	LOC90784	chr2:86247339-86250991:-	-0.39	-3.94	9.19E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LUSC	cis	1	rs7608697	chr2:61204641	C2orf74	chr2:61372243-61391964:+	0.35	6.39	3.91E-10	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LUSC	cis	1	rs7608910	chr2:61204856	C2orf74	chr2:61372243-61391964:+	-0.37	-6.8	3.17E-11	Crohn's disease;Ulcerative colitis;Inflammatory bowel disease	
LUSC	cis	1	rs7609851	chr3:156638503	LEKR1	chr3:156544076-156763918:+	-0.35	-5.88	7.67E-9	Bone mineral density	
LUSC	cis	1	rs7611611	chr3:134307877	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs7611828	chr3:134250325	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs76129108	chr7:1089159	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.24	2.48E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7613491	chr3:49508976	AMT	chr3:49454212-49460012:-	-0.19	-4.28	2.26E-5	Menarche (age at onset)	
LUSC	cis	1	rs7613491	chr3:49508976	KLHDC8B	chr3:49209068-49213918:+	0.24	3.86	0.000129	Menarche (age at onset)	
LUSC	cis	1	rs7613491	chr3:49508976	WDR6	chr3:49044637-49053386:+	0.19	3.88	0.00012	Menarche (age at onset)	
LUSC	cis	1	rs7615952	chr3:125649403	ALG1L	chr3:125648118-125655882:-	0.28	5.47	7.25E-8	Blood pressure (smoking interaction)	
LUSC	cis	1	rs7615952	chr3:125649403	LOC100125556	chr3:125635444-125648865:+	-0.24	-4.21	2.99E-5	Blood pressure (smoking interaction)	
LUSC	cis	1	rs7616044	chr3:125649354	ALG1L	chr3:125648118-125655882:-	-0.29	-5.53	5.38E-8	Blood pressure (smoking interaction)	
LUSC	cis	1	rs7616044	chr3:125649354	LOC100125556	chr3:125635444-125648865:+	0.26	4.3	2.06E-5	Blood pressure (smoking interaction)	
LUSC	cis	1	rs7617456	chr3:132727903	TMEM108	chr3:132757171-133116618:+	0.2	4.77	2.5E-6	IgE grass sensitization	
LUSC	cis	1	rs7617912	chr3:156576412	LEKR1	chr3:156544076-156763918:+	-0.39	-6.28	7.66E-10	Bone mineral density	
LUSC	cis	1	rs76191812	chr20:33563911	PROCR	chr20:33758727-33765164:+	-0.33	-4.15	4.01E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7619451	chr3:134233238	ANAPC13	chr3:134196547-134204865:-	0.41	7.98	1.11E-14	Height	
LUSC	cis	1	rs7619789	chr3:49476263	AMT	chr3:49454212-49460012:-	0.21	5.05	6.31E-7	Menarche (age at onset)	
LUSC	cis	1	rs7619789	chr3:49476263	TREX1	chr3:48501186-48509043:+	-0.23	-4.3	2.06E-5	Menarche (age at onset)	
LUSC	cis	1	rs7620458	chr3:156576850	LEKR1	chr3:156544076-156763918:+	-0.38	-6.31	6.26E-10	Bone mineral density	
LUSC	cis	1	rs76214082	chr7:1102097	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.76E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs762676	chr22:51017794	CPT1B	chr22:51007291-51017096:-	-0.37	-4.98	9.01E-7	Narcolepsy	
LUSC	cis	1	rs762677	chr22:51017713	CPT1B	chr22:51007291-51017096:-	-0.37	-4.87	1.53E-6	Narcolepsy	
LUSC	cis	1	rs7628948	chr3:85594169	CADM2	chr3:85008133-86117948:+	0.32	4.89	1.37E-6	Longevity (90 years and older)	
LUSC	cis	1	rs7629072	chr3:52305633	ITIH4	chr3:52847007-52866554:-	0.15	3.9	0.000109	Electroencephalogram traits	
LUSC	cis	1	rs763014	chr16:675680	WFIKKN1	chr16:679239-684116:+	0.34	6.39	3.94E-10	Height	
LUSC	cis	1	rs7630741	chr3:48419723	ATRIP	chr3:48488141-48507708:+	0.18	3.74	0.000205	Longevity	
LUSC	cis	1	rs7630741	chr3:48419723	TREX1	chr3:48501186-48509043:+	-0.44	-9.73	1.65E-20	Longevity	
LUSC	cis	1	rs7630874	chr3:134293291	ANAPC13	chr3:134196547-134204865:-	-0.41	-8.14	3.45E-15	Height	
LUSC	cis	1	rs7632387	chr3:41853161	ULK4	chr3:41288091-42003660:-	0.62	9.54	7.32E-20	Diastolic blood pressure	
LUSC	cis	1	rs7634377	chr3:48421258	ATRIP	chr3:48488141-48507708:+	0.19	3.88	0.000121	Longevity	
LUSC	cis	1	rs7634377	chr3:48421258	TREX1	chr3:48501186-48509043:+	-0.44	-9.83	7.06E-21	Longevity	
LUSC	cis	1	rs7634816	chr3:46350725	CCR2	chr3:46395235-46402412:+	-0.1	-3.78	0.000175	Celiac disease	
LUSC	cis	1	rs7635522	chr3:48423656	TREX1	chr3:48501186-48509043:+	-0.41	-9.09	2.61E-18	Longevity	
LUSC	cis	1	rs7636044	chr3:48484560	ATRIP	chr3:48488141-48507708:+	0.19	4.05	5.98E-5	Longevity	
LUSC	cis	1	rs7636044	chr3:48484560	TREX1	chr3:48501186-48509043:+	-0.39	-8.54	1.83E-16	Longevity	
LUSC	cis	1	rs76363448	chr20:33655535	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7636782	chr3:48421387	ATRIP	chr3:48488141-48507708:+	0.18	3.7	0.000245	Longevity	
LUSC	cis	1	rs7636782	chr3:48421387	TREX1	chr3:48501186-48509043:+	-0.4	-8.95	7.81E-18	Longevity	
LUSC	cis	1	rs7637227	chr3:134244155	ANAPC13	chr3:134196547-134204865:-	0.42	8.36	6.91E-16	Height	
LUSC	cis	1	rs76388414	chr7:1100694	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.76E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs763919	chr20:44016052	SYS1-DBNDD2	chr20:43991701-44039245:+	-0.23	-3.8	0.000166	Psoriasis	
LUSC	cis	1	rs7639514	chr3:156576067	LEKR1	chr3:156544076-156763918:+	-0.4	-6.59	1.17E-10	Bone mineral density	
LUSC	cis	1	rs76435840	chr11:58285981	CNTF	chr11:58390146-58393203:+	0.4	5.1	4.95E-7	Lymphoma	
LUSC	cis	1	rs7644148	chr3:49545241	AMT	chr3:49454212-49460012:-	-0.2	-4.73	2.92E-6	Menarche (age at onset)	
LUSC	cis	1	rs7645295	chr3:134307734	ANAPC13	chr3:134196547-134204865:-	0.4	7.92	1.69E-14	Height	
LUSC	cis	1	rs7646144	chr3:41853125	ULK4	chr3:41288091-42003660:-	0.61	9.5	9.96E-20	Diastolic blood pressure	
LUSC	cis	1	rs76466034	chr12:56719450	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs76466034	chr12:56719450	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs76475039	chr1:179476763	TDRD5	chr1:179561025-179660398:+	-0.42	-4.33	1.84E-5	Multiple sclerosis (age of onset)	
LUSC	cis	1	rs7647973	chr3:49510931	AMT	chr3:49454212-49460012:-	-0.19	-4.27	2.37E-5	Menarche (age at onset)	
LUSC	cis	1	rs7647973	chr3:49510931	KLHDC8B	chr3:49209068-49213918:+	0.24	3.85	0.000134	Menarche (age at onset)	
LUSC	cis	1	rs7647973	chr3:49510931	WDR6	chr3:49044637-49053386:+	0.19	3.86	0.000127	Menarche (age at onset)	
LUSC	cis	1	rs7648897	chr3:132723658	TMEM108	chr3:132757171-133116618:+	0.22	5.05	6.17E-7	IgE grass sensitization	
LUSC	cis	1	rs7648990	chr3:134244390	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs7648995	chr3:49438803	AMT	chr3:49454212-49460012:-	-0.2	-4.82	1.89E-6	Menarche (age at onset)	
LUSC	cis	1	rs7648995	chr3:49438803	TREX1	chr3:48501186-48509043:+	0.2	3.76	0.000193	Menarche (age at onset)	
LUSC	cis	1	rs76507298	chr20:33623522	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.46E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7651039	chr3:15648004	METTL6	chr3:15422784-15469042:-	-0.18	-3.84	0.000142	Coronary heart disease	
LUSC	cis	1	rs7651407	chr3:48443816	ATRIP	chr3:48488141-48507708:+	0.18	3.71	0.000234	Longevity	
LUSC	cis	1	rs7651407	chr3:48443816	TREX1	chr3:48501186-48509043:+	-0.44	-9.53	8.16E-20	Longevity	
LUSC	cis	1	rs7653691	chr3:48419689	ATRIP	chr3:48488141-48507708:+	-0.19	-3.79	0.000168	Longevity	
LUSC	cis	1	rs7653691	chr3:48419689	TREX1	chr3:48501186-48509043:+	0.43	9.45	1.52E-19	Longevity	
LUSC	cis	1	rs765527	chr19:22129555	ZNF257	chr19:22235266-22273901:+	-0.27	-4.1	4.9E-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs76553384	chr14:74383679	LIN52	chr14:74551656-74667117:+	0.29	4.31	2.0E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs7655792	chr4:90642025	MMRN1	chr4:90816003-90875778:+	0.26	4	7.22E-5	Parkinson's disease	
LUSC	cis	1	rs7656037	chr4:39717965	RPL9	chr4:39455747-39460568:-	-0.32	-5.98	4.47E-9	Plasma amyloid beta peptide concentrations (ABx-40)	
LUSC	cis	1	rs7657962	chr4:106966715	TBCK	chr4:106967233-107237861:-	0.31	5.67	2.47E-8	Airflow obstruction	
LUSC	cis	1	rs7661330	chr4:90663670	MMRN1	chr4:90816003-90875778:+	-0.24	-3.73	0.000217	Parkinson's disease	
LUSC	cis	1	rs76648234	chr20:33689941	PROCR	chr20:33758727-33765164:+	-0.3	-3.87	0.000126	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs76683169	chr10:102358397	SEC31B	chr10:102246403-102289636:-	-0.26	-7.14	3.48E-12	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs7675290	chr4:90645003	MMRN1	chr4:90816003-90875778:+	0.25	3.81	0.000157	Parkinson's disease	
LUSC	cis	1	rs7677248	chr4:106960497	TBCK	chr4:106967233-107237861:-	-0.29	-5.36	1.33E-7	Airflow obstruction	
LUSC	cis	1	rs7678847	chr4:106987426	TBCK	chr4:106967233-107237861:-	0.27	5.1	5.02E-7	Airflow obstruction	
LUSC	cis	1	rs76804143	chr7:1082021	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.44	8.59E-8	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs76812330	chr19:50531860	SIGLEC16	chr19:50472912-50479075:+	0.68	7.18	2.67E-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs7681312	chr4:90638527	MMRN1	chr4:90816003-90875778:+	0.26	4	7.22E-5	Parkinson's disease	
LUSC	cis	1	rs7681815	chr4:90638614	MMRN1	chr4:90816003-90875778:+	0.25	4.01	7.04E-5	Parkinson's disease	
LUSC	cis	1	rs76833820	chr7:1070278	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs76850134	chr20:33671725	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7686578	chr4:75712726	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs7687557	chr4:39769260	RPL9	chr4:39455747-39460568:-	-0.29	-5.55	4.79E-8	Plasma amyloid beta peptide concentrations (ABx-40)	
LUSC	cis	1	rs76901676	chr1:179452520	TDRD5	chr1:179561025-179660398:+	-0.39	-4.2	3.24E-5	Multiple sclerosis (age of onset)	
LUSC	cis	1	rs7692069	chr4:106959289	TBCK	chr4:106967233-107237861:-	0.29	5.27	2.03E-7	Airflow obstruction	
LUSC	cis	1	rs7692290	chr4:75712720	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs7692503	chr4:75712852	G3BP2	chr4:76567955-76598667:-	0.31	3.78	0.000179	Electroencephalogram traits	
LUSC	cis	1	rs7692669	chr4:75712905	G3BP2	chr4:76567955-76598667:-	0.31	3.8	0.000162	Electroencephalogram traits	
LUSC	cis	1	rs7694379	chr4:88186509	HSD17B13	chr4:88224941-88244056:-	-0.22	-4.48	9.34E-6	Platelet count	
LUSC	cis	1	rs76994419	chr15:40714150	C15orf23	chr15:40674922-40686488:+	0.32	4.82	1.95E-6	Heschl's gyrus morphology	
LUSC	cis	1	rs7705093	chr5:96290647	ERAP2	chr5:96211644-96255398:+	0.93	28.7	8.17E-106	Birdshot chorioretinopathy	
LUSC	cis	1	rs77083167	chr7:1071823	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs77187281	chr19:50507667	SIGLEC16	chr19:50472912-50479075:+	0.8	7.79	4.12E-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs77257477	chr8:96045399	C8orf38	chr8:95908040-96088396:+	-0.26	-3.71	0.000228	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	
LUSC	cis	1	rs7727038	chr5:131590257	SLC22A5	chr5:131705401-131731302:+	-0.19	-3.81	0.000156	Blood metabolite levels	
LUSC	cis	1	rs7727544	chr5:131590534	SLC22A5	chr5:131705401-131731302:+	-0.19	-3.81	0.000156	Blood metabolite levels	
LUSC	cis	1	rs77305932	chr7:1100861	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.76E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs77346188	chr7:1114023	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs77374467	chr6:24475278	GPLD1	chr6:24428405-24489850:-	0.52	5.91	6.65E-9	Hematological and biochemical traits	
LUSC	cis	1	rs7740682	chr6:49488745	CENPQ	chr6:49431096-49460820:+	0.18	3.81	0.00016	Brain structure	
LUSC	cis	1	rs77417616	chr1:169548053	SLC19A2	chr1:169433151-169455208:-	0.36	3.97	8.33E-5	Hippocampal atrophy	
LUSC	cis	1	rs7742626	chr6:136132496	PDE7B	chr6:136172834-136516708:+	-0.24	-4.69	3.64E-6	Phosphorus levels	
LUSC	cis	1	rs77437249	chr20:33564738	PROCR	chr20:33758727-33765164:+	-0.33	-4.14	4.06E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs77450480	chr1:169534584	SLC19A2	chr1:169433151-169455208:-	0.36	3.87	0.000123	Hippocampal atrophy	
LUSC	cis	1	rs77477310	chr14:35615793	PPP2R3C	chr14:35554679-35591679:-	0.3	5.27	2.07E-7	Atopic dermatitis	
LUSC	cis	1	rs7747824	chr6:86647106	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs7750918	chr6:49430082	CENPQ	chr6:49431096-49460820:+	-0.38	-8.3	1.1E-15	Folate pathway vitamin levels	
LUSC	cis	1	rs7750918	chr6:49430082	MUT	chr6:49398994-49431031:-	0.31	5.48	6.84E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs77531164	chr15:40673466	C15orf23	chr15:40674922-40686488:+	0.23	3.78	0.000176	Heschl's gyrus morphology	
LUSC	cis	1	rs77531164	chr15:40673466	IVD	chr15:40697686-40713512:+	-0.35	-4.12	4.42E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs7756203	chr6:86627707	SNHG5	chr6:86386726-86388451:-	-0.65	-12.15	8.93E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs7757014	chr6:49491690	CENPQ	chr6:49431096-49460820:+	-0.19	-3.96	8.8E-5	Brain structure	
LUSC	cis	1	rs7759001	chr6:27341409	ZNF391	chr6:27356524-27369227:+	0.29	5.74	1.72E-8	Glomerular filtration rate (creatinine)	
LUSC	cis	1	rs7759071	chr6:49433198	CENPQ	chr6:49431096-49460820:+	-0.39	-9.08	2.99E-18	Homocysteine levels	
LUSC	cis	1	rs7760207	chr6:86721700	SNHG5	chr6:86386726-86388451:-	-0.68	-12.85	1.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs77654484	chr11:47206594	MADD	chr11:47290927-47351582:+	0.45	5.32	1.57E-7	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs7766645	chr6:86622238	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs77702926	chr7:1088838	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.21	2.87E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7770848	chr6:44769237	MRPL14	chr6:44081374-44095191:-	-0.36	-4.16	3.74E-5	Asthma (childhood onset)	
LUSC	cis	1	rs7771342	chr6:86631936	SNHG5	chr6:86386726-86388451:-	-0.65	-12.15	8.93E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs7773987	chr6:135707486	AHI1	chr6:135605112-135818903:-	0.27	6.75	4.37E-11	Selective IgA deficiency	
LUSC	cis	1	rs7774688	chr6:49387292	CENPQ	chr6:49431096-49460820:+	-0.38	-8.76	3.55E-17	Homocysteine levels	
LUSC	cis	1	rs7774688	chr6:49387292	MUT	chr6:49398994-49431031:-	0.21	3.75	0.000196	Homocysteine levels	
LUSC	cis	1	rs77760339	chr7:1083927	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.33	1.55E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs77768890	chr12:56725121	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs77768890	chr12:56725121	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs7777389	chr7:143744802	ARHGEF35	chr7:143883677-143892736:-	-0.37	-7.51	2.92E-13	Obesity-related traits	
LUSC	cis	1	rs7777389	chr7:143744802	OR2A9P	chr7:143991573-143997832:+;chr7	-0.25	-4.54	6.98E-6	Obesity-related traits	
LUSC	cis	1	rs7781698	chr7:65896312	NCRNA00174	chr7:65841032-65865395:-	-0.27	-5.8	1.21E-8	Aortic root size	
LUSC	cis	1	rs7782320	chr7:66177098	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.48	6.84E-8	Aortic root size	
LUSC	cis	1	rs7783613	chr7:65805261	NCRNA00174	chr7:65841032-65865395:-	0.29	6.08	2.42E-9	Aortic root size	
LUSC	cis	1	rs7783924	chr7:66209057	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.48	7.03E-8	Aortic root size	
LUSC	cis	1	rs7785213	chr7:66138978	NCRNA00174	chr7:65841032-65865395:-	0.25	5.5	6.35E-8	Aortic root size	
LUSC	cis	1	rs77868187	chr7:1093968	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.11	4.6E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs778685	chr7:65836176	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.28	7.62E-10	Aortic root size	
LUSC	cis	1	rs778694	chr7:65871558	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs778696	chr7:65870813	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs778699	chr7:65868290	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs778706	chr7:65860424	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs778710	chr7:65854834	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.29	7.32E-10	Aortic root size	
LUSC	cis	1	rs778722	chr7:65844828	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.28	7.53E-10	Aortic root size	
LUSC	cis	1	rs778726	chr7:65828731	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.28	7.62E-10	Aortic root size	
LUSC	cis	1	rs7787274	chr7:2275993	FTSJ2	chr7:2273928-2281833:-	0.25	4.43	1.17E-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LUSC	cis	1	rs778758	chr2:61782161	AHSA2	chr2:61404553-61414058:+	-0.16	-5.73	1.76E-8	Tuberculosis	
LUSC	cis	1	rs778758	chr2:61782161	C2orf74	chr2:61372243-61391964:+	0.44	7.95	1.42E-14	Tuberculosis	
LUSC	cis	1	rs778762	chr2:61782921	AHSA2	chr2:61404553-61414058:+	-0.16	-5.58	4.09E-8	Tuberculosis	
LUSC	cis	1	rs778762	chr2:61782921	C2orf74	chr2:61372243-61391964:+	0.45	8.04	6.98E-15	Tuberculosis	
LUSC	cis	1	rs778763	chr2:61785639	AHSA2	chr2:61404553-61414058:+	-0.16	-5.86	8.9E-9	Tuberculosis	
LUSC	cis	1	rs778763	chr2:61785639	C2orf74	chr2:61372243-61391964:+	0.44	7.91	1.79E-14	Tuberculosis	
LUSC	cis	1	rs7787818	chr7:134251597	AKR1B15	chr7:134233849-134264300:+	0.21	4.22	2.92E-5	Longevity	
LUSC	cis	1	rs7788576	chr7:66148302	NCRNA00174	chr7:65841032-65865395:-	0.25	5.44	8.73E-8	Aortic root size	
LUSC	cis	1	rs7789181	chr7:97621263	MGC72080	chr7:97503667-97601638:-	0.36	4.01	7.15E-5	Sudden cardiac arrest	
LUSC	cis	1	rs7789184	chr7:66210195	NCRNA00174	chr7:65841032-65865395:-	-0.25	-5.48	7.03E-8	Aortic root size	
LUSC	cis	1	rs7789554	chr7:65946038	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs7789768	chr7:65938980	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.19	1.31E-9	Aortic root size	
LUSC	cis	1	rs77902909	chr6:24478715	GPLD1	chr6:24428405-24489850:-	0.52	5.86	8.79E-9	Hematological and biochemical traits	
LUSC	cis	1	rs7792762	chr7:66004138	NCRNA00174	chr7:65841032-65865395:-	-0.27	-5.66	2.65E-8	Aortic root size	
LUSC	cis	1	rs7797900	chr7:151117495	CRYGN	chr7:151127057-151137899:-	0.28	3.83	0.000147	Coronary heart disease	
LUSC	cis	1	rs7797900	chr7:151117495	WDR86	chr7:151078207-151107740:-	0.28	4.06	5.67E-5	Coronary heart disease	
LUSC	cis	1	rs7798194	chr7:151117695	CRYGN	chr7:151127057-151137899:-	0.29	3.95	9.15E-5	Coronary heart disease	
LUSC	cis	1	rs7798194	chr7:151117695	WDR86	chr7:151078207-151107740:-	0.28	4.19	3.26E-5	Coronary heart disease	
LUSC	cis	1	rs7801282	chr7:65613687	NCRNA00174	chr7:65841032-65865395:-	0.3	6.31	6.3E-10	Aortic root size	
LUSC	cis	1	rs78055011	chr20:33618606	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.46E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7810970	chr7:2276385	FTSJ2	chr7:2273928-2281833:-	0.24	4.36	1.6E-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	
LUSC	cis	1	rs78143408	chr7:1096846	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.07	5.8E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7815298	chr8:130732739	GSDMC	chr8:130760443-130799134:-	0.25	5.09	5.25E-7	Infant length;Height	
LUSC	cis	1	rs78153629	chr15:40673465	C15orf23	chr15:40674922-40686488:+	0.23	3.78	0.000176	Heschl's gyrus morphology	
LUSC	cis	1	rs78153629	chr15:40673465	IVD	chr15:40697686-40713512:+	-0.35	-4.12	4.42E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs78158942	chr7:1090440	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.24	2.48E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs78172786	chr17:61847114	FTSJ3	chr17:61896795-61905031:-	0.35	6.68	6.86E-11	Body mass index	
LUSC	cis	1	rs78172786	chr17:61847114	MAP3K3	chr17:61699775-61773669:+	0.17	4.01	7.13E-5	Body mass index	
LUSC	cis	1	rs78185558	chr7:1090183	ZFAND2A	chr7:1192544-1199855:-	-0.35	-4.95	1.03E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs78185801	chr7:1096367	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.07	5.8E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs78202808	chr20:33667424	PROCR	chr20:33758727-33765164:+	-0.31	-4.07	5.43E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs78207779	chr14:35506387	PPP2R3C	chr14:35554679-35591679:-	0.29	5.03	6.9E-7	Atopic dermatitis	
LUSC	cis	1	rs7821416	chr8:120657392	DSCC1	chr8:120846182-120868170:-	0.25	4.24	2.74E-5	Height	
LUSC	cis	1	rs7822232	chr8:145145687	KIAA1875	chr8:145162629-145173218:+	-0.27	-3.71	0.000235	Blood metabolite levels	
LUSC	cis	1	rs7824557	chr8:11104111	AMAC1L2	chr8:11188495-11189695:+	0.22	4.05	6.1E-5	Retinal vascular caliber	
LUSC	cis	1	rs782876	chr7:134240770	AKR1B15	chr7:134233849-134264300:+	0.24	4.71	3.25E-6	Longevity	
LUSC	cis	1	rs78308415	chr7:1072634	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7832232	chr8:38469303	PLEKHA2	chr8:38758753-38831428:+	-0.22	-4.1	4.9E-5	Pancreatic cancer	
LUSC	cis	1	rs7832232	chr8:38469303	PROSC	chr8:37620101-37637285:+	-0.21	-3.77	0.000187	Pancreatic cancer	
LUSC	cis	1	rs783531	chr15:83249119	LOC80154	chr15:82944795-82975797:+;chr15	0.25	5.22	2.69E-7	Schizophrenia	
LUSC	cis	1	rs783540	chr15:83254708	LOC80154	chr15:82944795-82975797:+;chr15	-0.21	-4.47	9.64E-6	Schizophrenia	
LUSC	cis	1	rs78420872	chr6:24464429	GPLD1	chr6:24428405-24489850:-	0.54	6.27	8.32E-10	Hematological and biochemical traits	
LUSC	cis	1	rs784408	chr15:48995881	DUT	chr15:48623621-48635568:+	0.2	3.79	0.000173	Insomnia	
LUSC	cis	1	rs7847663	chr9:100544868	CTSL2	chr9:99794940-99822167:-	-0.2	-3.74	0.000204	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs7850258	chr9:100549013	CTSL2	chr9:99794940-99822167:-	0.22	4.29	2.16E-5	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs78523927	chr7:1089458	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.24	2.48E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs785464	chr1:46523089	CCDC163P	chr1:45960581-45965646:-	-0.37	-7.66	1.04E-13	Body mass index	
LUSC	cis	1	rs785471	chr1:46518677	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.38	6.99E-13	Body mass index	
LUSC	cis	1	rs785479	chr1:46492144	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.75	4.32E-11	Body mass index	
LUSC	cis	1	rs785481	chr1:46554518	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.61E-13	Body mass index	
LUSC	cis	1	rs785485	chr1:46574424	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.57E-13	Body mass index	
LUSC	cis	1	rs785488	chr1:46576095	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.54E-13	Body mass index	
LUSC	cis	1	rs785489	chr1:46576390	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.63E-13	Body mass index	
LUSC	cis	1	rs785491	chr1:46583418	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.54E-13	Body mass index	
LUSC	cis	1	rs785492	chr1:46583607	CCDC163P	chr1:45960581-45965646:-	-0.35	-7.27	1.46E-12	Body mass index	
LUSC	cis	1	rs785494	chr1:46586626	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.54E-13	Body mass index	
LUSC	cis	1	rs785495	chr1:46587887	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.98	9.81E-12	Body mass index	
LUSC	cis	1	rs785503	chr1:46595868	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.54E-13	Body mass index	
LUSC	cis	1	rs785520	chr1:46568836	CCDC163P	chr1:45960581-45965646:-	-0.36	-7.53	2.66E-13	Body mass index	
LUSC	cis	1	rs7855278	chr9:131921365	CRAT	chr9:131857075-131873070:-	-0.26	-4.94	1.06E-6	Blood metabolite ratios	
LUSC	cis	1	rs78594996	chr17:40570109	CNTD1	chr17:40950854-40963604:+	0.18	3.86	0.000129	Crohn's disease	
LUSC	cis	1	rs78604110	chr15:40681854	IVD	chr15:40697686-40713512:+	-0.39	-4.47	9.99E-6	Heschl's gyrus morphology	
LUSC	cis	1	rs78628466	chr7:1068453	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.31	1.72E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs786425	chr12:124085502	ATP6V0A2	chr12:124196865-124246299:+	-0.31	-5.8	1.21E-8	Pubertal anthropometrics	
LUSC	cis	1	rs7864322	chr9:100548934	CTSL2	chr9:99794940-99822167:-	-0.2	-3.77	0.000181	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs78646493	chr2:86283195	LOC90784	chr2:86247339-86250991:-	-0.39	-3.94	9.19E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
LUSC	cis	1	rs78724141	chr8:82659661	CHMP4C	chr8:82644688-82671746:+	-0.66	-6.3	6.85E-10	Epithelial ovarian cancer;Ovarian cancer	
LUSC	cis	1	rs78808915	chr6:24481312	GPLD1	chr6:24428405-24489850:-	0.39	5.03	6.9E-7	Hematological and biochemical traits	
LUSC	cis	1	rs78861357	chr7:1095418	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.11	4.6E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs78896566	chr7:1080182	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.44	8.59E-8	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs78953187	chr1:93000574	EVI5	chr1:92974255-93257961:-	-0.32	-4.64	4.53E-6	Cholesterol, total	
LUSC	cis	1	rs78967641	chr20:33783053	GDF5	chr20:33897002-34042568:-	0.32	4.32	1.89E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs78967641	chr20:33783053	PROCR	chr20:33758727-33765164:+	-0.3	-3.9	0.000109	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs78998999	chr11:47228403	MADD	chr11:47290927-47351582:+	0.46	5.44	8.62E-8	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs790006	chr12:64606439	RASSF3	chr12:65004293-65089190:+	-0.19	-3.89	0.000116	Response to cytidine analogues (gemcitabine)	
LUSC	cis	1	rs7903456	chr10:88919319	FAM35A	chr10:88854953-88951220:+	-0.25	-4.84	1.75E-6	Renal underexcretion gout;Gout	
LUSC	cis	1	rs79044335	chr11:47200402	MADD	chr11:47290927-47351582:+	0.45	5.32	1.57E-7	Waist-to-hip ratio adjusted for body mass index	
LUSC	cis	1	rs79044944	chr15:40676285	C15orf23	chr15:40674922-40686488:+	0.23	3.72	0.000219	Heschl's gyrus morphology	
LUSC	cis	1	rs79044944	chr15:40676285	IVD	chr15:40697686-40713512:+	-0.38	-4.32	1.94E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs7905961	chr10:102297391	SEC31B	chr10:102246403-102289636:-	-0.28	-8.66	7.62E-17	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs79101914	chr12:56729739	NXPH4	chr12:57610578-57620231:+	0.43	3.73	0.000212	Psoriasis vulgaris	
LUSC	cis	1	rs79101914	chr12:56729739	PAN2	chr12:56710718-56727825:-	0.34	3.69	0.000246	Psoriasis vulgaris	
LUSC	cis	1	rs7917792	chr10:97365627	ENTPD1	chr10:97471536-97637022:+	0.16	4.86	1.58E-6	Blood metabolite levels	
LUSC	cis	1	rs791856	chr6:86681841	SNHG5	chr6:86386726-86388451:-	0.68	12.88	8.8E-33	Response to antipsychotic treatment	
LUSC	cis	1	rs79197732	chr20:33562476	PROCR	chr20:33758727-33765164:+	-0.33	-4.16	3.74E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs79199019	chr14:35581125	PPP2R3C	chr14:35554679-35591679:-	0.33	5.73	1.81E-8	Atopic dermatitis	
LUSC	cis	1	rs7927771	chr11:47781306	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.02	6.78E-5	Subjective well-being	
LUSC	cis	1	rs79318564	chr15:84786150	GOLGA6L5	chr15:85047738-85060078:-	-0.16	-3.7	0.000245	Schizophrenia	
LUSC	cis	1	rs79318564	chr15:84786150	LOC388152	chr15:84867600-84898920:-	-0.27	-4.74	2.78E-6	Schizophrenia	
LUSC	cis	1	rs7931984	chr11:48580835	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.76	0.000188	HDL cholesterol	
LUSC	cis	1	rs79327308	chr7:1108141	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.27	2.02E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7938380	chr11:64034866	C11orf20	chr11:64067863-64072238:+	-0.33	-4.62	4.98E-6	Mean platelet volume	
LUSC	cis	1	rs7939107	chr11:64034773	C11orf20	chr11:64067863-64072238:+	-0.33	-4.62	4.98E-6	Mean platelet volume	
LUSC	cis	1	rs7940310	chr11:117024481	PCSK7	chr11:117075789-117102811:-	-0.37	-5.12	4.44E-7	Protein quantitative trait loci	
LUSC	cis	1	rs79422648	chr7:1080241	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.44	8.59E-8	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs79436302	chr14:35578797	PPP2R3C	chr14:35554679-35591679:-	0.33	5.73	1.81E-8	Atopic dermatitis	
LUSC	cis	1	rs79438986	chr20:33702280	PROCR	chr20:33758727-33765164:+	-0.31	-3.96	8.64E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs79439610	chr20:33654689	PROCR	chr20:33758727-33765164:+	-0.33	-4.23	2.79E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs7944004	chr11:2311152	C11orf21	chr11:2317507-2323143:-	0.14	4.51	8.05E-6	Chronic lymphocytic leukemia	
LUSC	cis	1	rs79443843	chr7:1075245	ZFAND2A	chr7:1192544-1199855:-	-0.39	-5.46	7.54E-8	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7945192	chr11:48580737	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.76	0.000188	HDL cholesterol	
LUSC	cis	1	rs79475579	chr11:58295900	CNTF	chr11:58390146-58393203:+	0.38	4.92	1.2E-6	Lymphoma	
LUSC	cis	1	rs7947730	chr11:47786184	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.02	6.78E-5	Subjective well-being	
LUSC	cis	1	rs7949348	chr11:48493801	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.7	0.000241	HDL cholesterol	
LUSC	cis	1	rs7949554	chr11:48581992	C1QTNF4	chr11:47611216-47615961:-	-0.19	-3.72	0.00022	HDL cholesterol	
LUSC	cis	1	rs7950069	chr11:115140553	REXO2	chr11:114310108-114320998:+	0.28	4.5	8.6E-6	Orofacial clefts	
LUSC	cis	1	rs7950364	chr11:116898886	PCSK7	chr11:117075789-117102811:-	-0.35	-4.8	2.1E-6	Protein quantitative trait loci	
LUSC	cis	1	rs7953014	chr12:109998097	MYO1H	chr12:109826524-109886176:+	0.23	4.2	3.26E-5	HDL cholesterol	
LUSC	cis	1	rs7954144	chr12:110015893	MYO1H	chr12:109826524-109886176:+	0.24	4.36	1.6E-5	HDL cholesterol	
LUSC	cis	1	rs7957145	chr12:57302120	DCTN2	chr12:57924094-57940978:-	-0.27	-3.87	0.000122	Airway wall thickness	
LUSC	cis	1	rs7957635	chr12:1985156	ADIPOR2	chr12:1800247-1897844:+	0.34	4.4	1.37E-5	QRS duration in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs7957635	chr12:1985156	ITFG2	chr12:2921863-2939770:+	0.32	3.96	8.82E-5	QRS duration in Tripanosoma cruzi seropositivity	
LUSC	cis	1	rs7958864	chr12:58783716	PIP4K2C	chr12:57984942-57997210:+	-0.22	-3.86	0.000132	Obesity-related traits	
LUSC	cis	1	rs79602855	chr19:50525725	SIGLEC16	chr19:50472912-50479075:+	0.78	7.72	6.95E-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs79617366	chr7:1111958	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs79633979	chr19:50488612	SIGLEC16	chr19:50472912-50479075:+	0.8	7.7	8.23E-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs7964021	chr12:109997645	MYO1H	chr12:109826524-109886176:+	0.23	4.22	2.98E-5	HDL cholesterol	
LUSC	cis	1	rs79683221	chr7:1096139	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.07	5.8E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs79702597	chr14:35558856	PPP2R3C	chr14:35554679-35591679:-	0.33	5.85	8.99E-9	Atopic dermatitis	
LUSC	cis	1	rs79716074	chr2:277003	SH3YL1	chr2:218138-264810:-	-0.51	-9	5.46E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs79750959	chr12:56702012	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs79750959	chr12:56702012	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs79765398	chr7:1073764	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.25	2.25E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs7978895	chr12:43570515	ADAMTS20	chr12:43748013-43945724:-	-0.21	-4.02	6.77E-5	Type 2 diabetes	
LUSC	cis	1	rs7980687	chr12:123822711	ABCB9	chr12:123413540-123459752:-	0.32	4.6	5.54E-6	Educational attainment;Height;Head circumference (infant)	
LUSC	cis	1	rs7980687	chr12:123822711	CDK2AP1	chr12:123745542-123756687:-	-0.29	-4.32	1.91E-5	Educational attainment;Height;Head circumference (infant)	
LUSC	cis	1	rs79824801	chr12:56728137	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs79824801	chr12:56728137	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs79831012	chr10:102237059	SEC31B	chr10:102246403-102289636:-	-0.26	-7.97	1.22E-14	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs79846980	chr19:22141343	ZNF100	chr19:21906844-21950430:-	-0.31	-4.38	1.46E-5	Body mass index (change over time)	
LUSC	cis	1	rs79846980	chr19:22141343	ZNF429	chr19:21688437-21739068:+	-0.29	-4.05	5.92E-5	Body mass index (change over time)	
LUSC	cis	1	rs79846980	chr19:22141343	ZNF430	chr19:21203497-21241652:+	-0.27	-3.83	0.000144	Body mass index (change over time)	
LUSC	cis	1	rs79846980	chr19:22141343	ZNF43	chr19:21987753-22034830:-	-0.27	-3.91	0.000107	Body mass index (change over time)	
LUSC	cis	1	rs79846980	chr19:22141343	ZNF493	chr19:21579921-21610294:+	-0.25	-3.7	0.00024	Body mass index (change over time)	
LUSC	cis	1	rs798766	chr4:1734239	FAM53A	chr4:1641609-1685854:-	0.29	4.83	1.85E-6	Urinary bladder cancer;Bladder cancer	
LUSC	cis	1	rs79888893	chr14:35510676	PPP2R3C	chr14:35554679-35591679:-	0.31	5.41	1.02E-7	Atopic dermatitis	
LUSC	cis	1	rs800142	chr11:2385071	C11orf21	chr11:2317507-2323143:-	-0.2	-4.67	3.88E-6	Bacteremia	
LUSC	cis	1	rs800153	chr11:2373515	C11orf21	chr11:2317507-2323143:-	-0.2	-4.76	2.52E-6	Bacteremia	
LUSC	cis	1	rs800156	chr11:2376436	C11orf21	chr11:2317507-2323143:-	-0.2	-4.66	4.08E-6	Bacteremia	
LUSC	cis	1	rs800157	chr11:2376602	C11orf21	chr11:2317507-2323143:-	-0.2	-4.7	3.36E-6	Bacteremia	
LUSC	cis	1	rs800158	chr11:2378447	C11orf21	chr11:2317507-2323143:-	0.18	4.39	1.38E-5	Bacteremia	
LUSC	cis	1	rs800160	chr11:2380134	C11orf21	chr11:2317507-2323143:-	0.2	4.81	1.98E-6	Bacteremia	
LUSC	cis	1	rs80031817	chr7:1096793	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.07	5.8E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs8003506	chr14:75586288	MLH3	chr14:75480467-75518235:-	-0.27	-5.72	1.87E-8	Height	
LUSC	cis	1	rs8006419	chr14:65500735	CHURC1	chr14:65381140-65411309:+	-0.19	-3.83	0.000146	Red blood cell traits	
LUSC	cis	1	rs80076579	chr4:106991115	TBCK	chr4:106967233-107237861:-	0.27	5.1	4.88E-7	Airflow obstruction	
LUSC	cis	1	rs80094748	chr7:1103958	ZFAND2A	chr7:1192544-1199855:-	-0.36	-4.95	1.06E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs8010715	chr14:24609147	FAM158A	chr14:24608175-24610797:-	-0.34	-7.1	4.51E-12	IgG glycosylation	
LUSC	cis	1	rs80109502	chr20:33587596	PROCR	chr20:33758727-33765164:+	-0.34	-4.26	2.47E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8013540	chr14:35513760	PPP2R3C	chr14:35554679-35591679:-	0.31	5.53	5.29E-8	Atopic dermatitis	
LUSC	cis	1	rs8014170	chr14:50071694	RPL36AL	chr14:50085407-50087349:-	0.23	4.95	1.03E-6	Carotid intima media thickness	
LUSC	cis	1	rs80170004	chr20:33551462	PROCR	chr20:33758727-33765164:+	-0.33	-4.16	3.74E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8017642	chr14:75590822	MLH3	chr14:75480467-75518235:-	0.28	5.95	5.31E-9	Height	
LUSC	cis	1	rs8018967	chr14:73976934	HEATR4	chr14:73945193-74025651:-	-0.46	-8.81	2.42E-17	Blood metabolite ratios	
LUSC	cis	1	rs80202648	chr19:50494386	SIGLEC16	chr19:50472912-50479075:+	0.8	7.97	1.23E-14	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs80212261	chr7:1114012	ZFAND2A	chr7:1192544-1199855:-	-0.38	-5.28	2.01E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs8021692	chr14:104428576	TDRD9	chr14:104394817-104519002:+	0.26	4.32	1.9E-5	Bipolar disorder	
LUSC	cis	1	rs8024944	chr15:56125135	NEDD4	chr15:56119131-56285835:-	0.23	4.16	3.79E-5	Keloid	
LUSC	cis	1	rs8026172	chr15:56125182	NEDD4	chr15:56119131-56285835:-	0.23	4.17	3.68E-5	Keloid	
LUSC	cis	1	rs80277764	chr20:33739456	GDF5	chr20:33897002-34042568:-	0.29	3.71	0.000232	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs80277764	chr20:33739456	PROCR	chr20:33758727-33765164:+	-0.33	-4.08	5.31E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs80285556	chr19:50540170	SIGLEC16	chr19:50472912-50479075:+	0.71	7.19	2.53E-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs8029247	chr15:56273446	NEDD4	chr15:56119131-56285835:-	-0.22	-3.95	9.08E-5	Keloid	
LUSC	cis	1	rs80314222	chr19:50525514	SIGLEC16	chr19:50472912-50479075:+	0.78	7.64	1.2E-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
LUSC	cis	1	rs80317430	chr12:56727705	NXPH4	chr12:57610578-57620231:+	0.43	3.74	0.000206	Psoriasis vulgaris	
LUSC	cis	1	rs80317430	chr12:56727705	PAN2	chr12:56710718-56727825:-	0.34	3.7	0.00024	Psoriasis vulgaris	
LUSC	cis	1	rs8032158	chr15:56194877	NEDD4	chr15:56119131-56285835:-	0.24	4.36	1.6E-5	Keloid	
LUSC	cis	1	rs8032675	chr15:67959464	IQCH	chr15:67547188-67794139:+	0.21	3.83	0.000144	Motion sickness	
LUSC	cis	1	rs8033837	chr15:75353975	SCAMP5	chr15:75287901-75313836:+	0.27	4.38	1.48E-5	Blood trace element (Zn levels)	
LUSC	cis	1	rs8033938	chr15:40703114	C15orf23	chr15:40674922-40686488:+	0.25	3.96	8.53E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs8033938	chr15:40703114	IVD	chr15:40697686-40713512:+	-0.36	-4.08	5.26E-5	Heschl's gyrus morphology	
LUSC	cis	1	rs8035675	chr15:67965581	IQCH	chr15:67547188-67794139:+	0.21	3.72	0.00022	Motion sickness	
LUSC	cis	1	rs803688	chr15:83216793	LOC80154	chr15:82944795-82975797:+;chr15	0.23	4.59	5.71E-6	Schizophrenia	
LUSC	cis	1	rs8049173	chr16:11436882	C16orf75	chr16:11343506-11445617:+	0.29	5.17	3.54E-7	Vein graft stenosis in coronary artery bypass grafting	
LUSC	cis	1	rs8049439	chr16:28837515	EIF3CL	chr16:28699879-28747052:+;chr16	0.29	5.33	1.49E-7	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
LUSC	cis	1	rs8055427	chr16:11436883	C16orf75	chr16:11343506-11445617:+	0.29	5.17	3.54E-7	Vein graft stenosis in coronary artery bypass grafting	
LUSC	cis	1	rs8062783	chr16:74691264	RFWD3	chr16:74655298-74700779:-	0.22	4.97	9.38E-7	Testicular germ cell tumor	
LUSC	cis	1	rs8064261	chr17:61705212	FTSJ3	chr17:61896795-61905031:-	0.32	6.34	5.35E-10	Body mass index	
LUSC	cis	1	rs8065059	chr17:28417376	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.9	6.88E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs8065261	chr17:28418041	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.91	6.63E-9	Coffee consumption (cups per day)	
LUSC	cis	1	rs8065437	chr17:45721653	C17orf57	chr17:45401142-45518675:+	0.28	6.36	4.68E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs8065669	chr17:45724996	C17orf57	chr17:45401142-45518675:+	0.29	6.63	8.99E-11	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs8066719	chr17:61825764	FTSJ3	chr17:61896795-61905031:-	0.33	6.57	1.33E-10	Body mass index	
LUSC	cis	1	rs8067064	chr17:61825984	FTSJ3	chr17:61896795-61905031:-	0.33	6.56	1.43E-10	Body mass index	
LUSC	cis	1	rs8067431	chr17:61817048	FTSJ3	chr17:61896795-61905031:-	0.35	6.67	7.19E-11	Body mass index	
LUSC	cis	1	rs8067431	chr17:61817048	MAP3K3	chr17:61699775-61773669:+	0.16	3.78	0.000179	Body mass index	
LUSC	cis	1	rs8067892	chr17:65837983	LOC440461	chr17:66194801-66196436:+	0.25	3.94	9.51E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs8068603	chr17:61755211	FTSJ3	chr17:61896795-61905031:-	0.32	6.31	6.53E-10	Body mass index	
LUSC	cis	1	rs8068748	chr17:40532701	NKIRAS2	chr17:40169594-40177654:+	-0.2	-3.87	0.000122	Crohn's disease;Multiple sclerosis	
LUSC	cis	1	rs8069687	chr17:61883023	FTSJ3	chr17:61896795-61905031:-	-0.32	-6.28	7.66E-10	Body mass index	
LUSC	cis	1	rs8070454	chr17:38160754	GSDMA	chr17:38119226-38134019:+	-0.44	-8.97	6.98E-18	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs8070650	chr17:61744040	FTSJ3	chr17:61896795-61905031:-	0.32	6.3	6.96E-10	Body mass index	
LUSC	cis	1	rs8071789	chr17:38006333	GSDMA	chr17:38119226-38134019:+	0.19	3.75	0.000201	Selective IgA deficiency	
LUSC	cis	1	rs8071789	chr17:38006333	GSDMB	chr17:38060850-38074903:-	-0.15	-3.85	0.000134	Selective IgA deficiency	
LUSC	cis	1	rs8072100	chr17:45674687	C17orf57	chr17:45401142-45518675:+	-0.29	-6.49	2.22E-10	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
LUSC	cis	1	rs8073373	chr17:61703320	FTSJ3	chr17:61896795-61905031:-	0.33	6.5	2.03E-10	Body mass index	
LUSC	cis	1	rs8074708	chr17:40286354	DHX58	chr17:40253422-40264751:-	0.24	4.43	1.18E-5	Fibrinogen levels	
LUSC	cis	1	rs8074771	chr17:61735865	FTSJ3	chr17:61896795-61905031:-	0.32	6.3	6.96E-10	Body mass index	
LUSC	cis	1	rs8075061	chr17:61804723	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.97E-10	Body mass index	
LUSC	cis	1	rs8075257	chr17:61728750	FTSJ3	chr17:61896795-61905031:-	0.32	6.16	1.56E-9	Body mass index	
LUSC	cis	1	rs8075273	chr17:61728881	FTSJ3	chr17:61896795-61905031:-	0.29	5.32	1.6E-7	Body mass index	
LUSC	cis	1	rs8075273	chr17:61728881	MAP3K3	chr17:61699775-61773669:+	0.19	4.1	4.96E-5	Body mass index	
LUSC	cis	1	rs8075422	chr17:61804686	FTSJ3	chr17:61896795-61905031:-	0.34	6.74	4.6E-11	Body mass index	
LUSC	cis	1	rs8075521	chr17:61804954	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.97E-10	Body mass index	
LUSC	cis	1	rs807669	chr22:19154522	CLTCL1	chr22:19166989-19279239:-	-0.21	-3.83	0.000145	Metabolite levels	
LUSC	cis	1	rs807669	chr22:19154522	SLC25A1	chr22:19163095-19166301:-	-0.35	-7.01	8.17E-12	Metabolite levels	
LUSC	cis	1	rs807670	chr22:19154608	SLC25A1	chr22:19163095-19166301:-	-0.29	-6.12	2.0E-9	Metabolite levels	
LUSC	cis	1	rs8076717	chr17:61850301	FTSJ3	chr17:61896795-61905031:-	-0.36	-6.95	1.18E-11	Body mass index	
LUSC	cis	1	rs8076717	chr17:61850301	MAP3K3	chr17:61699775-61773669:+	-0.18	-4.16	3.77E-5	Body mass index	
LUSC	cis	1	rs8077265	chr17:61732727	FTSJ3	chr17:61896795-61905031:-	0.33	6.45	2.82E-10	Body mass index	
LUSC	cis	1	rs8077577	chr17:18064730	LOC220594	chr17:18414577-18445234:-	-0.27	-4.01	7.06E-5	Obesity-related traits	
LUSC	cis	1	rs8077577	chr17:18064730	MYO15A	chr17:18012020-18083115:+	0.23	4	7.21E-5	Obesity-related traits	
LUSC	cis	1	rs8078462	chr17:61857937	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.94E-10	Body mass index	
LUSC	cis	1	rs8078723	chr17:38166879	GSDMA	chr17:38119226-38134019:+	-0.43	-8.75	3.78E-17	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
LUSC	cis	1	rs8078862	chr17:61854068	FTSJ3	chr17:61896795-61905031:-	0.33	6.49	2.21E-10	Body mass index	
LUSC	cis	1	rs8079537	chr17:78600818	NPTX1	chr17:78440633-78450404:-	-0.24	-4.48	9.16E-6	Obesity	
LUSC	cis	1	rs8079754	chr17:65887896	LOC440461	chr17:66194801-66196436:+	0.23	3.72	0.000227	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs8080211	chr17:61729882	FTSJ3	chr17:61896795-61905031:-	0.35	6.73	4.94E-11	Body mass index	
LUSC	cis	1	rs8081517	chr17:65845697	LOC440461	chr17:66194801-66196436:+	0.25	3.95	9.11E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs8081541	chr17:61812483	FTSJ3	chr17:61896795-61905031:-	0.33	6.47	2.5E-10	Body mass index	
LUSC	cis	1	rs8081612	chr17:61724695	FTSJ3	chr17:61896795-61905031:-	-0.33	-6.48	2.29E-10	Body mass index	
LUSC	cis	1	rs8082512	chr17:65837059	LOC440461	chr17:66194801-66196436:+	0.26	3.92	0.000101	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs8086028	chr18:10737779	VAPA	chr18:9913955-9960017:+	0.22	3.76	0.000194	Venous thromboembolism (SNP x SNP interaction)	
LUSC	cis	1	rs809775	chr1:46538040	CCDC163P	chr1:45960581-45965646:-	-0.37	-7.69	8.81E-14	Body mass index	
LUSC	cis	1	rs8100042	chr19:22127841	ZNF100	chr19:21906844-21950430:-	-0.29	-4.09	5.08E-5	Body mass index (change over time)	
LUSC	cis	1	rs8100042	chr19:22127841	ZNF43	chr19:21987753-22034830:-	-0.26	-3.78	0.000178	Body mass index (change over time)	
LUSC	cis	1	rs8101881	chr19:33364628	SLC7A9	chr19:33321421-33360683:-	-0.31	-6.36	4.78E-10	Blood metabolite levels;Urinary metabolites (H-NMR features);Urinary metabolites	
LUSC	cis	1	rs8103622	chr19:18572834	LRRC25	chr19:18501955-18508421:-	-0.12	-4.03	6.43E-5	Breast cancer	
LUSC	cis	1	rs8103622	chr19:18572834	SSBP4	chr19:18530221-18545371:+	-0.19	-3.8	0.000161	Breast cancer	
LUSC	cis	1	rs8104559	chr19:22205167	ZNF100	chr19:21906844-21950430:-	-0.28	-4.01	7.05E-5	Body mass index (change over time)	
LUSC	cis	1	rs8104559	chr19:22205167	ZNF43	chr19:21987753-22034830:-	-0.26	-3.74	0.000205	Body mass index (change over time)	
LUSC	cis	1	rs8105895	chr19:22215457	ZNF100	chr19:21906844-21950430:-	-0.3	-4.37	1.54E-5	Body mass index (change over time)	
LUSC	cis	1	rs8105895	chr19:22215457	ZNF43	chr19:21987753-22034830:-	-0.27	-4	7.2E-5	Body mass index (change over time)	
LUSC	cis	1	rs8105994	chr19:18593553	SSBP4	chr19:18530221-18545371:+	-0.2	-3.91	0.000107	Breast cancer	
LUSC	cis	1	rs8107367	chr19:18564705	LRRC25	chr19:18501955-18508421:-	-0.12	-4.17	3.65E-5	Breast cancer	
LUSC	cis	1	rs8107367	chr19:18564705	SSBP4	chr19:18530221-18545371:+	-0.19	-3.8	0.000163	Breast cancer	
LUSC	cis	1	rs8107416	chr19:39237950	LGALS7B	chr19:39279850-39282393:+	0.22	4.52	7.79E-6	Heart rate	
LUSC	cis	1	rs8110011	chr19:37745813	ZNF781	chr19:38158650-38183216:-	0.24	3.87	0.000123	Coronary artery calcification	
LUSC	cis	1	rs8110727	chr19:24230916	LOC100101266	chr19:24344995-24346249:-	0.29	3.89	0.000116	Response to taxane treatment (placlitaxel)	
LUSC	cis	1	rs8111746	chr19:39212859	LGALS7B	chr19:39279850-39282393:+	0.2	4.19	3.29E-5	Heart rate	
LUSC	cis	1	rs8118005	chr20:33636219	GDF5	chr20:33897002-34042568:-	0.27	3.72	0.00022	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8118005	chr20:33636219	PROCR	chr20:33758727-33765164:+	-0.32	-4.2	3.21E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs811880	chr7:65818646	NCRNA00174	chr7:65841032-65865395:-	-0.29	-6.17	1.46E-9	Aortic root size	
LUSC	cis	1	rs8118978	chr20:33574458	PROCR	chr20:33758727-33765164:+	-0.32	-4.21	3.03E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8121957	chr20:33676109	PROCR	chr20:33758727-33765164:+	-0.3	-3.87	0.000126	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8123978	chr20:33598789	PROCR	chr20:33758727-33765164:+	-0.33	-4.24	2.65E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8124662	chr20:33639256	GDF5	chr20:33897002-34042568:-	0.28	3.78	0.000174	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8124662	chr20:33639256	PROCR	chr20:33758727-33765164:+	-0.33	-4.37	1.55E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs8125868	chr20:25324410	ENTPD6	chr20:25176339-25207360:+	0.2	3.72	0.000219	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs8135828	chr22:29929239	NIPSNAP1	chr22:29950800-29977144:-	-0.26	-4.4	1.33E-5	Lipid traits	
LUSC	cis	1	rs8137478	chr22:51017296	CPT1B	chr22:51007291-51017096:-	-0.37	-4.98	9.01E-7	Narcolepsy	
LUSC	cis	1	rs8138799	chr22:24556902	SUSD2	chr22:24577444-24585074:+	0.43	6.28	7.68E-10	Amyotrophic lateral sclerosis	
LUSC	cis	1	rs8138996	chr22:39047435	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs8141797	chr22:24582041	SUSD2	chr22:24577444-24585074:+	-0.35	-5.45	8.02E-8	Amyotrophic lateral sclerosis	
LUSC	cis	1	rs8142098	chr22:39058757	CBY1	chr22:39052658-39069853:+	0.21	3.9	0.000109	Resting heart rate	
LUSC	cis	1	rs815306	chr1:76168624	ACADM	chr1:76190043-76229353:+	0.25	5.02	7.5E-7	Daytime sleep phenotypes	
LUSC	cis	1	rs8180214	chr4:90644508	MMRN1	chr4:90816003-90875778:+	-0.29	-4.5	8.39E-6	Parkinson's disease	
LUSC	cis	1	rs8181644	chr12:58173466	FAM119B	chr12:58166383-58176323:+	0.52	9.08	3.02E-18	Multiple sclerosis	
LUSC	cis	1	rs8181644	chr12:58173466	TSFM	chr12:58176536-58191367:+	-0.4	-8.71	4.94E-17	Multiple sclerosis	
LUSC	cis	1	rs8181644	chr12:58173466	XRCC6BP1	chr12:58335445-58351051:+	-0.22	-4.5	8.52E-6	Multiple sclerosis	
LUSC	cis	1	rs823144	chr1:205744546	PM20D1	chr1:205797154-205819245:-	-0.26	-4.58	5.86E-6	Parkinson's disease	
LUSC	cis	1	rs823156	chr1:205764640	PM20D1	chr1:205797154-205819245:-	-0.3	-4.7	3.46E-6	Parkinson's disease	
LUSC	cis	1	rs832551	chr5:56180112	C5orf35	chr5:56205103-56213010:+	0.85	14.18	2.52E-38	Type 2 diabetes	
LUSC	cis	1	rs832553	chr5:56114786	C5orf35	chr5:56205103-56213010:+	0.86	14.83	3.64E-41	Type 2 diabetes	
LUSC	cis	1	rs832554	chr5:56115036	C5orf35	chr5:56205103-56213010:+	0.88	15.78	2.03E-45	Type 2 diabetes	
LUSC	cis	1	rs832565	chr5:56150803	C5orf35	chr5:56205103-56213010:+	0.87	15.3	2.94E-43	Type 2 diabetes	
LUSC	cis	1	rs832568	chr5:56153776	C5orf35	chr5:56205103-56213010:+	0.86	15.02	5.05E-42	Type 2 diabetes	
LUSC	cis	1	rs832569	chr5:56154584	C5orf35	chr5:56205103-56213010:+	0.86	14.83	3.87E-41	Type 2 diabetes	
LUSC	cis	1	rs832578	chr5:56164223	C5orf35	chr5:56205103-56213010:+	0.86	14.47	1.37E-39	Type 2 diabetes	
LUSC	cis	1	rs832582	chr5:56177743	C5orf35	chr5:56205103-56213010:+	0.85	13.99	1.74E-37	Type 2 diabetes	
LUSC	cis	1	rs832583	chr5:56178217	C5orf35	chr5:56205103-56213010:+	0.85	14.18	2.52E-38	Type 2 diabetes	
LUSC	cis	1	rs832584	chr5:56179212	C5orf35	chr5:56205103-56213010:+	-0.86	-14.13	4.11E-38	Type 2 diabetes	
LUSC	cis	1	rs840163	chr12:57320711	OS9	chr12:58087886-58115338:+	-0.32	-5.37	1.26E-7	Alzheimer's disease (survival time)	
LUSC	cis	1	rs858239	chr7:23286315	GPNMB	chr7:23286316-23314728:+	-0.25	-5.22	2.72E-7	Parkinson's disease	
LUSC	cis	1	rs858240	chr7:23284237	GPNMB	chr7:23286316-23314728:+	-0.25	-5.04	6.6E-7	Parkinson's disease	
LUSC	cis	1	rs8589	chr6:49403282	CENPQ	chr6:49431096-49460820:+	-0.38	-8.69	5.79E-17	Homocysteine levels	
LUSC	cis	1	rs8589	chr6:49403282	MUT	chr6:49398994-49431031:-	0.21	3.75	0.000196	Homocysteine levels	
LUSC	cis	1	rs860580	chr5:56149429	C5orf35	chr5:56205103-56213010:+	-0.85	-14.23	1.57E-38	Type 2 diabetes	
LUSC	cis	1	rs861283	chr5:56184610	C5orf35	chr5:56205103-56213010:+	0.85	13.99	1.7E-37	Type 2 diabetes	
LUSC	cis	1	rs861539	chr14:104165753	C14orf153	chr14:104029299-104057227:+	0.15	3.75	0.000198	Body mass index	
LUSC	cis	1	rs861539	chr14:104165753	CKB	chr14:103985996-103989170:-	0.2	3.89	0.000115	Body mass index	
LUSC	cis	1	rs863840	chr5:56128999	C5orf35	chr5:56205103-56213010:+	0.79	12.98	3.59E-33	Type 2 diabetes	
LUSC	cis	1	rs866222	chr5:56184444	C5orf35	chr5:56205103-56213010:+	0.85	13.99	1.7E-37	Type 2 diabetes	
LUSC	cis	1	rs867186	chr20:33764554	GDF5	chr20:33897002-34042568:-	-0.3	-4.3	2.12E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs873457	chr1:12046334	C1orf187	chr1:11751781-11780336:+	0.19	4.25	2.62E-5	Platelet count	
LUSC	cis	1	rs873686	chr4:185638876	MLF1IP	chr4:185615220-185655286:-	0.49	10.23	2.37E-22	Kawasaki disease	
LUSC	cis	1	rs8758	chr10:97366107	ENTPD1	chr10:97471536-97637022:+	0.16	4.82	1.98E-6	Blood metabolite levels	
LUSC	cis	1	rs875971	chr7:65617595	NCRNA00174	chr7:65841032-65865395:-	0.3	6.3	6.94E-10	Aortic root size	
LUSC	cis	1	rs876402	chr14:75601862	MLH3	chr14:75480467-75518235:-	-0.26	-5.66	2.62E-8	Height	
LUSC	cis	1	rs876403	chr14:75602834	MLH3	chr14:75480467-75518235:-	0.27	5.81	1.16E-8	Height	
LUSC	cis	1	rs877636	chr12:56480583	RPS26	chr12:56435686-56438005:+	-0.57	-11.86	1.29E-28	Cognitive function	
LUSC	cis	1	rs877710	chr12:109993976	MYO1H	chr12:109826524-109886176:+	0.23	4.13	4.38E-5	HDL cholesterol	
LUSC	cis	1	rs881375	chr9:123652898	LOC253039	chr9:123605320-123616644:+	-0.32	-6.12	1.95E-9	Rheumatoid arthritis	
LUSC	cis	1	rs881827	chr21:48019868	C21orf56	chr21:47581063-47604373:-	-0.28	-4.76	2.62E-6	Lymphocyte counts	
LUSC	cis	1	rs882803	chr1:45976147	CCDC163P	chr1:45960581-45965646:-	-0.72	-16.97	7.66E-51	Homocysteine levels	
LUSC	cis	1	rs883394	chr19:39205613	LGALS7B	chr19:39279850-39282393:+	0.2	4.16	3.79E-5	Heart rate	
LUSC	cis	1	rs883433	chr19:39206288	LGALS7B	chr19:39279850-39282393:+	-0.2	-4.15	3.89E-5	Heart rate	
LUSC	cis	1	rs883648	chr8:8569521	FLJ10661	chr8:8086092-8102386:+	0.24	4.11	4.69E-5	Obesity-related traits	
LUSC	cis	1	rs884841	chr6:86680300	SNHG5	chr6:86386726-86388451:-	-0.66	-12.15	8.77E-30	Response to antipsychotic treatment	
LUSC	cis	1	rs884977	chr7:1066410	ZFAND2A	chr7:1192544-1199855:-	-0.37	-5.41	1.02E-7	C-reactive protein levels or total cholesterol levels (pleiotropy)	
LUSC	cis	1	rs885000	chr8:8568875	FLJ10661	chr8:8086092-8102386:+	0.24	4.05	6.03E-5	Obesity-related traits	
LUSC	cis	1	rs885963	chr22:23460939	RTDR1	chr22:23401594-23484241:-	-0.25	-4.65	4.22E-6	Bone mineral density	
LUSC	cis	1	rs885964	chr22:23461003	RTDR1	chr22:23401594-23484241:-	-0.25	-4.69	3.5E-6	Bone mineral density	
LUSC	cis	1	rs885965	chr22:23461425	RTDR1	chr22:23401594-23484241:-	-0.24	-4.57	6.36E-6	Bone mineral density	
LUSC	cis	1	rs888192	chr12:109995097	MYO1H	chr12:109826524-109886176:+	-0.23	-4.14	4.16E-5	HDL cholesterol	
LUSC	cis	1	rs888331	chr9:90213209	DAPK1	chr9:90112658-90323548:+	-0.29	-3.73	0.000211	Immune reponse to smallpox (secreted IFN-alpha)	
LUSC	cis	1	rs889398	chr16:69556715	PDXDC2	chr16:70010210-70099851:-	0.14	4.47	9.69E-6	Body mass index	
LUSC	cis	1	rs889399	chr16:69556583	PDXDC2	chr16:70010210-70099851:-	0.14	4.45	1.09E-5	Body mass index	
LUSC	cis	1	rs889877	chr7:134232615	AKR1B15	chr7:134233849-134264300:+	0.21	4.24	2.64E-5	Longevity	
LUSC	cis	1	rs892974	chr3:49398514	AMT	chr3:49454212-49460012:-	0.19	4.5	8.44E-6	Menarche (age at onset)	
LUSC	cis	1	rs898225	chr3:48413179	ATRIP	chr3:48488141-48507708:+	-0.19	-3.89	0.000117	Longevity	
LUSC	cis	1	rs898225	chr3:48413179	TREX1	chr3:48501186-48509043:+	0.42	8.82	2.25E-17	Longevity	
LUSC	cis	1	rs900012	chr11:116966435	PCSK7	chr11:117075789-117102811:-	-0.33	-4.72	3.1E-6	Protein quantitative trait loci	
LUSC	cis	1	rs901064	chr17:78596040	NPTX1	chr17:78440633-78450404:-	0.22	4.12	4.53E-5	Obesity	
LUSC	cis	1	rs906867	chr2:30478628	LBH	chr2:30454397-30482899:+	-0.23	-3.74	0.000204	Systemic lupus erythematosus	
LUSC	cis	1	rs907611	chr11:1874072	LSP1	chr11:1874200-1913492:+	-0.19	-4.88	1.47E-6	Ulcerative colitis;Inflammatory bowel disease;Bladder cancer	
LUSC	cis	1	rs907613	chr11:1874292	LSP1	chr11:1874200-1913492:+	-0.19	-4.88	1.47E-6	Ulcerative colitis;Inflammatory bowel disease;Bladder cancer	
LUSC	cis	1	rs910316	chr14:75626042	MLH3	chr14:75480467-75518235:-	0.28	5.83	1.03E-8	Height	
LUSC	cis	1	rs910997	chr20:25267301	ENTPD6	chr20:25176339-25207360:+	-0.2	-3.8	0.000165	Liver enzyme levels (alkaline phosphatase)	
LUSC	cis	1	rs916583	chr22:23469267	RTDR1	chr22:23401594-23484241:-	-0.24	-4.53	7.61E-6	Bone mineral density	
LUSC	cis	1	rs916584	chr22:23469433	RTDR1	chr22:23401594-23484241:-	-0.24	-4.68	3.73E-6	Bone mineral density	
LUSC	cis	1	rs916585	chr22:23469438	RTDR1	chr22:23401594-23484241:-	-0.24	-4.66	4.15E-6	Bone mineral density	
LUSC	cis	1	rs9213	chr2:218386	SH3YL1	chr2:218138-264810:-	-0.5	-9	5.66E-18	Spherical equivalent (joint main effects and education interaction)	
LUSC	cis	1	rs922075	chr3:48489398	ATRIP	chr3:48488141-48507708:+	-0.18	-3.86	0.000131	Longevity	
LUSC	cis	1	rs922075	chr3:48489398	TREX1	chr3:48501186-48509043:+	0.37	8.05	6.58E-15	Longevity	
LUSC	cis	1	rs925098	chr4:17919811	NCAPG	chr4:17812525-17846485:+	0.21	4.72	3.12E-6	Height	
LUSC	cis	1	rs925489	chr9:100546600	CTSL2	chr9:99794940-99822167:-	-0.2	-3.81	0.000158	Thyroid cancer (Papillary, radiation-related);Thyroid cancer	
LUSC	cis	1	rs926299	chr22:39095698	CBY1	chr22:39052658-39069853:+	0.22	4.09	5.17E-5	Resting heart rate	
LUSC	cis	1	rs9283717	chr5:56078659	C5orf35	chr5:56205103-56213010:+	0.88	15.26	4.39E-43	Type 2 diabetes	
LUSC	cis	1	rs9288316	chr2:202163483	ALS2CR12	chr2:202153148-202222101:-	0.22	4.24	2.73E-5	Melanoma;Esophageal squamous cell carcinoma	
LUSC	cis	1	rs9289275	chr3:125648659	ALG1L	chr3:125648118-125655882:-	-0.29	-5.53	5.19E-8	Blood pressure (smoking interaction)	
LUSC	cis	1	rs9289275	chr3:125648659	LOC100125556	chr3:125635444-125648865:+	0.25	4.15	3.89E-5	Blood pressure (smoking interaction)	
LUSC	cis	1	rs9289471	chr3:134230811	ANAPC13	chr3:134196547-134204865:-	0.44	8.82	2.24E-17	Height	
LUSC	cis	1	rs9289475	chr3:134236459	ANAPC13	chr3:134196547-134204865:-	0.42	8.47	3.02E-16	Height	
LUSC	cis	1	rs9289476	chr3:134237103	ANAPC13	chr3:134196547-134204865:-	0.42	8.48	2.77E-16	Height	
LUSC	cis	1	rs9289478	chr3:134268619	ANAPC13	chr3:134196547-134204865:-	0.42	8.33	8.46E-16	Height	
LUSC	cis	1	rs9290663	chr3:178429939	GNB4	chr3:179113877-179169371:-	0.22	3.73	0.000213	Acute lymphoblastic leukemia (childhood)	
LUSC	cis	1	rs9294377	chr6:88084839	C6orf164	chr6:88032306-88109459:+	-0.23	-4.23	2.82E-5	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs929596	chr2:234674476	UGT1A4	chr2:234627438-234681945:+	0.21	4.12	4.38E-5	Total bilirubin levels in HIV-1 infection	
LUSC	cis	1	rs929596	chr2:234674476	UGT1A8	chr2:234526291-234681945:+	0.2	3.76	0.000189	Total bilirubin levels in HIV-1 infection	
LUSC	cis	1	rs9296404	chr6:42925803	GNMT	chr6:42928500-42931617:+	-0.52	-10.82	1.52E-24	Plasma homocysteine levels (post-methionine load test)	
LUSC	cis	1	rs9296404	chr6:42925803	PEX6	chr6:42931613-42946981:-	0.77	16.57	5.21E-49	Plasma homocysteine levels (post-methionine load test)	
LUSC	cis	1	rs9296616	chr6:49414235	CENPQ	chr6:49431096-49460820:+	-0.37	-8.12	4.17E-15	Folate pathway vitamin levels	
LUSC	cis	1	rs9296616	chr6:49414235	MUT	chr6:49398994-49431031:-	0.32	5.57	4.21E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9296617	chr6:49428360	CENPQ	chr6:49431096-49460820:+	-0.4	-8.77	3.17E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9296617	chr6:49428360	MUT	chr6:49398994-49431031:-	0.31	5.42	9.31E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9296832	chr6:56100909	COL21A1	chr6:55921389-56258892:-	0.19	3.9	0.000111	Pulse pressure	
LUSC	cis	1	rs929843	chr16:70045748	CLEC18A	chr16:69984626-69997887:+	-0.29	-4.61	5.11E-6	Menarche (age at onset)	
LUSC	cis	1	rs929843	chr16:70045748	PDXDC2	chr16:70010210-70099851:-	-0.2	-5.51	5.77E-8	Menarche (age at onset)	
LUSC	cis	1	rs9303401	chr17:56847945	RAD51C	chr17:56769963-56811690:+	0.29	6.17	1.5E-9	Cognitive test performance	
LUSC	cis	1	rs9304578	chr19:39250337	LGALS7B	chr19:39279850-39282393:+	-0.23	-4.67	3.88E-6	Heart rate	
LUSC	cis	1	rs9306329	chr22:39072454	CBY1	chr22:39052658-39069853:+	0.23	4.16	3.7E-5	Resting heart rate	
LUSC	cis	1	rs9307050	chr4:76905649	NAAA	chr4:76831809-76862166:-	-0.27	-5.79	1.31E-8	Longevity	
LUSC	cis	1	rs9309473	chr2:73743982	ALMS1P	chr2:73872046-73912692:+	0.4	7.65	1.13E-13	Metabolite levels	
LUSC	cis	1	rs9309473	chr2:73743982	NAT8	chr2:73867850-73869537:-	0.27	4.72	3.15E-6	Metabolite levels	
LUSC	cis	1	rs931058	chr5:150333698	LOC134466	chr5:150310000-150326146:-	0.4	4.94	1.11E-6	Crohn's disease	
LUSC	cis	1	rs9311423	chr3:48420308	ATRIP	chr3:48488141-48507708:+	0.19	3.88	0.000121	Longevity	
LUSC	cis	1	rs9311423	chr3:48420308	TREX1	chr3:48501186-48509043:+	-0.44	-9.83	7.06E-21	Longevity	
LUSC	cis	1	rs9311676	chr3:58470351	PDHB	chr3:58413355-58419565:-	-0.2	-3.87	0.000122	Systemic lupus erythematosus	
LUSC	cis	1	rs9320287	chr6:109744690	SMPD2	chr6:109761931-109765121:+	0.25	4.61	5.12E-6	Height	
LUSC	cis	1	rs9320656	chr6:118894468	C6orf204	chr6:118786239-119031238:-	0.23	3.76	0.000195	Renal cell carcinoma	
LUSC	cis	1	rs9320660	chr6:118956827	C6orf204	chr6:118786239-119031238:-	-0.23	-3.7	0.000245	Renal cell carcinoma	
LUSC	cis	1	rs9326244	chr11:114390106	FAM55D	chr11:114441314-114466484:-	0.38	5.45	8.05E-8	IgG glycosylation	
LUSC	cis	1	rs932644	chr6:167404187	RNASET2	chr6:167343008-167412795:-	-0.25	-4.83	1.88E-6	Crohn's disease	
LUSC	cis	1	rs932835	chr9:131887071	CRAT	chr9:131857075-131873070:-	0.25	5.12	4.5E-7	Blood metabolite ratios	
LUSC	cis	1	rs9332517	chr1:169542700	SLC19A2	chr1:169433151-169455208:-	0.39	4.45	1.06E-5	Hippocampal atrophy	
LUSC	cis	1	rs9332562	chr1:169530308	SLC19A2	chr1:169433151-169455208:-	0.36	3.87	0.000123	Hippocampal atrophy	
LUSC	cis	1	rs934093	chr3:134195885	ANAPC13	chr3:134196547-134204865:-	0.42	8.33	8.74E-16	Height	
LUSC	cis	1	rs9349804	chr6:56098876	COL21A1	chr6:55921389-56258892:-	0.19	3.81	0.000156	Pulse pressure	
LUSC	cis	1	rs9357037	chr6:27327349	ZNF391	chr6:27356524-27369227:+	0.29	5.75	1.56E-8	Glomerular filtration rate (creatinine)	
LUSC	cis	1	rs9357619	chr6:49490094	CENPQ	chr6:49431096-49460820:+	0.19	3.99	7.65E-5	Brain structure	
LUSC	cis	1	rs9362426	chr6:88089874	C6orf164	chr6:88032306-88109459:+	-0.21	-3.92	0.0001	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs936332	chr12:52640277	KRT1	chr12:53068520-53074191:-	0.22	3.89	0.000117	Diisocyanate-induced asthma	
LUSC	cis	1	rs9369898	chr6:49382193	CENPQ	chr6:49431096-49460820:+	-0.38	-8.78	2.98E-17	Homocysteine levels	
LUSC	cis	1	rs937495	chr7:65779798	NCRNA00174	chr7:65841032-65865395:-	0.29	6.14	1.76E-9	Aortic root size	
LUSC	cis	1	rs9381784	chr6:49398115	CENPQ	chr6:49431096-49460820:+	0.38	8.38	5.88E-16	Homocysteine levels	
LUSC	cis	1	rs938295	chr1:16087260	FAM131C	chr1:16361814-16400127:-	-0.23	-3.72	0.000221	Gut microbiota (bacterial taxa)	
LUSC	cis	1	rs938878	chr15:67993366	IQCH	chr15:67547188-67794139:+	0.22	3.89	0.000116	Motion sickness	
LUSC	cis	1	rs9393692	chr6:26276650	BTN3A2	chr6:26365398-26378546:+	0.21	4.76	2.55E-6	Educational attainment	
LUSC	cis	1	rs9394931	chr6:42873245	GNMT	chr6:42928500-42931617:+	0.32	6.13	1.83E-9	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
LUSC	cis	1	rs9394931	chr6:42873245	PEX6	chr6:42931613-42946981:-	-0.49	-8.78	3.06E-17	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
LUSC	cis	1	rs9395493	chr6:49427409	CENPQ	chr6:49431096-49460820:+	-0.39	-8.97	6.84E-18	Homocysteine levels	
LUSC	cis	1	rs9398235	chr6:110732116	DDO	chr6:110713384-110736753:-	-0.23	-4.24	2.72E-5	Systemic lupus erythematosus	
LUSC	cis	1	rs940045	chr3:49449638	AMT	chr3:49454212-49460012:-	0.21	5.05	6.36E-7	Menarche (age at onset)	
LUSC	cis	1	rs940045	chr3:49449638	TREX1	chr3:48501186-48509043:+	-0.2	-3.85	0.000133	Menarche (age at onset)	
LUSC	cis	1	rs940174	chr3:136309710	PCCB	chr3:135969167-136056737:+	0.19	3.97	8.18E-5	Schizophrenia	
LUSC	cis	1	rs941653	chr14:35592538	PPP2R3C	chr14:35554679-35591679:-	0.32	5.79	1.28E-8	Atopic dermatitis	
LUSC	cis	1	rs9419897	chr10:102246125	SEC31B	chr10:102246403-102289636:-	-0.27	-8.21	2.07E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs9420782	chr10:102235015	SEC31B	chr10:102246403-102289636:-	-0.26	-8.17	2.9E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs9420785	chr10:102240451	SEC31B	chr10:102246403-102289636:-	-0.27	-8.21	2.16E-15	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs9420797	chr10:102331147	SEC31B	chr10:102246403-102289636:-	-0.27	-8.57	1.52E-16	Palmitoleic acid (16:1n-7) plasma levels	
LUSC	cis	1	rs9420	chr11:57510294	MED19	chr11:57471182-57479673:-	0.21	4.34	1.72E-5	Schizophrenia	
LUSC	cis	1	rs9429183	chr1:46524582	CCDC163P	chr1:45960581-45965646:-	-0.37	-7.68	9.01E-14	Body mass index	
LUSC	cis	1	rs9434723	chr1:9292282	H6PD	chr1:9294863-9331392:+	-0.25	-4.28	2.23E-5	Height	
LUSC	cis	1	rs9436116	chr1:150454724	MRPS21	chr1:150266269-150280818:+	0.22	4.32	1.89E-5	Morning vs. evening chronotype	
LUSC	cis	1	rs9450662	chr6:88088593	C6orf164	chr6:88032306-88109459:+	-0.22	-4.16	3.75E-5	Depressive episodes in bipolar disorder	
LUSC	cis	1	rs945635	chr1:157670290	FCRL3	chr1:157646278-157670775:-	0.28	9.32	4.4E-19	Type 1 diabetes autoantibodies	
LUSC	cis	1	rs9457247	chr6:167392174	RNASET2	chr6:167343008-167412795:-	-0.25	-4.88	1.48E-6	Crohn's disease	
LUSC	cis	1	rs945961	chr20:33769926	GDF5	chr20:33897002-34042568:-	0.3	4.1	4.84E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs945961	chr20:33769926	PROCR	chr20:33758727-33765164:+	-0.31	-4.07	5.5E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs9461010	chr6:24440206	ALDH5A1	chr6:24495197-24537434:+	-0.25	-4.05	6.09E-5	Liver enzyme levels	
LUSC	cis	1	rs9461010	chr6:24440206	GPLD1	chr6:24428405-24489850:-	-0.22	-3.72	0.000221	Liver enzyme levels	
LUSC	cis	1	rs9461011	chr6:24440351	ALDH5A1	chr6:24495197-24537434:+	0.24	3.97	8.39E-5	Liver enzyme levels	
LUSC	cis	1	rs9463473	chr6:49380121	CENPQ	chr6:49431096-49460820:+	-0.39	-8.62	9.98E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9463473	chr6:49380121	MUT	chr6:49398994-49431031:-	0.31	5.38	1.17E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs9463474	chr6:49380199	CENPQ	chr6:49431096-49460820:+	-0.39	-8.62	9.98E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9463474	chr6:49380199	MUT	chr6:49398994-49431031:-	0.31	5.38	1.17E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs9463475	chr6:49380899	CENPQ	chr6:49431096-49460820:+	0.4	8.87	1.47E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9463475	chr6:49380899	MUT	chr6:49398994-49431031:-	-0.3	-5.27	2.04E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs9463477	chr6:49386446	CENPQ	chr6:49431096-49460820:+	-0.39	-8.75	3.62E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9463477	chr6:49386446	MUT	chr6:49398994-49431031:-	0.31	5.43	9.04E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9463478	chr6:49386564	CENPQ	chr6:49431096-49460820:+	-0.38	-8.76	3.43E-17	Homocysteine levels	
LUSC	cis	1	rs9463478	chr6:49386564	MUT	chr6:49398994-49431031:-	0.21	3.73	0.000216	Homocysteine levels	
LUSC	cis	1	rs9463479	chr6:49393275	CENPQ	chr6:49431096-49460820:+	-0.4	-8.76	3.48E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9463479	chr6:49393275	MUT	chr6:49398994-49431031:-	0.31	5.45	8.06E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9463480	chr6:49400795	CENPQ	chr6:49431096-49460820:+	-0.39	-8.55	1.75E-16	Folate pathway vitamin levels	
LUSC	cis	1	rs9463480	chr6:49400795	MUT	chr6:49398994-49431031:-	0.32	5.6	3.71E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs946529	chr1:46485548	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.94	1.29E-11	Body mass index	
LUSC	cis	1	rs9467157	chr6:24440644	ALDH5A1	chr6:24495197-24537434:+	-0.26	-4.13	4.33E-5	Liver enzyme levels	
LUSC	cis	1	rs9467157	chr6:24440644	GPLD1	chr6:24428405-24489850:-	-0.22	-3.72	0.000219	Liver enzyme levels	
LUSC	cis	1	rs9467158	chr6:24441215	ALDH5A1	chr6:24495197-24537434:+	-0.26	-3.97	8.31E-5	Liver enzyme levels	
LUSC	cis	1	rs9467160	chr6:24441746	ALDH5A1	chr6:24495197-24537434:+	-0.25	-4.09	5.07E-5	Liver enzyme levels	
LUSC	cis	1	rs9467161	chr6:24441963	ALDH5A1	chr6:24495197-24537434:+	-0.24	-3.79	0.000172	Liver enzyme levels	
LUSC	cis	1	rs9467162	chr6:24442047	ALDH5A1	chr6:24495197-24537434:+	-0.24	-3.79	0.000172	Liver enzyme levels	
LUSC	cis	1	rs9467176	chr6:24464907	GPLD1	chr6:24428405-24489850:-	-0.46	-6.03	3.23E-9	Hematological and biochemical traits	
LUSC	cis	1	rs9467182	chr6:24468654	GPLD1	chr6:24428405-24489850:-	0.44	5.52	5.69E-8	Hematological and biochemical traits	
LUSC	cis	1	rs9467190	chr6:24474771	GPLD1	chr6:24428405-24489850:-	0.44	5.44	8.49E-8	Hematological and biochemical traits	
LUSC	cis	1	rs947211	chr1:205752665	PM20D1	chr1:205797154-205819245:-	-0.29	-5.04	6.66E-7	Parkinson's disease	
LUSC	cis	1	rs9473549	chr6:49380020	CENPQ	chr6:49431096-49460820:+	-0.37	-8.13	3.88E-15	Folate pathway vitamin levels	
LUSC	cis	1	rs9473549	chr6:49380020	MUT	chr6:49398994-49431031:-	0.31	5.38	1.17E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs9473550	chr6:49385182	CENPQ	chr6:49431096-49460820:+	-0.38	-8.75	3.63E-17	Homocysteine levels	
LUSC	cis	1	rs9473552	chr6:49387154	CENPQ	chr6:49431096-49460820:+	-0.4	-8.75	3.88E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9473552	chr6:49387154	MUT	chr6:49398994-49431031:-	0.31	5.44	8.62E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9473553	chr6:49395977	CENPQ	chr6:49431096-49460820:+	-0.39	-8.55	1.64E-16	Folate pathway vitamin levels	
LUSC	cis	1	rs9473553	chr6:49395977	MUT	chr6:49398994-49431031:-	0.32	5.69	2.21E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9473555	chr6:49409487	CENPQ	chr6:49431096-49460820:+	-0.38	-8.5	2.42E-16	Folate pathway vitamin levels	
LUSC	cis	1	rs9473555	chr6:49409487	MUT	chr6:49398994-49431031:-	0.32	5.64	2.99E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9473560	chr6:49427918	CENPQ	chr6:49431096-49460820:+	-0.4	-8.77	3.17E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9473560	chr6:49427918	MUT	chr6:49398994-49431031:-	0.31	5.42	9.31E-8	Folate pathway vitamin levels	
LUSC	cis	1	rs9473561	chr6:49428755	CENPQ	chr6:49431096-49460820:+	-0.4	-8.79	2.84E-17	Folate pathway vitamin levels	
LUSC	cis	1	rs9473561	chr6:49428755	MUT	chr6:49398994-49431031:-	0.3	5.35	1.34E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs9473563	chr6:49453651	CENPQ	chr6:49431096-49460820:+	-0.39	-8.49	2.59E-16	Folate pathway vitamin levels	
LUSC	cis	1	rs9473563	chr6:49453651	MUT	chr6:49398994-49431031:-	0.3	5.21	2.77E-7	Folate pathway vitamin levels	
LUSC	cis	1	rs9473582	chr6:49488908	CENPQ	chr6:49431096-49460820:+	0.18	3.81	0.00016	Brain structure	
LUSC	cis	1	rs9475752	chr6:56780741	BEND6	chr6:56819773-56892138:+	-0.35	-5.19	3.05E-7	Menarche (age at onset)	
LUSC	cis	1	rs947583	chr6:136133659	PDE7B	chr6:136172834-136516708:+	0.24	4.46	1.02E-5	Phosphorus levels	
LUSC	cis	1	rs9480933	chr6:109671391	AKD1	chr6:109814059-110012415:-	-0.17	-4.07	5.42E-5	Height	
LUSC	cis	1	rs9480933	chr6:109671391	SMPD2	chr6:109761931-109765121:+	0.22	4.1	4.78E-5	Height	
LUSC	cis	1	rs9480953	chr6:109739144	SMPD2	chr6:109761931-109765121:+	0.25	4.52	7.65E-6	Height	
LUSC	cis	1	rs9480955	chr6:109744533	SMPD2	chr6:109761931-109765121:+	0.25	4.61	5.12E-6	Height	
LUSC	cis	1	rs9481076	chr6:110781933	SLC22A16	chr6:110745907-110797844:-	-0.42	-4.86	1.62E-6	Glucose homeostasis traits	
LUSC	cis	1	rs9481821	chr6:118846022	C6orf204	chr6:118786239-119031238:-	-0.23	-3.78	0.000175	Renal cell carcinoma	
LUSC	cis	1	rs9481825	chr6:118876092	C6orf204	chr6:118786239-119031238:-	-0.23	-3.77	0.000183	Renal cell carcinoma	
LUSC	cis	1	rs948562	chr11:58347765	CNTF	chr11:58390146-58393203:+	0.34	4.51	8.08E-6	Lymphoma	
LUSC	cis	1	rs9487094	chr6:109742015	SMPD2	chr6:109761931-109765121:+	0.25	4.54	7.29E-6	Height	
LUSC	cis	1	rs9487605	chr6:111582885	KIAA1919	chr6:111580482-111590259:+	-0.36	-6.13	1.88E-9	Inflammatory skin disease	
LUSC	cis	1	rs9489428	chr6:118852935	C6orf204	chr6:118786239-119031238:-	-0.23	-3.72	0.000227	Renal cell carcinoma	
LUSC	cis	1	rs9489433	chr6:118867006	C6orf204	chr6:118786239-119031238:-	-0.24	-3.96	8.56E-5	Renal cell carcinoma	
LUSC	cis	1	rs9489436	chr6:118873817	C6orf204	chr6:118786239-119031238:-	-0.24	-3.96	8.56E-5	Renal cell carcinoma	
LUSC	cis	1	rs9489442	chr6:118885950	C6orf204	chr6:118786239-119031238:-	-0.24	-3.93	9.58E-5	Renal cell carcinoma	
LUSC	cis	1	rs9489447	chr6:118900846	C6orf204	chr6:118786239-119031238:-	-0.23	-3.79	0.000168	Renal cell carcinoma	
LUSC	cis	1	rs9489460	chr6:118925754	C6orf204	chr6:118786239-119031238:-	-0.23	-3.7	0.000244	Renal cell carcinoma	
LUSC	cis	1	rs9489467	chr6:118935206	C6orf204	chr6:118786239-119031238:-	-0.24	-3.77	0.00018	Renal cell carcinoma	
LUSC	cis	1	rs9489477	chr6:118946192	C6orf204	chr6:118786239-119031238:-	-0.24	-3.83	0.000145	Renal cell carcinoma	
LUSC	cis	1	rs9494145	chr6:135432552	MYB	chr6:135502453-135540313:+	0.2	3.74	0.000208	Fetal hemoglobin levels in sickle cell anemia;Platelet count;Mean platelet volume;Red blood cell traits	
LUSC	cis	1	rs950169	chr15:84706461	LOC388152	chr15:84867600-84898920:-	-0.27	-4.67	3.89E-6	Schizophrenia	
LUSC	cis	1	rs9507341	chr13:25006578	C1QTNF9B	chr13:24465238-24471641:-	-0.23	-4.24	2.69E-5	Obesity-related traits	
LUSC	cis	1	rs9507983	chr13:28620036	MTIF3	chr13:28009783-28024711:-	0.18	3.96	8.74E-5	Body mass index	
LUSC	cis	1	rs951366	chr1:205685352	PM20D1	chr1:205797154-205819245:-	-0.31	-6.35	5.16E-10	Menarche (age at onset)	
LUSC	cis	1	rs9527	chr10:104623578	C10orf32	chr10:104613967-104624718:+	-0.49	-10.05	1.15E-21	Arsenic metabolism	
LUSC	cis	1	rs9528136	chr13:61013615	TDRD3	chr13:60970591-61148012:+	0.22	4.01	7.09E-5	Menopause (age at onset)	
LUSC	cis	1	rs9538719	chr13:61052747	TDRD3	chr13:60970591-61148012:+	0.23	4.18	3.54E-5	Menopause (age at onset)	
LUSC	cis	1	rs955196	chr6:86729951	SNHG5	chr6:86386726-86388451:-	0.69	12.85	1.2E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs955197	chr6:86729675	SNHG5	chr6:86386726-86388451:-	-0.68	-12.58	1.6E-31	Response to antipsychotic treatment	
LUSC	cis	1	rs955227	chr6:86651032	SNHG5	chr6:86386726-86388451:-	-0.66	-11.99	4.06E-29	Response to antipsychotic treatment	
LUSC	cis	1	rs957644	chr1:165616157	MGST3	chr1:165600450-165624853:+	0.31	5.63	3.06E-8	Total ventricular volume	
LUSC	cis	1	rs9579929	chr13:21282724	IFT88	chr13:21141208-21265574:+	-0.19	-3.7	0.000241	Dental caries	
LUSC	cis	1	rs9593	chr12:109994870	MYO1H	chr12:109826524-109886176:+	0.23	4.17	3.69E-5	HDL cholesterol	
LUSC	cis	1	rs959617	chr1:165616881	MGST3	chr1:165600450-165624853:+	0.31	5.7	2.08E-8	Total ventricular volume	
LUSC	cis	1	rs9607566	chr22:39075434	CBY1	chr22:39052658-39069853:+	0.23	4.18	3.53E-5	Resting heart rate	
LUSC	cis	1	rs9610986	chr22:39025277	CBY1	chr22:39052658-39069853:+	0.2	3.72	0.000225	Resting heart rate	
LUSC	cis	1	rs9610993	chr22:39042818	CBY1	chr22:39052658-39069853:+	0.21	3.94	9.27E-5	Resting heart rate	
LUSC	cis	1	rs962221	chr1:92970770	EVI5	chr1:92974255-93257961:-	-0.32	-4.6	5.42E-6	Cholesterol, total	
LUSC	cis	1	rs962222	chr1:92970953	EVI5	chr1:92974255-93257961:-	-0.32	-4.6	5.42E-6	Cholesterol, total	
LUSC	cis	1	rs9624447	chr22:24681555	POM121L9P	chr22:24647589-24661490:+	-0.28	-6.63	8.91E-11	Gut microbiome composition (summer)	
LUSC	cis	1	rs9630182	chr11:13620172	TEAD1	chr11:12695969-12966298:+	0.18	3.72	0.000225	Bone mineral density	
LUSC	cis	1	rs9647603	chr6:86639341	SNHG5	chr6:86386726-86388451:-	-0.67	-12.68	6.22E-32	Response to antipsychotic treatment	
LUSC	cis	1	rs9653557	chr2:73795962	ALMS1P	chr2:73872046-73912692:+	0.41	7.7	7.86E-14	Metabolite levels	
LUSC	cis	1	rs9653557	chr2:73795962	NAT8	chr2:73867850-73869537:-	0.27	4.78	2.37E-6	Metabolite levels	
LUSC	cis	1	rs9655607	chr7:151114229	CRYGN	chr7:151127057-151137899:-	0.28	3.77	0.000183	Coronary heart disease	
LUSC	cis	1	rs9655607	chr7:151114229	WDR86	chr7:151078207-151107740:-	0.27	4.03	6.58E-5	Coronary heart disease	
LUSC	cis	1	rs9661504	chr1:205915667	PM20D1	chr1:205797154-205819245:-	0.36	6.74	4.49E-11	Cystic fibrosis-related diabetes	
LUSC	cis	1	rs9662221	chr1:205915745	PM20D1	chr1:205797154-205819245:-	0.39	7.26	1.55E-12	Cystic fibrosis-related diabetes	
LUSC	cis	1	rs9674872	chr17:79581931	TSPAN10	chr17:79609349-79615778:+	0.46	9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs9677476	chr2:232126290	ARMC9	chr2:232063342-232238606:+	-0.22	-4.76	2.52E-6	Food antigen IgG levels	
LUSC	cis	1	rs9689	chr1:25688276	RHCE	chr1:25688741-25756683:-	0.35	6.66	7.69E-11	Erythrocyte sedimentation rate	
LUSC	cis	1	rs9689	chr1:25688276	RHD	chr1:25598981-25656935:+	-0.57	-10.94	5.19E-25	Erythrocyte sedimentation rate	
LUSC	cis	1	rs9689	chr1:25688276	TMEM50A	chr1:25664811-25688850:+	0.17	3.96	8.61E-5	Erythrocyte sedimentation rate	
LUSC	cis	1	rs974495	chr3:49400482	AMT	chr3:49454212-49460012:-	0.21	5.02	7.39E-7	Menarche (age at onset)	
LUSC	cis	1	rs974495	chr3:49400482	TREX1	chr3:48501186-48509043:+	-0.2	-3.73	0.000217	Menarche (age at onset)	
LUSC	cis	1	rs9747164	chr17:61864787	FTSJ3	chr17:61896795-61905031:-	0.35	6.64	8.61E-11	Body mass index	
LUSC	cis	1	rs9747164	chr17:61864787	MAP3K3	chr17:61699775-61773669:+	0.17	3.98	8.04E-5	Body mass index	
LUSC	cis	1	rs9747349	chr17:79584297	TSPAN10	chr17:79609349-79615778:+	0.46	9.54	7.23E-20	Eye color traits	
LUSC	cis	1	rs9748176	chr17:79584043	TSPAN10	chr17:79609349-79615778:+	0.45	9.34	3.7E-19	Eye color traits	
LUSC	cis	1	rs9783304	chr11:43660255	HSD17B12	chr11:43702143-43878160:+	0.46	8.09	5.04E-15	Forced vital capacity	
LUSC	cis	1	rs979532	chr4:17901679	NCAPG	chr4:17812525-17846485:+	-0.2	-4.37	1.54E-5	Height	
LUSC	cis	1	rs979971	chr19:39144244	HNRNPL	chr19:39308091-39342979:-	-0.18	-4.07	5.53E-5	Heart rate	
LUSC	cis	1	rs9805979	chr14:75566209	MLH3	chr14:75480467-75518235:-	0.27	5.84	9.78E-9	Height	
LUSC	cis	1	rs9807989	chr2:102971200	IL1RL1	chr2:102927962-102968497:+	0.22	4.54	7.19E-6	Asthma	
LUSC	cis	1	rs9809569	chr3:132718240	TMEM108	chr3:132757171-133116618:+	0.21	4.92	1.17E-6	IgE grass sensitization	
LUSC	cis	1	rs9809619	chr3:134280948	ANAPC13	chr3:134196547-134204865:-	0.41	8.07	5.72E-15	Height	
LUSC	cis	1	rs9809843	chr3:48434398	TREX1	chr3:48501186-48509043:+	-0.44	-9.75	1.38E-20	Longevity	
LUSC	cis	1	rs9810089	chr3:135807609	PCCB	chr3:135969167-136056737:+	-0.18	-3.74	0.000207	Gestational age at birth (child effect)	
LUSC	cis	1	rs9812647	chr3:48448914	ATRIP	chr3:48488141-48507708:+	-0.18	-3.77	0.000187	Longevity	
LUSC	cis	1	rs9812647	chr3:48448914	TREX1	chr3:48501186-48509043:+	0.38	8.44	3.85E-16	Longevity	
LUSC	cis	1	rs9813712	chr3:129971101	COL6A4P2	chr3:129931663-129992648:+	0.19	3.75	0.0002	Response to amphetamines	
LUSC	cis	1	rs9813756	chr3:46349352	CCR2	chr3:46395235-46402412:+	-0.1	-3.96	8.67E-5	Celiac disease	
LUSC	cis	1	rs9813774	chr3:134227100	ANAPC13	chr3:134196547-134204865:-	0.42	8.41	4.72E-16	Height	
LUSC	cis	1	rs9814567	chr3:134218557	ANAPC13	chr3:134196547-134204865:-	-0.4	-8.2	2.33E-15	Height	
LUSC	cis	1	rs9815103	chr3:48414215	ATRIP	chr3:48488141-48507708:+	0.2	3.93	9.72E-5	Longevity	
LUSC	cis	1	rs9815103	chr3:48414215	TREX1	chr3:48501186-48509043:+	-0.44	-9.5	1.04E-19	Longevity	
LUSC	cis	1	rs9815289	chr3:132728527	TMEM108	chr3:132757171-133116618:+	0.2	4.56	6.42E-6	IgE grass sensitization	
LUSC	cis	1	rs9815354	chr3:41912651	ULK4	chr3:41288091-42003660:-	0.61	9.14	1.8E-18	Diastolic blood pressure	
LUSC	cis	1	rs9817615	chr3:48470756	ATRIP	chr3:48488141-48507708:+	0.18	3.82	0.000149	Longevity	
LUSC	cis	1	rs9817615	chr3:48470756	TREX1	chr3:48501186-48509043:+	-0.39	-8.76	3.39E-17	Longevity	
LUSC	cis	1	rs9818169	chr3:41860599	ULK4	chr3:41288091-42003660:-	0.57	8.73	4.38E-17	Diastolic blood pressure	
LUSC	cis	1	rs9818941	chr3:157686457	RSRC1	chr3:157827892-158262574:+	0.19	3.72	0.000222	Height	
LUSC	cis	1	rs9819532	chr3:134288644	ANAPC13	chr3:134196547-134204865:-	0.41	8.05	6.68E-15	Height	
LUSC	cis	1	rs9822322	chr3:171320227	PLD1	chr3:171318620-171528273:-	0.16	3.71	0.000234	Gut microbiome composition (summer and winter)	
LUSC	cis	1	rs9823254	chr3:41894768	ULK4	chr3:41288091-42003660:-	0.62	9.43	1.81E-19	Diastolic blood pressure	
LUSC	cis	1	rs9824252	chr3:132705311	TMEM108	chr3:132757171-133116618:+	0.19	4.47	9.69E-6	IgE grass sensitization	
LUSC	cis	1	rs9824731	chr3:41889698	ULK4	chr3:41288091-42003660:-	0.63	9.45	1.49E-19	Diastolic blood pressure	
LUSC	cis	1	rs9826195	chr3:48433635	TREX1	chr3:48501186-48509043:+	-0.44	-9.75	1.38E-20	Longevity	
LUSC	cis	1	rs9826496	chr3:134224437	ANAPC13	chr3:134196547-134204865:-	0.41	8.31	1.02E-15	Height	
LUSC	cis	1	rs9827987	chr3:134272621	ANAPC13	chr3:134196547-134204865:-	0.42	8.38	5.82E-16	Height	
LUSC	cis	1	rs9828815	chr3:134265749	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs9829092	chr3:134229866	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.14E-16	Height	
LUSC	cis	1	rs9832785	chr3:134213070	ANAPC13	chr3:134196547-134204865:-	0.43	8.67	7.02E-17	Height	
LUSC	cis	1	rs9834137	chr3:132714362	TMEM108	chr3:132757171-133116618:+	0.2	4.71	3.3E-6	IgE grass sensitization	
LUSC	cis	1	rs9834755	chr3:134206845	ANAPC13	chr3:134196547-134204865:-	0.43	8.67	6.91E-17	Height	
LUSC	cis	1	rs9835183	chr3:132737794	TMEM108	chr3:132757171-133116618:+	0.2	4.75	2.75E-6	IgE grass sensitization	
LUSC	cis	1	rs9835204	chr3:134261342	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs9837038	chr3:156568469	LEKR1	chr3:156544076-156763918:+	-0.26	-6.05	2.93E-9	Multiple sclerosis (severity)	
LUSC	cis	1	rs9838618	chr3:48487353	ATRIP	chr3:48488141-48507708:+	0.22	4.55	6.77E-6	Longevity	
LUSC	cis	1	rs9838618	chr3:48487353	TREX1	chr3:48501186-48509043:+	-0.39	-8.41	4.87E-16	Longevity	
LUSC	cis	1	rs9841144	chr3:85531199	CADM2	chr3:85008133-86117948:+	-0.26	-3.95	9.04E-5	Longevity (90 years and older)	
LUSC	cis	1	rs9841212	chr3:134191938	ANAPC13	chr3:134196547-134204865:-	0.46	9.47	1.29E-19	Height	
LUSC	cis	1	rs9841212	chr3:134191938	CEP63	chr3:134204575-134293852:+	0.21	3.91	0.000105	Height	
LUSC	cis	1	rs9842132	chr3:49427933	AMT	chr3:49454212-49460012:-	-0.2	-4.82	1.89E-6	Menarche (age at onset)	
LUSC	cis	1	rs9842132	chr3:49427933	TREX1	chr3:48501186-48509043:+	0.2	3.76	0.000193	Menarche (age at onset)	
LUSC	cis	1	rs984222	chr1:119503843	WARS2	chr1:119573841-119683295:-	-0.25	-4.59	5.6E-6	Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio	
LUSC	cis	1	rs9844512	chr3:85544070	CADM2	chr3:85008133-86117948:+	0.3	4.51	8.14E-6	Longevity (90 years and older)	
LUSC	cis	1	rs9846634	chr3:41894049	ULK4	chr3:41288091-42003660:-	0.63	9.47	1.37E-19	Diastolic blood pressure	
LUSC	cis	1	rs9847975	chr3:41786904	ULK4	chr3:41288091-42003660:-	0.61	8.97	7.04E-18	Diastolic blood pressure	
LUSC	cis	1	rs9849399	chr3:85537665	CADM2	chr3:85008133-86117948:+	0.3	4.51	8.05E-6	Longevity (90 years and older)	
LUSC	cis	1	rs9849509	chr3:48483432	ATRIP	chr3:48488141-48507708:+	0.19	4.05	6.08E-5	Longevity	
LUSC	cis	1	rs9849509	chr3:48483432	TREX1	chr3:48501186-48509043:+	-0.39	-8.54	1.77E-16	Longevity	
LUSC	cis	1	rs9850015	chr3:134269541	ANAPC13	chr3:134196547-134204865:-	0.42	8.38	5.82E-16	Height	
LUSC	cis	1	rs9851441	chr3:134315091	ANAPC13	chr3:134196547-134204865:-	0.41	8.09	4.96E-15	Height	
LUSC	cis	1	rs9854299	chr3:134206728	ANAPC13	chr3:134196547-134204865:-	0.43	8.59	1.24E-16	Height	
LUSC	cis	1	rs9855965	chr3:41860508	ULK4	chr3:41288091-42003660:-	0.57	8.73	4.38E-17	Diastolic blood pressure	
LUSC	cis	1	rs9856088	chr3:41860482	ULK4	chr3:41288091-42003660:-	0.57	8.73	4.38E-17	Diastolic blood pressure	
LUSC	cis	1	rs9856098	chr3:46349905	CCR2	chr3:46395235-46402412:+	-0.1	-3.78	0.000175	Celiac disease	
LUSC	cis	1	rs9856633	chr3:42013850	ULK4	chr3:41288091-42003660:-	0.66	10.55	1.65E-23	Diastolic blood pressure	
LUSC	cis	1	rs9856693	chr3:134306913	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs9857625	chr3:87494596	ZNF654	chr3:88188262-88193812:+	0.38	3.71	0.000234	Brain connectivity	
LUSC	cis	1	rs9860055	chr3:49506900	AMT	chr3:49454212-49460012:-	-0.2	-4.73	2.92E-6	Menarche (age at onset)	
LUSC	cis	1	rs9860055	chr3:49506900	TREX1	chr3:48501186-48509043:+	0.24	4.39	1.38E-5	Menarche (age at onset)	
LUSC	cis	1	rs9860378	chr3:132717559	TMEM108	chr3:132757171-133116618:+	0.21	4.95	1.05E-6	IgE grass sensitization	
LUSC	cis	1	rs9862534	chr3:49598064	AMT	chr3:49454212-49460012:-	0.22	5.11	4.74E-7	Menarche (age at onset)	
LUSC	cis	1	rs9863786	chr3:134247203	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs9864346	chr3:134312352	ANAPC13	chr3:134196547-134204865:-	0.41	8.08	5.24E-15	Height	
LUSC	cis	1	rs9864371	chr3:48426766	TREX1	chr3:48501186-48509043:+	-0.45	-9.92	3.44E-21	Longevity	
LUSC	cis	1	rs9864439	chr3:134298671	ANAPC13	chr3:134196547-134204865:-	0.41	8.02	8.13E-15	Height	
LUSC	cis	1	rs9864582	chr3:129970462	COL6A4P2	chr3:129931663-129992648:+	0.19	3.72	0.000222	Response to amphetamines	
LUSC	cis	1	rs9864694	chr3:132718017	TMEM108	chr3:132757171-133116618:+	0.21	4.95	1.05E-6	IgE grass sensitization	
LUSC	cis	1	rs9865905	chr3:156649594	LEKR1	chr3:156544076-156763918:+	0.25	5.59	3.92E-8	Multiple sclerosis (severity)	
LUSC	cis	1	rs9867627	chr3:41795841	ULK4	chr3:41288091-42003660:-	-0.59	-9.2	1.17E-18	Diastolic blood pressure	
LUSC	cis	1	rs9869981	chr3:134248801	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs9871024	chr3:49554241	AMT	chr3:49454212-49460012:-	-0.2	-4.73	2.98E-6	Menarche (age at onset)	
LUSC	cis	1	rs9871305	chr3:134213538	ANAPC13	chr3:134196547-134204865:-	0.42	8.51	2.27E-16	Height	
LUSC	cis	1	rs9871812	chr3:132737180	TMEM108	chr3:132757171-133116618:+	0.2	4.75	2.75E-6	IgE grass sensitization	
LUSC	cis	1	rs9872999	chr3:133457514	TF	chr3:133419211-133497635:+	-0.4	-7.46	4.27E-13	Iron status biomarkers	
LUSC	cis	1	rs9873207	chr3:41884750	ULK4	chr3:41288091-42003660:-	0.62	9.36	3.28E-19	Diastolic blood pressure	
LUSC	cis	1	rs9873398	chr3:132724912	TMEM108	chr3:132757171-133116618:+	-0.21	-4.83	1.86E-6	IgE grass sensitization	
LUSC	cis	1	rs9873400	chr3:85590097	CADM2	chr3:85008133-86117948:+	0.31	4.77	2.42E-6	Longevity (90 years and older)	
LUSC	cis	1	rs9874513	chr3:41909508	ULK4	chr3:41288091-42003660:-	0.62	9.32	4.23E-19	Diastolic blood pressure	
LUSC	cis	1	rs9876658	chr3:134179453	ANAPC13	chr3:134196547-134204865:-	-0.37	-7.61	1.53E-13	Height	
LUSC	cis	1	rs9876781	chr3:48487338	ATRIP	chr3:48488141-48507708:+	0.2	4.23	2.76E-5	Longevity	
LUSC	cis	1	rs9876781	chr3:48487338	TREX1	chr3:48501186-48509043:+	-0.4	-8.94	8.85E-18	Longevity	
LUSC	cis	1	rs9876960	chr3:41985812	ULK4	chr3:41288091-42003660:-	-0.65	-10.3	1.41E-22	Diastolic blood pressure	
LUSC	cis	1	rs9881491	chr3:48487911	ATRIP	chr3:48488141-48507708:+	0.21	4.21	3.09E-5	Longevity	
LUSC	cis	1	rs9881491	chr3:48487911	TREX1	chr3:48501186-48509043:+	-0.41	-8.81	2.43E-17	Longevity	
LUSC	cis	1	rs9883753	chr3:134247231	ANAPC13	chr3:134196547-134204865:-	0.42	8.33	8.46E-16	Height	
LUSC	cis	1	rs9883759	chr3:48463618	ATRIP	chr3:48488141-48507708:+	0.19	3.83	0.000143	Longevity	
LUSC	cis	1	rs9883759	chr3:48463618	TREX1	chr3:48501186-48509043:+	-0.42	-9.17	1.48E-18	Longevity	
LUSC	cis	1	rs9883927	chr3:48463711	ATRIP	chr3:48488141-48507708:+	0.18	3.82	0.000149	Longevity	
LUSC	cis	1	rs9883927	chr3:48463711	TREX1	chr3:48501186-48509043:+	-0.4	-8.79	2.67E-17	Longevity	
LUSC	cis	1	rs9884031	chr3:134256500	ANAPC13	chr3:134196547-134204865:-	0.42	8.32	9.31E-16	Height	
LUSC	cis	1	rs9890205	chr17:28382704	EFCAB5	chr17:28256874-28435469:+	-0.3	-5.66	2.68E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs9890886	chr17:28391076	EFCAB5	chr17:28256874-28435469:+	-0.29	-5.57	4.17E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs9891018	chr17:61827856	FTSJ3	chr17:61896795-61905031:-	0.33	6.51	1.87E-10	Body mass index	
LUSC	cis	1	rs9891871	chr17:28370191	EFCAB5	chr17:28256874-28435469:+	-0.3	-5.59	3.91E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs9892365	chr17:59491384	C17orf82	chr17:59489112-59490641:+	0.16	3.76	0.000193	Sitting height ratio	
LUSC	cis	1	rs9893348	chr17:61676534	FTSJ3	chr17:61896795-61905031:-	0.34	6.48	2.24E-10	Body mass index	
LUSC	cis	1	rs9894429	chr17:79596811	TSPAN10	chr17:79609349-79615778:+	0.46	9.47	1.33E-19	Eye color traits	
LUSC	cis	1	rs9895920	chr17:61852719	FTSJ3	chr17:61896795-61905031:-	0.34	6.72	5.21E-11	Body mass index	
LUSC	cis	1	rs9896062	chr17:28357047	EFCAB5	chr17:28256874-28435469:+	-0.31	-5.79	1.29E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs9897206	chr17:28406108	EFCAB5	chr17:28256874-28435469:+	-0.29	-5.49	6.54E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs9899491	chr17:61934384	FTSJ3	chr17:61896795-61905031:-	0.32	6.32	6.05E-10	Body mass index	
LUSC	cis	1	rs9899788	chr17:61756384	FTSJ3	chr17:61896795-61905031:-	0.32	6.31	6.53E-10	Body mass index	
LUSC	cis	1	rs9901112	chr17:61730617	FTSJ3	chr17:61896795-61905031:-	0.34	6.69	6.33E-11	Body mass index	
LUSC	cis	1	rs9901507	chr17:61765524	FTSJ3	chr17:61896795-61905031:-	0.33	6.43	3.1E-10	Body mass index	
LUSC	cis	1	rs9902453	chr17:28349095	EFCAB5	chr17:28256874-28435469:+	-0.3	-5.77	1.42E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs9903897	chr17:61716705	FTSJ3	chr17:61896795-61905031:-	0.33	6.45	2.78E-10	Body mass index	
LUSC	cis	1	rs9903903	chr17:61762044	FTSJ3	chr17:61896795-61905031:-	0.32	6.31	6.53E-10	Body mass index	
LUSC	cis	1	rs9904677	chr17:56873025	RAD51C	chr17:56769963-56811690:+	0.29	6.14	1.76E-9	Cognitive test performance	
LUSC	cis	1	rs9905385	chr17:59498250	C17orf82	chr17:59489112-59490641:+	0.16	3.75	0.000197	Sitting height ratio	
LUSC	cis	1	rs9905704	chr17:56632543	RAD51C	chr17:56769963-56811690:+	0.19	3.81	0.000157	Testicular germ cell tumor	
LUSC	cis	1	rs9906340	chr17:28398977	EFCAB5	chr17:28256874-28435469:+	-0.29	-5.29	1.89E-7	Coffee consumption (cups per day)	
LUSC	cis	1	rs9908044	chr17:61747032	FTSJ3	chr17:61896795-61905031:-	0.32	6.31	6.53E-10	Body mass index	
LUSC	cis	1	rs9909992	chr17:61731931	FTSJ3	chr17:61896795-61905031:-	0.33	6.49	2.1E-10	Body mass index	
LUSC	cis	1	rs9909	chr11:47799775	C1QTNF4	chr11:47611216-47615961:-	-0.22	-4.02	6.78E-5	Subjective well-being	
LUSC	cis	1	rs9912084	chr17:65868035	LOC440461	chr17:66194801-66196436:+	0.25	3.99	7.59E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs9912201	chr17:61763208	FTSJ3	chr17:61896795-61905031:-	0.34	6.54	1.55E-10	Body mass index	
LUSC	cis	1	rs9912741	chr17:28359511	EFCAB5	chr17:28256874-28435469:+	-0.3	-5.59	3.91E-8	Coffee consumption (cups per day)	
LUSC	cis	1	rs9912770	chr17:65868233	LOC440461	chr17:66194801-66196436:+	0.25	3.99	7.59E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs9912904	chr17:61763534	FTSJ3	chr17:61896795-61905031:-	0.32	6.3	6.96E-10	Body mass index	
LUSC	cis	1	rs9913471	chr17:65874495	LOC440461	chr17:66194801-66196436:+	0.26	4.06	5.8E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs991427	chr12:91474422	KERA	chr12:91444273-91452131:-	0.22	3.72	0.000227	Systolic blood pressure (alcohol consumption interaction)	
LUSC	cis	1	rs9915108	chr17:65874463	LOC440461	chr17:66194801-66196436:+	0.26	4.06	5.8E-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma	
LUSC	cis	1	rs9919218	chr1:228997482	WNT3A	chr1:228194752-228248961:+	0.21	3.72	0.000222	Basal cell carcinoma	
LUSC	cis	1	rs9921338	chr16:11416839	C16orf75	chr16:11343506-11445617:+	-0.26	-4.7	3.42E-6	Vein graft stenosis in coronary artery bypass grafting	
LUSC	cis	1	rs9923145	chr16:74686166	RFWD3	chr16:74655298-74700779:-	-0.24	-5.6	3.58E-8	Testicular germ cell tumor	
LUSC	cis	1	rs992416	chr17:61745905	FTSJ3	chr17:61896795-61905031:-	0.32	6.3	6.96E-10	Body mass index	
LUSC	cis	1	rs9925964	chr16:31129895	MYST1	chr16:31128985-31142713:+	-0.2	-3.83	0.000147	Body mass index	
LUSC	cis	1	rs9929496	chr16:74668473	RFWD3	chr16:74655298-74700779:-	-0.24	-5.4	1.03E-7	Testicular germ cell tumor	
LUSC	cis	1	rs9931225	chr16:74699293	RFWD3	chr16:74655298-74700779:-	-0.23	-5.3	1.75E-7	Testicular germ cell tumor	
LUSC	cis	1	rs993394	chr6:117117143	GPRC6A	chr6:117113248-117150198:-	-0.21	-3.98	8.09E-5	C-reactive protein levels	
LUSC	cis	1	rs9941751	chr20:33645709	GDF5	chr20:33897002-34042568:-	0.28	3.77	0.000182	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs9941751	chr20:33645709	PROCR	chr20:33758727-33765164:+	-0.33	-4.34	1.73E-5	Anticoagulant levels;D-dimer levels;Protein C levels;Factor VII levels;Hemostatic factors and hematological phenotypes	
LUSC	cis	1	rs9959145	chr18:12606463	SPIRE1	chr18:12446512-12657912:-	-0.31	-3.75	0.000202	Immune response to smallpox vaccine (IL-6)	
LUSC	cis	1	rs9968172	chr3:134231251	ANAPC13	chr3:134196547-134204865:-	-0.44	-8.77	3.28E-17	Height	
LUSC	cis	1	rs997295	chr15:68016343	IQCH	chr15:67547188-67794139:+	0.22	3.91	0.000106	Motion sickness	
LUSC	cis	1	rs997872	chr22:25878614	CRYBB2	chr22:25615612-25627836:+	0.74	8.43	4.08E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs997873	chr22:25878282	CRYBB2	chr22:25615612-25627836:+	0.74	8.43	4.08E-16	Bipolar disorder with mood-incongruent psychosis	
LUSC	cis	1	rs9985356	chr3:134232920	ANAPC13	chr3:134196547-134204865:-	-0.44	-8.9	1.14E-17	Height	
LUSC	cis	1	rs9986696	chr7:65704576	NCRNA00174	chr7:65841032-65865395:-	0.3	6.5	2.01E-10	Aortic root size	
LUSC	cis	1	rs9987357	chr8:124187620	FAM83A	chr8:124191287-124222317:+	-0.27	-4.33	1.8E-5	Urinary uromodulin levels	
LUSC	cis	1	rs9989967	chr3:134238964	ANAPC13	chr3:134196547-134204865:-	0.42	8.48	2.77E-16	Height	
LUSC	cis	1	rs9990351	chr3:134239191	ANAPC13	chr3:134196547-134204865:-	-0.42	-8.67	6.72E-17	Height	
LUSC	cis	1	rs9995007	chr4:76897791	NAAA	chr4:76831809-76862166:-	-0.27	-5.82	1.06E-8	Longevity	
LUSC	trans	1	rs10037055	chr5:176691279	LOC388955	chr2:63849182-63850159:-	-0.44	-8.44	3.89E-16	Migraine without aura	
LUSC	trans	1	rs10214634	chr6:26564582	ZNF322B	chr9:99957633-99961910:-	0.34	7.1	4.59E-12	Educational attainment	
LUSC	trans	1	rs10456362	chr6:28221816	BTN3A2	chr6:26365398-26378546:+	0.44	7.64	1.19E-13	Depression	
LUSC	trans	1	rs10456362	chr6:28221816	HLA-DQB1	chr6:32627657-32634466:-	0.32	5.97	4.55E-9	Depression	
LUSC	trans	1	rs10484442	chr6:26555879	ZNF322B	chr9:99957633-99961910:-	0.34	7.12	3.96E-12	Educational attainment	
LUSC	trans	1	rs10501336	chr11:55315519	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs1056667	chr6:26510564	ZNF322B	chr9:99957633-99961910:-	0.36	7.68	9.19E-14	Educational attainment	
LUSC	trans	1	rs10742862	chr11:48649316	FOLH1B	chr11:89392465-89431885:+	-0.48	-9.79	9.36E-21	HDL cholesterol	
LUSC	trans	1	rs10769371	chr11:48531184	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.58	5.27E-20	HDL cholesterol	
LUSC	trans	1	rs10769390	chr11:48618222	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.72	1.69E-20	HDL cholesterol	
LUSC	trans	1	rs1078679	chr6:26568741	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs10794671	chr1:121168242	NBPF14	chr1:148003643-148346791:-	0.36	7.86	2.62E-14	Hip geometry	
LUSC	trans	1	rs10838801	chr11:48098280	FOLH1B	chr11:89392465-89431885:+	-0.42	-7.67	9.98E-14	Height	
LUSC	trans	1	rs10838912	chr11:48496477	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.37	2.99E-19	HDL cholesterol	
LUSC	trans	1	rs10838917	chr11:48503127	FOLH1B	chr11:89392465-89431885:+	-0.45	-9.27	6.59E-19	HDL cholesterol	
LUSC	trans	1	rs10838931	chr11:48540973	FOLH1B	chr11:89392465-89431885:+	-0.45	-9.22	9.82E-19	HDL cholesterol	
LUSC	trans	1	rs10838943	chr11:48557442	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.62	3.95E-20	HDL cholesterol	
LUSC	trans	1	rs10838944	chr11:48559571	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.62	3.95E-20	HDL cholesterol	
LUSC	trans	1	rs10838954	chr11:48579323	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.7	2.0E-20	HDL cholesterol	
LUSC	trans	1	rs10838966	chr11:48589723	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.64	3.29E-20	HDL cholesterol	
LUSC	trans	1	rs10838971	chr11:48606624	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.48	1.26E-19	HDL cholesterol	
LUSC	trans	1	rs10838975	chr11:48617615	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.45	1.58E-19	HDL cholesterol	
LUSC	trans	1	rs10839171	chr11:48923034	FOLH1B	chr11:89392465-89431885:+	0.47	9.67	2.68E-20	HDL cholesterol	
LUSC	trans	1	rs10896042	chr11:55898588	FOLH1B	chr11:89392465-89431885:+	0.33	5.95	5.26E-9	Odorant perception (&beta;-damascenone)	
LUSC	trans	1	rs10903159	chr1:121181997	NBPF14	chr1:148003643-148346791:-	0.38	8.22	1.9E-15	Hip geometry	
LUSC	trans	1	rs10903161	chr1:121178741	NBPF14	chr1:148003643-148346791:-	0.36	7.81	3.57E-14	Hip geometry	
LUSC	trans	1	rs10946834	chr6:26533664	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.21E-13	Educational attainment	
LUSC	trans	1	rs10946835	chr6:26533757	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.21E-13	Educational attainment	
LUSC	trans	1	rs11039745	chr11:48463811	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.35	3.57E-19	HDL cholesterol	
LUSC	trans	1	rs11039777	chr11:48517049	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.57	5.81E-20	HDL cholesterol	
LUSC	trans	1	rs11039779	chr11:48517895	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.59	4.94E-20	HDL cholesterol	
LUSC	trans	1	rs11039800	chr11:48542579	FOLH1B	chr11:89392465-89431885:+	0.45	9.24	8.48E-19	HDL cholesterol	
LUSC	trans	1	rs11039817	chr11:48561480	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.7	2.1E-20	HDL cholesterol	
LUSC	trans	1	rs11039819	chr11:48562181	FOLH1B	chr11:89392465-89431885:+	-0.45	-9.45	1.57E-19	HDL cholesterol	
LUSC	trans	1	rs11039820	chr11:48562252	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.76	1.23E-20	HDL cholesterol	
LUSC	trans	1	rs11039821	chr11:48562875	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.7	2.1E-20	HDL cholesterol	
LUSC	trans	1	rs11039851	chr11:48600839	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.67	2.6E-20	HDL cholesterol	
LUSC	trans	1	rs11039854	chr11:48607688	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.75	1.35E-20	HDL cholesterol	
LUSC	trans	1	rs11039857	chr11:48610853	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.48	1.26E-19	HDL cholesterol	
LUSC	trans	1	rs11039859	chr11:48611988	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.48	1.26E-19	HDL cholesterol	
LUSC	trans	1	rs11039862	chr11:48618306	FOLH1B	chr11:89392465-89431885:+	-0.48	-9.82	7.81E-21	HDL cholesterol	
LUSC	trans	1	rs11039868	chr11:48622146	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.72	1.69E-20	HDL cholesterol	
LUSC	trans	1	rs11039871	chr11:48626620	FOLH1B	chr11:89392465-89431885:+	0.47	9.64	3.38E-20	HDL cholesterol	
LUSC	trans	1	rs11039890	chr11:48653468	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.41	2.16E-19	HDL cholesterol	
LUSC	trans	1	rs11039904	chr11:48682597	FOLH1B	chr11:89392465-89431885:+	0.49	6.61	1.01E-10	Axial length	
LUSC	trans	1	rs11039978	chr11:48760237	FOLH1B	chr11:89392465-89431885:+	0.49	6.57	1.29E-10	Axial length	
LUSC	trans	1	rs1119153	chr11:55324134	FOLH1B	chr11:89392465-89431885:+	0.7	6.01	3.68E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs11246602	chr11:51512090	FOLH1B	chr11:89392465-89431885:+	0.54	6.53	1.66E-10	HDL cholesterol	
LUSC	trans	1	rs11249350	chr1:121178446	NBPF14	chr1:148003643-148346791:-	0.38	8.16	3.01E-15	Hip geometry	
LUSC	trans	1	rs11249351	chr1:121171942	NBPF14	chr1:148003643-148346791:-	0.34	7.46	4.15E-13	Hip geometry	
LUSC	trans	1	rs114502840	chr11:54899615	FOLH1B	chr11:89392465-89431885:+	0.74	6.4	3.8E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs114635668	chr11:54812845	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs115224187	chr11:48757499	FOLH1B	chr11:89392465-89431885:+	0.48	9.7	2.02E-20	HDL cholesterol	
LUSC	trans	1	rs11530232	chr11:48622376	FOLH1B	chr11:89392465-89431885:+	0.52	6.28	7.68E-10	Axial length	
LUSC	trans	1	rs115429994	chr11:48761183	FOLH1B	chr11:89392465-89431885:+	0.49	6.57	1.29E-10	Axial length	
LUSC	trans	1	rs116777062	chr11:54802952	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs116849536	chr11:55473875	FOLH1B	chr11:89392465-89431885:+	0.72	6.08	2.43E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs116858638	chr11:55184859	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs116868501	chr11:55353720	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs116912712	chr11:55123489	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs116966729	chr11:55225831	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs116969778	chr11:55213922	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs116984732	chr11:54901489	FOLH1B	chr11:89392465-89431885:+	0.76	6.55	1.46E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs117067781	chr11:55572932	FOLH1B	chr11:89392465-89431885:+	0.7	6.23	1.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117110854	chr11:55325763	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117154767	chr11:55356741	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117189006	chr11:55263160	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs117233182	chr11:55011757	FOLH1B	chr11:89392465-89431885:+	0.73	6.14	1.79E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117245504	chr11:55175422	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117292063	chr11:54987085	FOLH1B	chr11:89392465-89431885:+	0.71	6.1	2.26E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117311484	chr11:55224735	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117352062	chr11:55135019	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117427130	chr11:55189935	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117431413	chr11:55147469	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117438754	chr11:55101588	FOLH1B	chr11:89392465-89431885:+	0.72	6.19	1.28E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117533468	chr11:55293193	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs11756120	chr6:26529808	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.27E-13	Educational attainment	
LUSC	trans	1	rs117696469	chr11:55003433	FOLH1B	chr11:89392465-89431885:+	0.73	6.14	1.79E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117722297	chr11:54841706	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs117788647	chr11:55187201	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs117961171	chr11:54828312	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs117967582	chr11:54979275	FOLH1B	chr11:89392465-89431885:+	0.74	6.34	5.42E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs117975165	chr11:54807491	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs117987119	chr11:54986601	FOLH1B	chr11:89392465-89431885:+	0.74	6.28	7.58E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs117999297	chr11:55164192	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs118079991	chr11:55347493	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs118121544	chr11:55263793	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs118186653	chr11:54846271	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs11821647	chr11:54978609	FOLH1B	chr11:89392465-89431885:+	0.71	6.11	2.1E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs11824344	chr11:54955198	FOLH1B	chr11:89392465-89431885:+	0.74	6.4	3.8E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs11826744	chr11:54895914	FOLH1B	chr11:89392465-89431885:+	0.74	6.4	3.8E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs11828245	chr11:55116941	FOLH1B	chr11:89392465-89431885:+	0.69	5.96	4.97E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs11965538	chr6:28239915	BTN3A2	chr6:26365398-26378546:+	-0.46	-7.69	8.81E-14	Depression	
LUSC	trans	1	rs12047116	chr1:121185770	NBPF14	chr1:148003643-148346791:-	0.38	8.39	5.56E-16	Hip geometry	
LUSC	trans	1	rs12145080	chr1:121185531	NBPF14	chr1:148003643-148346791:-	-0.36	-7.77	4.92E-14	Hip geometry	
LUSC	trans	1	rs12225599	chr11:48755868	FOLH1B	chr11:89392465-89431885:+	0.49	6.57	1.29E-10	Axial length	
LUSC	trans	1	rs12280020	chr11:48618844	FOLH1B	chr11:89392465-89431885:+	0.47	6.45	2.72E-10	Axial length	
LUSC	trans	1	rs12281162	chr11:48650491	FOLH1B	chr11:89392465-89431885:+	0.48	6.56	1.43E-10	Axial length	
LUSC	trans	1	rs12293522	chr11:49558425	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.42	1.96E-19	Height	
LUSC	trans	1	rs12361812	chr11:48563104	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.68	2.34E-20	HDL cholesterol	
LUSC	trans	1	rs12365220	chr11:48555957	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.62	3.95E-20	HDL cholesterol	
LUSC	trans	1	rs12366208	chr11:48563128	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.4	2.25E-19	HDL cholesterol	
LUSC	trans	1	rs12419576	chr11:48581644	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.64	3.29E-20	HDL cholesterol	
LUSC	trans	1	rs12420372	chr11:48497603	FOLH1B	chr11:89392465-89431885:+	0.44	8.99	5.99E-18	HDL cholesterol	
LUSC	trans	1	rs12421159	chr11:48624841	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.72	1.69E-20	HDL cholesterol	
LUSC	trans	1	rs12421879	chr11:48689978	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.45	1.5E-19	HDL cholesterol	
LUSC	trans	1	rs12526680	chr6:26550954	ZNF322B	chr9:99957633-99961910:-	0.34	7.11	4.17E-12	Educational attainment	
LUSC	trans	1	rs12570188	chr10:100855702	CUEDC2	chr10:104183002-104192423:-	-0.51	-6.12	1.9E-9	Asthma (childhood onset)	
LUSC	trans	1	rs12570188	chr10:100855702	GHITM	chr10:85899185-85913311:+	-0.45	-5.9	6.95E-9	Asthma (childhood onset)	
LUSC	trans	1	rs12570188	chr10:100855702	PDCD11	chr10:105156412-105206019:+	-0.48	-6.22	1.07E-9	Asthma (childhood onset)	
LUSC	trans	1	rs12570188	chr10:100855702	RRP12	chr10:99116459-99161127:-	-0.54	-6.47	2.47E-10	Asthma (childhood onset)	
LUSC	trans	1	rs12806328	chr11:48647971	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.58	5.62E-20	HDL cholesterol	
LUSC	trans	1	rs13200462	chr6:28218199	BTN3A2	chr6:26365398-26378546:+	-0.47	-7.57	2.02E-13	Depression	
LUSC	trans	1	rs1321479	chr6:26501897	ZNF322B	chr9:99957633-99961910:-	-0.33	-6.96	1.1E-11	Educational attainment	
LUSC	trans	1	rs1321480	chr6:26532742	ZNF322B	chr9:99957633-99961910:-	0.35	7.61	1.51E-13	Educational attainment	
LUSC	trans	1	rs1321481	chr6:26538210	ZNF322B	chr9:99957633-99961910:-	0.35	7.57	2.02E-13	Educational attainment	
LUSC	trans	1	rs1351696	chr11:48382471	FOLH1B	chr11:89392465-89431885:+	-0.47	-6.4	3.83E-10	D-dimer levels	
LUSC	trans	1	rs1419183	chr6:28242794	BTN3A2	chr6:26365398-26378546:+	-0.46	-7.7	7.98E-14	Depression	
LUSC	trans	1	rs1425192	chr11:55139994	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs1459105	chr11:55317617	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs1459106	chr11:55317814	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs1504670	chr11:55321254	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs1504671	chr11:55321156	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs1535277	chr6:26567802	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs1580922	chr11:55324138	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs1591882	chr1:121183313	NBPF14	chr1:148003643-148346791:-	0.37	8.06	6.09E-15	Hip geometry	
LUSC	trans	1	rs1605364	chr11:48684843	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.69	2.19E-20	HDL cholesterol	
LUSC	trans	1	rs1679709	chr6:28228342	BTN3A2	chr6:26365398-26378546:+	0.46	7.48	3.6E-13	Depression	
LUSC	trans	1	rs1679732	chr6:28221264	BTN3A2	chr6:26365398-26378546:+	0.46	7.47	3.83E-13	Depression	
LUSC	trans	1	rs16910486	chr8:140352359	DMRT3	chr9:976964-991732:+	0.37	6.22	1.1E-9	Visceral adipose tissue	
LUSC	trans	1	rs16926279	chr12:23639847	CT47A10	chrX:120082278-120085594:-;chrX	-0.2	-7.16	3.07E-12	Schizophrenia	
LUSC	trans	1	rs17492564	chr11:55129798	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17492571	chr11:55129994	FOLH1B	chr11:89392465-89431885:+	0.68	6.01	3.67E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17493401	chr11:55171930	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17493596	chr11:55200610	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17493710	chr11:55204758	FOLH1B	chr11:89392465-89431885:+	-0.66	-6	3.89E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17494990	chr11:55277761	FOLH1B	chr11:89392465-89431885:+	0.67	6.05	2.9E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17495071	chr11:55278447	FOLH1B	chr11:89392465-89431885:+	0.72	6.14	1.8E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17495142	chr11:55282594	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17495303	chr11:55290011	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17496054	chr11:55310280	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17496160	chr11:55314073	FOLH1B	chr11:89392465-89431885:+	0.72	6.37	4.58E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs17496444	chr11:55319012	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs17496724	chr11:55322099	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17499703	chr11:55492391	FOLH1B	chr11:89392465-89431885:+	0.68	5.98	4.4E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17501618	chr11:55568216	FOLH1B	chr11:89392465-89431885:+	-0.67	-6.04	3.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17578388	chr11:55200433	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17579334	chr11:55261146	FOLH1B	chr11:89392465-89431885:+	0.68	6.02	3.41E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17579348	chr11:55261238	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs17579755	chr11:55273190	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs17581191	chr11:55316023	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs17581261	chr11:55318210	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs17581303	chr11:55318698	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs17581700	chr11:55322606	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17581742	chr11:55326524	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17592197	chr11:55531324	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.01E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs17604267	chr8:20631887	CLASP2	chr3:33537741-33759848:-	0.62	6.02	3.52E-9	Serum tamsulosin hydrochloride concentration	
LUSC	trans	1	rs17752619	chr6:155976535	ABHD10	chr3:111697828-111712208:+	-0.4	-5.97	4.61E-9	Schizophrenia	
LUSC	trans	1	rs1778508	chr6:28229881	BTN3A2	chr6:26365398-26378546:+	0.47	7.97	1.19E-14	Depression	
LUSC	trans	1	rs1778511	chr6:28229411	BTN3A2	chr6:26365398-26378546:+	0.46	7.48	3.71E-13	Depression	
LUSC	trans	1	rs1809986	chr11:48987539	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.47	1.36E-19	HDL cholesterol	
LUSC	trans	1	rs1814175	chr11:49559172	FOLH1B	chr11:89392465-89431885:+	-0.49	-10.17	3.96E-22	Height	
LUSC	trans	1	rs1832558	chr1:121177380	NBPF14	chr1:148003643-148346791:-	0.36	7.79	4.27E-14	Hip geometry	
LUSC	trans	1	rs1856572	chr1:121169579	NBPF14	chr1:148003643-148346791:-	0.37	7.87	2.35E-14	Hip geometry	
LUSC	trans	1	rs1884946	chr6:26545308	ZNF322B	chr9:99957633-99961910:-	0.35	7.52	2.84E-13	Educational attainment	
LUSC	trans	1	rs1884948	chr6:26567988	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs1884949	chr6:26568067	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs1936365	chr6:28268452	BTN3A2	chr6:26365398-26378546:+	0.44	7.51	3.04E-13	Depression	
LUSC	trans	1	rs1986111	chr1:121204788	NBPF14	chr1:148003643-148346791:-	0.4	8.54	1.82E-16	Hip geometry	
LUSC	trans	1	rs2185281	chr1:121179991	NBPF14	chr1:148003643-148346791:-	0.38	8.13	3.74E-15	Hip geometry	
LUSC	trans	1	rs2194091	chr3:64725485	DCAF12L1	chrX:125683368-125686842:-	0.27	5.89	7.21E-9	Visceral adipose tissue adjusted for BMI	
LUSC	trans	1	rs2204238	chr11:54922520	FOLH1B	chr11:89392465-89431885:+	0.76	6.55	1.46E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs2208331	chr6:26507319	ZNF322B	chr9:99957633-99961910:-	0.36	7.68	9.34E-14	Educational attainment	
LUSC	trans	1	rs2221559	chr11:48707973	FOLH1B	chr11:89392465-89431885:+	0.46	9.58	5.34E-20	HDL cholesterol	
LUSC	trans	1	rs2224380	chr6:26553943	ZNF322B	chr9:99957633-99961910:-	0.34	7.19	2.46E-12	Educational attainment	
LUSC	trans	1	rs2255070	chr6:26501777	ZNF322B	chr9:99957633-99961910:-	0.36	7.72	6.94E-14	Educational attainment	
LUSC	trans	1	rs2319969	chr1:121207335	NBPF14	chr1:148003643-148346791:-	0.36	7.88	2.22E-14	Hip geometry	
LUSC	trans	1	rs2393670	chr6:26535541	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.21E-13	Educational attainment	
LUSC	trans	1	rs2524005	chr6:29899677	BTN3A2	chr6:26365398-26378546:+	-0.32	-6.03	3.29E-9	Bipolar disorder and schizophrenia	
LUSC	trans	1	rs2715131	chr7:50749079	TNC	chr9:117782806-117880486:-	0.35	5.96	5.03E-9	Fasting glucose-related traits (interaction with BMI)	
LUSC	trans	1	rs2715133	chr7:50749425	TNC	chr9:117782806-117880486:-	0.36	5.99	4.16E-9	Fasting glucose-related traits (interaction with BMI)	
LUSC	trans	1	rs2799077	chr6:28234597	BTN3A2	chr6:26365398-26378546:+	-0.48	-7.88	2.2E-14	Depression	
LUSC	trans	1	rs2799079	chr6:28235176	BTN3A2	chr6:26365398-26378546:+	-0.47	-8.33	8.47E-16	Depression	
LUSC	trans	1	rs2799079	chr6:28235176	HLA-DQB1	chr6:32627657-32634466:-	-0.31	-5.97	4.77E-9	Depression	
LUSC	trans	1	rs28558133	chr6:26531433	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.27E-13	Educational attainment	
LUSC	trans	1	rs28752322	chr11:54798443	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs28805394	chr11:54813776	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs28809233	chr11:54824518	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs28839871	chr11:54800231	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs28846177	chr11:54813850	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs28848478	chr11:54799302	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs28867852	chr11:54795118	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs28871886	chr11:54822390	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs34636547	chr11:48590103	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.64	3.29E-20	HDL cholesterol	
LUSC	trans	1	rs3736781	chr6:26505362	ZNF322B	chr9:99957633-99961910:-	0.36	7.68	9.34E-14	Educational attainment	
LUSC	trans	1	rs3736782	chr6:26505403	ZNF322B	chr9:99957633-99961910:-	0.36	7.68	9.34E-14	Educational attainment	
LUSC	trans	1	rs41266839	chr6:26409890	RNF5P1	chr8:38457695-38458775:-	0.62	6.14	1.77E-9	Schizophrenia	
LUSC	trans	1	rs4316524	chr11:55159965	FOLH1B	chr11:89392465-89431885:+	-0.71	-6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs4341558	chr11:54869378	FOLH1B	chr11:89392465-89431885:+	0.76	6.58	1.24E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs4713006	chr6:26519872	ZNF322B	chr9:99957633-99961910:-	0.35	7.43	5.12E-13	Educational attainment	
LUSC	trans	1	rs4713008	chr6:26538268	ZNF322B	chr9:99957633-99961910:-	0.34	7.4	6.1E-13	Educational attainment	
LUSC	trans	1	rs4844380	chr1:121193620	NBPF14	chr1:148003643-148346791:-	0.4	8.61	1.08E-16	Hip geometry	
LUSC	trans	1	rs4844381	chr1:121184898	NBPF14	chr1:148003643-148346791:-	0.36	7.77	4.82E-14	Hip geometry	
LUSC	trans	1	rs4844607	chr1:121184059	NBPF14	chr1:148003643-148346791:-	-0.36	-7.86	2.59E-14	Hip geometry	
LUSC	trans	1	rs4844616	chr1:121171208	NBPF14	chr1:148003643-148346791:-	0.36	7.79	4.23E-14	Hip geometry	
LUSC	trans	1	rs4871	chr6:26545632	ZNF322B	chr9:99957633-99961910:-	0.35	7.59	1.7E-13	Educational attainment	
LUSC	trans	1	rs4881994	chr11:48498139	FOLH1B	chr11:89392465-89431885:+	-0.45	-9.27	6.34E-19	HDL cholesterol	
LUSC	trans	1	rs4882010	chr11:48559173	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.62	3.95E-20	HDL cholesterol	
LUSC	trans	1	rs4882015	chr11:48565573	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.4	2.39E-19	HDL cholesterol	
LUSC	trans	1	rs4882016	chr11:48570125	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.72	1.76E-20	HDL cholesterol	
LUSC	trans	1	rs4882017	chr11:48570182	FOLH1B	chr11:89392465-89431885:+	0.45	9.29	5.39E-19	HDL cholesterol	
LUSC	trans	1	rs4882019	chr11:48598748	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.37	3.04E-19	HDL cholesterol	
LUSC	trans	1	rs4882021	chr11:48615966	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.45	1.58E-19	HDL cholesterol	
LUSC	trans	1	rs4882096	chr11:48534102	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.58	5.27E-20	HDL cholesterol	
LUSC	trans	1	rs4882111	chr11:48558447	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.62	3.95E-20	HDL cholesterol	
LUSC	trans	1	rs4882117	chr11:48565468	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.4	2.39E-19	HDL cholesterol	
LUSC	trans	1	rs4882120	chr11:48573529	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.72	1.73E-20	HDL cholesterol	
LUSC	trans	1	rs4882123	chr11:48575739	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.72	1.73E-20	HDL cholesterol	
LUSC	trans	1	rs4882129	chr11:48588774	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.64	3.29E-20	HDL cholesterol	
LUSC	trans	1	rs4882130	chr11:48588954	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.64	3.29E-20	HDL cholesterol	
LUSC	trans	1	rs4882132	chr11:48593125	FOLH1B	chr11:89392465-89431885:+	-0.44	-8.65	7.75E-17	HDL cholesterol	
LUSC	trans	1	rs4882134	chr11:48598795	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.37	3.04E-19	HDL cholesterol	
LUSC	trans	1	rs4882136	chr11:48615311	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.72	1.69E-20	HDL cholesterol	
LUSC	trans	1	rs4929903	chr11:48913332	FOLH1B	chr11:89392465-89431885:+	-0.43	-8.78	3.0E-17	HDL cholesterol	
LUSC	trans	1	rs505338	chr11:55320583	FOLH1B	chr11:89392465-89431885:+	-0.68	-6.03	3.25E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55636526	chr11:55341726	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55637752	chr11:54838621	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs55654725	chr11:55331229	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55663900	chr11:54800112	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs55667318	chr11:55210291	FOLH1B	chr11:89392465-89431885:+	0.71	5.98	4.43E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55669714	chr11:55362393	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55686425	chr11:55297270	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55696537	chr11:55264605	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs55708507	chr11:55341154	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55716293	chr11:55134486	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55720733	chr11:55352466	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55744313	chr11:54872326	FOLH1B	chr11:89392465-89431885:+	0.76	6.58	1.24E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs55770365	chr11:55276880	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs55828496	chr11:55321661	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55833102	chr11:55512176	FOLH1B	chr11:89392465-89431885:+	0.68	5.98	4.4E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55834832	chr11:48562583	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.7	2.1E-20	HDL cholesterol	
LUSC	trans	1	rs55837706	chr11:55142112	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55854157	chr11:55192464	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55869276	chr11:55316412	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs55881253	chr11:55310743	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55884431	chr11:55151822	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55889092	chr11:55192872	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55899800	chr11:54810250	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs55902215	chr11:55352483	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55912300	chr11:55297127	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55917312	chr11:55180056	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55959477	chr11:55352289	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs55972122	chr11:55320834	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs55999106	chr11:55257965	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs56045005	chr11:55257798	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs56055236	chr11:55192754	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56056425	chr11:55352227	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56058343	chr11:55362428	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56068831	chr11:55045363	FOLH1B	chr11:89392465-89431885:+	0.7	5.95	5.25E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56080803	chr11:54821372	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs56082718	chr11:55296318	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56118676	chr11:55341735	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56127747	chr11:55337259	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56152577	chr11:55307780	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56160445	chr11:55155815	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56182407	chr11:55155797	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56182790	chr11:54799991	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs56184662	chr11:55180816	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56189573	chr11:54810461	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs56190422	chr11:55202643	FOLH1B	chr11:89392465-89431885:+	0.72	6.09	2.29E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56234219	chr11:54866274	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs56266612	chr11:55304962	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56381852	chr11:55264455	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs56400349	chr11:55435962	FOLH1B	chr11:89392465-89431885:+	0.72	6.18	1.39E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs56410859	chr11:55193186	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894220	chr11:55343454	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894221	chr11:55343809	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894222	chr11:55344293	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894224	chr11:55344825	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894241	chr11:55351097	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894242	chr11:55351153	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894243	chr11:55351244	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894244	chr11:55351528	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894765	chr11:55460012	FOLH1B	chr11:89392465-89431885:+	0.73	6.07	2.63E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894766	chr11:55462473	FOLH1B	chr11:89392465-89431885:+	0.73	6.07	2.63E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894769	chr11:55465984	FOLH1B	chr11:89392465-89431885:+	0.73	6.07	2.63E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894770	chr11:55469059	FOLH1B	chr11:89392465-89431885:+	0.73	6.07	2.63E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894771	chr11:55469143	FOLH1B	chr11:89392465-89431885:+	0.73	6.07	2.63E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894774	chr11:55478092	FOLH1B	chr11:89392465-89431885:+	0.71	6.22	1.07E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894789	chr11:55486919	FOLH1B	chr11:89392465-89431885:+	0.71	6.22	1.07E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894790	chr11:55488052	FOLH1B	chr11:89392465-89431885:+	0.71	6.22	1.07E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894792	chr11:55498659	FOLH1B	chr11:89392465-89431885:+	0.68	5.98	4.4E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894793	chr11:55500102	FOLH1B	chr11:89392465-89431885:+	0.68	5.98	4.4E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894794	chr11:55502938	FOLH1B	chr11:89392465-89431885:+	0.68	5.98	4.4E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894797	chr11:55514318	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.01E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894830	chr11:54978120	FOLH1B	chr11:89392465-89431885:+	0.71	6.13	1.89E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894831	chr11:54978139	FOLH1B	chr11:89392465-89431885:+	0.71	6.13	1.89E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894847	chr11:55530776	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.01E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894851	chr11:55537356	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.24E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894852	chr11:55537513	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.24E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894853	chr11:55538625	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.24E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894854	chr11:55548453	FOLH1B	chr11:89392465-89431885:+	0.69	5.94	5.62E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894856	chr11:55550232	FOLH1B	chr11:89392465-89431885:+	0.69	5.94	5.62E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61894895	chr11:55037442	FOLH1B	chr11:89392465-89431885:+	0.73	6.14	1.79E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895191	chr11:55352786	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895192	chr11:55354108	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895193	chr11:55354239	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895194	chr11:55354435	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895195	chr11:55354636	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895196	chr11:55355308	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895197	chr11:55355735	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895199	chr11:55356496	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895200	chr11:55357348	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895201	chr11:55358164	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895202	chr11:55358456	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895203	chr11:55359728	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895204	chr11:55359925	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895206	chr11:55362587	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895207	chr11:55362826	FOLH1B	chr11:89392465-89431885:+	0.72	6.18	1.35E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61895804	chr11:54798190	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895808	chr11:54802000	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895817	chr11:54804311	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895825	chr11:54808326	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61895830	chr11:54810605	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895833	chr11:54812147	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895834	chr11:54812253	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895838	chr11:54819428	FOLH1B	chr11:89392465-89431885:+	0.76	6.62	9.97E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895839	chr11:54820200	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61895859	chr11:54828661	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61896312	chr11:55572698	FOLH1B	chr11:89392465-89431885:+	0.7	6.23	1.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61896314	chr11:55573704	FOLH1B	chr11:89392465-89431885:+	0.7	6.23	1.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61896315	chr11:55575952	FOLH1B	chr11:89392465-89431885:+	0.7	6.23	1.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61896316	chr11:55576553	FOLH1B	chr11:89392465-89431885:+	0.7	6.23	1.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61896320	chr11:55580588	FOLH1B	chr11:89392465-89431885:+	0.7	6.23	1.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61897266	chr11:54931514	FOLH1B	chr11:89392465-89431885:+	0.76	6.55	1.46E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61897286	chr11:54943203	FOLH1B	chr11:89392465-89431885:+	0.76	6.55	1.46E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61897323	chr11:54955299	FOLH1B	chr11:89392465-89431885:+	0.77	6.61	1.03E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61898060	chr11:54830021	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61898061	chr11:54830100	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61898062	chr11:54830140	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61898073	chr11:54840287	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61898074	chr11:54842180	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61898076	chr11:54847536	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61898077	chr11:54849654	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61898112	chr11:54859595	FOLH1B	chr11:89392465-89431885:+	0.76	6.58	1.24E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61898116	chr11:54863390	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61898130	chr11:54866139	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61898136	chr11:54873052	FOLH1B	chr11:89392465-89431885:+	0.76	6.58	1.24E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61898140	chr11:54875529	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61898141	chr11:54875569	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs61898149	chr11:54880953	FOLH1B	chr11:89392465-89431885:+	0.76	6.55	1.46E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61916171	chr11:55122112	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916173	chr11:55123586	FOLH1B	chr11:89392465-89431885:+	0.68	6.01	3.67E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916175	chr11:55124088	FOLH1B	chr11:89392465-89431885:+	0.68	6.01	3.67E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916177	chr11:55125502	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916184	chr11:55135689	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916211	chr11:55138710	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916223	chr11:55153050	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916231	chr11:55156941	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916286	chr11:55271699	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61916290	chr11:55274688	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61916297	chr11:55279382	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916299	chr11:55281175	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916320	chr11:55282293	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916321	chr11:55282371	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916322	chr11:55282687	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916351	chr11:55290727	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916362	chr11:55207383	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916375	chr11:55211015	FOLH1B	chr11:89392465-89431885:+	0.71	5.98	4.43E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916376	chr11:55211925	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916396	chr11:55212611	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916398	chr11:55216248	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916400	chr11:55218146	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916402	chr11:55219714	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916404	chr11:55221576	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916405	chr11:55221776	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916411	chr11:55224905	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916453	chr11:55233726	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916457	chr11:55234186	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916561	chr11:55336203	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916562	chr11:55336207	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916563	chr11:55337027	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916564	chr11:55337782	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916565	chr11:55338095	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916566	chr11:55338435	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916567	chr11:55339242	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61916568	chr11:55340170	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917375	chr11:55159324	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917376	chr11:55159677	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917377	chr11:55160040	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917378	chr11:55160192	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917395	chr11:55167773	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917397	chr11:55168405	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917398	chr11:55170016	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917404	chr11:55172653	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917431	chr11:55172955	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917439	chr11:55175027	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917451	chr11:55182769	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917454	chr11:55183543	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917455	chr11:55183705	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917457	chr11:55183759	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917458	chr11:55184196	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917891	chr11:55295283	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917897	chr11:55298533	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917927	chr11:55305170	FOLH1B	chr11:89392465-89431885:+	0.72	6.18	1.34E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917936	chr11:55311417	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917940	chr11:55313406	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61917941	chr11:55314405	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61917942	chr11:55315533	FOLH1B	chr11:89392465-89431885:+	0.78	5.87	8.21E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917958	chr11:55318492	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61917959	chr11:55318782	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61917983	chr11:55235812	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61917984	chr11:55237729	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918160	chr11:55184667	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918212	chr11:55187947	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918213	chr11:55187973	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918217	chr11:55188818	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918222	chr11:55191116	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918227	chr11:55193679	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918228	chr11:55194403	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918236	chr11:55198427	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918251	chr11:55199875	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61918254	chr11:55202417	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919260	chr11:55205628	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919565	chr11:55319985	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61919569	chr11:55322464	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919570	chr11:55322490	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919571	chr11:55322902	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919573	chr11:55323347	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919574	chr11:55324704	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919575	chr11:55324862	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919578	chr11:55326379	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919579	chr11:55326454	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919580	chr11:55326458	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919581	chr11:55327662	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919583	chr11:55328053	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919585	chr11:55328400	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919586	chr11:55328550	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919587	chr11:55328906	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919613	chr11:55329105	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919614	chr11:55329211	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919616	chr11:55330088	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919618	chr11:55332687	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919619	chr11:55333285	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919620	chr11:55333439	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919621	chr11:55333613	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919622	chr11:55333895	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919624	chr11:55334179	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919678	chr11:55255320	FOLH1B	chr11:89392465-89431885:+	0.71	6.21	1.15E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs61919681	chr11:55258063	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61919683	chr11:55258709	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61919686	chr11:55262910	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61919688	chr11:55263224	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs61919689	chr11:55263948	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs62427476	chr6:155952577	ABHD10	chr3:111697828-111712208:+	-0.41	-5.88	7.55E-9	Schizophrenia	
LUSC	trans	1	rs6456733	chr6:26566804	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs6456734	chr6:26566965	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs6485872	chr11:48579710	FOLH1B	chr11:89392465-89431885:+	-0.45	-9.33	3.92E-19	HDL cholesterol	
LUSC	trans	1	rs6485875	chr11:48581034	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.64	3.29E-20	HDL cholesterol	
LUSC	trans	1	rs6485882	chr11:48592435	FOLH1B	chr11:89392465-89431885:+	0.42	8.52	2.07E-16	HDL cholesterol	
LUSC	trans	1	rs6485888	chr11:48605339	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.48	1.26E-19	HDL cholesterol	
LUSC	trans	1	rs6485903	chr11:48639004	FOLH1B	chr11:89392465-89431885:+	-0.48	-9.83	7.03E-21	HDL cholesterol	
LUSC	trans	1	rs6485907	chr11:48651695	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.44	1.71E-19	HDL cholesterol	
LUSC	trans	1	rs6485908	chr11:48652198	FOLH1B	chr11:89392465-89431885:+	-0.47	-6.46	2.66E-10	Axial length	
LUSC	trans	1	rs6485911	chr11:48654784	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.69	2.26E-20	HDL cholesterol	
LUSC	trans	1	rs6591439	chr11:55179208	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs6591466	chr11:55213206	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs6600669	chr1:121213639	NBPF14	chr1:148003643-148346791:-	0.38	8.22	1.91E-15	Hip geometry	
LUSC	trans	1	rs6600671	chr1:121200490	NBPF14	chr1:148003643-148346791:-	-0.36	-7.6	1.61E-13	Hip geometry	
LUSC	trans	1	rs67311847	chr3:64704322	DCAF12L1	chrX:125683368-125686842:-	0.3	6.44	2.91E-10	Visceral adipose tissue adjusted for BMI	
LUSC	trans	1	rs6770866	chr3:64705181	DCAF12L1	chrX:125683368-125686842:-	0.3	6.53	1.74E-10	Visceral adipose tissue adjusted for BMI	
LUSC	trans	1	rs68141011	chr6:28217797	BTN3A2	chr6:26365398-26378546:+	-0.47	-7.57	2.02E-13	Depression	
LUSC	trans	1	rs6886255	chr5:176718361	LOC388955	chr2:63849182-63850159:-	0.44	8.47	3.17E-16	Migraine without aura	
LUSC	trans	1	rs6901575	chr6:28250984	BTN3A2	chr6:26365398-26378546:+	-0.47	-7.76	5.21E-14	Depression	
LUSC	trans	1	rs6903973	chr6:26499942	ZNF322B	chr9:99957633-99961910:-	0.36	7.73	6.69E-14	Educational attainment	
LUSC	trans	1	rs6905391	chr6:28262686	BTN3A2	chr6:26365398-26378546:+	-0.45	-7.59	1.71E-13	Depression	
LUSC	trans	1	rs6910899	chr6:26524339	ZNF322B	chr9:99957633-99961910:-	0.35	7.45	4.34E-13	Educational attainment	
LUSC	trans	1	rs6922824	chr6:26553815	ZNF322B	chr9:99957633-99961910:-	-0.36	-7.82	3.52E-14	Educational attainment	
LUSC	trans	1	rs6924838	chr6:26571756	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.95E-12	Educational attainment	
LUSC	trans	1	rs6925703	chr6:26521589	ZNF322B	chr9:99957633-99961910:-	0.35	7.43	5.12E-13	Educational attainment	
LUSC	trans	1	rs6925895	chr6:26572165	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.95E-12	Educational attainment	
LUSC	trans	1	rs6926629	chr6:26499903	ZNF322B	chr9:99957633-99961910:-	0.36	7.73	6.69E-14	Educational attainment	
LUSC	trans	1	rs6930120	chr6:26555484	ZNF322B	chr9:99957633-99961910:-	0.34	7.19	2.46E-12	Educational attainment	
LUSC	trans	1	rs6932156	chr6:26571506	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.95E-12	Educational attainment	
LUSC	trans	1	rs6933176	chr6:26540178	ZNF322B	chr9:99957633-99961910:-	0.35	7.57	2.02E-13	Educational attainment	
LUSC	trans	1	rs6940053	chr6:26562122	ZNF322B	chr9:99957633-99961910:-	0.34	7.08	5.28E-12	Educational attainment	
LUSC	trans	1	rs6940188	chr6:26562029	ZNF322B	chr9:99957633-99961910:-	0.34	7.08	5.19E-12	Educational attainment	
LUSC	trans	1	rs7102958	chr11:55298631	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7103234	chr11:55141298	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7107184	chr11:48577069	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.42	1.99E-19	HDL cholesterol	
LUSC	trans	1	rs7109010	chr11:55137386	FOLH1B	chr11:89392465-89431885:+	0.71	6.16	1.53E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7112469	chr11:55266600	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7112674	chr11:55342067	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7117005	chr11:55169003	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7121460	chr11:48545232	FOLH1B	chr11:89392465-89431885:+	-0.45	-9.35	3.56E-19	HDL cholesterol	
LUSC	trans	1	rs7121992	chr11:48592582	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.69	2.19E-20	HDL cholesterol	
LUSC	trans	1	rs7122234	chr11:55137715	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7122704	chr11:55150606	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7124611	chr11:55361189	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7124739	chr11:55361272	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7124871	chr11:55541620	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.24E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7125205	chr11:55178992	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7125559	chr11:48984207	FOLH1B	chr11:89392465-89431885:+	0.47	6.46	2.66E-10	Axial length	
LUSC	trans	1	rs7125913	chr11:48984318	FOLH1B	chr11:89392465-89431885:+	0.47	6.46	2.66E-10	Axial length	
LUSC	trans	1	rs7128331	chr11:55361156	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7129386	chr11:48616694	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.45	1.58E-19	HDL cholesterol	
LUSC	trans	1	rs7129556	chr11:77300048	INTS4L1	chr7:64601603-64694599:+	-0.41	-7.27	1.47E-12	Weight loss (gastric bypass surgery)	
LUSC	trans	1	rs7131020	chr11:48642132	FOLH1B	chr11:89392465-89431885:+	0.48	6.48	2.24E-10	Axial length	
LUSC	trans	1	rs72843784	chr6:26498758	RNF5P1	chr8:38457695-38458775:-	0.65	6.46	2.56E-10	Schizophrenia	
LUSC	trans	1	rs735765	chr6:28170297	BTN3A2	chr6:26365398-26378546:+	-0.57	-8.68	6.61E-17	Depression	
LUSC	trans	1	rs735765	chr6:28170297	RNF5P1	chr8:38457695-38458775:-	0.49	6.29	7.29E-10	Depression	
LUSC	trans	1	rs7395662	chr11:48518893	FOLH1B	chr11:89392465-89431885:+	0.46	9.42	1.91E-19	HDL cholesterol	
LUSC	trans	1	rs74331841	chr11:55322422	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs74625780	chr11:55225873	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7478900	chr11:48544003	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.67	2.61E-20	HDL cholesterol	
LUSC	trans	1	rs7479134	chr11:48625409	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.71	1.9E-20	HDL cholesterol	
LUSC	trans	1	rs7479498	chr11:48660499	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.54	7.7E-20	HDL cholesterol	
LUSC	trans	1	rs7481308	chr11:48600067	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.67	2.6E-20	HDL cholesterol	
LUSC	trans	1	rs7481880	chr11:48609347	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.75	1.35E-20	HDL cholesterol	
LUSC	trans	1	rs7482176	chr11:48604620	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.68	2.31E-20	HDL cholesterol	
LUSC	trans	1	rs7482528	chr11:48640052	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.41	2.06E-19	HDL cholesterol	
LUSC	trans	1	rs7483920	chr11:48599969	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.37	3.04E-19	HDL cholesterol	
LUSC	trans	1	rs75226237	chr11:55158788	FOLH1B	chr11:89392465-89431885:+	0.67	5.91	6.72E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs75287308	chr11:54823902	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs7532615	chr1:121172840	NBPF14	chr1:148003643-148346791:-	-0.35	-7.81	3.7E-14	Hip geometry	
LUSC	trans	1	rs75519906	chr11:55115611	FOLH1B	chr11:89392465-89431885:+	0.72	6.14	1.72E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs75768461	chr11:55292919	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs75881957	chr11:55339712	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs76097560	chr11:55329853	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs76202438	chr11:54801567	FOLH1B	chr11:89392465-89431885:+	0.69	6.07	2.66E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs76388671	chr11:55329854	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs76426677	chr11:55225921	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs76515019	chr11:54842025	FOLH1B	chr11:89392465-89431885:+	0.76	6.6	1.1E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs76670300	chr11:55344192	FOLH1B	chr11:89392465-89431885:+	0.7	6.35	4.94E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs767471	chr6:26557854	ZNF322B	chr9:99957633-99961910:-	0.34	7.13	3.88E-12	Educational attainment	
LUSC	trans	1	rs76906133	chr11:55224695	FOLH1B	chr11:89392465-89431885:+	0.71	5.97	4.73E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs76914796	chr11:55521982	FOLH1B	chr11:89392465-89431885:+	0.69	5.92	6.01E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs77021942	chr11:54800918	FOLH1B	chr11:89392465-89431885:+	0.79	6.77	3.82E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs77053681	chr11:55135053	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs77219956	chr11:55183893	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs77248666	chr11:55294317	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs77298220	chr11:55290368	FOLH1B	chr11:89392465-89431885:+	0.72	6.15	1.63E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7740487	chr6:28216486	BTN3A2	chr6:26365398-26378546:+	-0.47	-7.57	1.89E-13	Depression	
LUSC	trans	1	rs77611127	chr11:55314571	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs77650525	chr11:55322921	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs77792938	chr11:55312829	FOLH1B	chr11:89392465-89431885:+	0.7	5.9	7.04E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs78036162	chr11:54839925	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs78253765	chr11:55343347	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs78612916	chr11:55339704	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs78785256	chr11:55282643	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs78875307	chr11:55173669	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs79259102	chr12:23639392	CT47A10	chrX:120082278-120085594:-;chrX	0.22	7.55	2.18E-13	Schizophrenia	
LUSC	trans	1	rs7925927	chr11:55171160	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7925955	chr11:48647533	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.58	5.62E-20	HDL cholesterol	
LUSC	trans	1	rs7927370	chr11:55136219	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7928083	chr11:48613148	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.45	1.58E-19	HDL cholesterol	
LUSC	trans	1	rs7930341	chr11:55269816	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7931984	chr11:48580835	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.8	9.25E-21	HDL cholesterol	
LUSC	trans	1	rs7933811	chr11:55298265	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7935445	chr11:55288780	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7938739	chr11:55206830	FOLH1B	chr11:89392465-89431885:+	0.71	6.02	3.59E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7938880	chr11:48642154	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.6	4.74E-20	HDL cholesterol	
LUSC	trans	1	rs7940290	chr11:55274849	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7941275	chr11:55269686	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7941839	chr11:55270154	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7942480	chr11:55257480	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7943092	chr11:55261104	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7944356	chr11:48610154	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.48	1.26E-19	HDL cholesterol	
LUSC	trans	1	rs7944383	chr11:55487252	FOLH1B	chr11:89392465-89431885:+	0.71	6.22	1.07E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7944525	chr11:55487391	FOLH1B	chr11:89392465-89431885:+	0.71	6.22	1.07E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7945192	chr11:48580737	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.8	9.25E-21	HDL cholesterol	
LUSC	trans	1	rs7945896	chr11:55445243	FOLH1B	chr11:89392465-89431885:+	0.72	6.18	1.39E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7947870	chr11:55444514	FOLH1B	chr11:89392465-89431885:+	0.72	6.18	1.39E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7948486	chr11:48912140	FOLH1B	chr11:89392465-89431885:+	0.47	9.7	1.96E-20	HDL cholesterol	
LUSC	trans	1	rs7949348	chr11:48493801	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.37	2.99E-19	HDL cholesterol	
LUSC	trans	1	rs7949554	chr11:48581992	FOLH1B	chr11:89392465-89431885:+	-0.47	-9.64	3.29E-20	HDL cholesterol	
LUSC	trans	1	rs7950685	chr11:55260691	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs7950848	chr11:55175602	FOLH1B	chr11:89392465-89431885:+	0.71	6.19	1.31E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs7951100	chr11:55590296	FOLH1B	chr11:89392465-89431885:+	0.65	6.02	3.46E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs79551837	chr11:54858233	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs79577263	chr11:54840579	FOLH1B	chr11:89392465-89431885:+	0.79	6.79	3.26E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs79727833	chr11:55293051	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs80123215	chr11:55339466	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs80210585	chr11:55339740	FOLH1B	chr11:89392465-89431885:+	0.72	6.17	1.47E-9	Systemic lupus erythematosus	
LUSC	trans	1	rs8188963	chr11:48685693	FOLH1B	chr11:89392465-89431885:+	0.49	6.61	1.01E-10	Axial length	
LUSC	trans	1	rs8189391	chr11:48859789	FOLH1B	chr11:89392465-89431885:+	0.45	9.18	1.31E-18	HDL cholesterol	
LUSC	trans	1	rs853676	chr6:28299687	BTN3A2	chr6:26365398-26378546:+	-0.48	-7.52	2.77E-13	Depression	
LUSC	trans	1	rs853678	chr6:28297313	BTN3A2	chr6:26365398-26378546:+	-0.48	-7.55	2.25E-13	Depression	
LUSC	trans	1	rs853679	chr6:28296863	BTN3A2	chr6:26365398-26378546:+	-0.48	-7.55	2.25E-13	Depression	
LUSC	trans	1	rs853685	chr6:28288785	BTN3A2	chr6:26365398-26378546:+	-0.48	-7.58	1.77E-13	Depression	
LUSC	trans	1	rs853694	chr6:28279100	BTN3A2	chr6:26365398-26378546:+	-0.47	-7.66	1.08E-13	Depression	
LUSC	trans	1	rs9295695	chr6:26528250	ZNF322B	chr9:99957633-99961910:-	-0.34	-7.21	2.28E-12	Educational attainment	
LUSC	trans	1	rs9357010	chr6:26527945	ZNF322B	chr9:99957633-99961910:-	0.35	7.54	2.37E-13	Educational attainment	
LUSC	trans	1	rs9393728	chr6:26509330	ZNF322B	chr9:99957633-99961910:-	0.36	7.68	9.32E-14	Educational attainment	
LUSC	trans	1	rs9393729	chr6:26514166	ZNF322B	chr9:99957633-99961910:-	0.35	7.43	5.05E-13	Educational attainment	
LUSC	trans	1	rs9393731	chr6:26529374	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.27E-13	Educational attainment	
LUSC	trans	1	rs9393732	chr6:26530898	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.27E-13	Educational attainment	
LUSC	trans	1	rs9461259	chr6:26504835	ZNF322B	chr9:99957633-99961910:-	0.36	7.68	9.34E-14	Educational attainment	
LUSC	trans	1	rs9461271	chr6:26554968	ZNF322B	chr9:99957633-99961910:-	0.34	7.19	2.46E-12	Educational attainment	
LUSC	trans	1	rs9467773	chr6:26498426	ZNF322B	chr9:99957633-99961910:-	0.36	7.73	6.69E-14	Educational attainment	
LUSC	trans	1	rs9467774	chr6:26505036	ZNF322B	chr9:99957633-99961910:-	0.36	7.68	9.34E-14	Educational attainment	
LUSC	trans	1	rs9467778	chr6:26534743	ZNF322B	chr9:99957633-99961910:-	0.35	7.55	2.21E-13	Educational attainment	
LUSC	trans	1	rs9467779	chr6:26536687	ZNF322B	chr9:99957633-99961910:-	-0.36	-7.88	2.26E-14	Educational attainment	
LUSC	trans	1	rs9467782	chr6:26542773	ZNF322B	chr9:99957633-99961910:-	0.35	7.59	1.69E-13	Educational attainment	
LUSC	trans	1	rs9467783	chr6:26542894	ZNF322B	chr9:99957633-99961910:-	0.37	7.81	3.6E-14	Educational attainment	
LUSC	trans	1	rs9467787	chr6:26556769	ZNF322B	chr9:99957633-99961910:-	0.34	7.13	3.88E-12	Educational attainment	
LUSC	trans	1	rs9467791	chr6:26562486	ZNF322B	chr9:99957633-99961910:-	-0.33	-6.73	5.01E-11	Educational attainment	
LUSC	trans	1	rs9467796	chr6:26568411	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs9467797	chr6:26568473	ZNF322B	chr9:99957633-99961910:-	0.34	7.09	4.83E-12	Educational attainment	
LUSC	trans	1	rs9645642	chr11:48705455	FOLH1B	chr11:89392465-89431885:+	-0.46	-9.45	1.5E-19	HDL cholesterol	
LUSC	trans	1	rs9666078	chr11:54900223	FOLH1B	chr11:89392465-89431885:+	0.76	6.54	1.62E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs9666206	chr11:54850932	FOLH1B	chr11:89392465-89431885:+	0.79	6.78	3.67E-11	Systemic lupus erythematosus	
LUSC	trans	1	rs9666260	chr11:55272410	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs982276	chr11:55320099	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs982277	chr11:55320394	FOLH1B	chr11:89392465-89431885:+	0.72	6.34	5.28E-10	Systemic lupus erythematosus	
LUSC	trans	1	rs9986382	chr6:26550619	ZNF322B	chr9:99957633-99961910:-	0.35	7.4	6.03E-13	Educational attainment	
LUSC	trans	1	rs9986596	chr6:28219661	BTN3A2	chr6:26365398-26378546:+	-0.47	-7.51	3.03E-13	Depression	
LUSC	trans	1	rs9986596	chr6:28219661	HLA-DQB1	chr6:32627657-32634466:-	-0.34	-5.91	6.42E-9	Depression	
